Processing 00000000.tx.1: ER stress and SREBP-1 activation are implicated in -cell glucolipotoxicity Haiyan Wang*, Georgia Kouri and Claes B. 

Phrase: "ER stress"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C3178870:Endoplasmic Reticulum Stress [Cell or Molecular Dysfunction]
   901   C0014239:Endoplasmic Reticulum [Cell Component]
   827   C0035295:Reticulum [Body Part, Organ, or Organ Component]
   827   C0038435:Stress [Finding]
   755 E C0231297:Stressful [Functional Concept]
   755   C0598268:Endoplasm [Cell Component]

Phrase: "and"

Phrase: "SREBP-1 activation"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   829   C0599177:protein activation [Genetic Function]
   795   C1879547:Activation [Activity]
   787   C0217529:Sterol Regulatory Element Binding Protein 1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   787   C1420398:STEROL REGULATORY ELEMENT-BINDING PROTEIN 1 [Gene or Genome]

Phrase: "are"

Phrase: "implicated"

Phrase: "in -cell glucolipotoxicity Haiyan Wang"

Phrase: "*,"

Phrase: "Georgia Kouri"

Phrase: "and"

Phrase: "Claes B."
Processing 00000000.tx.2: Wollheim Department of Cell Physiology and Metabolism, University Medical Center, Geneva, CH-1211, Switzerland * Author for correspondence (e-mail: Haiyan.Wang{at}medecine.unige.ch ) Accepted 25 May 2005  Summary Top Summary Introduction Materials and Methods Results Discussion References  The reduction in insulin secretory capacity and -cell mass observed in type 2 diabetes is thought to be caused by glucolipotoxicity secondary to hyperglycemia and hyperlipidemia. 

Phrase: "Wollheim Department of Cell Physiology"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1704729:Department [Organization]

Phrase: "and"

Phrase: "Metabolism,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0025519:Metabolism [Organism Function]
  1000   C0025520:metabolism [Functional Concept]

Phrase: "University Medical Center,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0000872:University Medical Center [Health Care Related Organization,Manufactured Object]
   901   C0565990:Medical center [Health Care Related Organization,Manufactured Object]
   901   C1552471:Medical Center [Health Care Related Organization,Manufactured Object]
   827   C0041740:University [Manufactured Object,Organization]
   827   C0205099:Center [Spatial Concept]
   827   C0205476:Medical [Functional Concept]

Phrase: "Geneva,"

Phrase: "CH-1211,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0558269:Ch. [Professional or Occupational Group]
   861   C1552984:[Ch] [Quantitative Concept]

Phrase: "Switzerland"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0039021:Switzerland [Geographic Area]

Phrase: "* Author for correspondence"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0221193:Author [Professional or Occupational Group]

Phrase: "(e-mail"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0013849:E-Mail [Intellectual Product]
  1000   C1705961:E-mail [Intellectual Product]
   861   C0024492:Mail [Manufactured Object]
   861   C1538057:MAIL [Gene or Genome]
   861   C1547565:Mail [Idea or Concept]

Phrase: ":"

Phrase: "Haiyan.Wang{at}medecine.unige.ch )"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   799   C0558269:Ch. [Professional or Occupational Group]
   799   C1552984:[Ch] [Quantitative Concept]

Phrase: "Accepted"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1272684:Accepted [Qualitative Concept]
  1000   C1548435:Accepted [Idea or Concept]
   966 E C1548601:Accept [Idea or Concept]

Phrase: "25 May 2005  Summary Top Summary Introduction Materials"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   793   C0520510:Materials [Substance]

Phrase: "and"

Phrase: "Methods Results Discussion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "References"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "The reduction in insulin secretory capacity"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0301630:Reduction [Natural Phenomenon or Process]
   753   C0392756:Reduction [Qualitative Concept]
   753   C0441610:Reduction [Therapeutic or Preventive Procedure]

Phrase: "and -"

Phrase: "cell mass"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0577559:Mass [Finding]
   861   C1306372:*Mass [Quantitative Concept]
   861   C3152252:Mass [Quantitative Concept]

Phrase: "observed in type 2 diabetes"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   862   C0011860:Type 2 Diabetes [Disease or Syndrome]
   806   C0441730:Type 2 [Classification]
   797   C1320657:Diabetes type [Finding]
   760   C0011847:Diabetes [Disease or Syndrome]
   760   C0011849:Diabetes [Disease or Syndrome]
   760   C0332307:Type [Qualitative Concept]
   760   C1441672:Observed [Functional Concept]
   760   C1547052:*Type [Quantitative Concept]

Phrase: "is"

Phrase: "thought"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0039869:Thought [Mental Process]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "caused by glucolipotoxicity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   756   C0015127:cause [Functional Concept]
   756   C1524003:Cause [Conceptual Entity]

Phrase: "secondary to hyperglycemia"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   882   C0175668:Secondary to [Temporal Concept]
           Secondary
   790   C0027627:secondary [Neoplastic Process]
   790   C0205436:Secondary [Quantitative Concept]

Phrase: "and"

Phrase: "hyperlipidemia."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0020473:Hyperlipidaemia [Disease or Syndrome]
Processing 00000000.tx.3: Our aim in this study was to elucidate the underlying molecular mechanisms. 

Phrase: "Our aim in this study"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C1947946:Aim [Idea or Concept]
   760   C2948600:Aim [Pharmacologic Substance]
   760   C3540471:AIM [Gene or Genome]
   760   C3540472:AIM [Functional Concept]

Phrase: "was"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "elucidate"

Phrase: "the underlying molecular mechanisms."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0441712:Mechanisms [Functional Concept]
   793 E C1706376:Mechanism [Manufactured Object]
Processing 00000000.tx.4: We found a strong correlation between chronic high-glucose treatment and SREBP-1c activation in INS-1 cells and rat islets. 

Phrase: "We"

Phrase: "found"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0150312:Found [Quantitative Concept]
   966 E C0243095:Find [Finding]

Phrase: "a strong correlation between chronic high-glucose treatment"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C1707520:Correlation [Qualitative Concept]

Phrase: "and"

Phrase: "SREBP-1c activation in"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   767   C0599177:protein activation [Genetic Function]
   744   C1879547:Activation [Activity]
   743   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "INS-1 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "and"

Phrase: "rat islets."
Processing 00000000.tx.5: Both high-glucose treatment and SREBP-1c activation in INS-1 cells resulted in lipid accumulation, impaired glucose-stimulated insulin secretion, apoptosis, and strikingly similar gene expression patterns, including upregulation of lipogenic and pro-apoptotic genes and downregulation of IRS2, Bclxl and Pdx1. 

Phrase: "Both high-glucose treatment"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   827   C0039798:treatment [Functional Concept]
   827   C0087111:Treatment [Therapeutic or Preventive Procedure]
   827   C1522326:Treatment [Functional Concept]
   827   C1533734:Treatment [Therapeutic or Preventive Procedure]
   827   C1705169:Treatment [Conceptual Entity]
   827   C3538994:TREATMENT [Research Activity]
   734   C0860803:high glucose [Finding]

Phrase: "and"

Phrase: "SREBP-1c activation in"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   767   C0599177:protein activation [Genetic Function]
   744   C1879547:Activation [Activity]
   743   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "INS-1 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "resulted in lipid accumulation,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   833   C0333574:Lipid accumulation [Finding]
   770   C0023779:Lipid [Lipid]
   737   C1274040:Result [Functional Concept]
   737   C1546471:Result [Idea or Concept]
   737   C2825142:Result [Finding]

Phrase: "impaired glucose-stimulated insulin secretion,"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   853   C1719133:Glucose/Insulin [Quantitative Concept]
   840   C1256369:insulin secretion [Cell Function]
   804   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   804   C0036536:secretion [Biologic Function]
   804   C0036537:Secretion [Body Substance]
   804   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   804   C1579433:Insulin [Pharmacologic Substance]
   748 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   721 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "apoptosis,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0162638:Apoptosis [Cell Function]
   928 E C1516044:Apoptotic [Qualitative Concept]

Phrase: "and"

Phrase: "strikingly similar gene expression patterns,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0449774:Patterns [Spatial Concept]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "upregulation of lipogenic"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0041904:Up-Regulation [Cell Function,Molecular Function]
   790   C0162493:Up-Regulation [Genetic Function]

Phrase: "and"

Phrase: "pro-apoptotic genes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0017337:Genes [Gene or Genome]

Phrase: "and"

Phrase: "downregulation of IRS2,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   783   C0949469:Receptor Down-Regulation [Molecular Function]
   753   C0013081:Down-Regulation [Cell Function,Molecular Function]
   716   C0381451:Insulin Receptor Substrate-2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   716   C1334141:INSULIN RECEPTOR SUBSTRATE 2 [Gene or Genome]
   716   C1334191:Insulin Receptor Substrate 2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "Bclxl"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1332397:BCLXL [Gene or Genome]

Phrase: "and"

Phrase: "Pdx1."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1427500:PDX1 [Gene or Genome]
  1000   C1826562:PDX1 [Gene or Genome]
Processing 00000000.tx.6: These lipotoxic effects of high glucose were largely prevented by induction of a dominant-negative mutant of SREBP-1c, suggesting SREBP-1c is a major factor responsible for  cell glucolipotoxicity. 

Phrase: "These lipotoxic effects of high glucose"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   767   C1158774:glucose effect [Genetic Function]
   753   C1280500:effects [Qualitative Concept]
   719 E C2348382:Effect [Qualitative Concept]

Phrase: "were"

Phrase: "largely"

Phrase: "prevented by induction of a dominant-negative mutant"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   800   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
           Dominant Negative
   744   C0205160:Negative [Qualitative Concept]
   744   C0205263:Induction [Functional Concept]
   744   C0596988:Mutant [Cell or Molecular Dysfunction]
   744   C0857127:induction [Therapeutic or Preventive Procedure]
   744   C1513916:Negative [Finding]
   744   C1527180:Dominant [Functional Concept]
   744   C2825415:Negative [Conceptual Entity]
   744   C2825491:Negative [Qualitative Concept]
   711   C0309872:PREVENT [Pharmacologic Substance]

Phrase: "of SREBP-1c,"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
  1000   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C2246292:sterol binding [Molecular Function]
   827   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0013879:Element [Element, Ion, or Isotope]
   799   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0038323:Sterol [Steroid]
   799   C0220905:regulatory [Regulation or Law]
   799   C0243122:binding [Functional Concept]
   799   C1145667:Binding [Activity]
   799   C1167622:Binding [Molecular Function]
   799   C1704735:Regulatory [Conceptual Entity]
   799   C1705248:Element [Conceptual Entity]

Phrase: "suggesting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "SREBP-1c"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
  1000   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C2246292:sterol binding [Molecular Function]
   827   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0013879:Element [Element, Ion, or Isotope]
   799   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0038323:Sterol [Steroid]
   799   C0220905:regulatory [Regulation or Law]
   799   C0243122:binding [Functional Concept]
   799   C1145667:Binding [Activity]
   799   C1167622:Binding [Molecular Function]
   799   C1704735:Regulatory [Conceptual Entity]
   799   C1705248:Element [Conceptual Entity]

Phrase: "is"

Phrase: "a major factor"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1521761:Factor [Functional Concept]
   861   C2827422:Factor [Conceptual Entity]

Phrase: "responsible for  cell glucolipotoxicity."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1273518:Responsible [Finding]
Processing 00000000.tx.7: Moreover, overexpression of another lipogenic transcription factor, ChREBP, in INS-1 cells did not cause lipotoxicity. 

Phrase: "Moreover,"

Phrase: "overexpression of another lipogenic transcription factor,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1514559:Overexpression [Genetic Function]

Phrase: "ChREBP,"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C1826259:carbohydrate response element binding protein [Gene or Genome]
   937   C3158709:carbohydrate response element binding [Genetic Function]
   911   C0108401:carbohydrate-binding protein [Amino Acid, Peptide, or Protein,Receptor]
   875   C1148582:carbohydrate binding [Molecular Function]
   840   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0243122:binding [Functional Concept]
   804   C1145667:Binding [Activity]
   804   C1167622:Binding [Molecular Function]

Phrase: "in"

Phrase: "INS-1 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "cause"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0015127:cause [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]

Phrase: "lipotoxicity."
Processing 00000000.tx.8: Intriguingly, chronic high glucose treatment in INS-1 cells led to pronounced induction of the ER stress marker genes, BIP and Chop10. 

Phrase: "Intriguingly,"

Phrase: "chronic high glucose treatment in"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   760   C0039798:treatment [Functional Concept]
   760   C0087111:Treatment [Therapeutic or Preventive Procedure]
   760   C1522326:Treatment [Functional Concept]
   760   C1533734:Treatment [Therapeutic or Preventive Procedure]
   760   C1705169:Treatment [Conceptual Entity]
   760   C3538994:TREATMENT [Research Activity]

Phrase: "INS-1 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "led to pronounced induction of the ER stress marker genes,"
Meta Candidates (Total=15; Excluded=5; Pruned=0; Remaining=10)
   775   C3178870:Endoplasmic Reticulum Stress [Cell or Molecular Dysfunction]
   756   C0014239:Endoplasmic Reticulum [Cell Component]
   738   C0005516:Marker [Clinical Attribute]
   738   C0017337:Genes [Gene or Genome]
   738   C0035295:Reticulum [Body Part, Organ, or Organ Component]
   738   C0038435:Stress [Finding]
   738   C0205263:Induction [Functional Concept]
   738   C0857127:induction [Therapeutic or Preventive Procedure]
   738   C1708698:LED [Manufactured Object]
   737   C0920532:gene induction [Genetic Function]
   704 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   704 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   704 E C1522538:Lead [Functional Concept]
   704 E C2348269:Lead [Element, Ion, or Isotope]
   704 E C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "BIP"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0063423:BiP [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1415761:BIP [Gene or Genome]

Phrase: "and"

Phrase: "Chop10."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1413947:CHOP10 [Gene or Genome]
  1000   C2985165:CHOP10 [Gene or Genome]
Processing 00000000.tx.9: Treatment of rat islets with both chronic high glucose and two ER stress inducers, thapsigargin and tunicamycin, enhanced SREBP-1 binding to the human IRS2 promoter. 

Phrase: "Treatment of rat islets"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C0039798:treatment [Functional Concept]
   770   C0087111:Treatment [Therapeutic or Preventive Procedure]
   770   C1522326:Treatment [Functional Concept]
   770   C1533734:Treatment [Therapeutic or Preventive Procedure]
   770   C1705169:Treatment [Conceptual Entity]
   770   C3538994:TREATMENT [Research Activity]

Phrase: "with both chronic high glucose"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C0860803:high glucose [Finding]
   827   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "and"

Phrase: "two ER stress inducers,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   717   C3178870:Endoplasmic Reticulum Stress [Cell or Molecular Dysfunction]

Phrase: "thapsigargin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0076374:Thapsigargin [Hazardous or Poisonous Substance,Organic Chemical]

Phrase: "and"

Phrase: "tunicamycin,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0041385:Tunicamycin [Antibiotic,Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "enhanced SREBP-1 binding"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   756   C0217529:Sterol Regulatory Element Binding Protein 1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   756   C1420398:STEROL REGULATORY ELEMENT-BINDING PROTEIN 1 [Gene or Genome]

Phrase: "to the human IRS2 promoter."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   799   C0086860:Promoter [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   780   C1334191:insulin receptor substrate 2, human [Amino Acid, Peptide, or Protein,Biologically Active Substance]
           Insulin Receptor Substrate 2
   734   C0381451:Insulin Receptor Substrate-2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   734   C1334141:INSULIN RECEPTOR SUBSTRATE 2 [Gene or Genome]
Processing 00000000.tx.10: These results suggest that SREBP-1 activation caused by ER stress is implicated in -cell glucolipotoxicity. 

Phrase: "These results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "suggest"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that SREBP-1 activation"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   829   C0599177:protein activation [Genetic Function]
   795   C1879547:Activation [Activity]
   787   C0217529:Sterol Regulatory Element Binding Protein 1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   787   C1420398:STEROL REGULATORY ELEMENT-BINDING PROTEIN 1 [Gene or Genome]

Phrase: "caused by ER stress"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   862   C3178870:Endoplasmic Reticulum Stress [Cell or Molecular Dysfunction]
   806   C0014239:Endoplasmic Reticulum [Cell Component]
   760   C0035295:Reticulum [Body Part, Organ, or Organ Component]
   760   C0038435:Stress [Finding]
   726   C0015127:cause [Functional Concept]
   726   C1524003:Cause [Conceptual Entity]

Phrase: "is"

Phrase: "implicated"

Phrase: "in -cell glucolipotoxicity."
Processing 00000000.tx.11: Key words: ER stress, SREBP-1c, Glucolipotoxicity,  cell  Introduction Top Summary Introduction Materials and Methods Results Discussion References  The reduction in insulin secretary capacity and -cell mass observed in type 2 diabetes is thought to be caused at least in part by hyperglycemia and hyperlipidemia (Butler et al., 2003; Unger, 2002; Unger and Zhou, 2001; Unger et al., 1999; Weir et al., 2001). 

Phrase: "Key words"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   827   C1705313:Word [Idea or Concept]
   789 E C0439824:Verbal [Qualitative Concept]
   761 E C0871946:verb [Intellectual Product]

Phrase: ":"

Phrase: "ER stress,"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C3178870:Endoplasmic Reticulum Stress [Cell or Molecular Dysfunction]
   901   C0014239:Endoplasmic Reticulum [Cell Component]
   827   C0035295:Reticulum [Body Part, Organ, or Organ Component]
   827   C0038435:Stress [Finding]
   755 E C0231297:Stressful [Functional Concept]
   755   C0598268:Endoplasm [Cell Component]

Phrase: "SREBP-1c,"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
  1000   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C2246292:sterol binding [Molecular Function]
   827   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0013879:Element [Element, Ion, or Isotope]
   799   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0038323:Sterol [Steroid]
   799   C0220905:regulatory [Regulation or Law]
   799   C0243122:binding [Functional Concept]
   799   C1145667:Binding [Activity]
   799   C1167622:Binding [Molecular Function]
   799   C1704735:Regulatory [Conceptual Entity]
   799   C1705248:Element [Conceptual Entity]

Phrase: "Glucolipotoxicity,"

Phrase: "cell  Introduction Top Summary Introduction Materials"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   799   C0520510:Materials [Substance]

Phrase: "and"

Phrase: "Methods Results Discussion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "References"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "The reduction in insulin secretary capacity"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0301630:Reduction [Natural Phenomenon or Process]
   753   C0392756:Reduction [Qualitative Concept]
   753   C0441610:Reduction [Therapeutic or Preventive Procedure]

Phrase: "and -"

Phrase: "cell mass"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0577559:Mass [Finding]
   861   C1306372:*Mass [Quantitative Concept]
   861   C3152252:Mass [Quantitative Concept]

Phrase: "observed in type 2 diabetes"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   862   C0011860:Type 2 Diabetes [Disease or Syndrome]
   806   C0441730:Type 2 [Classification]
   797   C1320657:Diabetes type [Finding]
   760   C0011847:Diabetes [Disease or Syndrome]
   760   C0011849:Diabetes [Disease or Syndrome]
   760   C0332307:Type [Qualitative Concept]
   760   C1441672:Observed [Functional Concept]
   760   C1547052:*Type [Quantitative Concept]

Phrase: "is"

Phrase: "thought"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0039869:Thought [Mental Process]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "caused at least"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   756   C0015127:cause [Functional Concept]
   756   C1524003:Cause [Conceptual Entity]

Phrase: "in part"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0449719:Part [Spatial Concept]
  1000   C1709471:Part [Quantitative Concept]

Phrase: "by hyperglycemia"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0020456:Hyperglycaemia [Disease or Syndrome]

Phrase: "and"

Phrase: "hyperlipidemia"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0020473:Hyperlipidaemia [Disease or Syndrome]

Phrase: "(Butler et al.,"

Phrase: "2003"

Phrase: "; Unger,"

Phrase: "2002"

Phrase: "; Unger"

Phrase: "and"

Phrase: "Zhou,"

Phrase: "2001"

Phrase: "; Unger et al.,"

Phrase: "1999"

Phrase: "; Weir et al.,"

Phrase: "2001"

Phrase: ")."
Processing 00000000.tx.12: Hyperglycemia is proposed as the prerequisite for hyperlipidemia-induced -cell lipotoxicity (Bonner-Weir et al., 1983; Harmon et al., 2001; Poitout and Robertson, 2002; Roche et al., 1998; Weir, 1982; Weir et al., 2001). 

Phrase: "Hyperglycemia"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0020456:Hyperglycaemia [Disease or Syndrome]

Phrase: "is"

Phrase: "proposed as the prerequisite"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0679209:prerequisite [Idea or Concept]
   770   C1441414:PROPOSED [Idea or Concept]
   770   C1553874:Proposed [Qualitative Concept]
   770   C1578820:Proposed [Idea or Concept]

Phrase: "for hyperlipidemia-"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0020473:Hyperlipidaemia [Disease or Syndrome]

Phrase: "induced -"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induced [Functional Concept]

Phrase: "cell lipotoxicity"

Phrase: "(Bonner-Weir et al.,"

Phrase: "1983"

Phrase: "; Harmon et al.,"

Phrase: "2001"

Phrase: "; Poitout"

Phrase: "and"

Phrase: "Robertson,"

Phrase: "2002"

Phrase: "; Roche et al.,"

Phrase: "1998"

Phrase: "; Weir,"

Phrase: "1982"

Phrase: "; Weir et al.,"

Phrase: "2001"

Phrase: ")."
Processing 00000000.tx.13: Over accumulation of lipids in non-adipose tissues such as the pancreatic islets, liver and heart is often associated with type 2 diabetes and its complications (Unger, 2002; Unger and Zhou, 2001; Unger et al., 1999). 

Phrase: "Over accumulation of lipids"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   802   C0333574:Lipid accumulation [Finding]
   770   C0205136:Over [Spatial Concept]

Phrase: "in non-adipose tissues"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   901   C0001527:Adipose tissues [Tissue]
   827   C0040300:Tissues [Tissue]
   793 E C1547928:Tissue [Intellectual Product]

Phrase: "such as the pancreatic islets,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0022131:Pancreatic Islets [Body Part, Organ, or Organ Component]
   861   C0030274:Pancreatic [Body Part, Organ, or Organ Component]

Phrase: "liver"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0023884:Liver [Body Part, Organ, or Organ Component]
  1000   C0736268:LIVER [Body Part, Organ, or Organ Component]
  1000   C1278929:Liver [Body Part, Organ, or Organ Component]
  1000   C2346688:LIVER [Food]
   944 E C0205054:Hepatic [Body Location or Region]

Phrase: "and"

Phrase: "heart"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0018787:Heart [Body Part, Organ, or Organ Component]
  1000   C1281570:Heart [Body Part, Organ, or Organ Component]

Phrase: "is"

Phrase: "often"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332183:Often [Temporal Concept]

Phrase: "associated with type 2 diabetes"
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   862   C0011860:Type 2 Diabetes [Disease or Syndrome]
   806   C0332281:Associated with [Qualitative Concept]
           Associated
   806   C0441730:Type 2 [Classification]
   797   C1320657:Diabetes type [Finding]
   760   C0011847:Diabetes [Disease or Syndrome]
   760   C0011849:Diabetes [Disease or Syndrome]
   760   C0332307:Type [Qualitative Concept]
   760   C1547052:*Type [Quantitative Concept]
   726 E C0750490:Associate [Idea or Concept]
   726 E C1706221:Associate [Professional or Occupational Group]

Phrase: "and"

Phrase: "its complications"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0009566:Complications [Pathologic Function]
  1000   C1171258:complications [Pathologic Function]
   966 E C2362589:Complication [Idea or Concept]
   916 E C0231242:Complicated [Functional Concept]

Phrase: "(Unger,"

Phrase: "2002"

Phrase: "; Unger"

Phrase: "and"

Phrase: "Zhou,"

Phrase: "2001"

Phrase: "; Unger et al.,"

Phrase: "1999"

Phrase: ")."
Processing 00000000.tx.14: However, the molecular mechanism underlying the pathogenesis of lipotoxicity in pancreatic  cells and other non-adipose tissues remain undefined. 

Phrase: "However,"

Phrase: "the molecular mechanism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0441712:Mechanism [Functional Concept]
   861   C1706376:Mechanism [Manufactured Object]

Phrase: "underlying"

Phrase: "the pathogenesis of lipotoxicity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0543483:pathogenesis [Functional Concept]
   770   C0699748:Pathogenesis [Pathologic Function]

Phrase: "in pancreatic  cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "and"

Phrase: "other non-adipose tissues"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   901   C0001527:Adipose tissues [Tissue]
   827   C0040300:Tissues [Tissue]
   793 E C1547928:Tissue [Intellectual Product]

Phrase: "remain"

Phrase: "undefined."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750600:undefined [Idea or Concept]
Processing 00000000.tx.15: Lipogenic gene expression in adipocytes and liver are known to be regulated by several transcription factors including sterol regulatory element binding proteins (SREBPs), carbohydrate-response element binding protein (ChREBP), CCAAT-enhancer binding proteins (C/EBP), and peroxisome proliferator-activated receptors (PPAR) (Dentin et al., 2004; Iizuka et al., 2004; Ishii et al., 2004; Loftus and Lane, 1997). 

Phrase: "Lipogenic gene expression in adipocytes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   806   C0017262:Gene Expression [Genetic Function]
   760   C0017337:Gene [Gene or Genome]
   760   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "and"

Phrase: "liver"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0023884:Liver [Body Part, Organ, or Organ Component]
  1000   C0736268:LIVER [Body Part, Organ, or Organ Component]
  1000   C1278929:Liver [Body Part, Organ, or Organ Component]
  1000   C2346688:LIVER [Food]
   944 E C0205054:Hepatic [Body Location or Region]

Phrase: "are"

Phrase: "known"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205309:Known [Qualitative Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "regulated by several transcription factors"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   806   C0040648:Transcription Factors [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   760   C0040649:Transcription [Genetic Function]
   760   C0851285:Regulated [Governmental or Regulatory Activity]
   726   C1521761:Factor [Functional Concept]
   726   C2827422:Factor [Conceptual Entity]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "sterol regulatory element binding proteins (SREBPs),"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
  1000   C1566548:Sterol Regulatory Element Binding Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   875   C0815047:regulatory proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   875   C2246292:sterol binding [Molecular Function]
   840   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   840   C0242210:Binding Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0013879:Element [Element, Ion, or Isotope]
   804   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0038323:Sterol [Steroid]
   804   C0220905:regulatory [Regulation or Law]
   804   C0243122:binding [Functional Concept]
   804   C1145667:Binding [Activity]
   804   C1167622:Binding [Molecular Function]
   804   C1704735:Regulatory [Conceptual Entity]
   804   C1705248:Element [Conceptual Entity]

Phrase: "carbohydrate-response element binding protein (ChREBP),"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C1826259:carbohydrate response element binding protein [Gene or Genome]
   937   C3158709:carbohydrate response element binding [Genetic Function]
   911   C0108401:carbohydrate-binding protein [Amino Acid, Peptide, or Protein,Receptor]
   875   C1148582:carbohydrate binding [Molecular Function]
   840   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0243122:binding [Functional Concept]
   804   C1145667:Binding [Activity]
   804   C1167622:Binding [Molecular Function]

Phrase: "CCAAT-enhancer binding proteins (C/EBP),"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C0108685:CCAAT-Enhancer-Binding Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   906   C0597716:Enhancer Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C0242210:Binding Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C2752241:enhancer binding [Genetic Function]
   812   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   812   C0086222:Enhancer [Nucleic Acid, Nucleoside, or Nucleotide]
   812   C0243122:binding [Functional Concept]
   812   C1145667:Binding [Activity]
   812   C1167622:Binding [Molecular Function]

Phrase: "and"

Phrase: "peroxisome proliferator-activated receptors (PPAR)"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
  1000   C0166418:Peroxisome Proliferator-Activated Receptors [Amino Acid, Peptide, or Protein,Receptor]
   988 E C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   861   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   812   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   812   C0752063:Peroxysome [Cell Component]
   812   C1879547:Activated [Activity]
   812   C2984308:Peroxisome [Functional Concept]
   779 E C1515877:Activate [Functional Concept]
   741 E C3546463:peroxisomal [Cell Component]

Phrase: "(Dentin et al.,"

Phrase: "2004"

Phrase: "; Iizuka et al.,"

Phrase: "2004"

Phrase: "; Ishii et al.,"

Phrase: "2004"

Phrase: "; Loftus"

Phrase: "and"

Phrase: "Lane,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1708639:Lane [Spatial Concept]

Phrase: "1997"

Phrase: ")."
Processing 00000000.tx.16: SREBP are transmembrane proteins of the endoplasmic reticulum (ER). 

Phrase: "SREBP"
Meta Candidates (Total=13; Excluded=0; Pruned=0; Remaining=13)
   875   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   875   C2246292:sterol binding [Molecular Function]
   840   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   840   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0013879:Element [Element, Ion, or Isotope]
   804   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0038323:Sterol [Steroid]
   804   C0220905:regulatory [Regulation or Law]
   804   C0243122:binding [Functional Concept]
   804   C1145667:Binding [Activity]
   804   C1167622:Binding [Molecular Function]
   804   C1704735:Regulatory [Conceptual Entity]
   804   C1705248:Element [Conceptual Entity]

Phrase: "are"

Phrase: "transmembrane proteins of the endoplasmic reticulum (ER)."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   756   C0021699:Transmembrane protein [Amino Acid, Peptide, or Protein]
   753   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   753   C1167322:transmembrane [Cell Component]
   753   C2752508:transmembrane [Cell Component]
Processing 00000000.tx.17: In response to low sterol and other unidentified factors, SREBP cleavage-activating protein (SCAP) escorts SREBPs from the ER to the Golgi, where SREBPs are sequentially cleaved by site-1 protease (S1P) and site-2 protease (S2P). 

Phrase: "In response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0871261:Response [Organism Attribute]
  1000   C1704632:Response [Finding]
  1000   C1706817:Response [Intellectual Product]
  1000   C2911692:Response [Mental Process]

Phrase: "to low sterol"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0038323:Sterol [Steroid]

Phrase: "and"

Phrase: "other unidentified factors,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1521761:Factor [Functional Concept]
   827   C2827422:Factor [Conceptual Entity]

Phrase: "SREBP cleavage-activating protein (SCAP)"
Meta Candidates (Total=20; Excluded=1; Pruned=0; Remaining=19)
   923   C1327378:sterol regulatory element binding protein cleavage [Molecular Function]
   836   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   836   C2246292:sterol binding [Molecular Function]
   812   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   812   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   812   C0597304:Protein Cleavage [Molecular Function]
   793   C0010813:cleavage [Cell Function]
   793   C0013879:Element [Element, Ion, or Isotope]
   793   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   793   C0038323:Sterol [Steroid]
   793   C0220905:regulatory [Regulation or Law]
   793   C0243122:binding [Functional Concept]
   793   C0596311:Cleavage [Phenomenon or Process]
   793   C1145667:Binding [Activity]
   793   C1167622:Binding [Molecular Function]
   793   C1330957:cleavage [Cell Function]
   793   C1704735:Regulatory [Conceptual Entity]
   793   C1705248:Element [Conceptual Entity]
   793   C1879547:activating [Activity]
   760 E C1515877:Activate [Functional Concept]

Phrase: "escorts"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1545958:ESCORT [Population Group]
  1000   C1550481:escort [Idea or Concept]

Phrase: "SREBPs from the ER"
Meta Candidates (Total=15; Excluded=1; Pruned=0; Remaining=14)
   849   C1566548:Sterol Regulatory Element Binding Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   764   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   764   C0242210:Binding Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   762   C0815047:regulatory proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   762   C2246292:sterol binding [Molecular Function]
   745 E C0033618:Protein Binding [Molecular Function]
   742   C0013879:Element [Element, Ion, or Isotope]
   742   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   742   C0038323:Sterol [Steroid]
   742   C0220905:regulatory [Regulation or Law]
   742   C0243122:binding [Functional Concept]
   742   C1145667:Binding [Activity]
   742   C1167622:Binding [Molecular Function]
   742   C1704735:Regulatory [Conceptual Entity]
   742   C1705248:Element [Conceptual Entity]

Phrase: "to the Golgi,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0018042:Golgi [Cell Component]

Phrase: "where SREBPs"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
   947   C1566548:Sterol Regulatory Element Binding Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C0815047:regulatory proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C2246292:sterol binding [Molecular Function]
   827   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0242210:Binding Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0013879:Element [Element, Ion, or Isotope]
   799   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0038323:Sterol [Steroid]
   799   C0220905:regulatory [Regulation or Law]
   799   C0243122:binding [Functional Concept]
   799   C1145667:Binding [Activity]
   799   C1167622:Binding [Molecular Function]
   799   C1704735:Regulatory [Conceptual Entity]
   799   C1705248:Element [Conceptual Entity]

Phrase: "are"

Phrase: "sequentially"

Phrase: "cleaved by site-1 protease (S1P)"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   862   C0759784:site-1 protease [Amino Acid, Peptide, or Protein,Enzyme]
   862   C1423502:SITE-1 PROTEASE [Gene or Genome]
   760   C0030946:Protease [Amino Acid, Peptide, or Protein,Enzyme,Pharmacologic Substance]
   760   C0205145:Site [Spatial Concept]
   760   C0205242:Cleaved [Spatial Concept]
   760   C0333853:Cleaved [Cell]
   760   C1515974:Site [Body Location or Region]
   760   C1947941:Protease [Enzyme]
   760   C2825164:Site [Spatial Concept]

Phrase: "and"

Phrase: "site-2 protease (S2P)."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1423501:SITE-2 PROTEASE [Gene or Genome]
   827   C0030946:Protease [Amino Acid, Peptide, or Protein,Enzyme,Pharmacologic Substance]
   827   C1947941:Protease [Enzyme]
Processing 00000000.tx.18: The processed mature SREBPs enter the nucleus and transactivate target genes (Brown and Goldstein, 1997). 

Phrase: "The processed mature SREBPs"
Meta Candidates (Total=15; Excluded=0; Pruned=0; Remaining=15)
   913   C1566548:Sterol Regulatory Element Binding Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   860   C0033666:process protein [Molecular Function]
   845   C0815047:regulatory proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   845   C2246292:sterol binding [Molecular Function]
   818   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   818   C0242210:Binding Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   795   C0013879:Element [Element, Ion, or Isotope]
   795   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   795   C0038323:Sterol [Steroid]
   795   C0220905:regulatory [Regulation or Law]
   795   C0243122:binding [Functional Concept]
   795   C1145667:Binding [Activity]
   795   C1167622:Binding [Molecular Function]
   795   C1704735:Regulatory [Conceptual Entity]
   795   C1705248:Element [Conceptual Entity]

Phrase: "enter"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1522196:ENTER [Functional Concept]

Phrase: "the nucleus"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0007610:Nucleus [Cell Component]

Phrase: "and"

Phrase: "transactivate"

Phrase: "target genes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   983   C1332838:Target Gene [Gene or Genome]
   861   C0017337:Genes [Gene or Genome]

Phrase: "(SCAP) escorts SREBPs from the ER to the Golgi, where SREBPs are sequentially cleaved by site-1 protease (S1P) and site-2 protease (S2P). The processed mature SREBPs enter the nucleus and transactivate target genes (Brown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0678579:Brown [Natural Phenomenon or Process]

Phrase: "and"

Phrase: "Goldstein,"

Phrase: "1997"

Phrase: ") escorts SREBPs from the ER to the Golgi, where SREBPs are sequentially cleaved by site-1 protease (S1P) and site-2 protease (S2P). The processed mature SREBPs enter the nucleus and transactivate target genes (Brown and Goldstein, 1997)."
Processing 00000000.tx.19: Three SREBP isoforms have been identified: SREBP-1a and -1c (alternatively known as adipocyte determination and differentiation factor-1; ADD-1) (Tontonoz et al., 1993) that are derived from the same gene through alternative splicing, and SREBP-2 that is encoded by a distinct gene (Brown and Goldstein, 1997). 

Phrase: "Three SREBP isoforms"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   818   C0597298:Protein Isoforms [Amino Acid, Peptide, or Protein]
           Isoforms

Phrase: "have"

Phrase: "been"

Phrase: "identified"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205396:Identified [Qualitative Concept]
  1000   C1550043:Identified [Finding]
  1000   C1551388:Identified [Functional Concept]

Phrase: ":"

Phrase: "SREBP-1a"
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
  1000   C0753747:Sterol Regulatory Element Binding Protein 1a [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C2246292:sterol binding [Molecular Function]
   827   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0013879:Element [Element, Ion, or Isotope]
   799   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0038323:Sterol [Steroid]
   799   C0220905:regulatory [Regulation or Law]
   799   C0243122:binding [Functional Concept]
   799   C0450344:1A [Intellectual Product]
   799   C1145667:Binding [Activity]
   799   C1167622:Binding [Molecular Function]
   799   C1553633:1a [Medical Device]
   799   C1704735:Regulatory [Conceptual Entity]
   799   C1705248:Element [Conceptual Entity]

Phrase: "and -"

Phrase: "1c"

Phrase: "(Brown and Goldstein, 1997). Three SREBP isoforms have been identified: SREBP-1a and -1c (alternatively"

Phrase: "known as adipocyte determination"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0205309:Known [Qualitative Concept]
   770   C0206131:Adipocyte [Cell]
   770   C1148554:determination [Laboratory Procedure]

Phrase: "and"

Phrase: "differentiation factor-1"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   827   C0007589:Differentiation [Cell Function]
   827   C1511938:Differentiation [Clinical Attribute]
   827   C1521761:Factor [Functional Concept]
   827   C2827422:Factor [Conceptual Entity]
   827   C2945687:Differentiation [Functional Concept]
   755 E C0205615:Differentiated [Qualitative Concept]

Phrase: "; ADD-1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0945818:Add 1 [Quantitative Concept]
   861   C1883712:Add [Functional Concept]

Phrase: ")"

Phrase: "(alternatively known as adipocyte determination and differentiation factor-1; ADD-1) (Tontonoz et al.,"

Phrase: "1993"

Phrase: ")"

Phrase: "that"

Phrase: "are"

Phrase: "derived from the same gene"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0017337:Gene [Gene or Genome]
   760   C0445247:Same [Qualitative Concept]
   760   C1441547:Derived [Qualitative Concept]
   760   C3245521:derived [Idea or Concept]

Phrase: "through alternative splicing,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0002345:Alternative Splicing [Genetic Function]
   861   C0035687:Splicing [Genetic Function]
   861   C2610186:splicing [Genetic Function]

Phrase: "and"

Phrase: "SREBP-2"
Meta Candidates (Total=15; Excluded=0; Pruned=0; Remaining=15)
  1000   C0250036:Sterol Regulatory Element Binding Protein 2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
  1000   C1420399:STEROL REGULATORY ELEMENT-BINDING PROTEIN 2 [Gene or Genome]
   858   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C2246292:sterol binding [Molecular Function]
   827   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0013879:Element [Element, Ion, or Isotope]
   799   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0038323:Sterol [Steroid]
   799   C0220905:regulatory [Regulation or Law]
   799   C0243122:binding [Functional Concept]
   799   C1145667:Binding [Activity]
   799   C1167622:Binding [Molecular Function]
   799   C1704735:Regulatory [Conceptual Entity]
   799   C1705248:Element [Conceptual Entity]

Phrase: "that"

Phrase: "is"

Phrase: "encoded by a distinct gene"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0017337:Gene [Gene or Genome]
   760   C0679058:encoded [Mental Process]
   760   C2700640:Encoded [Activity]

Phrase: "(Tontonoz et al., 1993) that are derived from the same gene through alternative splicing, and SREBP-2 that is encoded by a distinct gene (Brown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0678579:Brown [Natural Phenomenon or Process]

Phrase: "and"

Phrase: "Goldstein,"

Phrase: "1997"

Phrase: ") that are derived from the same gene through alternative splicing, and SREBP-2 that is encoded by a distinct gene (Brown and Goldstein, 1997)."
Processing 00000000.tx.20: SREBPs are expressed ubiquitously, play an essential role in regulation of lipid homeostasis in animals and have been shown to directly activate the expression of more than 30 genes dedicated to the biosynthesis of cholesterol, fatty acids, triglycerides and phospholipids (Horton et al., 2002). 

Phrase: "SREBPs"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
  1000   C1566548:Sterol Regulatory Element Binding Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   875   C0815047:regulatory proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   875   C2246292:sterol binding [Molecular Function]
   840   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   840   C0242210:Binding Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0013879:Element [Element, Ion, or Isotope]
   804   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0038323:Sterol [Steroid]
   804   C0220905:regulatory [Regulation or Law]
   804   C0243122:binding [Functional Concept]
   804   C1145667:Binding [Activity]
   804   C1167622:Binding [Molecular Function]
   804   C1704735:Regulatory [Conceptual Entity]
   804   C1705248:Element [Conceptual Entity]

Phrase: "are"

Phrase: "expressed"

Phrase: "ubiquitously,"

Phrase: "play"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032214:Play [Daily or Recreational Activity]
  1000   C0600138:play [Finding]

Phrase: "an essential role in regulation of lipid homeostasis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0035820:Role [Social Behavior]
   744   C1705810:Role [Conceptual Entity]

Phrase: "in animals"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0003062:Animals [Animal]

Phrase: "and"

Phrase: "have"

Phrase: "been"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "to directly"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1883351:To [Qualitative Concept]
   861   C1947931:Directly [Qualitative Concept]

Phrase: "activate"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1515877:Activate [Functional Concept]
  1000   C1879547:Activate [Activity]

Phrase: "the expression of more"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "than 30 genes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0017337:Genes [Gene or Genome]

Phrase: "dedicated to the biosynthesis of cholesterol,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   783   C0599474:biosynthesis cholesterol [Molecular Function]
   753   C0005572:biosynthesis [Functional Concept]
   753   C0008377:Cholesterol [Biologically Active Substance,Steroid]
   753   C0220781:Biosynthesis [Biologic Function]

Phrase: "fatty acids,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0015684:Fatty Acids [Lipid]
   861   C0001128:Acids [Chemical]
   827 E C0202406:Acid [Laboratory Procedure]

Phrase: "triglycerides"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0041004:Triglycerides [Biologically Active Substance,Lipid]

Phrase: "and"

Phrase: "phospholipids"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0031676:Phospholipids [Biologically Active Substance,Lipid]
   966 E C0202177:Phospholipid [Laboratory Procedure]

Phrase: "(Brown and Goldstein, 1997). SREBPs are expressed ubiquitously, play an essential role in regulation of lipid homeostasis in animals and have been shown to directly activate the expression of more than 30 genes dedicated to the biosynthesis of cholesterol, fatty acids, triglycerides and phospholipids (Horton et al.,"

Phrase: "2002"

Phrase: "). SREBPs are expressed ubiquitously, play an essential role in regulation of lipid homeostasis in animals and have been shown to directly activate the expression of more than 30 genes dedicated to the biosynthesis of cholesterol, fatty acids, triglycerides and phospholipids (Horton et al., 2002)."
Processing 00000000.tx.21: Elevated expression of SREBP-1c has been demonstrated in islets and liver of many animal models of diabetes (Kakuma et al., 2000; Lin et al., 2000; Matsuzaka et al., 2004; Riddle et al., 2001; Shimomura et al., 1999a; Shimomura et al., 1999b; Shimomura et al., 1999c; Shimomura et al., 2000; Sun et al., 2002; Takaishi et al., 2004; Tobe et al., 2001; Ueki et al., 2004; Unger and Zhou, 2001; Unger et al., 1999; Werstuck et al., 2001; Xu et al., 2004; Yahagi et al., 2002; You et al., 2002) and patients with severe lipodystrophy (Bastard et al., 2002; Petersen et al., 2002). 

Phrase: "Elevated expression of SREBP-1c"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   762   C1171362:expression protein [Genetic Function]
   742   C0185117:Expression [Therapeutic or Preventive Procedure]
   716   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "has"

Phrase: "been"

Phrase: "demonstrated in islets"

Phrase: "and"

Phrase: "liver of many animal models of diabetes"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0023884:Liver [Body Part, Organ, or Organ Component]
   748   C0736268:LIVER [Body Part, Organ, or Organ Component]
   748   C1278929:Liver [Body Part, Organ, or Organ Component]
   748   C2346688:LIVER [Food]

Phrase: "(Horton et al., 2002). Elevated expression of SREBP-1c has been demonstrated in islets and liver of many animal models of diabetes (Kakuma et al.,"

Phrase: "2000"

Phrase: "; Lin et al.,"

Phrase: "2000"

Phrase: "; Matsuzaka et al.,"

Phrase: "2004"

Phrase: "; Riddle et al.,"

Phrase: "2001"

Phrase: "; Shimomura et al.,"

Phrase: "1999a"

Phrase: "; Shimomura et al.,"

Phrase: "1999b"

Phrase: "; Shimomura et al.,"

Phrase: "1999c"

Phrase: "; Shimomura et al.,"

Phrase: "2000"

Phrase: "; Sun et al.,"

Phrase: "2002"

Phrase: "; Takaishi et al.,"

Phrase: "2004"

Phrase: "; Tobe et al.,"

Phrase: "2001"

Phrase: "; Ueki et al.,"

Phrase: "2004"

Phrase: "; Unger"

Phrase: "and"

Phrase: "Zhou,"

Phrase: "2001"

Phrase: "; Unger et al.,"

Phrase: "1999"

Phrase: "; Werstuck et al.,"

Phrase: "2001"

Phrase: "; Xu et al.,"

Phrase: "2004"

Phrase: "; Yahagi et al.,"

Phrase: "2002"

Phrase: ";"

Phrase: "You et al.,"

Phrase: "2002"

Phrase: ")"

Phrase: "and"

Phrase: "patients with severe lipodystrophy"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0030705:Patients [Patient or Disabled Group]

Phrase: "(Kakuma et al., 2000; Lin et al., 2000; Matsuzaka et al., 2004; Riddle et al., 2001; Shimomura et al., 1999a; Shimomura et al., 1999b; Shimomura et al., 1999c; Shimomura et al., 2000; Sun et al., 2002; Takaishi et al., 2004; Tobe et al., 2001; Ueki et al., 2004; Unger and Zhou, 2001; Unger et al., 1999; Werstuck et al., 2001; Xu et al., 2004; Yahagi et al., 2002; You et al., 2002) and patients with severe lipodystrophy (Bastard et al.,"

Phrase: "2002"

Phrase: "; Petersen et al.,"

Phrase: "2002"

Phrase: ") and patients with severe lipodystrophy (Bastard et al., 2002; Petersen et al., 2002)."
Processing 00000000.tx.22: Lipid accumulation, impaired glucose-stimulated insulin secretion, defective -cell gene expression (insulin, Pdx1, glucokinase and Glut2), disorganized mitochondrial ultrastructure and `lipoapoptosis' have been reported in the  cells of diabetic animals (Unger and Zhou, 2001; Unger et al., 1999). 

Phrase: "Lipid accumulation,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0333574:Lipid accumulation [Finding]

Phrase: "impaired glucose-stimulated insulin secretion,"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   853   C1719133:Glucose/Insulin [Quantitative Concept]
   840   C1256369:insulin secretion [Cell Function]
   804   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   804   C0036536:secretion [Biologic Function]
   804   C0036537:Secretion [Body Substance]
   804   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   804   C1579433:Insulin [Pharmacologic Substance]
   748 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   721 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "defective -cell gene expression"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0017262:Gene Expression [Genetic Function]
   861   C1861886:CELL Gene [Gene or Genome]
   812   C0017337:Gene [Gene or Genome]
   812   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "(Bastard et al., 2002; Petersen et al., 2002). Lipid accumulation, impaired glucose-stimulated insulin secretion, defective -cell gene expression (insulin,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1579433:Insulin [Pharmacologic Substance]
   944 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   916 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "Pdx1,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1427500:PDX1 [Gene or Genome]
  1000   C1826562:PDX1 [Gene or Genome]

Phrase: "glucokinase"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0017713:Glucokinase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1415014:GLUCOKINASE [Gene or Genome]

Phrase: "and"

Phrase: "Glut2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1420172:GLUT2 [Gene or Genome]

Phrase: ")"

Phrase: ","

Phrase: "disorganized mitochondrial ultrastructure"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0041623:Ultrastructure [Idea or Concept]

Phrase: "and `"

Phrase: "lipoapoptosis'"

Phrase: "have"

Phrase: "been"

Phrase: "reported in the  cells of diabetic animals"
Meta Candidates (Total=11; Excluded=4; Pruned=0; Remaining=7)
   748   C0003062:Animals [Animal]
   748   C0007634:Cells [Cell]
   748   C0241863:DIABETIC [Finding]
   748   C0684224:Reported [Intellectual Product]
   748   C0700287:Reported [Health Care Activity]
   748   C3282337:Cells [Cell]
   748   C3496591:Reported [Clinical Attribute]
   714 E C1269647:Cell [Cell]
   714 E C1704653:Cell [Medical Device]
   714 E C1948049:Cell [Spatial Concept]
   714 E C3273238:Report [Intellectual Product]

Phrase: "(insulin, Pdx1, glucokinase and Glut2), disorganized mitochondrial ultrastructure and `lipoapoptosis' have been reported in the  cells of diabetic animals (Unger"

Phrase: "and"

Phrase: "Zhou,"

Phrase: "2001"

Phrase: "; Unger et al.,"

Phrase: "1999"

Phrase: "), disorganized mitochondrial ultrastructure and `lipoapoptosis' have been reported in the  cells of diabetic animals (Unger and Zhou, 2001; Unger et al., 1999)."
Processing 00000000.tx.23: Moreover, preventing SREBP-1c overexpression and activation is common to leptin, metformin, adiponectin and PPAR agonists. 

Phrase: "Moreover,"

Phrase: "preventing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0309872:PREVENT [Pharmacologic Substance]

Phrase: "SREBP-1c overexpression"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   829   C1514559:Protein Overexpression [Genetic Function]
           Overexpression
   787   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "and"

Phrase: "activation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1879547:Activation [Activity]

Phrase: "is"

Phrase: "common to leptin,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0205214:Common [Quantitative Concept]
   790   C1522138:Common [Functional Concept]
   790   C3245511:common [Intellectual Product]

Phrase: "metformin,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025598:Metformin [Organic Chemical,Pharmacologic Substance]

Phrase: "adiponectin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0389071:Adiponectin [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "and"

Phrase: "PPAR agonists."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   804   C0243192:agonists [Pharmacologic Substance]
   804   C2987634:agonists [Pharmacologic Substance]
   771   C0166418:Peroxisome Proliferator-Activated Receptors [Amino Acid, Peptide, or Protein,Receptor]
   759 E C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
Processing 00000000.tx.24: Thus there is a good correlation between suppression of SREBP-1c function and antidiabetic effects of these agents (Kakuma et al., 2000; Lin et al., 2000; Petersen et al., 2002; Shimomura et al., 1999a; Shimomura et al., 1999b; Shimomura et al., 1999c; Tobe et al., 2001; Unger and Zhou, 2001; Unger et al., 1999; Wang, M. Y. et al., 1998; Xu et al., 2004; Zhou et al., 2001). 

Phrase: "Thus there"

Phrase: "is"

Phrase: "a good correlation between suppression"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1707520:Correlation [Qualitative Concept]

Phrase: "of SREBP-1c function"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   829   C0815043:protein function [Amino Acid, Peptide, or Protein]
   829   C1527118:Protein Function [Molecular Function]
   795   C0031843:function [Physiologic Function]
   795   C0542341:Function [Functional Concept]
   795   C0700205:FUNCTION [Classification]
   795   C1705273:Function [Intellectual Product]
   787   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   724 E C0205245:Functional [Functional Concept]
   724 E C2700217:Functional [Conceptual Entity]

Phrase: "and"

Phrase: "antidiabetic effects of these agents"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C1280500:effects [Qualitative Concept]
   726 E C2348382:Effect [Qualitative Concept]

Phrase: "(Unger and Zhou, 2001; Unger et al., 1999). Moreover, preventing SREBP-1c overexpression and activation is common to leptin, metformin, adiponectin and PPAR agonists. Thus there is a good correlation between suppression of SREBP-1c function and antidiabetic effects of these agents (Kakuma et al.,"

Phrase: "2000"

Phrase: "; Lin et al.,"

Phrase: "2000"

Phrase: "; Petersen et al.,"

Phrase: "2002"

Phrase: "; Shimomura et al.,"

Phrase: "1999a"

Phrase: "; Shimomura et al.,"

Phrase: "1999b"

Phrase: "; Shimomura et al.,"

Phrase: "1999c"

Phrase: "; Tobe et al.,"

Phrase: "2001"

Phrase: "; Unger"

Phrase: "and"

Phrase: "Zhou,"

Phrase: "2001"

Phrase: "; Unger et al.,"

Phrase: "1999"

Phrase: "; Wang,"

Phrase: "M. Y. et al.,"

Phrase: "1998"

Phrase: "; Xu et al.,"

Phrase: "2004"

Phrase: "; Zhou et al.,"

Phrase: "2001"

Phrase: "). Moreover, preventing SREBP-1c overexpression and activation is common to leptin, metformin, adiponectin and PPAR agonists. Thus there is a good correlation between suppression of SREBP-1c function and antidiabetic effects of these agents (Kakuma et al., 2000; Lin et al., 2000; Petersen et al., 2002; Shimomura et al., 1999a; Shimomura et al., 1999b; Shimomura et al., 1999c; Tobe et al., 2001; Unger and Zhou, 2001; Unger et al., 1999; Wang, M. Y. et al., 1998; Xu et al., 2004; Zhou et al., 2001)."
Processing 00000000.tx.25: We and others have demonstrated that overexpression of a nuclear active form of SREBP-1c (naSREBP-1c) in insulinoma (INS-1 and MIN6) cells and isolated rat islets results in -cell lipotoxicity (Andreolas et al., 2002; Diraison et al., 2004; Wang et al., 2003; Yamashita et al., 2004). 

Phrase: "We"

Phrase: "and"

Phrase: "others"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1955473:Others [Finding]
   966 E C0205394:Other [Qualitative Concept]

Phrase: "have"

Phrase: "demonstrated"

Phrase: "that overexpression of a nuclear active form"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1514559:Overexpression [Genetic Function]

Phrase: "of SREBP-1c"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
  1000   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C2246292:sterol binding [Molecular Function]
   827   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0013879:Element [Element, Ion, or Isotope]
   799   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0038323:Sterol [Steroid]
   799   C0220905:regulatory [Regulation or Law]
   799   C0243122:binding [Functional Concept]
   799   C1145667:Binding [Activity]
   799   C1167622:Binding [Molecular Function]
   799   C1704735:Regulatory [Conceptual Entity]
   799   C1705248:Element [Conceptual Entity]

Phrase: "(Kakuma et al., 2000; Lin et al., 2000; Petersen et al., 2002; Shimomura et al., 1999a; Shimomura et al., 1999b; Shimomura et al., 1999c; Tobe et al., 2001; Unger and Zhou, 2001; Unger et al., 1999; Wang, M. Y. et al., 1998; Xu et al., 2004; Zhou et al., 2001). We and others have demonstrated that overexpression of a nuclear active form of SREBP-1c (naSREBP-1c"

Phrase: ")"

Phrase: "in insulinoma"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0021670:insulinoma [Neoplastic Process]

Phrase: "("

Phrase: "INS-1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: "and"

Phrase: "MIN6"

Phrase: ")"

Phrase: "cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "and"

Phrase: "isolated rat islets"

Phrase: "results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1274040:Result [Functional Concept]
  1000   C1546471:Result [Idea or Concept]
  1000   C2825142:Result [Finding]

Phrase: "in -cell lipotoxicity"

Phrase: "(INS-1 and MIN6) cells and isolated rat islets results in -cell lipotoxicity (Andreolas et al.,"

Phrase: "2002"

Phrase: "; Diraison et al.,"

Phrase: "2004"

Phrase: "; Wang et al.,"

Phrase: "2003"

Phrase: "; Yamashita et al.,"

Phrase: "2004"

Phrase: ") cells and isolated rat islets results in -cell lipotoxicity (Andreolas et al., 2002; Diraison et al., 2004; Wang et al., 2003; Yamashita et al., 2004)."
Processing 00000000.tx.26: We have previously shown that long-term exposure of INS-1 cells to 30 mM glucose generated the mature nuclear form of SREBP-1c (Wang et al., 2003). 

Phrase: "We"

Phrase: "have"

Phrase: "previously"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "that long-term exposure of"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0274281:Exposure, NOS [Injury or Poisoning]
   760   C0332157:Exposure [Clinical Attribute]

Phrase: "INS-1 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "to 30 mM glucose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "generated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3146294:Generated [Activity]

Phrase: "the mature nuclear form of SREBP-1c"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   738   C0348078:Form [Qualitative Concept]
   738   C0376315:Form [Manufactured Object]
   738   C1522492:Form [Functional Concept]

Phrase: "(Andreolas et al., 2002; Diraison et al., 2004; Wang et al., 2003; Yamashita et al., 2004). We have previously shown that long-term exposure of INS-1 cells to 30 mM glucose generated the mature nuclear form of SREBP-1c (Wang et al.,"

Phrase: "2003"

Phrase: "). We have previously shown that long-term exposure of INS-1 cells to 30 mM glucose generated the mature nuclear form of SREBP-1c (Wang et al., 2003)."
Processing 00000000.tx.27: Glucose also raises SREBP-1c mRNA levels in rat  cells (Flamez et al., 2002). 

Phrase: "Glucose also"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "raises"

Phrase: "SREBP-1c mRNA levels in rat  cells"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   754   C1148853:mRNA binding [Genetic Function]
   738   C0035696:mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   738   C0441889:Levels [Qualitative Concept]
   737   C0428479:Protein level [Laboratory or Test Result]
   704 E C0456079:Level [Classification]
   704 E C1547707:Level [Geographic Area]
   704 E C2946261:Level [Pharmacologic Substance]

Phrase: "(Wang et al., 2003). Glucose also raises SREBP-1c mRNA levels in rat  cells (Flamez et al.,"

Phrase: "2002"

Phrase: "). Glucose also raises SREBP-1c mRNA levels in rat  cells (Flamez et al., 2002)."
Processing 00000000.tx.28: It is well known that chronic high glucose treatment causes glucolipotoxicity in both insulinoma cells and rat islets (Efanova et al., 1998; Roche et al., 1998). 

Phrase: "It"

Phrase: "is"

Phrase: "well known"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205170:Well [Qualitative Concept]
   861   C0205309:Known [Qualitative Concept]
   861   C3146287:Well [Manufactured Object]

Phrase: "that chronic high glucose treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   812   C0039798:treatment [Functional Concept]
   812   C0087111:Treatment [Therapeutic or Preventive Procedure]
   812   C1522326:Treatment [Functional Concept]
   812   C1533734:Treatment [Therapeutic or Preventive Procedure]
   812   C1705169:Treatment [Conceptual Entity]
   812   C3538994:TREATMENT [Research Activity]

Phrase: "causes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0015127:cause [Functional Concept]
  1000   C1314792:Causes [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]

Phrase: "glucolipotoxicity in both insulinoma cells"

Phrase: "and"

Phrase: "rat islets"

Phrase: "(Flamez et al., 2002). It is well known that chronic high glucose treatment causes glucolipotoxicity in both insulinoma cells and rat islets (Efanova et al.,"

Phrase: "1998"

Phrase: "; Roche et al.,"

Phrase: "1998"

Phrase: "). It is well known that chronic high glucose treatment causes glucolipotoxicity in both insulinoma cells and rat islets (Efanova et al., 1998; Roche et al., 1998)."
Processing 00000000.tx.29: We hypothesise that SREBP-1c activation could play an essential role in development of -cell glucolipotoxicity. 

Phrase: "We"

Phrase: "hypothesise"

Phrase: "that SREBP-1c activation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   829   C0599177:protein activation [Genetic Function]
   795   C1879547:Activation [Activity]
   787   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "could"

Phrase: "play"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032214:Play [Daily or Recreational Activity]
  1000   C0600138:play [Finding]

Phrase: "an essential role in development of -cell glucolipotoxicity."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0035820:Role [Social Behavior]
   744   C1705810:Role [Conceptual Entity]
Processing 00000000.tx.30: To further substantiate this notion we established an INS-1 stable cell line that allowed suppression of SREBP-1c function through induction of a dominant-negative mutant of SREBP-1c (DN-SREBP-1c) (Kim and Spiegelman, 1996). 

Phrase: "To further"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C1517331:Further [Spatial Concept]
   861   C1883351:To [Qualitative Concept]
   827 E C0205108:far [Spatial Concept]

Phrase: "substantiate"

Phrase: "this notion"

Phrase: "we"

Phrase: "established"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0443211:Established [Qualitative Concept]
  1000   C1272684:Established [Qualitative Concept]

Phrase: "an INS-1 stable cell line"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
   833   C0598091:stable cell line [Cell]
   790   C0007600:Cell Line [Cell]
   790   C1414685:INS-1 [Gene or Genome]
   790   C3538717:INS-1 [Gene or Genome]
   783   C0950951:AN 1 [Organic Chemical,Pharmacologic Substance]
   753   C0007634:Cell [Cell]
   753   C0205132:Line [Spatial Concept]
   753   C0205360:Stable [Qualitative Concept]
   753   C1269647:Cell [Cell]
   753   C1547311:Stable [Intellectual Product]
   753   C1550648:Line [Substance]
   753   C1552960:Line [Quantitative Concept]
   753   C1704653:Cell [Medical Device]
   753   C1948049:Cell [Spatial Concept]

Phrase: "that allowed suppression of SREBP-1c function"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   738   C0221103:Suppression [Pathologic Function]
   738   C0301625:Suppression [Organism Function]
   738   C0439181:% suppression [Quantitative Concept]
   738   C0728721:suppression [Mental Process]

Phrase: "through induction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205263:Induction [Functional Concept]
  1000   C0857127:induction [Therapeutic or Preventive Procedure]

Phrase: "of a dominant-negative mutant"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
           Dominant Negative
   827   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: "of SREBP-1c (DN-SREBP-1c)"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
  1000   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C2246292:sterol binding [Molecular Function]
   827   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0013879:Element [Element, Ion, or Isotope]
   799   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0038323:Sterol [Steroid]
   799   C0220905:regulatory [Regulation or Law]
   799   C0243122:binding [Functional Concept]
   799   C1145667:Binding [Activity]
   799   C1167622:Binding [Molecular Function]
   799   C1704735:Regulatory [Conceptual Entity]
   799   C1705248:Element [Conceptual Entity]

Phrase: "(Efanova et al., 1998; Roche et al., 1998). We hypothesise that SREBP-1c activation could play an essential role in development of -cell glucolipotoxicity. To further substantiate this notion we established an INS-1 stable cell line that allowed suppression of SREBP-1c function through induction of a dominant-negative mutant of SREBP-1c (DN-SREBP-1c) (Kim"

Phrase: "and"

Phrase: "Spiegelman,"

Phrase: "1996"

Phrase: "). We hypothesise that SREBP-1c activation could play an essential role in development of -cell glucolipotoxicity. To further substantiate this notion we established an INS-1 stable cell line that allowed suppression of SREBP-1c function through induction of a dominant-negative mutant of SREBP-1c (DN-SREBP-1c) (Kim and Spiegelman, 1996)."
Processing 00000000.tx.31: Strong experimental evidence demonstrated that dominant-negative suppression of SREBP-1c activity markedly prevented -cell glucolipotoxicity. 

Phrase: "Strong experimental evidence"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0332120:Evidence [Functional Concept]

Phrase: "demonstrated"

Phrase: "that dominant-negative suppression"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   827   C0221103:Suppression [Pathologic Function]
   827   C0301625:Suppression [Organism Function]
   827   C0439181:% suppression [Quantitative Concept]
   827   C0728721:suppression [Mental Process]
   734   C1512032:Dominant Negative [Cell or Molecular Dysfunction]

Phrase: "of SREBP-1c activity markedly"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   836   C2266866:Binding Activity [Molecular Function]
   822   C1537044:protein activity [Molecular Function]
   793   C0205177:Activity [Functional Concept]
   793   C0439167:% activity [Quantitative Concept]
   793   C0441655:Activity [Activity]
   793   C1561536:*Activity [Idea or Concept]
   756   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "prevented -"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0309872:PREVENT [Pharmacologic Substance]

Phrase: "cell glucolipotoxicity."
Processing 00000000.tx.32: In addition, we found that ER-stress-generated SREBP-1c processing and activation could be the underlying mechanism in -cell glucolipotoxicity.  

Phrase: "In addition,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1883712:Addition [Functional Concept]
   928 E C1524062:Additional [Functional Concept]

Phrase: "we"

Phrase: "found"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0150312:Found [Quantitative Concept]
   966 E C0243095:Find [Finding]

Phrase: "that ER-stress-generated SREBP-1c processing"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   809   C0033666:protein processing [Molecular Function]
   788   C1709694:Processing [Activity]
   704   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "and"

Phrase: "activation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1879547:Activation [Activity]

Phrase: "could"

Phrase: "be"

Phrase: "the underlying mechanism in -cell glucolipotoxicity."
Processing 00000000.tx.33: Materials and Methods Top Summary Introduction Materials and Methods Results Discussion References  Cell culture The standard rat insulinoma INS-1E cells and two previously established INS-1-derived stable cell lines, ChREBP*16 (Wang and Wollheim, 2002) and naSREBP-1c*233 (Wang et al., 2003), allowing inducible expression, respectively, of ChREBP and a nuclear active form of SREBP-1c, were cultured in RPMI1640 containing 11.2 mM glucose (Asfari et al., 1992), unless otherwise indicated. 

Phrase: "Materials"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0520510:Materials [Substance]

Phrase: "and"

Phrase: "Methods Top Summary Introduction Materials"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0520510:Materials [Substance]

Phrase: "and"

Phrase: "Methods Results Discussion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "References"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Cell culture"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C0007585:Cell Culture [Laboratory Procedure]
   861   C0007634:Cell [Cell]
   861   C0010453:Culture [Idea or Concept]
   861   C0220814:culture [Functional Concept]
   861   C0430400:Culture [Laboratory Procedure]
   861   C1269647:Cell [Cell]
   861   C1704653:Cell [Medical Device]
   861   C1948049:Cell [Spatial Concept]
   861   C2242979:Culture [Laboratory Procedure]

Phrase: "The standard rat insulinoma INS-1E cells"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0021670:insulinoma [Neoplastic Process]

Phrase: "and"

Phrase: "two previously established INS-1-derived stable cell lines,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   767   C0598089:established cell line [Cell]
   742   C0443211:Established [Qualitative Concept]
   742   C1272684:Established [Qualitative Concept]

Phrase: "ChREBP"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C1826259:carbohydrate response element binding protein [Gene or Genome]
   937   C3158709:carbohydrate response element binding [Genetic Function]
   911   C0108401:carbohydrate-binding protein [Amino Acid, Peptide, or Protein,Receptor]
   875   C1148582:carbohydrate binding [Molecular Function]
   840   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0243122:binding [Functional Concept]
   804   C1145667:Binding [Activity]
   804   C1167622:Binding [Molecular Function]

Phrase: "*16"

Phrase: "(Kim and Spiegelman, 1996). Strong experimental evidence demonstrated that dominant-negative suppression of SREBP-1c activity markedly prevented -cell glucolipotoxicity. In addition, we found that ER-stress-generated SREBP-1c processing and activation could be the underlying mechanism in -cell glucolipotoxicity.  Materials and Methods Top Summary Introduction Materials and Methods Results Discussion References  Cell culture The standard rat insulinoma INS-1E cells and two previously established INS-1-derived stable cell lines, ChREBP*16 (Wang"

Phrase: "and"

Phrase: "Wollheim,"

Phrase: "2002"

Phrase: ")"

Phrase: "and"

Phrase: "naSREBP-1c"

Phrase: "*233"

Phrase: "(Wang and Wollheim, 2002) and naSREBP-1c*233 (Wang et al.,"

Phrase: "2003"

Phrase: ")"

Phrase: ","

Phrase: "allowing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0683607:allowing [Social Behavior]

Phrase: "inducible expression,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "respectively,"

Phrase: "of ChREBP"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C1826259:carbohydrate response element binding protein [Gene or Genome]
   937   C3158709:carbohydrate response element binding [Genetic Function]
   911   C0108401:carbohydrate-binding protein [Amino Acid, Peptide, or Protein,Receptor]
   875   C1148582:carbohydrate binding [Molecular Function]
   840   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0243122:binding [Functional Concept]
   804   C1145667:Binding [Activity]
   804   C1167622:Binding [Molecular Function]

Phrase: "and"

Phrase: "a nuclear active form of SREBP-1c,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   738   C0348078:Form [Qualitative Concept]
   738   C0376315:Form [Manufactured Object]
   738   C1522492:Form [Functional Concept]

Phrase: "were"

Phrase: "cultured in RPMI1640"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   756   C0010453:Culture [Idea or Concept]
   756   C0220814:culture [Functional Concept]
   756   C0430400:Culture [Laboratory Procedure]
   756   C2242979:Culture [Laboratory Procedure]

Phrase: "containing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:Containing [Functional Concept]
  1000   C2700400:Containing [Activity]

Phrase: "11.2 mM glucose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "(Wang et al., 2003), allowing inducible expression, respectively, of ChREBP and a nuclear active form of SREBP-1c, were cultured in RPMI1640 containing 11.2 mM glucose (Asfari et al.,"

Phrase: "1992"

Phrase: ")"

Phrase: ","

Phrase: "unless"

Phrase: "otherwise"

Phrase: "indicated."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1444656:Indicated [Finding]
Processing 00000000.tx.34: Establishment of INS-1 cells permitting inducible expression of DN-SREBP-1c The first step stable INS-r (also refer to as r9) cell line, which carries the reverse tetracycline/doxycycline-dependent transactivator (Gossen et al., 1995), was described previously (Wang and Iynedjian, 1997; Wang et al., 2001). 

Phrase: "Establishment of"

Phrase: "INS-1 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "permitting"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0023636:Permit [Regulation or Law]
   966   C0329040:Permit [Fish]

Phrase: "inducible expression of DN-SREBP-1c"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "The first"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205435:First [Quantitative Concept]
  1000   C1279901:First [Qualitative Concept]

Phrase: "step"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C1261552:Step [Conceptual Entity]
  1000   C1704379:Step [Functional Concept]
  1000   C1705117:Step [Quantitative Concept]
  1000   C2825408:Step [Manufactured Object]

Phrase: "stable INS-r (also"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0205360:Stable [Qualitative Concept]
   770   C1547311:Stable [Intellectual Product]

Phrase: "refer"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205543:refer [Functional Concept]

Phrase: "to as r9"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1883351:To [Qualitative Concept]

Phrase: ")"

Phrase: "cell line,"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
  1000   C0007600:Cell Line [Cell]
   861   C0007634:Cell [Cell]
   861   C0205132:Line [Spatial Concept]
   861   C1269647:Cell [Cell]
   861   C1550648:Line [Substance]
   861   C1552960:Line [Quantitative Concept]
   861   C1704653:Cell [Medical Device]
   861   C1948049:Cell [Spatial Concept]

Phrase: "which"

Phrase: "carries"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0206243:Carry [Activity]
  1000   C0699809:Carries [Finding]

Phrase: "the reverse tetracycline/doxycycline-dependent transactivator"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0040627:Trans-Activator [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "(Asfari et al., 1992), unless otherwise indicated. Establishment of INS-1 cells permitting inducible expression of DN-SREBP-1c The first step stable INS-r (also refer to as r9) cell line, which carries the reverse tetracycline/doxycycline-dependent transactivator (Gossen et al.,"

Phrase: "1995"

Phrase: ")"

Phrase: ","

Phrase: "was"

Phrase: "described"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]

Phrase: "previously"

Phrase: "(Gossen et al., 1995), was described previously (Wang"

Phrase: "and"

Phrase: "Iynedjian,"

Phrase: "1997"

Phrase: "; Wang et al.,"

Phrase: "2001"

Phrase: "), was described previously (Wang and Iynedjian, 1997; Wang et al., 2001)."
Processing 00000000.tx.35: The plasmid used in the secondary stable transfection was constructed by subcloning the cDNA encoding the dominant-negative form of SREBP-1c (DN-SREBP-1c/ADD1 1-403(Y320A) [(Kim and Spiegelman, 1996) kindly supplied by B.M. Spiegelman] into the expression vector PUHD10-3 [(Gossen et al., 1995) a generous gift from H. Bujard]. 

Phrase: "The plasmid"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0032136:Plasmid [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "used in the secondary stable transfection"
Meta Candidates (Total=10; Excluded=3; Pruned=0; Remaining=7)
   753   C0027627:secondary [Neoplastic Process]
   753   C0040669:Transfection [Genetic Function,Molecular Biology Research Technique]
   753   C0175668:Secondary [Temporal Concept]
   753   C0205360:Stable [Qualitative Concept]
   753   C0205436:Secondary [Quantitative Concept]
   753   C1273517:used [Finding]
   753   C1547311:Stable [Intellectual Product]
   719 E C0042153:use [Functional Concept]
   719 E C0457083:Use [Functional Concept]
   719 E C1947944:Use [Intellectual Product]

Phrase: "was"

Phrase: "constructed by subcloning"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   756   C2827421:Construct [Classification]

Phrase: "the cDNA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0006556:cDNA [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "encoding"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1547699:Encoding [Idea or Concept]
  1000   C2700640:Encoding [Activity]

Phrase: "the dominant-negative form of SREBP-1c"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   813   C1420310:negative regulatory element-binding protein [Gene or Genome]
   756   C1512032:Dominant Negative [Cell or Molecular Dysfunction]
   738   C0205160:Negative [Qualitative Concept]
   738   C0348078:Form [Qualitative Concept]
   738   C0376315:Form [Manufactured Object]
   738   C1513916:Negative [Finding]
   738   C1522492:Form [Functional Concept]
   738   C1527180:Dominant [Functional Concept]
   738   C2825415:Negative [Conceptual Entity]
   738   C2825491:Negative [Qualitative Concept]

Phrase: "(Wang and Iynedjian, 1997; Wang et al., 2001). The plasmid used in the secondary stable transfection was constructed by subcloning the cDNA encoding the dominant-negative form of SREBP-1c (DN-SREBP-1c/ADD1 1-403"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
   742   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: "(DN-SREBP-1c/ADD1 1-403(Y320A"

Phrase: ")"

Phrase: "["

Phrase: "(Y320A) [(Kim"

Phrase: "and"

Phrase: "Spiegelman,"

Phrase: "1996"

Phrase: ")"

Phrase: "kindly"

Phrase: "supplied by B.M. Spiegelman"
Meta Candidates (Total=8; Excluded=5; Pruned=0; Remaining=3)
   760   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   760   C0441923:M+ [Intellectual Product]
   760   C1999230:Supplied [Activity]
   726 E C0243163:supply [Idea or Concept]
   726 E C0699914:supply [Quantitative Concept]
   726 E C1314650:SUPPLY, NOT OTHERWISE SPECIFIED [Medical Device]
   726 E C1561604:supply [Functional Concept]
   726 E C1875802:SUPPLY [Medical Device]

Phrase: "]"

Phrase: "into the expression vector PUHD10-3"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C0599566:expression vector [Nucleic Acid, Nucleoside, or Nucleotide]
   812   C0086022:Vector [Nucleic Acid, Nucleoside, or Nucleotide]
   812   C0185117:Expression [Therapeutic or Preventive Procedure]
   812   C0442335:Vector [Spatial Concept]
   812   C1705099:Vector [Idea or Concept]

Phrase: "["

Phrase: "(Kim and Spiegelman, 1996) kindly supplied by B.M. Spiegelman] into the expression vector PUHD10-3 [(Gossen et al.,"

Phrase: "1995"

Phrase: ")"

Phrase: "a generous gift from H. Bujard"

Phrase: "]."
Processing 00000000.tx.36: The procedures for stable transfection, clone selection and screening were described previously (Wang and Iynedjian, 1997). 

Phrase: "The procedures for stable transfection,"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
   760   C0025664:procedures [Intellectual Product]
   760   C0184661:Procedures [Diagnostic Procedure,Therapeutic or Preventive Procedure]
   760   C2700391:procedures [Activity]
   726 E C1948041:Procedure [Therapeutic or Preventive Procedure]
   726 E C3274430:PROCEDURE [Health Care Activity]
   726 E C3538935:Procedure [Idea or Concept]
   726 E C3539779:Procedure [Intellectual Product]

Phrase: "clone selection"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0036576:selection [Genetic Function]

Phrase: "and"

Phrase: "screening"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0220908:Screening [Health Care Activity]
  1000   C0220909:screening [Functional Concept]
  1000   C1698960:screening [Intellectual Product]
  1000   C1710031:Screening [Diagnostic Procedure]
  1000   C1710477:SCREENING [Research Activity]

Phrase: "were"

Phrase: "described"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]

Phrase: "previously"

Phrase: "(Gossen et al., 1995) a generous gift from H. Bujard]. The procedures for stable transfection, clone selection and screening were described previously (Wang"

Phrase: "and"

Phrase: "Iynedjian,"

Phrase: "1997"

Phrase: ") a generous gift from H. Bujard]. The procedures for stable transfection, clone selection and screening were described previously (Wang and Iynedjian, 1997)."
Processing 00000000.tx.37: Immunofluorescence Cells grown on polyornithine-treated glass coverslips were treated for 24 hours with or without 500 ng/ml doxycycline. 

Phrase: "Immunofluorescence Cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "grown on polyornithine-treated glass coverslips"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   753   C0017596:Glass [Manufactured Object]
   753   C0071632:polyornithine [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]
   753   C0332293:treated [Therapeutic or Preventive Procedure]
   753   C1522326:Treated [Functional Concept]
   753   C1947936:Glass [Medical Device]
   719 E C1292734:TREAT [Functional Concept]

Phrase: "were"

Phrase: "treated for 24 hours"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   833   C0439584:24 hours [Temporal Concept]
   833   C0456696:/24 hours [Temporal Concept]
   833   C1442770:24 Hours [Temporal Concept]
   770   C0332293:treated [Therapeutic or Preventive Procedure]
   770   C0439227:hours [Temporal Concept]
   770   C1522326:Treated [Functional Concept]
   737 E C0564385:/hour [Quantitative Concept]
   737 E C1292734:TREAT [Functional Concept]

Phrase: "with"

Phrase: "or without 500 ng/ml doxycycline."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0439275:ng/mL [Quantitative Concept]
   753   C0013090:Doxycycline [Antibiotic,Organic Chemical]
   753   C0439526:/mL [Quantitative Concept]
Processing 00000000.tx.38: Cells were then washed, fixed in 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 in phosphate-buffered saline containing 1% BSA (PBS-BSA). 

Phrase: "Cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "then"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883708:Then [Temporal Concept]

Phrase: "washed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1548982:Washed [Idea or Concept]
   966 E C0441648:Wash [Activity]

Phrase: ","

Phrase: "fixed in 4% paraformaldehyde,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0070066:Paraformaldehyde [Biomedical or Dental Material,Organic Chemical,Pharmacologic Substance]
   770   C0231441:Fixed [Finding]
   770   C0443218:Fixed [Qualitative Concept]
   770   C2827483:Fixed [Body Substance]

Phrase: "permeabilized with 0.1% Triton X-100"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   814   C0146951:Triton X-100 [Biomedical or Dental Material,Organic Chemical,Pharmacologic Substance]
   778   C0133689:Triton X [Organic Chemical,Pharmacologic Substance]
   748   C0242759:Triton [Geographic Area]

Phrase: "in phosphate-buffered saline containing 1% BSA (PBS-BSA)."
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   801   C0991865:Phosphate Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   795   C0006353:Buffered [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   795   C0031603:Phosphate [Inorganic Chemical,Pharmacologic Substance]
   795   C0031701:phosphate [Organophosphorus Compound]
   795   C0036082:Saline [Substance]
   795   C0150312:In [Quantitative Concept]
   795   C0332256:Containing [Functional Concept]
   795   C0332285:In [Spatial Concept]
   795   C1601799:PHOSPHATE [Inorganic Chemical,Pharmacologic Substance]
   795   C2700400:Containing [Activity]
Processing 00000000.tx.39: The preparation was then blocked with PBS-BSA before incubating with the first antibody, anti-SREBP-1 (Santa Cruz, Basel, Switzerland; 

Phrase: "The preparation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0455052:Preparation [Health Care Activity]
  1000   C1521827:Preparation [Functional Concept]

Phrase: "was"

Phrase: "then"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883708:Then [Temporal Concept]

Phrase: "blocked with PBS-BSA"
Meta Candidates (Total=14; Excluded=3; Pruned=0; Remaining=11)
   767   C0991865:buffered phosphate [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   744   C0006353:Buffered [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   744   C0028778:Blocked [Pathologic Function]
   744   C0031603:Phosphate [Inorganic Chemical,Pharmacologic Substance]
   744   C0031701:phosphate [Organophosphorus Compound]
   744   C0036082:Saline [Substance]
   744   C0332206:Blocked [Functional Concept]
   744   C0332256:Containing [Functional Concept]
   744   C1601799:PHOSPHATE [Inorganic Chemical,Pharmacologic Substance]
   744   C2700400:Containing [Activity]
   744   C2983591:BLOCKED [Research Activity]
   711 E C1533157:Block [Substance]
   711 E C1706084:Block [Geographic Area]
   711 E C2828370:Block [Quantitative Concept]

Phrase: "before incubating"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1439852:incubating [Laboratory Procedure]

Phrase: "with the first antibody,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   861   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "anti-SREBP-1"
Meta Candidates (Total=17; Excluded=0; Pruned=0; Remaining=17)
   954   C0217529:Sterol Regulatory Element Binding Protein 1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   954   C1420398:STEROL REGULATORY ELEMENT-BINDING PROTEIN 1 [Gene or Genome]
   845   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   845   C2246292:sterol binding [Molecular Function]
   818   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   818   C0087044:protein i [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   818   C0103404:Protein I [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   818   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   795   C0013879:Element [Element, Ion, or Isotope]
   795   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   795   C0038323:Sterol [Steroid]
   795   C0220905:regulatory [Regulation or Law]
   795   C0243122:binding [Functional Concept]
   795   C1145667:Binding [Activity]
   795   C1167622:Binding [Molecular Function]
   795   C1704735:Regulatory [Conceptual Entity]
   795   C1705248:Element [Conceptual Entity]

Phrase: "(Wang and Iynedjian, 1997). Immunofluorescence Cells grown on polyornithine-treated glass coverslips were treated for 24 hours with or without 500 ng/ml doxycycline. Cells were then washed, fixed in 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 in phosphate-buffered saline containing 1% BSA (PBS-BSA). The preparation was then blocked with PBS-BSA before incubating with the first antibody, anti-SREBP-1 (Santa Cruz,"

Phrase: "Basel,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0331779:Basel [Health Care Related Organization]

Phrase: "Switzerland"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0039021:Switzerland [Geographic Area]

Phrase: ";"
Processing 00000000.tx.40: 1:100 dilution), followed by the second antibody labelling. 

Phrase: "1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: ":"

Phrase: "100 dilution"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0079240:Dilution [Laboratory Procedure]
   861   C1948037:Dilution [Functional Concept]

Phrase: ")"

Phrase: ","

Phrase: "followed by the second antibody labelling."
Meta Candidates (Total=13; Excluded=1; Pruned=0; Remaining=12)
   790   C0332283:Followed by [Temporal Concept]
           followed
   753   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   753   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   753   C0205436:Second [Quantitative Concept]
   753   C0457385:Second [Temporal Concept]
   753   C0565930:/second [Quantitative Concept]
   753   C1167624:Labeling [Mental Process]
   753   C1561503:second [Idea or Concept]
   753   C1705190:Second [Qualitative Concept]
   753   C1947902:Labeling [Manufactured Object]
   753   C2827499:Labeling [Governmental or Regulatory Activity]
   719 E C1719822:Follow [Intellectual Product]
Processing 00000000.tx.41: Nuclear protein extraction and electrophoretic mobility-shift assay (EMSA) Nuclear extracts from INS-1 cells were prepared according to the method of Schreiber et al. 

Phrase: "Nuclear protein extraction and electrophoretic mobility-shift assay (EMSA) Nuclear extracts"
Meta Candidates (Total=21; Excluded=2; Pruned=0; Remaining=19)
   874   C1518434:Nuclear Extract [Biomedical or Dental Material]
   840   C0949632:Electrophoretic Mobility Shift Assay [Laboratory Procedure]
           Mobility Shift Assay
   804   C0028589:Nuclear Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0949374:Nuclear Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   790   C0005507:Assay [Laboratory Procedure]
   790   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   790   C0185115:Extraction [Therapeutic or Preventive Procedure]
   790   C0243073:assay [Qualitative Concept]
   790   C0333051:Shift [Functional Concept]
   790   C0425245:Mobility [Finding]
   790   C0449580:Mobility [Qualitative Concept]
   790   C0521447:Nuclear [Spatial Concept]
   790   C0684295:extraction [Laboratory Procedure]
   790   C1510438:Assay [Laboratory Procedure]
   790   C2347509:Shift [Phenomenon or Process]
   788   C0201719:Protein electrophoresis [Laboratory Procedure]
   756   C2828366:Extract [Substance]
   718   C0013855:Electrophoreses [Laboratory Procedure]
   718 E C0231435:Mobile [Functional Concept]
   718 E C1552449:Mobile [Health Care Related Organization,Manufactured Object]

Phrase: "from"

Phrase: "INS-1 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "prepared according to the method of Schreiber et al."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   742   C0025663:Method [Intellectual Product]
   742   C0449851:Method [Functional Concept]
   742   C0680240:according [Social Behavior]
   742   C0871511:METHOD [Intellectual Product]
   708   C1521827:Prepare [Functional Concept]
Processing 00000000.tx.42: (Schreiber et al., 1988). 

Phrase: "(Santa Cruz, Basel, Switzerland; 1:100 dilution), followed by the second antibody labelling. Nuclear protein extraction and electrophoretic mobility-shift assay (EMSA) Nuclear extracts from INS-1 cells were prepared according to the method of Schreiber et al. (Schreiber et al.,"

Phrase: "1988"

Phrase: "), followed by the second antibody labelling. Nuclear protein extraction and electrophoretic mobility-shift assay (EMSA) Nuclear extracts from INS-1 cells were prepared according to the method of Schreiber et al. (Schreiber et al., 1988)."
Processing 00000000.tx.43: Rat islets were isolated by collagenase digestion as described previously (Rubi et al., 2001) and their nuclear proteins were extracted as previously reported (Schreiber et al., 1988). 

Phrase: "Rat islets"

Phrase: "were"

Phrase: "isolated by collagenase digestion"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   770   C0012238:Digestion [Organism Function]
   770   C0162745:COLLAGENASE [Amino Acid, Peptide, or Protein,Enzyme,Pharmacologic Substance]
   770   C0205409:Isolated [Functional Concept]
   770   C1548221:Isolated [Idea or Concept]
   770   C2349986:Digestion [Research Activity]
   737 E C0370215:Isolate [Substance]
   737 E C1875400:ISOLATE [Pharmacologic Substance]
   715 E C0443277:Peptic [Functional Concept]

Phrase: "as"

Phrase: "described"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]

Phrase: "previously"

Phrase: "(Schreiber et al., 1988). Rat islets were isolated by collagenase digestion as described previously (Rubi et al.,"

Phrase: "2001"

Phrase: ")"

Phrase: "and"

Phrase: "their nuclear proteins"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0028589:Nuclear Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   966 E C0949374:Nuclear Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C0521447:Nuclear [Spatial Concept]

Phrase: "were"

Phrase: "extracted as previously"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0185115:Extracted [Therapeutic or Preventive Procedure]
   790   C3541890:EXTRACTED [Finding]
   756 E C2828366:Extract [Substance]

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "(Rubi et al., 2001) and their nuclear proteins were extracted as previously reported (Schreiber et al.,"

Phrase: "1988"

Phrase: ") and their nuclear proteins were extracted as previously reported (Schreiber et al., 1988)."
Processing 00000000.tx.44: The double-stranded oligonucleotides corresponding to the sterol regulatory element (SRE) in the human insulin receptor substrate 2 (IRS2) promoter (Ide et al., 2004), 5'cctgcgtaacgccgagtcacatgttgtt3', was used as a probe. 

Phrase: "The double-stranded oligonucleotides"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0028953:Oligonucleotides [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "corresponding to the sterol regulatory element (SRE)"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   753   C0013879:Element [Element, Ion, or Isotope]
   753   C0038323:Sterol [Steroid]
   753   C0220905:regulatory [Regulation or Law]
   753   C1704735:Regulatory [Conceptual Entity]
   753   C1705248:Element [Conceptual Entity]

Phrase: "in the human insulin receptor substrate 2 (IRS2) promoter"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   799   C0086860:Promoter [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   780   C1334191:insulin receptor substrate 2, human [Amino Acid, Peptide, or Protein,Biologically Active Substance]
           Insulin Receptor Substrate 2
   734   C0381451:Insulin Receptor Substrate-2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   734   C1334141:INSULIN RECEPTOR SUBSTRATE 2 [Gene or Genome]

Phrase: "(Schreiber et al., 1988). The double-stranded oligonucleotides corresponding to the sterol regulatory element (SRE) in the human insulin receptor substrate 2 (IRS2) promoter (Ide et al.,"

Phrase: "2004"

Phrase: ")"

Phrase: ","

Phrase: "5'cctgcgtaacgccgagtcacatgttgtt3',"

Phrase: "was"

Phrase: "used as a probe."
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   770   C0182400:Probe [Medical Device]
   770   C1273517:used [Finding]
   770   C1704681:Probe [Gene or Genome]
   770   C2347609:Probe [Chemical Viewed Functionally]
   770   C3536729:Probe [Manufactured Object]
   737 E C0042153:use [Functional Concept]
   737 E C0457083:Use [Functional Concept]
   737 E C1947944:Use [Intellectual Product]
Processing 00000000.tx.45: EMSA procedures, including conditions for probe labelling and binding reactions were performed as in Wang et al. 

Phrase: "EMSA procedures,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   893   C0185115:extraction procedures [Therapeutic or Preventive Procedure]
           Extraction
   795   C0684295:extraction [Laboratory Procedure]
   710   C0949632:Electrophoretic Mobility Shift Assay [Laboratory Procedure]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "conditions for probe labelling"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   737   C0012634:condition [Disease or Syndrome]
   737   C0348080:Condition [Qualitative Concept]
   737   C1705253:Condition [Conceptual Entity]

Phrase: "and"

Phrase: "binding reactions"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0443286:Reaction [Functional Concept]
   827   C1114821:Reaction [Clinical Attribute]

Phrase: "were"

Phrase: "performed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0884358:Performed [Functional Concept]
   966 E C2947996:Perform [Pharmacologic Substance]

Phrase: "as in Wang et al."
Processing 00000000.tx.46: (Wang, H. et al., 1998). 

Phrase: "(Ide et al., 2004), 5'cctgcgtaacgccgagtcacatgttgtt3', was used as a probe. EMSA procedures, including conditions for probe labelling and binding reactions were performed as in Wang et al. (Wang,"

Phrase: "H. et al.,"

Phrase: "1998"

Phrase: "), 5'cctgcgtaacgccgagtcacatgttgtt3', was used as a probe. EMSA procedures, including conditions for probe labelling and binding reactions were performed as in Wang et al. (Wang, H. et al., 1998)."
Processing 00000000.tx.47: Mouse monoclonal antibodies against SREBP-1 (NeoMarkers, Fremont CA, USA) and SREBP-2 (purified from the supernatant of the hybridoma cell line CRL2121, American Tissue Culture Collection, Rockville, MD, USA) were used for supershift experiments. 

Phrase: "Mouse monoclonal antibodies against SREBP-1"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   765   C0359168:Mouse monoclonal antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   760   C0003250:Monoclonal Antibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]
   757   C0443737:Monoclonal protein [Amino Acid, Peptide, or Protein,Immunologic Factor]
   757   C0700271:monoclonal protein [Amino Acid, Peptide, or Protein,Immunologic Factor]
   757   C1317659:Protein.monoclonal [Laboratory or Test Result]
   741   C1445860:Protein antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   739   C0003241:Antibodies [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   739   C0746619:monoclonal [Finding]
   706 E C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "(Wang, H. et al., 1998). Mouse monoclonal antibodies against SREBP-1 (NeoMarkers,"

Phrase: "Fremont CA,"

Phrase: "USA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0041703:USA [Geographic Area]

Phrase: ")"

Phrase: "and"

Phrase: "SREBP-2"
Meta Candidates (Total=15; Excluded=0; Pruned=0; Remaining=15)
  1000   C0250036:Sterol Regulatory Element Binding Protein 2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
  1000   C1420399:STEROL REGULATORY ELEMENT-BINDING PROTEIN 2 [Gene or Genome]
   858   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C2246292:sterol binding [Molecular Function]
   827   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0013879:Element [Element, Ion, or Isotope]
   799   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0038323:Sterol [Steroid]
   799   C0220905:regulatory [Regulation or Law]
   799   C0243122:binding [Functional Concept]
   799   C1145667:Binding [Activity]
   799   C1167622:Binding [Molecular Function]
   799   C1704735:Regulatory [Conceptual Entity]
   799   C1705248:Element [Conceptual Entity]

Phrase: "("

Phrase: "purified from the supernatant of the hybridoma cell line CRL2121,"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   760   C0007600:Cell Line [Cell]
   757   C0020204:cell hybridoma [Cell]
           Hybridoma
   739   C0007634:Cell [Cell]
   739   C0205132:Line [Spatial Concept]
   739   C1269647:Cell [Cell]
   739   C1550101:Supernatant [Body Substance]
   739   C1550648:Line [Substance]
   739   C1552960:Line [Quantitative Concept]
   739   C1704653:Cell [Medical Device]
   739   C1948049:Cell [Spatial Concept]
   739   C1998793:Purified [Functional Concept]

Phrase: "American Tissue Culture Collection,"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   875   C0040278:Tissue Collection [Health Care Related Organization,Manufactured Object]
   812   C1516698:Collection [Functional Concept]
   812   C1704814:Collection [Idea or Concept]
   741 E C1516695:Collected [Idea or Concept]

Phrase: "Rockville,"

Phrase: "MD,"

Phrase: "USA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0041703:USA [Geographic Area]

Phrase: ")"

Phrase: "were"

Phrase: "used for supershift experiments."
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
   770   C0681814:Experiments [Research Activity]
   770   C1273517:used [Finding]
   737 E C0042153:use [Functional Concept]
   737 E C0457083:Use [Functional Concept]
   737 E C1706386:Experiment [Conceptual Entity]
   737 E C1947944:Use [Intellectual Product]
Processing 00000000.tx.48: Staining of lipid accumulation by Oil Red O Cells were cultured in standard (11.2 mM) or 30 mM glucose medium in the presence or absence of 500 ng/ml doxycycline for 48 hours. 

Phrase: "Staining of lipid accumulation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0487602:Staining [Laboratory Procedure]
   770   C1704680:Staining [Finding]

Phrase: "by Oil Red O Cells"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   875   C0014792:Red cells [Cell]
   812   C0007634:Cells [Cell]
   812   C3282337:Cells [Cell]
   779 E C1269647:Cell [Cell]
   779 E C1704653:Cell [Medical Device]
   779 E C1948049:Cell [Spatial Concept]
   756   C0069388:oil red O [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]

Phrase: "were"

Phrase: "cultured in standard"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C1442989:Standard [Qualitative Concept]
   790   C2828392:Standard [Intellectual Product]
   756   C0010453:Culture [Idea or Concept]
   756   C0220814:culture [Functional Concept]
   756   C0430400:Culture [Laboratory Procedure]
   756   C2242979:Culture [Laboratory Procedure]

Phrase: "(purified from the supernatant of the hybridoma cell line CRL2121, American Tissue Culture Collection, Rockville, MD, USA) were used for supershift experiments. Staining of lipid accumulation by Oil Red O Cells were cultured in standard (11.2 mM)"

Phrase: "or"

Phrase: "30 mM glucose medium in the presence"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0009458:Medium [Intellectual Product]
   748   C0439536:Medium [Quantitative Concept]
   748   C1705217:Medium [Substance]
   748   C3244283:medium [Intellectual Product]

Phrase: "or"

Phrase: "absence of 500 ng/ml doxycycline"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0332197:absence [Quantitative Concept]
   753   C1689985:Absence [Anatomical Abnormality]

Phrase: "for 48 hours."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0439586:48 hours [Temporal Concept]
  1000   C1442464:48 Hours [Temporal Concept]
   861   C0439227:hours [Temporal Concept]
   827 E C0564385:/hour [Quantitative Concept]
Processing 00000000.tx.49: Cells were fixed and stained as previously reported (Kim and Spiegelman, 1996). 

Phrase: "Cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "fixed"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0231441:Fixed [Finding]
  1000   C0443218:Fixed [Qualitative Concept]
  1000   C2827483:Fixed [Body Substance]

Phrase: "and"

Phrase: "stained"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C2986582:Stained [Qualitative Concept]
   966 E C0038128:Stain [Indicator, Reagent, or Diagnostic Aid]

Phrase: "as"

Phrase: "previously"

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "(11.2 mM) or 30 mM glucose medium in the presence or absence of 500 ng/ml doxycycline for 48 hours. Cells were fixed and stained as previously reported (Kim"

Phrase: "and"

Phrase: "Spiegelman,"

Phrase: "1996"

Phrase: ") were used for supershift experiments. Staining of lipid accumulation by Oil Red O Cells were cultured in standard (11.2 mM) or 30 mM glucose medium in the presence or absence of 500 ng/ml doxycycline for 48 hours. Cells were fixed and stained as previously reported (Kim and Spiegelman, 1996)."
Processing 00000000.tx.50: Lipid droplets were visualized using phase-contrast microscopy (Nikon Diaphot). 

Phrase: "Lipid droplets"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0230704:Lipid droplets [Cell Component]

Phrase: "were"

Phrase: "visualized"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0234621:Visualized [Functional Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "phase-contrast microscopy"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0026024:Microscopy, Phase-Contrast [Laboratory Procedure]
   901   C0444701:Phase contrast [Laboratory Procedure]
   827   C0026018:Microscopy [Laboratory Procedure]
   827   C0205390:Phase [Temporal Concept]
   827   C1979874:Contrast [Qualitative Concept]
   755 E C0205288:Microscopic [Qualitative Concept]

Phrase: "(Kim and Spiegelman, 1996). Lipid droplets were visualized using phase-contrast microscopy (Nikon Diaphot"

Phrase: "). Lipid droplets were visualized using phase-contrast microscopy (Nikon Diaphot)."
Processing 00000000.tx.51: Measurements of insulin secretion and cellular insulin content Insulin secretion in INS-1E or DN-SREBP-1c#23 cells was measured in 24-well plates over a period of 30 minutes, in Krebs-Ringer-bicarbonate-Hepes buffer (KRBH, 140 mM NaCl, 3.6 mM KCl, 0.5 mM NaH2PO4, 0.5 mM MgSO4, 1.5 mM CaCl2, 2 mM NaHCO3, 10 mM Hepes, 0.1% BSA) containing the indicated concentrations of glucose. 

Phrase: "Measurements of insulin secretion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   802   C0202098:Insulin measurement [Laboratory Procedure]
   770   C0242485:measurements [Functional Concept]

Phrase: "and"

Phrase: "cellular insulin content Insulin secretion in"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   783   C1256369:insulin secretion [Cell Function]
   783   C1327616:Cellular Secretion [Cell Function]
   753   C0036536:secretion [Biologic Function]
   753   C0036537:Secretion [Body Substance]

Phrase: "INS-1E"

Phrase: "or"

Phrase: "DN-SREBP-1c#23 cells"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   800   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
   744   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: "was"

Phrase: "measured in 24-well"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   770   C0205170:Well [Qualitative Concept]
   770   C0444706:Measured [Qualitative Concept]
   770   C3146287:Well [Manufactured Object]
   770   C3541902:MEASURED [Diagnostic Procedure]
   737 E C0079809:Measure [Quantitative Concept]
   737 E C0242485:Measure [Functional Concept]

Phrase: "plates over a period of 30 minutes,"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   778   C0456693:/30 minutes [Temporal Concept]
   778   C1442458:30 Minutes [Temporal Concept]
   748   C0005971:Plate [Medical Device]
   748   C0439232:minute [Temporal Concept]
   748   C0439531:/period [Temporal Concept]
   748   C0700321:minute [Quantitative Concept]
   748   C0702093:/minute [Temporal Concept]
   748   C1139930:plate [Medical Device]
   748   C1282918:Minute [Quantitative Concept]
   748   C1948053:Period [Temporal Concept]
   748   C2347166:Minute [Quantitative Concept]
   748   C3537155:Plate [Manufactured Object]

Phrase: "in Krebs-Ringer-bicarbonate-Hepes buffer"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0006353:Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]

Phrase: "(Nikon Diaphot). Measurements of insulin secretion and cellular insulin content Insulin secretion in INS-1E or DN-SREBP-1c#23 cells was measured in 24-well plates over a period of 30 minutes, in Krebs-Ringer-bicarbonate-Hepes buffer (KRBH,"

Phrase: "140 mM NaCl,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0037494:NaCl [Biologically Active Substance,Inorganic Chemical,Pharmacologic Substance]
   827   C1959973:% NaCl [Quantitative Concept]

Phrase: "3.6 mM KCl,"

Phrase: "0.5 mM NaH2PO4,"

Phrase: "0.5 mM MgSO4,"

Phrase: "1.5 mM CaCl2,"

Phrase: "2 mM NaHCO3,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0074722:NaHCO3 [Organic Chemical,Pharmacologic Substance]

Phrase: "10 mM Hepes,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0019215:HEPES [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]

Phrase: "0.1% BSA)"

Phrase: "containing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:Containing [Functional Concept]
  1000   C2700400:Containing [Activity]

Phrase: "the indicated concentrations of glucose."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   797   C0427743:concentrations glucose [Laboratory Procedure]
   797   C1287281:concentrations glucose [Laboratory or Test Result]
   760   C0086045:Concentrations [Mental Process]
   726 E C1446561:Concentration [Quantitative Concept]
Processing 00000000.tx.52: Cellular insulin content was determined after extraction with acid ethanol following the procedures of Wang et al. 

Phrase: "Cellular insulin content"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   827   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C0423896:Content [Mental Process]
   827   C0456205:Content [Conceptual Entity]
   827   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C1579433:Insulin [Pharmacologic Substance]
   771 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   743 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "was"

Phrase: "determined after extraction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0185115:Extraction [Therapeutic or Preventive Procedure]
   790   C0684295:extraction [Laboratory Procedure]

Phrase: "with acid ethanol"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0001962:Ethanol [Organic Chemical]

Phrase: "following"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332282:Following [Temporal Concept]
   966 E C0332283:follow [Temporal Concept]
   966 E C1719822:Follow [Intellectual Product]

Phrase: "the procedures of Wang et al."
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
   753   C0025664:procedures [Intellectual Product]
   753   C0184661:Procedures [Diagnostic Procedure,Therapeutic or Preventive Procedure]
   753   C2700391:procedures [Activity]
   719 E C1948041:Procedure [Therapeutic or Preventive Procedure]
   719 E C3274430:PROCEDURE [Health Care Activity]
   719 E C3538935:Procedure [Idea or Concept]
   719 E C3539779:Procedure [Intellectual Product]
Processing 00000000.tx.53: (Wang, H. et al., 1998). 

Phrase: "(KRBH, 140 mM NaCl, 3.6 mM KCl, 0.5 mM NaH2PO4, 0.5 mM MgSO4, 1.5 mM CaCl2, 2 mM NaHCO3, 10 mM Hepes, 0.1% BSA) containing the indicated concentrations of glucose. Cellular insulin content was determined after extraction with acid ethanol following the procedures of Wang et al. (Wang,"

Phrase: "H. et al.,"

Phrase: "1998"

Phrase: "). Measurements of insulin secretion and cellular insulin content Insulin secretion in INS-1E or DN-SREBP-1c#23 cells was measured in 24-well plates over a period of 30 minutes, in Krebs-Ringer-bicarbonate-Hepes buffer (KRBH, 140 mM NaCl, 3.6 mM KCl, 0.5 mM NaH2PO4, 0.5 mM MgSO4, 1.5 mM CaCl2, 2 mM NaHCO3, 10 mM Hepes, 0.1% BSA) containing the indicated concentrations of glucose. Cellular insulin content was determined after extraction with acid ethanol following the procedures of Wang et al. (Wang, H. et al., 1998)."
Processing 00000000.tx.54: Insulin was detected by radio-immunoassay using rat insulin as a standard (Wang, H. et al., 1998). 

Phrase: "Insulin"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1579433:Insulin [Pharmacologic Substance]
   944 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   916 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "was"

Phrase: "detected by radio-immunoassay"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C0020980:Immunoassay [Laboratory Procedure]
   770   C0021060:immunoassay [Laboratory Procedure]
   770   C0034546:Radio [Intellectual Product]
   770   C0442726:Detected [Finding]
   770   C1304639:Radio [Manufactured Object]
   770   C1511790:Detected [Therapeutic or Preventive Procedure]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "rat insulin as a standard"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   760   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C1579433:Insulin [Pharmacologic Substance]
   704 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]

Phrase: "(Wang, H. et al., 1998). Insulin was detected by radio-immunoassay using rat insulin as a standard (Wang,"

Phrase: "H. et al.,"

Phrase: "1998"

Phrase: "). Insulin was detected by radio-immunoassay using rat insulin as a standard (Wang, H. et al., 1998)."
Processing 00000000.tx.55: Total RNA isolation and northern blotting Total RNA was extracted and blotted to nylon membranes as described previously (Wang and Iynedjian, 1997). 

Phrase: "Total RNA isolation"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   827   C0204727:Isolation [Therapeutic or Preventive Procedure]
   827   C0205409:Isolation [Functional Concept]
   827   C0220862:isolation [Laboratory Procedure]
   755 E C1548221:Isolated [Idea or Concept]

Phrase: "and"

Phrase: "northern blotting Total RNA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0035668:RNA [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "was"

Phrase: "extracted"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0185115:Extracted [Therapeutic or Preventive Procedure]
  1000   C3541890:EXTRACTED [Finding]
   966 E C2828366:Extract [Substance]

Phrase: "and"

Phrase: "blotted to nylon membranes"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   770   C0025255:Membranes [Tissue]
   770   C0028736:Nylon [Biomedical or Dental Material,Organic Chemical]
   770   C0740034:Nylon [Biomedical or Dental Material]
   737 E C0596901:Membrane [Cell Component]
   737 E C1706182:Membrane [Manufactured Object]

Phrase: "as"

Phrase: "described"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]

Phrase: "previously"

Phrase: "(Wang, H. et al., 1998). Total RNA isolation and northern blotting Total RNA was extracted and blotted to nylon membranes as described previously (Wang"

Phrase: "and"

Phrase: "Iynedjian,"

Phrase: "1997"

Phrase: "). Total RNA isolation and northern blotting Total RNA was extracted and blotted to nylon membranes as described previously (Wang and Iynedjian, 1997)."
Processing 00000000.tx.56: The membrane was prehybridized and then hybridized to 32P-labelled random primer cDNA probes according to the method of Wang and Iynedijian (Wang and Iynedjian, 1997). 

Phrase: "The membrane"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0025255:Membrane [Tissue]
  1000   C0596901:Membrane [Cell Component]
  1000   C1706182:Membrane [Manufactured Object]
   928 E C0205287:Membranous [Qualitative Concept]

Phrase: "was"

Phrase: "prehybridized"

Phrase: "and"

Phrase: "then"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883708:Then [Temporal Concept]

Phrase: "hybridized to 32P-labelled random primer cDNA"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   748   C0006556:cDNA [Nucleic Acid, Nucleoside, or Nucleotide]
   748   C0034656:RANDOM [Research Activity]
   748   C0206415:Primer [Nucleic Acid, Nucleoside, or Nucleotide]
   748   C0439605:Random [Qualitative Concept]
   748   C1553631:32p [Medical Device]
   714   C0181496:Label [Manufactured Object]
   714   C2827499:Label [Governmental or Regulatory Activity]

Phrase: "probes according to the method of Wang"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   748   C0025663:Method [Intellectual Product]
   748   C0182400:Probe [Medical Device]
   748   C0449851:Method [Functional Concept]
   748   C0680240:according [Social Behavior]
   748   C0871511:METHOD [Intellectual Product]
   748   C1704681:Probe [Gene or Genome]
   748   C2347609:Probe [Chemical Viewed Functionally]
   748   C3536729:Probe [Manufactured Object]

Phrase: "and"

Phrase: "Iynedijian"

Phrase: "(Wang and Iynedjian, 1997). The membrane was prehybridized and then hybridized to 32P-labelled random primer cDNA probes according to the method of Wang and Iynedijian (Wang"

Phrase: "and"

Phrase: "Iynedjian,"

Phrase: "1997"

Phrase: "). The membrane was prehybridized and then hybridized to 32P-labelled random primer cDNA probes according to the method of Wang and Iynedijian (Wang and Iynedjian, 1997)."
Processing 00000000.tx.57: To ensure equal RNA loading and even transfer, all membranes were stripped and re-hybridized with a `house-keeping gene' probe, cyclophilin. 

Phrase: "To"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "ensure"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0218063:Ensure [Food]

Phrase: "equal RNA loading"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1708715:Loading [Activity]

Phrase: "and"

Phrase: "even"

Phrase: "transfer"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0040671:Transfer [Mental Process]
  1000   C1705822:Transfer [Activity]

Phrase: ","

Phrase: "all membranes"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0025255:Membranes [Tissue]
   966 E C0596901:Membrane [Cell Component]
   966 E C1706182:Membrane [Manufactured Object]
   916 E C0205287:Membranous [Qualitative Concept]

Phrase: "were"

Phrase: "stripped"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1321564:Strip [Medical Device]

Phrase: "and"

Phrase: "re-hybridized with a `house-keeping gene' probe,"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   800   C1334046:House-keeping Gene [Gene or Genome]
   770   C0441088:Gene probe [Medical Device]
   744   C0017337:Gene [Gene or Genome]
   744   C0182400:Probe [Medical Device]
   744   C0442519:house [Conceptual Entity]
   744   C1704681:Probe [Gene or Genome]
   744   C2003847:House [Manufactured Object]
   744   C2347609:Probe [Chemical Viewed Functionally]
   744   C2986904:RE [Idea or Concept]
   744   C3536729:Probe [Manufactured Object]
   711   C0333118:Keep [Functional Concept]

Phrase: "cyclophilin."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0136073:Cyclophilin [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C0917877:Cyclophilin [Amino Acid, Peptide, or Protein,Enzyme,Receptor]
  1000   C1325303:cyclophilin [Molecular Function]
Processing 00000000.tx.58: cDNA fragments used as probes for SREBP-1c, ChREBP, glucokinase, GLUT2, L-pyruvate kinase, insulin, BIP, CHOP10 and PDX1 mRNA detection were digested from the corresponding plasmids. 

Phrase: "cDNA fragments"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0332255:fragments [Functional Concept]
   861   C0486805:Fragments [Body Substance]
   827 E C1708096:Fragment [Qualitative Concept]

Phrase: "used as probes"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
   790   C0182400:Probes [Medical Device]
   790   C1273517:used [Finding]
   756 E C0042153:use [Functional Concept]
   756 E C0457083:Use [Functional Concept]
   756 E C1704681:Probe [Gene or Genome]
   756 E C1947944:Use [Intellectual Product]
   756 E C2347609:Probe [Chemical Viewed Functionally]
   756 E C3536729:Probe [Manufactured Object]

Phrase: "for SREBP-1c,"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
  1000   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C2246292:sterol binding [Molecular Function]
   827   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0013879:Element [Element, Ion, or Isotope]
   799   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0038323:Sterol [Steroid]
   799   C0220905:regulatory [Regulation or Law]
   799   C0243122:binding [Functional Concept]
   799   C1145667:Binding [Activity]
   799   C1167622:Binding [Molecular Function]
   799   C1704735:Regulatory [Conceptual Entity]
   799   C1705248:Element [Conceptual Entity]

Phrase: "ChREBP,"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C1826259:carbohydrate response element binding protein [Gene or Genome]
   937   C3158709:carbohydrate response element binding [Genetic Function]
   911   C0108401:carbohydrate-binding protein [Amino Acid, Peptide, or Protein,Receptor]
   875   C1148582:carbohydrate binding [Molecular Function]
   840   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0243122:binding [Functional Concept]
   804   C1145667:Binding [Activity]
   804   C1167622:Binding [Molecular Function]

Phrase: "glucokinase,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0017713:Glucokinase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1415014:GLUCOKINASE [Gene or Genome]

Phrase: "GLUT2,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1420172:GLUT2 [Gene or Genome]

Phrase: "L-pyruvate kinase,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0034348:Pyruvate Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0031727:Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0034354:pyruvate [Organic Chemical]
   827   C0244104:Pyruvate [Biologically Active Substance,Organic Chemical]

Phrase: "insulin,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1579433:Insulin [Pharmacologic Substance]
   944 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   916 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "BIP,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0063423:BiP [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1415761:BIP [Gene or Genome]

Phrase: "CHOP10"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1413947:CHOP10 [Gene or Genome]
  1000   C2985165:CHOP10 [Gene or Genome]

Phrase: "and"

Phrase: "PDX1 mRNA detection"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1511790:Detection [Therapeutic or Preventive Procedure]

Phrase: "were"

Phrase: "digested from the corresponding plasmids."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0032136:Plasmids [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   760   C0868946:digested [Physiologic Function]
Processing 00000000.tx.59: cDNA probes for rat mitochondrial uncoupling protein 2 (UCP2), aldolase B, fatty acid synthase, acetyl-CoA carboxylase, glycerol-phosphate acyltransferase, HMG-CoA reductase, P21WAF1/CIP1, BAD, APO1, BclXL, IRS2 and low density lipoprotein receptor (LDLR), were prepared by RT-PCR and confirmed by sequencing. 

Phrase: "cDNA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0006556:cDNA [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "probes for rat mitochondrial uncoupling protein 2 (UCP2),"
Meta Candidates (Total=15; Excluded=0; Pruned=0; Remaining=15)
   853   C0536847:mitochondrial uncoupling protein 2 [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
           uncoupling protein-2
   814   C0066604:mitochondrial uncoupling protein [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   814   C1421314:UNCOUPLING PROTEIN 2 [Gene or Genome]
   774   C0949610:Mitochondrial Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   774   C1335665:Rat Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   748   C0026237:Mitochondrial [Cell Component]
   748   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   748   C0034693:Rat, NOS [Mammal]
   748   C0034721:Rat [Mammal]
   748   C0182400:Probe [Medical Device]
   748   C0521451:Mitochondrial [Functional Concept]
   748   C1704681:Probe [Gene or Genome]
   748   C2347609:Probe [Chemical Viewed Functionally]
   748   C3536729:Probe [Manufactured Object]

Phrase: "aldolase B,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0001999:Aldolase B [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1412347:ALDOLASE B [Gene or Genome]
   861   C0016762:Aldolase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "fatty acid synthase,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0015683:Fatty-acid synthase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1367441:FATTY ACID SYNTHASE [Gene or Genome]
   901   C0015684:Fatty acid [Lipid]
   827   C0001128:Acid [Chemical]
   827   C0132555:synthase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0202406:Acid [Laboratory Procedure]

Phrase: "acetyl-CoA carboxylase,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0001022:Acetyl-CoA Carboxylase [Amino Acid, Peptide, or Protein,Enzyme]
   901   C0001026:Acetyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0007064:Carboxylase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "glycerol-phosphate acyltransferase,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0017874:Glycerolphosphate Acyltransferase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0001390:Acyl transferase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0017861:Glycerol [Biologically Active Substance,Organic Chemical,Pharmacologic Substance]
   827   C0031603:Phosphate [Inorganic Chemical,Pharmacologic Substance]
   827   C0031701:phosphate [Organophosphorus Compound]
   827   C1601799:PHOSPHATE [Inorganic Chemical,Pharmacologic Substance]

Phrase: "HMG-CoA reductase,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0020374:HMG CoA Reductase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C0063164:HMG-CoA reductase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1415615:HMG-CoA REDUCTASE [Gene or Genome]
   901   C0047420:HMG-CoA [Biologically Active Substance,Organic Chemical]
   827   C0030016:Reductase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "P21WAF1/CIP1,"

Phrase: "BAD,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205169:Bad [Qualitative Concept]

Phrase: "APO1,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1539477:APO1 [Gene or Genome]

Phrase: "BclXL,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1332397:BCLXL [Gene or Genome]

Phrase: "IRS2"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
  1000   C0381451:Insulin Receptor Substrate-2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
  1000   C1334141:INSULIN RECEPTOR SUBSTRATE 2 [Gene or Genome]
  1000   C1334191:Insulin Receptor Substrate 2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C0034818:Insulin Receptor [Amino Acid, Peptide, or Protein,Enzyme,Receptor]
   861   C1334133:INSULIN RECEPTOR [Gene or Genome]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   812   C1710236:Substrate [Manufactured Object]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "low density lipoprotein receptor (LDLR),"
Meta Candidates (Total=11; Excluded=1; Pruned=0; Remaining=10)
  1000   C0034821:Low Density Lipoprotein Receptor [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1366529:LOW DENSITY LIPOPROTEIN RECEPTOR [Gene or Genome]
   923   C0023823:Low density lipoprotein [Amino Acid, Peptide, or Protein,Biologically Active Substance,Lipid]
   861   C0065059:Lipoprotein Receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C0023820:Lipoprotein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   812   C0178587:density [Quantitative Concept]
   812   C0205251:low [Qualitative Concept]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C1299352:Low [Qualitative Concept]
   812   C1550472:low [Idea or Concept]
   741 E C0439794:Dense [Qualitative Concept]

Phrase: "were"

Phrase: "prepared by RT-PCR"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   833   C0599161:RT-PCR [Molecular Biology Research Technique]
   770   C0032520:PCR [Laboratory Procedure,Molecular Biology Research Technique]
   770   C0677874:pCR [Finding]
   737   C1521827:Prepare [Functional Concept]

Phrase: "and"

Phrase: "confirmed by sequencing."
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   882   C0521093:Confirmed by [Qualitative Concept]
           confirmed
   790   C0750484:Confirmed [Idea or Concept]
   790   C1553778:Sequencing [Intellectual Product]
   790   C1561491:Sequencing [Functional Concept]
   756 E C1456348:Confirm [Qualitative Concept]
Processing 00000000.tx.60: Cell proliferation/viability and apoptosis Quantification of cell proliferation/viability was measured using a Quick Cell Proliferation Assay Kit (LabForce/MBL, Nunningen, Switzerland) according to manufacturer's protocol. 

Phrase: "Cell proliferation/viability"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   913   C0007620:Cell Viability [Cell Function]
   827   C0443348:viability [Qualitative Concept]
   734   C0596290:Cell Proliferation [Cell Function]

Phrase: "and"

Phrase: "apoptosis Quantification of cell proliferation/viability"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1709793:Quantification [Quantitative Concept]

Phrase: "was"

Phrase: "measured"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0444706:Measured [Qualitative Concept]
  1000   C3541902:MEASURED [Diagnostic Procedure]
   966 E C0079809:Measure [Quantitative Concept]
   966 E C0242485:Measure [Functional Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "a Quick Cell Proliferation Assay Kit (LabForce/MBL,"

Phrase: "Nunningen,"

Phrase: "Switzerland"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0039021:Switzerland [Geographic Area]

Phrase: ")"

Phrase: "according to manufacturer's protocol."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0442711:Protocol [Intellectual Product]
   861   C1507394:Protocol [Intellectual Product]
   861   C1522729:Protocol [Intellectual Product]
   861   C2348563:Protocol [Intellectual Product]
Processing 00000000.tx.61: This assay is based on the cleavage of a tetrazolium salt WST-1 to formazan by mitochondrial dehydrogenases. 

Phrase: "This assay"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0005507:Assay [Laboratory Procedure]
  1000   C0243073:assay [Qualitative Concept]
  1000   C1510438:Assay [Laboratory Procedure]

Phrase: "is"

Phrase: "based on the cleavage of a tetrazolium salt WST-1"
Meta Candidates (Total=14; Excluded=3; Pruned=0; Remaining=11)
   777   C0671437:WST-1 salt [Organic Chemical]
   760   C0039704:tetrazolium salt [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]
           tetrazolium
   739   C0010813:cleavage [Cell Function]
   739   C0036140:Salt [Chemical Viewed Structurally]
   739   C0037494:Salt [Biologically Active Substance,Inorganic Chemical,Pharmacologic Substance]
   739   C0206136:Salt [Food,Inorganic Chemical]
   739   C0596311:Cleavage [Phenomenon or Process]
   739   C1330957:cleavage [Cell Function]
   739   C1527178:Based [Functional Concept]
   739   C1705938:Based [Idea or Concept]
   706 E C0002055:base [Inorganic Chemical]
   706 E C0178499:Base [Chemical Viewed Functionally]
   706 E C1880279:Base [Biomedical or Dental Material]

Phrase: "to formazan"

Phrase: "by mitochondrial dehydrogenases."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030016:Dehydrogenases [Amino Acid, Peptide, or Protein,Enzyme]
Processing 00000000.tx.62: Expansion in the number of viable cells results in an increase in the overall activity of the mitochondrial dehydrogenases and subsequently an augmentation in the amount of formazan dye formed. 

Phrase: "Expansion in the number of viable cells"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   757   C0007595:cell expansion [Cell Function]

Phrase: "results in an increase"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0442805:Increase [Functional Concept]
   770   C1274040:Result [Functional Concept]
   770   C1546471:Result [Idea or Concept]
   770   C2825142:Result [Finding]

Phrase: "in the overall activity"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0205177:Activity [Functional Concept]
   861   C0439167:% activity [Quantitative Concept]
   861   C0441655:Activity [Activity]
   861   C1561536:*Activity [Idea or Concept]

Phrase: "of the mitochondrial dehydrogenases"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030016:Dehydrogenases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "and"

Phrase: "subsequently"

Phrase: "an augmentation in the amount of formazan dye"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C1293122:Augmentation [Therapeutic or Preventive Procedure]

Phrase: "formed."
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0205431:Formed [Functional Concept]
   966 E C0348078:Form [Qualitative Concept]
   966 E C0376315:Form [Manufactured Object]
   966 E C1522492:Form [Functional Concept]
Processing 00000000.tx.63: The formazan dye produced by viable cells was quantified with a multiwell spectrophotometer by measuring the absorbance at 440 nm. 

Phrase: "The formazan dye"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0013343:Dye [Indicator, Reagent, or Diagnostic Aid]

Phrase: "produced by viable cells"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   833   C1441322:Viable cells [Cell]
   770   C0007634:Cells [Cell]
   770   C0443348:Viable [Qualitative Concept]
   770   C3282337:Cells [Cell]
   737 E C1269647:Cell [Cell]
   737 E C1704653:Cell [Medical Device]
   737 E C1948049:Cell [Spatial Concept]

Phrase: "was"

Phrase: "quantified with a multiwell spectrophotometer"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0183400:Spectrophotometer [Medical Device]
   726   C1709793:Quantify [Quantitative Concept]

Phrase: "by measuring"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0444706:measuring [Qualitative Concept]
  1000   C0449770:measuring [Quantitative Concept]
   966 E C0079809:Measure [Quantitative Concept]
   966 E C0242485:Measure [Functional Concept]

Phrase: "the absorbance at 440 nm."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1268822:Absorbance [Clinical Attribute]
   760   C2825050:Absorbance [Phenomenon or Process]
Processing 00000000.tx.64: Experiments for DNA fragmentation were performed using a Quick Apoptosis DNA Ladder Detection Kit (LabForce/MBL, Nunningen, Switzerland) following the manufacturer's protocol. 

Phrase: "Experiments for DNA fragmentation"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0681814:Experiments [Research Activity]
   737 E C1706386:Experiment [Conceptual Entity]

Phrase: "were"

Phrase: "performed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0884358:Performed [Functional Concept]
   966 E C2947996:Perform [Pharmacologic Substance]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "a Quick Apoptosis DNA Ladder Detection Kit (LabForce/MBL,"

Phrase: "Nunningen,"

Phrase: "Switzerland"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0039021:Switzerland [Geographic Area]

Phrase: ")"

Phrase: "following"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332282:Following [Temporal Concept]
   966 E C0332283:follow [Temporal Concept]
   966 E C1719822:Follow [Intellectual Product]

Phrase: "the manufacturer's protocol."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0442711:Protocol [Intellectual Product]
   861   C1507394:Protocol [Intellectual Product]
   861   C1522729:Protocol [Intellectual Product]
   861   C2348563:Protocol [Intellectual Product]
Processing 00000000.tx.65: Statistics Results are expressed as mean  s.e.m. and statistical analyses were performed using Student's t-test.  

Phrase: "Statistics Results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1274040:Result [Functional Concept]
   827   C1546471:Result [Idea or Concept]
   827   C2825142:Result [Finding]

Phrase: "are"

Phrase: "expressed as mean"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0444504:Mean [Quantitative Concept]
   790   C2347634:Mean [Quantitative Concept]
   790   C2348143:Mean [Quantitative Concept]

Phrase: "s."

Phrase: "e.m."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "and"

Phrase: "statistical analyses"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   983   C0871424:statistical analysis [Research Activity]
   827   C0002778:Analysis [Laboratory Procedure]
   827   C0936012:Analysis [Research Activity]
   827   C1524024:analysis [Functional Concept]

Phrase: "were"

Phrase: "performed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0884358:Performed [Functional Concept]
   966 E C2947996:Perform [Pharmacologic Substance]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "Student's t-test."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   827   C0022885:Test [Laboratory Procedure]
   827   C0038492:student [Professional or Occupational Group]
   827   C0039593:Test [Functional Concept]
   827   C0392366:test [Intellectual Product]
   827   C1551041:student [Idea or Concept]
   827   C1552573:student [Intellectual Product]
Processing 00000000.tx.66: Results Top Summary Introduction Materials and Methods Results Discussion References  Effects of chronic high-glucose treatment on insulin secretion and -cell gene expression in INS-1E cells As shown in Fig. 

Phrase: "Results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1274040:Result [Functional Concept]
  1000   C1546471:Result [Idea or Concept]
  1000   C2825142:Result [Finding]

Phrase: "Top Summary Introduction Materials"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0520510:Materials [Substance]

Phrase: "and"

Phrase: "Methods Results Discussion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "References"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Effects of chronic high-glucose treatment"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   767   C1158774:glucose effect [Genetic Function]
   767   C1518681:Treatment Effect [Finding]
   753   C1280500:effects [Qualitative Concept]
   719 E C2348382:Effect [Qualitative Concept]

Phrase: "on insulin secretion"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C1256369:insulin secretion [Cell Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036536:secretion [Biologic Function]
   861   C0036537:Secretion [Body Substance]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and -"

Phrase: "cell gene expression in"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   833   C0017262:Gene Expression [Genetic Function]
   833   C1861886:CELL Gene [Gene or Genome]
   770   C0017337:Gene [Gene or Genome]
   770   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "INS-1E cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "As"

Phrase: "shown in Fig."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0349966:Fig [Food]
   790   C1337208:FIG [Food]
   756   C1547282:Show [Intellectual Product]
Processing 00000000.tx.67: 1A, 30 mM glucose treatment of INS-1E cells for 48 hours resulted in reduced glucose- and leucine-stimulated insulin secretion. 

Phrase: "1A,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0450344:1A [Intellectual Product]
  1000   C1553633:1a [Medical Device]

Phrase: "30 mM glucose treatment of"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   760   C0039798:treatment [Functional Concept]
   760   C0087111:Treatment [Therapeutic or Preventive Procedure]
   760   C1522326:Treatment [Functional Concept]
   760   C1533734:Treatment [Therapeutic or Preventive Procedure]
   760   C1705169:Treatment [Conceptual Entity]
   760   C3538994:TREATMENT [Research Activity]

Phrase: "INS-1E cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "for 48 hours"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0439586:48 hours [Temporal Concept]
  1000   C1442464:48 Hours [Temporal Concept]
   861   C0439227:hours [Temporal Concept]
   827 E C0564385:/hour [Quantitative Concept]

Phrase: "resulted in reduced glucose-"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   770   C0392756:Reduced [Qualitative Concept]
   737   C1274040:Result [Functional Concept]
   737   C1546471:Result [Idea or Concept]
   737   C2825142:Result [Finding]

Phrase: "and"

Phrase: "leucine-stimulated insulin secretion."
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   861   C1256369:insulin secretion [Cell Function]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0036536:secretion [Biologic Function]
   812   C0036537:Secretion [Body Substance]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]
Processing 00000000.tx.68: In contrast, KCl-depolarization-elicited insulin release was unaffected, suggesting that Ca2+-stimulated exocytosis was unaffected. 

Phrase: "In contrast,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1979874:Contrast [Qualitative Concept]

Phrase: "KCl-depolarization-elicited insulin release"
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   804   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   804   C0030685:Release [Health Care Activity]
   804   C0391871:Release [Functional Concept]
   804   C0439180:% release [Quantitative Concept]
   804   C0680255:release [Health Care Activity]
   804   C1283071:Release [Functional Concept]
   804   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   804   C1579433:Insulin [Pharmacologic Substance]
   804   C1963578:Release [Therapeutic or Preventive Procedure]
   748 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   721 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "was"

Phrase: "unaffected,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2986417:Unaffected [Conceptual Entity]

Phrase: "suggesting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "that Ca2+-stimulated exocytosis"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0015283:Exocytosis [Cell Function]

Phrase: "was"

Phrase: "unaffected."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2986417:Unaffected [Conceptual Entity]
Processing 00000000.tx.69: We could also confirm, as previously reported (Roche et al., 1998), that chronic high glucose treatment led to lipid accumulation and INS-1 cell apoptosis (see below). 

Phrase: "We"

Phrase: "could"

Phrase: "also"

Phrase: "confirm"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0521093:confirm [Qualitative Concept]
  1000   C0750484:confirm [Idea or Concept]
  1000   C1456348:Confirm [Qualitative Concept]

Phrase: ","

Phrase: "as"

Phrase: "previously"

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "(Wang and Iynedjian, 1997). To ensure equal RNA loading and even transfer, all membranes were stripped and re-hybridized with a `house-keeping gene' probe, cyclophilin. cDNA fragments used as probes for SREBP-1c, ChREBP, glucokinase, GLUT2, L-pyruvate kinase, insulin, BIP, CHOP10 and PDX1 mRNA detection were digested from the corresponding plasmids. cDNA probes for rat mitochondrial uncoupling protein 2 (UCP2), aldolase B, fatty acid synthase, acetyl-CoA carboxylase, glycerol-phosphate acyltransferase, HMG-CoA reductase, P21WAF1/CIP1, BAD, APO1, BclXL, IRS2 and low density lipoprotein receptor (LDLR), were prepared by RT-PCR and confirmed by sequencing. Cell proliferation/viability and apoptosis Quantification of cell proliferation/viability was measured using a Quick Cell Proliferation Assay Kit (LabForce/MBL, Nunningen, Switzerland) according to manufacturer's protocol. This assay is based on the cleavage of a tetrazolium salt WST-1 to formazan by mitochondrial dehydrogenases. Expansion in the number of viable cells results in an increase in the overall activity of the mitochondrial dehydrogenases and subsequently an augmentation in the amount of formazan dye formed. The formazan dye produced by viable cells was quantified with a multiwell spectrophotometer by measuring the absorbance at 440 nm. Experiments for DNA fragmentation were performed using a Quick Apoptosis DNA Ladder Detection Kit (LabForce/MBL, Nunningen, Switzerland) following the manufacturer's protocol. Statistics Results are expressed as mean  s.e.m. and statistical analyses were performed using Student's t-test.  Results Top Summary Introduction Materials and Methods Results Discussion References  Effects of chronic high-glucose treatment on insulin secretion and -cell gene expression in INS-1E cells As shown in Fig. 1A, 30 mM glucose treatment of INS-1E cells for 48 hours resulted in reduced glucose- and leucine-stimulated insulin secretion. In contrast, KCl-depolarization-elicited insulin release was unaffected, suggesting that Ca2+-stimulated exocytosis was unaffected. We could also confirm, as previously reported (Roche et al.,"

Phrase: "1998"

Phrase: ")"

Phrase: ","

Phrase: "that chronic high glucose treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   812   C0039798:treatment [Functional Concept]
   812   C0087111:Treatment [Therapeutic or Preventive Procedure]
   812   C1522326:Treatment [Functional Concept]
   812   C1533734:Treatment [Therapeutic or Preventive Procedure]
   812   C1705169:Treatment [Conceptual Entity]
   812   C3538994:TREATMENT [Research Activity]

Phrase: "led to lipid accumulation"
Meta Candidates (Total=8; Excluded=5; Pruned=0; Remaining=3)
   833   C0333574:Lipid accumulation [Finding]
   770   C0023779:Lipid [Lipid]
   770   C1708698:LED [Manufactured Object]
   737 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   737 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   737 E C1522538:Lead [Functional Concept]
   737 E C2348269:Lead [Element, Ion, or Isotope]
   737 E C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "and INS-1 cell apoptosis"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   806   C1414685:INS-1 [Gene or Genome]
   806   C3538717:INS-1 [Gene or Genome]
   760   C0007634:Cell [Cell]
   760   C0162638:Apoptosis [Cell Function]
   760   C1269647:Cell [Cell]
   760   C1515981:And [Idea or Concept]
   760   C1704653:Cell [Medical Device]
   760   C1948049:Cell [Spatial Concept]

Phrase: "("

Phrase: "see below"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C0042789:see [Organism Function]
   833   C1947903:See [Activity]

Phrase: "), that chronic high glucose treatment led to lipid accumulation and INS-1 cell apoptosis (see below)."
Processing 00000000.tx.70: To explore the underlying mechanism, quantitative northern blotting was performed to investigate the gene expression patterns in INS-1E cells treated for 48 hours with 30 mM glucose. 

Phrase: "To"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "explore"

Phrase: "the underlying mechanism,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0441712:Mechanism [Functional Concept]
   861   C1706376:Mechanism [Manufactured Object]

Phrase: "quantitative northern blotting"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   901   C0005861:Northern Blotting [Molecular Biology Research Technique]
   884 E C1621557:Northern Blot [Research Device]
   827   C1709269:Northern [Spatial Concept]

Phrase: "was"

Phrase: "performed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0884358:Performed [Functional Concept]
   966 E C2947996:Perform [Pharmacologic Substance]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "investigate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1292732:investigate [Functional Concept]

Phrase: "the gene expression patterns in"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0449774:Patterns [Spatial Concept]

Phrase: "INS-1E cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "treated for 48 hours"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   833   C0439586:48 hours [Temporal Concept]
   833   C1442464:48 Hours [Temporal Concept]
   770   C0332293:treated [Therapeutic or Preventive Procedure]
   770   C0439227:hours [Temporal Concept]
   770   C1522326:Treated [Functional Concept]
   737 E C0564385:/hour [Quantitative Concept]
   737 E C1292734:TREAT [Functional Concept]

Phrase: "with 30 mM glucose."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
Processing 00000000.tx.71: The mRNA levels of essential -cell genes such as insulin, Pdx1, Glut2, glucokinase and IRS2 were drastically suppressed by high-glucose treatment (Fig. 1B). 

Phrase: "The mRNA levels of essential -cell genes"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   748   C0035696:mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   748   C0441889:Levels [Qualitative Concept]
   714 E C0456079:Level [Classification]
   714 E C1547707:Level [Geographic Area]
   714 E C2946261:Level [Pharmacologic Substance]

Phrase: "such as insulin,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1579433:Insulin [Pharmacologic Substance]
   944 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   916 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "Pdx1,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1427500:PDX1 [Gene or Genome]
  1000   C1826562:PDX1 [Gene or Genome]

Phrase: "Glut2,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1420172:GLUT2 [Gene or Genome]

Phrase: "glucokinase"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0017713:Glucokinase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1415014:GLUCOKINASE [Gene or Genome]

Phrase: "and"

Phrase: "IRS2"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
  1000   C0381451:Insulin Receptor Substrate-2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
  1000   C1334141:INSULIN RECEPTOR SUBSTRATE 2 [Gene or Genome]
  1000   C1334191:Insulin Receptor Substrate 2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C0034818:Insulin Receptor [Amino Acid, Peptide, or Protein,Enzyme,Receptor]
   861   C1334133:INSULIN RECEPTOR [Gene or Genome]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   812   C1710236:Substrate [Manufactured Object]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "were"

Phrase: "drastically"

Phrase: "suppressed by high-glucose treatment"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   806   C0860803:high glucose [Finding]
   760   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   760   C0039798:treatment [Functional Concept]
   760   C0087111:Treatment [Therapeutic or Preventive Procedure]
   760   C0205250:High [Qualitative Concept]
   760   C1260953:Suppressed [Functional Concept]
   760   C1299351:High [Qualitative Concept]
   760   C1522326:Treatment [Functional Concept]
   760   C1533734:Treatment [Therapeutic or Preventive Procedure]
   760   C1705169:Treatment [Conceptual Entity]
   760   C2700149:HIGH [Intellectual Product]
   760   C3538994:TREATMENT [Research Activity]

Phrase: "(see below). To explore the underlying mechanism, quantitative northern blotting was performed to investigate the gene expression patterns in INS-1E cells treated for 48 hours with 30 mM glucose. The mRNA levels of essential -cell genes such as insulin, Pdx1, Glut2, glucokinase and IRS2 were drastically suppressed by high-glucose treatment (Fig. 1B"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0450345:1B [Intellectual Product]

Phrase: "). To explore the underlying mechanism, quantitative northern blotting was performed to investigate the gene expression patterns in INS-1E cells treated for 48 hours with 30 mM glucose. The mRNA levels of essential -cell genes such as insulin, Pdx1, Glut2, glucokinase and IRS2 were drastically suppressed by high-glucose treatment (Fig. 1B)."
Processing 00000000.tx.72: In addition, pro-apoptotic genes, P21, Bad and APO-1 were upregulated, whereas the anti-apoptotic gene Bclxl was downregulated (Fig. 1B). 

Phrase: "In addition,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1883712:Addition [Functional Concept]
   928 E C1524062:Additional [Functional Concept]

Phrase: "pro-apoptotic genes,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0017337:Genes [Gene or Genome]

Phrase: "P21,"

Phrase: "Bad"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205169:Bad [Qualitative Concept]

Phrase: "and"

Phrase: "APO-1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1539477:APO-1 [Gene or Genome]
  1000   C1705955:APO-1 [Gene or Genome]

Phrase: "were"

Phrase: "upregulated"

Phrase: ","

Phrase: "whereas"

Phrase: "the anti-apoptotic gene Bclxl"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C1332397:BCLXL [Gene or Genome]

Phrase: "was"

Phrase: "downregulated"

Phrase: "(Fig. 1B). In addition, pro-apoptotic genes, P21, Bad and APO-1 were upregulated, whereas the anti-apoptotic gene Bclxl was downregulated (Fig. 1B"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0450345:1B [Intellectual Product]

Phrase: "). In addition, pro-apoptotic genes, P21, Bad and APO-1 were upregulated, whereas the anti-apoptotic gene Bclxl was downregulated (Fig. 1B)."
Processing 00000000.tx.73: Furthermore, lipogenic genes, fatty acid synthase, acetyl-CoA carboxylase, glycerol-phosphate acyltransferase, HMG-CoA reductase and LDL receptor were all markedly induced by high glucose treatment (Fig. 1C). 

Phrase: "Furthermore,"

Phrase: "lipogenic genes,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0017337:Genes [Gene or Genome]

Phrase: "fatty acid synthase,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0015683:Fatty-acid synthase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1367441:FATTY ACID SYNTHASE [Gene or Genome]
   901   C0015684:Fatty acid [Lipid]
   827   C0001128:Acid [Chemical]
   827   C0132555:synthase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0202406:Acid [Laboratory Procedure]

Phrase: "acetyl-CoA carboxylase,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0001022:Acetyl-CoA Carboxylase [Amino Acid, Peptide, or Protein,Enzyme]
   901   C0001026:Acetyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0007064:Carboxylase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "glycerol-phosphate acyltransferase,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0017874:Glycerolphosphate Acyltransferase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0001390:Acyl transferase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0017861:Glycerol [Biologically Active Substance,Organic Chemical,Pharmacologic Substance]
   827   C0031603:Phosphate [Inorganic Chemical,Pharmacologic Substance]
   827   C0031701:phosphate [Organophosphorus Compound]
   827   C1601799:PHOSPHATE [Inorganic Chemical,Pharmacologic Substance]

Phrase: "HMG-CoA reductase"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0020374:HMG CoA Reductase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C0063164:HMG-CoA reductase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1415615:HMG-CoA REDUCTASE [Gene or Genome]
   901   C0047420:HMG-CoA [Biologically Active Substance,Organic Chemical]
   827   C0030016:Reductase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "and"

Phrase: "LDL receptor"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0034821:LDL Receptor [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1149327:LDL receptor [Molecular Function]
   861   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "were"

Phrase: "all markedly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0522501:Markedly [Qualitative Concept]

Phrase: "induced by high glucose treatment"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   806   C0860803:high glucose [Finding]
   760   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   760   C0039798:treatment [Functional Concept]
   760   C0087111:Treatment [Therapeutic or Preventive Procedure]
   760   C0205250:High [Qualitative Concept]
   760   C0205263:Induced [Functional Concept]
   760   C1299351:High [Qualitative Concept]
   760   C1522326:Treatment [Functional Concept]
   760   C1533734:Treatment [Therapeutic or Preventive Procedure]
   760   C1705169:Treatment [Conceptual Entity]
   760   C2700149:HIGH [Intellectual Product]
   760   C3538994:TREATMENT [Research Activity]

Phrase: "(Fig. 1B). Furthermore, lipogenic genes, fatty acid synthase, acetyl-CoA carboxylase, glycerol-phosphate acyltransferase, HMG-CoA reductase and LDL receptor were all markedly induced by high glucose treatment (Fig. 1C"

Phrase: "). Furthermore, lipogenic genes, fatty acid synthase, acetyl-CoA carboxylase, glycerol-phosphate acyltransferase, HMG-CoA reductase and LDL receptor were all markedly induced by high glucose treatment (Fig. 1C)."
Processing 00000000.tx.74: Similar alterations in all genes mentioned above have been reported in an INS-1 stable cell line expressing naSREBP-1c (Wang et al., 2003). 

Phrase: "Similar alterations in all genes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   764   C0596611:Gene Alteration [Genetic Function]
   726   C1515926:Alteration [Idea or Concept]

Phrase: "mentioned"

Phrase: "above"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1282910:Above [Spatial Concept]
  1000   C1552828:above [Idea or Concept]

Phrase: "have"

Phrase: "been"

Phrase: "reported in an INS-1 stable cell line expressing naSREBP-1c"
Meta Candidates (Total=17; Excluded=1; Pruned=0; Remaining=16)
   775   C0598091:stable cell line [Cell]
   756   C0007600:Cell Line [Cell]
   756   C1414685:INS-1 [Gene or Genome]
   756   C3538717:INS-1 [Gene or Genome]
   738   C0007634:Cell [Cell]
   738   C0205132:Line [Spatial Concept]
   738   C0205360:Stable [Qualitative Concept]
   738   C0684224:Reported [Intellectual Product]
   738   C0700287:Reported [Health Care Activity]
   738   C1269647:Cell [Cell]
   738   C1547311:Stable [Intellectual Product]
   738   C1550648:Line [Substance]
   738   C1552960:Line [Quantitative Concept]
   738   C1704653:Cell [Medical Device]
   738   C1948049:Cell [Spatial Concept]
   738   C3496591:Reported [Clinical Attribute]
   704 E C3273238:Report [Intellectual Product]

Phrase: "(Fig. 1C). Similar alterations in all genes mentioned above have been reported in an INS-1 stable cell line expressing naSREBP-1c (Wang et al.,"

Phrase: "2003"

Phrase: "). Similar alterations in all genes mentioned above have been reported in an INS-1 stable cell line expressing naSREBP-1c (Wang et al., 2003)."
Processing 00000000.tx.75: This strikingly similar gene expression profile suggested that chronic high glucose could cause -cell glucolipotoxicity through activation of SREBP-1c. 

Phrase: "This strikingly similar gene expression profile"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   884   C1449575:gene expression profile [Laboratory Procedure]
   884   C1956267:Profile, Gene Expression [Quantitative Concept]
   804   C1979963:Profile [Laboratory Procedure]
   804   C2003903:Profile [Functional Concept]

Phrase: "suggested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "that chronic high glucose"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C0860803:high glucose [Finding]
   827   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "could"

Phrase: "cause -"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0015127:cause [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]

Phrase: "cell glucolipotoxicity through activation of SREBP-1c."
Processing 00000000.tx.76: View larger version (60K): [in this window] [in a new window]  Fig. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(Wang et al., 2003). This strikingly similar gene expression profile suggested that chronic high glucose could cause -cell glucolipotoxicity through activation of SREBP-1c. View larger version (60K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Fig."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.77: 1. 

Phrase: "1."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]
Processing 00000000.tx.78: Effects of chronic high glucose treatment on insulin secretion and gene expression in INS-1E cell. 

Phrase: "Effects of chronic high glucose treatment"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   767   C1158774:glucose effect [Genetic Function]
   767   C1518681:Treatment Effect [Finding]
   753   C1280500:effects [Qualitative Concept]
   719 E C2348382:Effect [Qualitative Concept]

Phrase: "on insulin secretion"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C1256369:insulin secretion [Cell Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036536:secretion [Biologic Function]
   861   C0036537:Secretion [Body Substance]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "gene expression in"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   882   C0017262:Gene Expression [Genetic Function]
   790   C0017337:Gene [Gene or Genome]
   790   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "INS-1E cell."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0007634:Cell [Cell]
   861   C1269647:Cell [Cell]
   861   C1704653:Cell [Medical Device]
   861   C1948049:Cell [Spatial Concept]
Processing 00000000.tx.79: (A) INS-1E cells in 24-well dishes were cultured in either standard (11.2 mM) or 30 mM glucose medium for 48 hours. 

Phrase: "(60K): [in this window] [in a new window]  Fig. 1. Effects of chronic high glucose treatment on insulin secretion and gene expression in INS-1E cell. (A) INS-1E cells"

Phrase: "in 24-well dishes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   793   C0020498:DISH [Disease or Syndrome]

Phrase: "were"

Phrase: "cultured in either standard"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C1442989:Standard [Qualitative Concept]
   770   C2828392:Standard [Intellectual Product]
   737   C0010453:Culture [Idea or Concept]
   737   C0220814:culture [Functional Concept]
   737   C0430400:Culture [Laboratory Procedure]
   737   C2242979:Culture [Laboratory Procedure]

Phrase: "(A) INS-1E cells in 24-well dishes were cultured in either standard (11.2 mM)"

Phrase: "or"

Phrase: "30 mM glucose medium for 48 hours."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0009458:Medium [Intellectual Product]
   748   C0439536:Medium [Quantitative Concept]
   748   C1705217:Medium [Substance]
   748   C3244283:medium [Intellectual Product]
Processing 00000000.tx.80: After 5 hours equilibration in 2.5 mM glucose medium, cells were washed twice with KRBH. 

Phrase: "After 5 hours equilibration"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   734   C1442467:5 Hours [Temporal Concept]

Phrase: "in 2.5 mM glucose medium,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0009458:Medium [Intellectual Product]
   804   C0439536:Medium [Quantitative Concept]
   804   C1705217:Medium [Substance]
   804   C3244283:medium [Intellectual Product]

Phrase: "cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "washed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1548982:Washed [Idea or Concept]
   966 E C0441648:Wash [Activity]

Phrase: "twice with KRBH."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C1720725:Twice [Intellectual Product]
   790   C1948050:Twice [Quantitative Concept]
Processing 00000000.tx.81: Insulin release from INS-1E cells stimulated with 20 mM glucose, 20 mM leucine and 20 mM KCl in KRBH buffer containing 2.5 mM (referred to Basal) was determined by radio-immunoassay and expressed as a percentage of cellular insulin content. 

Phrase: "Insulin release from"
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   790   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   790   C0030685:Release [Health Care Activity]
   790   C0391871:Release [Functional Concept]
   790   C0439180:% release [Quantitative Concept]
   790   C0680255:release [Health Care Activity]
   790   C1283071:Release [Functional Concept]
   790   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   790   C1579433:Insulin [Pharmacologic Substance]
   790   C1963578:Release [Therapeutic or Preventive Procedure]
   734 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   706 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "INS-1E cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "stimulated with 20 mM glucose,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   760   C1948023:Stimulated [Natural Phenomenon or Process]

Phrase: "20 mM leucine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0023401:Leucine [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]

Phrase: "and"

Phrase: "20 mM KCl in KRBH buffer"

Phrase: "containing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:Containing [Functional Concept]
  1000   C2700400:Containing [Activity]

Phrase: "2.5 mM ("
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   734   C0450346:2 5 [Quantitative Concept]

Phrase: "referred to Basal"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   882   C1555599:Referred to [Idea or Concept]
   882   C1691010:Referred to [Functional Concept]
           Referred
   790   C0205112:Basal [Spatial Concept]
   790   C0205543:referred [Functional Concept]

Phrase: ")"

Phrase: "was"

Phrase: "determined by radio-immunoassay"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0020980:Immunoassay [Laboratory Procedure]
   770   C0021060:immunoassay [Laboratory Procedure]
   770   C0034546:Radio [Intellectual Product]
   770   C1304639:Radio [Manufactured Object]

Phrase: "and"

Phrase: "expressed as a percentage of cellular insulin content."
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   744   C0007634:Cellular [Cell]
   744   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C0178539:Cellular [Functional Concept]
   744   C0423896:Content [Mental Process]
   744   C0439165:Percentage [Quantitative Concept]
   744   C0456205:Content [Conceptual Entity]
   744   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C1549488:Percentage [Idea or Concept]
   744   C1561533:Percentage [Idea or Concept]
   744   C1579433:Insulin [Pharmacologic Substance]
Processing 00000000.tx.82: The equilibration period is necessary to see the glucose-responsiveness of insulin release in INS-1 cells. 

Phrase: "The equilibration period"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0439531:/period [Temporal Concept]
   861   C1948053:Period [Temporal Concept]
   789 E C0332182:Periodic [Temporal Concept]
   789 E C1706381:PERIODIC [Intellectual Product]
   761 E C0031084:Periodicities [Temporal Concept]

Phrase: "is"

Phrase: "necessary to"

Phrase: "see"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0042789:see [Organism Function]
  1000   C1947903:See [Activity]

Phrase: "the glucose-responsiveness of insulin release"

Phrase: "in"

Phrase: "INS-1 cells."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.83: Cellular insulin content was decreased by 32.46.7% after 48 hours treatment with 30 mM glucose. 

Phrase: "Cellular insulin content"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   827   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C0423896:Content [Mental Process]
   827   C0456205:Content [Conceptual Entity]
   827   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C1579433:Insulin [Pharmacologic Substance]
   771 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   743 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "was"

Phrase: "decreased by 32.46.7%"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   760   C0205216:Decreased [Quantitative Concept]
   760   C0392756:Decreased [Qualitative Concept]
   760   C0442797:decreased [Qualitative Concept]
   726 E C0547047:Decrease [Quantitative Concept]

Phrase: "after 48 hours treatment"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   827   C0039798:treatment [Functional Concept]
   827   C0087111:Treatment [Therapeutic or Preventive Procedure]
   827   C1522326:Treatment [Functional Concept]
   827   C1533734:Treatment [Therapeutic or Preventive Procedure]
   827   C1705169:Treatment [Conceptual Entity]
   827   C3538994:TREATMENT [Research Activity]
   734   C0439586:48 hours [Temporal Concept]
   734   C1442464:48 Hours [Temporal Concept]

Phrase: "with 30 mM glucose."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
Processing 00000000.tx.84: Data represent mean  s.e.m. of six independent experiments. 

Phrase: "Data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "represent"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882932:Represent [Activity]

Phrase: "mean"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0444504:Mean [Quantitative Concept]
  1000   C2347634:Mean [Quantitative Concept]
  1000   C2348143:Mean [Quantitative Concept]

Phrase: "s."

Phrase: "e.m."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "of six independent experiments."
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   827   C0681814:Experiments [Research Activity]
   793 E C1706386:Experiment [Conceptual Entity]
   743 E C1517586:Experimental [Qualitative Concept]
Processing 00000000.tx.85: **P<0.001. 

Phrase: "*"

Phrase: "*P<0.001."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]
Processing 00000000.tx.86: (B,C) The gene expression patterns in INS-1E cells cultured in either standard (11.2 mM) or 30 mM glucose medium for 48 hours were quantified by northern blotting. 

Phrase: "(11.2 mM) or 30 mM glucose medium for 48 hours. After 5 hours equilibration in 2.5 mM glucose medium, cells were washed twice with KRBH. Insulin release from INS-1E cells stimulated with 20 mM glucose, 20 mM leucine and 20 mM KCl in KRBH buffer containing 2.5 mM (referred to Basal) was determined by radio-immunoassay and expressed as a percentage of cellular insulin content. The equilibration period is necessary to see the glucose-responsiveness of insulin release in INS-1 cells. Cellular insulin content was decreased by 32.46.7% after 48 hours treatment with 30 mM glucose. Data represent mean  s.e.m. of six independent experiments. **P<0.001. (B,C)"

Phrase: "The gene expression patterns in"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0449774:Patterns [Spatial Concept]

Phrase: "INS-1E cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "cultured in either standard"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C1442989:Standard [Qualitative Concept]
   770   C2828392:Standard [Intellectual Product]
   737   C0010453:Culture [Idea or Concept]
   737   C0220814:culture [Functional Concept]
   737   C0430400:Culture [Laboratory Procedure]
   737   C2242979:Culture [Laboratory Procedure]

Phrase: "(B,C) The gene expression patterns in INS-1E cells cultured in either standard (11.2 mM)"

Phrase: "or"

Phrase: "30 mM glucose medium for 48 hours"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0009458:Medium [Intellectual Product]
   748   C0439536:Medium [Quantitative Concept]
   748   C1705217:Medium [Substance]
   748   C3244283:medium [Intellectual Product]

Phrase: "were"

Phrase: "quantified by northern blotting."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   833   C0005861:Northern Blotting [Molecular Biology Research Technique]
   816 E C1621557:Northern Blot [Research Device]
   770   C1709269:Northern [Spatial Concept]
   737   C1709793:Quantify [Quantitative Concept]
Processing 00000000.tx.87: Total RNA samples (20 g/lane) were analysed by hybridizing with the indicated cDNA probes. 

Phrase: "Total RNA samples"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   793   C0370003:Sample [Substance]
   793   C2347026:Sample [Conceptual Entity]

Phrase: "(11.2 mM) or 30 mM glucose medium for 48 hours were quantified by northern blotting. Total RNA samples (20 g/lane"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1708639:Lane [Spatial Concept]

Phrase: ")"

Phrase: "were"

Phrase: "analysed by hybridizing"

Phrase: "with the indicated cDNA probes."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   901   C0007512:cDNA Probes [Indicator, Reagent, or Diagnostic Aid,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0182400:Probes [Medical Device]
   793 E C1704681:Probe [Gene or Genome]
   793 E C2347609:Probe [Chemical Viewed Functionally]
   793 E C3536729:Probe [Manufactured Object]
Processing 00000000.tx.88: Four independent experiments are shown side by side to demonstrate the consistency of the results.  

Phrase: "Four independent experiments"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   827   C0681814:Experiments [Research Activity]
   793 E C1706386:Experiment [Conceptual Entity]
   743 E C1517586:Experimental [Qualitative Concept]

Phrase: "are"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "side by side to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0441987:Side [Spatial Concept]

Phrase: "demonstrate"

Phrase: "the consistency of the results."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0332529:Consistency [Qualitative Concept]
   760   C1547017:Consistency [Quantitative Concept]
Processing 00000000.tx.89: However, we have also reported that the transcription, nuclear translocation and DNA-binding activity of ChREBP are regulated by glucose in INS-1 cells (Wang and Wollheim, 2002). 

Phrase: "However,"

Phrase: "we"

Phrase: "have"

Phrase: "also"

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "that"

Phrase: "the transcription,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0040649:Transcription [Genetic Function]

Phrase: "nuclear translocation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1518440:Nuclear Translocation [Molecular Function]
   861   C0040715:Translocation [Cell or Molecular Dysfunction]
   861   C2987521:Translocation [Activity]

Phrase: "and"

Phrase: "DNA-binding activity of ChREBP"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   764   C2266866:Binding Activity [Molecular Function]
   762   C1537044:protein activity [Molecular Function]
   742   C0205177:Activity [Functional Concept]
   742   C0439167:% activity [Quantitative Concept]
   742   C0441655:Activity [Activity]
   742   C1561536:*Activity [Idea or Concept]

Phrase: "are"

Phrase: "regulated by glucose"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   790   C0851285:Regulated [Governmental or Regulatory Activity]

Phrase: "in"

Phrase: "INS-1 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "(20 g/lane) were analysed by hybridizing with the indicated cDNA probes. Four independent experiments are shown side by side to demonstrate the consistency of the results.  However, we have also reported that the transcription, nuclear translocation and DNA-binding activity of ChREBP are regulated by glucose in INS-1 cells (Wang"

Phrase: "and"

Phrase: "Wollheim,"

Phrase: "2002"

Phrase: ") were analysed by hybridizing with the indicated cDNA probes. Four independent experiments are shown side by side to demonstrate the consistency of the results.  However, we have also reported that the transcription, nuclear translocation and DNA-binding activity of ChREBP are regulated by glucose in INS-1 cells (Wang and Wollheim, 2002)."
Processing 00000000.tx.90: As demonstrated in Fig. 

Phrase: "As"

Phrase: "demonstrated in Fig."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0349966:Fig [Food]
   790   C1337208:FIG [Food]
Processing 00000000.tx.91: 1C, mRNA levels of ChREBP, L-PK and aldolase B were markedly increased by high glucose. 

Phrase: "1C,"

Phrase: "mRNA levels of ChREBP,"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   767   C1148853:mRNA binding [Genetic Function]
   750   C0428479:Protein level [Laboratory or Test Result]
   750   C1547597:Response level [Idea or Concept]
   744   C0035696:mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   744   C0441889:Levels [Qualitative Concept]
   711 E C0456079:Level [Classification]
   711 E C1547707:Level [Geographic Area]
   711 E C2946261:Level [Pharmacologic Substance]
   703   C1826259:carbohydrate response element binding protein [Gene or Genome]

Phrase: "L-PK"

Phrase: "and"

Phrase: "aldolase B"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0001999:Aldolase B [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1412347:ALDOLASE B [Gene or Genome]
   861   C0016762:Aldolase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "were"

Phrase: "markedly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0522501:Markedly [Qualitative Concept]

Phrase: "increased by high glucose."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   833   C0860803:high glucose [Finding]
           glucose increased
   770   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   770   C0205217:Increased [Quantitative Concept]
   770   C0205250:High [Qualitative Concept]
   770   C0442805:Increased [Functional Concept]
   770   C1299351:High [Qualitative Concept]
   770   C2700149:HIGH [Intellectual Product]
Processing 00000000.tx.92: ChREBP is known to regulate lipogenic gene expression in the liver (Dentin et al., 2004; Iizuka et al., 2004; Ishii et al., 2004), we therefore examined whether it is also involved in -cell glucolipotoxicity. 

Phrase: "ChREBP"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C1826259:carbohydrate response element binding protein [Gene or Genome]
   937   C3158709:carbohydrate response element binding [Genetic Function]
   911   C0108401:carbohydrate-binding protein [Amino Acid, Peptide, or Protein,Receptor]
   875   C1148582:carbohydrate binding [Molecular Function]
   840   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0243122:binding [Functional Concept]
   804   C1145667:Binding [Activity]
   804   C1167622:Binding [Molecular Function]

Phrase: "is"

Phrase: "known"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205309:Known [Qualitative Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "regulate"

Phrase: "lipogenic gene expression in the liver"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0017262:Gene Expression [Genetic Function]
   753   C0017337:Gene [Gene or Genome]
   753   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "(Wang and Wollheim, 2002). As demonstrated in Fig. 1C, mRNA levels of ChREBP, L-PK and aldolase B were markedly increased by high glucose. ChREBP is known to regulate lipogenic gene expression in the liver (Dentin et al.,"

Phrase: "2004"

Phrase: "; Iizuka et al.,"

Phrase: "2004"

Phrase: "; Ishii et al.,"

Phrase: "2004"

Phrase: ")"

Phrase: ","

Phrase: "we therefore"

Phrase: "examined"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332128:Examined [Finding]

Phrase: "whether"

Phrase: "it"

Phrase: "is"

Phrase: "also"

Phrase: "involved"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1314939:Involved [Functional Concept]

Phrase: "in -cell glucolipotoxicity."
Processing 00000000.tx.93: SREBP-1c rather than ChREBP is implicated in glucolipotoxicity in INS-1 cells Differential gene expression patterns in INS-1 cells induced by ChREBP and naSREBP-1c are illustrated in Fig. 

Phrase: "SREBP-1c"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
  1000   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C2246292:sterol binding [Molecular Function]
   827   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0013879:Element [Element, Ion, or Isotope]
   799   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0038323:Sterol [Steroid]
   799   C0220905:regulatory [Regulation or Law]
   799   C0243122:binding [Functional Concept]
   799   C1145667:Binding [Activity]
   799   C1167622:Binding [Molecular Function]
   799   C1704735:Regulatory [Conceptual Entity]
   799   C1705248:Element [Conceptual Entity]

Phrase: "rather than"

Phrase: "ChREBP"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C1826259:carbohydrate response element binding protein [Gene or Genome]
   937   C3158709:carbohydrate response element binding [Genetic Function]
   911   C0108401:carbohydrate-binding protein [Amino Acid, Peptide, or Protein,Receptor]
   875   C1148582:carbohydrate binding [Molecular Function]
   840   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0243122:binding [Functional Concept]
   804   C1145667:Binding [Activity]
   804   C1167622:Binding [Molecular Function]

Phrase: "is"

Phrase: "implicated in glucolipotoxicity"

Phrase: "in"

Phrase: "INS-1 cells Differential gene expression patterns"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   799   C0449774:Patterns [Spatial Concept]

Phrase: "in"

Phrase: "INS-1 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "induced by ChREBP"
Meta Candidates (Total=19; Excluded=1; Pruned=0; Remaining=18)
   897   C1826259:carbohydrate response element binding protein [Gene or Genome]
   853   C3158709:carbohydrate response element binding [Genetic Function]
   804   C0108401:carbohydrate-binding protein [Amino Acid, Peptide, or Protein,Receptor]
   778   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   778   C0600508:Response Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   774 E C0033618:Protein Binding [Molecular Function]
   774   C1148582:carbohydrate binding [Molecular Function]
   748   C0007004:Carbohydrate [Carbohydrate]
   748   C0013879:Element [Element, Ion, or Isotope]
   748   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   748   C0205263:Induced [Functional Concept]
   748   C0243122:binding [Functional Concept]
   748   C0871261:Response [Organism Attribute]
   748   C1145667:Binding [Activity]
   748   C1167622:Binding [Molecular Function]
   748   C1704632:Response [Finding]
   748   C1705248:Element [Conceptual Entity]
   748   C1706817:Response [Intellectual Product]
   748   C2911692:Response [Mental Process]

Phrase: "and"

Phrase: "naSREBP-1c"

Phrase: "are"

Phrase: "illustrated in Fig."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0349966:Fig [Food]
   790   C1337208:FIG [Food]
Processing 00000000.tx.94: 2A,B. 

Phrase: "2A,"

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.95: Quantitative northern blotting was performed in two stable INS-1 cell lines previously established to express, respectively, ChREBP (Wang and Wollheim, 2002) and naSREBP-1c (Wang et al., 2003) in a doxycycline-dependent manner. 

Phrase: "Quantitative northern blotting"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   901   C0005861:Northern Blotting [Molecular Biology Research Technique]
   884 E C1621557:Northern Blot [Research Device]
   827   C1709269:Northern [Spatial Concept]

Phrase: "was"

Phrase: "performed in two stable"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   770   C0205360:Stable [Qualitative Concept]
   770   C0205448:Two [Quantitative Concept]
   770   C0884358:Performed [Functional Concept]
   770   C1547311:Stable [Intellectual Product]
   737 E C2947996:Perform [Pharmacologic Substance]

Phrase: "INS-1 cell lines previously"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   861   C0007600:Cell lines [Cell]
   812   C0007634:Cell [Cell]
   812   C0205132:lines [Spatial Concept]
   812   C1269647:Cell [Cell]
   812   C1704653:Cell [Medical Device]
   812   C1948049:Cell [Spatial Concept]
   779 E C1550648:Line [Substance]
   779 E C1552960:Line [Quantitative Concept]

Phrase: "established"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0443211:Established [Qualitative Concept]
  1000   C1272684:Established [Qualitative Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "express"

Phrase: ","

Phrase: "respectively,"

Phrase: "ChREBP"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C1826259:carbohydrate response element binding protein [Gene or Genome]
   937   C3158709:carbohydrate response element binding [Genetic Function]
   911   C0108401:carbohydrate-binding protein [Amino Acid, Peptide, or Protein,Receptor]
   875   C1148582:carbohydrate binding [Molecular Function]
   840   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0243122:binding [Functional Concept]
   804   C1145667:Binding [Activity]
   804   C1167622:Binding [Molecular Function]

Phrase: "(Dentin et al., 2004; Iizuka et al., 2004; Ishii et al., 2004), we therefore examined whether it is also involved in -cell glucolipotoxicity. SREBP-1c rather than ChREBP is implicated in glucolipotoxicity in INS-1 cells Differential gene expression patterns in INS-1 cells induced by ChREBP and naSREBP-1c are illustrated in Fig. 2A,B. Quantitative northern blotting was performed in two stable INS-1 cell lines previously established to express, respectively, ChREBP (Wang"

Phrase: "and"

Phrase: "Wollheim,"

Phrase: "2002"

Phrase: ")"

Phrase: "and"

Phrase: "naSREBP-1c"

Phrase: "(Wang and Wollheim, 2002) and naSREBP-1c (Wang et al.,"

Phrase: "2003"

Phrase: ")"

Phrase: "in a doxycycline-dependent manner."
Processing 00000000.tx.96: The results displayed in Fig. 

Phrase: "The results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "displayed in Fig."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C0349966:Fig [Food]
   790   C0870432:displayed [Functional Concept]
   790   C1337208:FIG [Food]
   756 E C1705417:Display [Manufactured Object]
Processing 00000000.tx.97: 2A indicate that ChREBP predominantly targeted L-PK and aldolase B, although induction of ChREBP also slightly enhanced the expression of fatty acid synthase and acetyl-CoA carboxylase. 

Phrase: "2A"

Phrase: "indicate"

Phrase: "that ChREBP predominantly targeted L-PK"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   707   C1826259:carbohydrate response element binding protein [Gene or Genome]

Phrase: "and"

Phrase: "aldolase B,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0001999:Aldolase B [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1412347:ALDOLASE B [Gene or Genome]
   861   C0016762:Aldolase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "although"

Phrase: "induction of ChREBP also slightly"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C0205263:Induction [Functional Concept]
   742   C0857127:induction [Therapeutic or Preventive Procedure]

Phrase: "enhanced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2349975:Enhanced [Activity]

Phrase: "the expression of fatty acid synthase"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "and"

Phrase: "acetyl-CoA carboxylase."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0001022:Acetyl-CoA Carboxylase [Amino Acid, Peptide, or Protein,Enzyme]
   901   C0001026:Acetyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0007064:Carboxylase [Amino Acid, Peptide, or Protein,Enzyme]
Processing 00000000.tx.98: In contrast, induction of SREBP-1c drastically increased the lipogenic gene expression for proteins such as, fatty acid synthase, acetyl-CoA carboxylase, HMG-CoA reductase and LDL receptor, whereas it did not affect the mRNA levels of L-PK and aldolase B (Fig. 2B). 

Phrase: "In contrast,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1979874:Contrast [Qualitative Concept]

Phrase: "induction of SREBP-1c drastically"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   742   C0205263:Induction [Functional Concept]
   742   C0857127:induction [Therapeutic or Preventive Procedure]
   716   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "increased"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
  1000   C0205217:Increased [Quantitative Concept]
  1000   C0442805:Increased [Functional Concept]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C1301820:Obtain [Functional Concept]
   907 E C1706701:Acquire [Activity]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "the lipogenic gene expression for proteins"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C0017262:Gene Expression [Genetic Function]
   783   C0751455:Gene Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   767   C1171362:expression protein [Genetic Function]
   753   C0017337:Gene [Gene or Genome]
   753   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "such as,"

Phrase: "fatty acid synthase,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0015683:Fatty-acid synthase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1367441:FATTY ACID SYNTHASE [Gene or Genome]
   901   C0015684:Fatty acid [Lipid]
   827   C0001128:Acid [Chemical]
   827   C0132555:synthase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0202406:Acid [Laboratory Procedure]

Phrase: "acetyl-CoA carboxylase,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0001022:Acetyl-CoA Carboxylase [Amino Acid, Peptide, or Protein,Enzyme]
   901   C0001026:Acetyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0007064:Carboxylase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "HMG-CoA reductase"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0020374:HMG CoA Reductase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C0063164:HMG-CoA reductase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1415615:HMG-CoA REDUCTASE [Gene or Genome]
   901   C0047420:HMG-CoA [Biologically Active Substance,Organic Chemical]
   827   C0030016:Reductase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "and"

Phrase: "LDL receptor,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0034821:LDL Receptor [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1149327:LDL receptor [Molecular Function]
   861   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "whereas"

Phrase: "it"

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "affect"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001721:Affect [Mental Process]

Phrase: "the mRNA levels of L-PK"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   753   C0035696:mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   753   C0441889:Levels [Qualitative Concept]
   719 E C0456079:Level [Classification]
   719 E C1547707:Level [Geographic Area]
   719 E C2946261:Level [Pharmacologic Substance]

Phrase: "and"

Phrase: "aldolase B"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0001999:Aldolase B [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1412347:ALDOLASE B [Gene or Genome]
   861   C0016762:Aldolase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "(Wang et al., 2003) in a doxycycline-dependent manner. The results displayed in Fig. 2A indicate that ChREBP predominantly targeted L-PK and aldolase B, although induction of ChREBP also slightly enhanced the expression of fatty acid synthase and acetyl-CoA carboxylase. In contrast, induction of SREBP-1c drastically increased the lipogenic gene expression for proteins such as, fatty acid synthase, acetyl-CoA carboxylase, HMG-CoA reductase and LDL receptor, whereas it did not affect the mRNA levels of L-PK and aldolase B (Fig. 2B"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0450354:2b [Intellectual Product]
   861   C1706096:2B [Research Activity]

Phrase: ") in a doxycycline-dependent manner. The results displayed in Fig. 2A indicate that ChREBP predominantly targeted L-PK and aldolase B, although induction of ChREBP also slightly enhanced the expression of fatty acid synthase and acetyl-CoA carboxylase. In contrast, induction of SREBP-1c drastically increased the lipogenic gene expression for proteins such as, fatty acid synthase, acetyl-CoA carboxylase, HMG-CoA reductase and LDL receptor, whereas it did not affect the mRNA levels of L-PK and aldolase B (Fig. 2B)."
Processing 00000000.tx.99: It is noteworthy that the function of SREBP-1c may also overlap with the function of SREBP-2 on target gene expression in INS-1 cells since HMG-CoA reductase is regulated by naSREBP-1c. 

Phrase: "It"

Phrase: "is"

Phrase: "noteworthy"

Phrase: "that"

Phrase: "the function of SREBP-1c"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   781   C0033618:Protein binding, function [Molecular Function]
   762   C0815043:function protein [Amino Acid, Peptide, or Protein]
   762   C1527118:Protein Function [Molecular Function]
   742   C0031843:function [Physiologic Function]
   742   C0542341:Function [Functional Concept]
   742   C0700205:FUNCTION [Classification]
   742   C1705273:Function [Intellectual Product]
   716   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "may"

Phrase: "also"

Phrase: "overlap with the function of SREBP-2"
Meta Candidates (Total=25; Excluded=1; Pruned=0; Remaining=24)
   846   C0250036:Sterol Regulatory Element Binding Protein 2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   846   C1420399:STEROL REGULATORY ELEMENT-BINDING PROTEIN 2 [Gene or Genome]
   770   C0033618:Protein binding, function [Molecular Function]
       E   Protein Binding
   756   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   756   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   754   C0815043:function protein [Amino Acid, Peptide, or Protein]
   754   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   754   C1527118:Protein Function [Molecular Function]
   754   C2246292:sterol binding [Molecular Function]
   738   C0013879:Element [Element, Ion, or Isotope]
   738   C0031843:function [Physiologic Function]
   738   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   738   C0038323:Sterol [Steroid]
   738   C0185027:overlap [Therapeutic or Preventive Procedure]
   738   C0220905:regulatory [Regulation or Law]
   738   C0243122:binding [Functional Concept]
   738   C0542341:Function [Functional Concept]
   738   C0700205:FUNCTION [Classification]
   738   C1145667:Binding [Activity]
   738   C1167622:Binding [Molecular Function]
   738   C1704735:Regulatory [Conceptual Entity]
   738   C1705248:Element [Conceptual Entity]
   738   C1705273:Function [Intellectual Product]
   738   C1948020:Overlap [Conceptual Entity]

Phrase: "on target gene expression"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0017262:Gene Expression [Genetic Function]
   901   C1332838:Target Gene [Gene or Genome]
   827   C0017337:Gene [Gene or Genome]
   827   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "in"

Phrase: "INS-1 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "since"

Phrase: "HMG-CoA reductase"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0020374:HMG CoA Reductase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C0063164:HMG-CoA reductase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1415615:HMG-CoA REDUCTASE [Gene or Genome]
   901   C0047420:HMG-CoA [Biologically Active Substance,Organic Chemical]
   827   C0030016:Reductase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "is"

Phrase: "regulated by naSREBP-1c."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0851285:Regulated [Governmental or Regulatory Activity]
Processing 00000000.tx.100: In addition, the expression of IRS2 was suppressed by naSREBP-1c but unaffected by ChREBP. 

Phrase: "In addition,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1883712:Addition [Functional Concept]
   928 E C1524062:Additional [Functional Concept]

Phrase: "the expression of IRS2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   774   C0597360:receptor expression [Genetic Function]
   748   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "was"

Phrase: "suppressed by naSREBP-1c"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1260953:Suppressed [Functional Concept]

Phrase: "but"

Phrase: "unaffected by ChREBP."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C2986417:Unaffected [Conceptual Entity]
   731   C1826259:carbohydrate response element binding protein [Gene or Genome]
Processing 00000000.tx.101: It has been reported recently that SREBP-1c binds to the human IRS2 promoter and suppresses its activity in rat and mouse hepatocytes (Ide et al., 2004). 

Phrase: "It"

Phrase: "has"

Phrase: "been"

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "recently"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332185:Recently [Temporal Concept]

Phrase: "that SREBP-1c"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
  1000   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C2246292:sterol binding [Molecular Function]
   827   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0013879:Element [Element, Ion, or Isotope]
   799   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0038323:Sterol [Steroid]
   799   C0220905:regulatory [Regulation or Law]
   799   C0243122:binding [Functional Concept]
   799   C1145667:Binding [Activity]
   799   C1167622:Binding [Molecular Function]
   799   C1704735:Regulatory [Conceptual Entity]
   799   C1705248:Element [Conceptual Entity]

Phrase: "binds to the human IRS2 promoter"
Meta Candidates (Total=17; Excluded=0; Pruned=0; Remaining=17)
   849   C1334191:insulin receptor substrate 2, human [Amino Acid, Peptide, or Protein,Biologically Active Substance]
           Insulin Receptor Substrate 2
   818   C0381451:Insulin Receptor Substrate-2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   818   C1334141:INSULIN RECEPTOR SUBSTRATE 2 [Gene or Genome]
   790   C1448132:insulin receptor, human [Amino Acid, Peptide, or Protein,Receptor]
   764   C0034818:Insulin Receptor [Amino Acid, Peptide, or Protein,Enzyme,Receptor]
   764   C0795635:Human insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   764   C1334133:INSULIN RECEPTOR [Gene or Genome]
   742   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   742   C0086418:Human [Human]
   742   C0086860:Promoter [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   742   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   742   C1145667:Bind [Activity]
   742   C1167622:bind [Molecular Function]
   742   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   742   C1579433:Insulin [Pharmacologic Substance]
   742   C1710236:Substrate [Manufactured Object]

Phrase: "and"

Phrase: "suppresses"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1260953:suppress [Functional Concept]

Phrase: "its activity in rat"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0205177:Activity [Functional Concept]
   770   C0439167:% activity [Quantitative Concept]
   770   C0441655:Activity [Activity]
   770   C1561536:*Activity [Idea or Concept]

Phrase: "and"

Phrase: "mouse hepatocytes"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   983   C1522062:Mouse Hepatocyte [Tissue]
   861   C0227525:Hepatocytes [Cell]
   827 E C0669372:Hepatocyte NOS [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "(Fig. 2B). It is noteworthy that the function of SREBP-1c may also overlap with the function of SREBP-2 on target gene expression in INS-1 cells since HMG-CoA reductase is regulated by naSREBP-1c. In addition, the expression of IRS2 was suppressed by naSREBP-1c but unaffected by ChREBP. It has been reported recently that SREBP-1c binds to the human IRS2 promoter and suppresses its activity in rat and mouse hepatocytes (Ide et al.,"

Phrase: "2004"

Phrase: "). It is noteworthy that the function of SREBP-1c may also overlap with the function of SREBP-2 on target gene expression in INS-1 cells since HMG-CoA reductase is regulated by naSREBP-1c. In addition, the expression of IRS2 was suppressed by naSREBP-1c but unaffected by ChREBP. It has been reported recently that SREBP-1c binds to the human IRS2 promoter and suppresses its activity in rat and mouse hepatocytes (Ide et al., 2004)."
Processing 00000000.tx.102: View larger version (51K): [in this window] [in a new window]  Fig. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(Ide et al., 2004). View larger version (51K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Fig."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.103: 2. 

Phrase: "2."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]
Processing 00000000.tx.104: Comparison of gene expression patterns in INS-1 cells allowing inducible expression, respectively, of ChREBP and the nuclear active form (na) of SREBP-1c. 

Phrase: "Comparison of gene expression patterns"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1707455:Comparison [Activity]

Phrase: "in"

Phrase: "INS-1 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "allowing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0683607:allowing [Social Behavior]

Phrase: "inducible expression,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "respectively,"

Phrase: "of ChREBP"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C1826259:carbohydrate response element binding protein [Gene or Genome]
   937   C3158709:carbohydrate response element binding [Genetic Function]
   911   C0108401:carbohydrate-binding protein [Amino Acid, Peptide, or Protein,Receptor]
   875   C1148582:carbohydrate binding [Molecular Function]
   840   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0243122:binding [Functional Concept]
   804   C1145667:Binding [Activity]
   804   C1167622:Binding [Molecular Function]

Phrase: "and"

Phrase: "the nuclear active form (na) of SREBP-1c."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   738   C0348078:Form [Qualitative Concept]
   738   C0376315:Form [Manufactured Object]
   738   C1522492:Form [Functional Concept]
Processing 00000000.tx.105: (A) ChREBP*16 cells were cultured in standard medium (11.2 mM glucose) with 0, 75, 150 or 500 ng/ml doxycycline for 24 hours. 

Phrase: "(51K): [in this window] [in a new window]  Fig. 2. Comparison of gene expression patterns in INS-1 cells allowing inducible expression, respectively, of ChREBP and the nuclear active form (na) of SREBP-1c. (A) ChREBP"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   947   C1826259:carbohydrate response element binding protein [Gene or Genome]
   901   C3158709:carbohydrate response element binding [Genetic Function]
   895   C0038164:a protein [Amino Acid, Peptide, or Protein,Immunologic Factor,Indicator, Reagent, or Diagnostic Aid]
   885   C0108401:carbohydrate-binding protein [Amino Acid, Peptide, or Protein,Receptor]
   858   C1148582:carbohydrate binding [Molecular Function]
   827   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0243122:binding [Functional Concept]
   799   C1145667:Binding [Activity]
   799   C1167622:Binding [Molecular Function]

Phrase: "*16 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "cultured in standard medium"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   802   C0010454:Culture medium [Indicator, Reagent, or Diagnostic Aid]
   770   C0009458:Medium [Intellectual Product]
   770   C0439536:Medium [Quantitative Concept]
   770   C1442989:Standard [Qualitative Concept]
   770   C1705217:Medium [Substance]
   770   C2828392:Standard [Intellectual Product]
   770   C3244283:medium [Intellectual Product]
   737   C0010453:Culture [Idea or Concept]
   737   C0220814:culture [Functional Concept]
   737   C0430400:Culture [Laboratory Procedure]
   737   C2242979:Culture [Laboratory Procedure]

Phrase: "(A) ChREBP*16 cells were cultured in standard medium (11.2 mM glucose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: ")"

Phrase: "with 0,"

Phrase: "75,"

Phrase: "150"

Phrase: "or"

Phrase: "500 ng/ml doxycycline for 24 hours."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0013090:Doxycycline [Antibiotic,Organic Chemical]
Processing 00000000.tx.106: The culture was continued in 2.5 mmol/l glucose medium with the indicated concentrations of doxycycline for 16 hours, followed by an additional 8 hours in culture medium with 2.5, 6, 12 and 24 mM glucose and with or without doxycycline. 

Phrase: "The culture"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0010453:Culture [Idea or Concept]
  1000   C0220814:culture [Functional Concept]
  1000   C0430400:Culture [Laboratory Procedure]
  1000   C2242979:Culture [Laboratory Procedure]

Phrase: "was"

Phrase: "continued in 2.5 mmol/l glucose medium"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   770   C1532563:mmol/L [Quantitative Concept]
   744   C0009458:Medium [Intellectual Product]
   744   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   744   C0439190:MMOLE [Quantitative Concept]
   744   C0439536:Medium [Quantitative Concept]
   744   C0549178:Continued [Idea or Concept]
   744   C1705217:Medium [Substance]
   744   C3244283:medium [Intellectual Product]

Phrase: "with the indicated concentrations"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0086045:Concentrations [Mental Process]
   827 E C1446561:Concentration [Quantitative Concept]
   777 E C1880165:Concentrated [Biomedical or Dental Material]

Phrase: "of doxycycline"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0013090:Doxycycline [Antibiotic,Organic Chemical]
   944 E C0699957:Vibramycin [Antibiotic,Organic Chemical]

Phrase: "for 16 hours,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439227:hours [Temporal Concept]
   827 E C0564385:/hour [Quantitative Concept]

Phrase: "followed by an additional 8 hours"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   790   C0332283:Followed by [Temporal Concept]
           followed
   790   C1292429:8 Hours [Temporal Concept]
   753   C0439227:hours [Temporal Concept]
   753   C1524062:Additional [Functional Concept]
   719 E C0564385:/hour [Quantitative Concept]
   719 E C1719822:Follow [Intellectual Product]

Phrase: "in culture medium"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C0010454:Culture medium [Indicator, Reagent, or Diagnostic Aid]
   861   C0009458:Medium [Intellectual Product]
   861   C0010453:Culture [Idea or Concept]
   861   C0220814:culture [Functional Concept]
   861   C0430400:Culture [Laboratory Procedure]
   861   C0439536:Medium [Quantitative Concept]
   861   C1705217:Medium [Substance]
   861   C2242979:Culture [Laboratory Procedure]
   861   C3244283:medium [Intellectual Product]

Phrase: "with 2.5,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0450346:2 5 [Quantitative Concept]
   861   C0740116:+2 [Quantitative Concept]
   861   C2827735:2+ [Quantitative Concept]
   861   C2981700:2+ [Classification]

Phrase: "6,"

Phrase: "12"

Phrase: "and"

Phrase: "24 mM glucose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "and with"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   833   C1515981:And [Idea or Concept]

Phrase: "or without doxycycline."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   790   C0013090:Doxycycline [Antibiotic,Organic Chemical]
   734 E C0699957:Vibramycin [Antibiotic,Organic Chemical]
Processing 00000000.tx.107: The equilibration period is necessary to see the glucose-responsiveness of gene expression. 

Phrase: "The equilibration period"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0439531:/period [Temporal Concept]
   861   C1948053:Period [Temporal Concept]
   789 E C0332182:Periodic [Temporal Concept]
   789 E C1706381:PERIODIC [Intellectual Product]
   761 E C0031084:Periodicities [Temporal Concept]

Phrase: "is"

Phrase: "necessary to"

Phrase: "see"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0042789:see [Organism Function]
  1000   C1947903:See [Activity]

Phrase: "the glucose-responsiveness of gene expression."
Processing 00000000.tx.108: (B) SREBP-1c*233 cells were cultured in 2.5 mM glucose medium with the indicated concentrations of doxycycline for 16 hours, followed by an additional 8 hours in culture medium with 2.5, 6, 12 and 24 mM glucose and with or without doxycycline. 

Phrase: "(11.2 mM glucose) with 0, 75, 150 or 500 ng/ml doxycycline for 24 hours. The culture was continued in 2.5 mmol/l glucose medium with the indicated concentrations of doxycycline for 16 hours, followed by an additional 8 hours in culture medium with 2.5, 6, 12 and 24 mM glucose and with or without doxycycline. The equilibration period is necessary to see the glucose-responsiveness of gene expression. (B) SREBP-1c"
Meta Candidates (Total=18; Excluded=0; Pruned=0; Remaining=18)
   954   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   877   C0377800:b protein [Amino Acid, Peptide, or Protein,Receptor]
   877   C1336694:b-PROTEIN [Gene or Genome]
   877   C1455498:B-Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   845   C0006030:B element [Element, Ion, or Isotope]
   845   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   845   C2246292:sterol binding [Molecular Function]
   818   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   818   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   795   C0013879:Element [Element, Ion, or Isotope]
   795   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   795   C0038323:Sterol [Steroid]
   795   C0220905:regulatory [Regulation or Law]
   795   C0243122:binding [Functional Concept]
   795   C1145667:Binding [Activity]
   795   C1167622:Binding [Molecular Function]
   795   C1704735:Regulatory [Conceptual Entity]
   795   C1705248:Element [Conceptual Entity]

Phrase: "*233 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "cultured in 2.5 mM glucose medium"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   757   C0010454:Culture medium [Indicator, Reagent, or Diagnostic Aid]
   748   C0009458:Medium [Intellectual Product]
   748   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   748   C0439536:Medium [Quantitative Concept]
   748   C1705217:Medium [Substance]
   748   C3244283:medium [Intellectual Product]
   714   C0010453:Culture [Idea or Concept]
   714   C0220814:culture [Functional Concept]
   714   C0430400:Culture [Laboratory Procedure]
   714   C2242979:Culture [Laboratory Procedure]

Phrase: "with the indicated concentrations"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0086045:Concentrations [Mental Process]
   827 E C1446561:Concentration [Quantitative Concept]
   777 E C1880165:Concentrated [Biomedical or Dental Material]

Phrase: "of doxycycline"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0013090:Doxycycline [Antibiotic,Organic Chemical]
   944 E C0699957:Vibramycin [Antibiotic,Organic Chemical]

Phrase: "for 16 hours,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439227:hours [Temporal Concept]
   827 E C0564385:/hour [Quantitative Concept]

Phrase: "followed by an additional 8 hours"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   790   C0332283:Followed by [Temporal Concept]
           followed
   790   C1292429:8 Hours [Temporal Concept]
   753   C0439227:hours [Temporal Concept]
   753   C1524062:Additional [Functional Concept]
   719 E C0564385:/hour [Quantitative Concept]
   719 E C1719822:Follow [Intellectual Product]

Phrase: "in culture medium"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C0010454:Culture medium [Indicator, Reagent, or Diagnostic Aid]
   861   C0009458:Medium [Intellectual Product]
   861   C0010453:Culture [Idea or Concept]
   861   C0220814:culture [Functional Concept]
   861   C0430400:Culture [Laboratory Procedure]
   861   C0439536:Medium [Quantitative Concept]
   861   C1705217:Medium [Substance]
   861   C2242979:Culture [Laboratory Procedure]
   861   C3244283:medium [Intellectual Product]

Phrase: "with 2.5,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0450346:2 5 [Quantitative Concept]
   861   C0740116:+2 [Quantitative Concept]
   861   C2827735:2+ [Quantitative Concept]
   861   C2981700:2+ [Classification]

Phrase: "6,"

Phrase: "12"

Phrase: "and"

Phrase: "24 mM glucose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "and with"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   833   C1515981:And [Idea or Concept]

Phrase: "or without doxycycline."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   790   C0013090:Doxycycline [Antibiotic,Organic Chemical]
   734 E C0699957:Vibramycin [Antibiotic,Organic Chemical]
Processing 00000000.tx.109: SREBP-1c was induced for a total of 24 hours to avoid its apoptotic effects. 

Phrase: "SREBP-1c"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
  1000   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C2246292:sterol binding [Molecular Function]
   827   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0013879:Element [Element, Ion, or Isotope]
   799   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0038323:Sterol [Steroid]
   799   C0220905:regulatory [Regulation or Law]
   799   C0243122:binding [Functional Concept]
   799   C1145667:Binding [Activity]
   799   C1167622:Binding [Molecular Function]
   799   C1704735:Regulatory [Conceptual Entity]
   799   C1705248:Element [Conceptual Entity]

Phrase: "was"

Phrase: "induced for a total of 24 hours to"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   770   C0439584:24 hours [Temporal Concept]
   770   C0456696:/24 hours [Temporal Concept]
   770   C1442770:24 Hours [Temporal Concept]
   744   C0205263:Induced [Functional Concept]
   744   C0439175:% total [Quantitative Concept]
   744   C0439227:hours [Temporal Concept]
   744   C0439810:Total [Qualitative Concept]
   711 E C0564385:/hour [Quantitative Concept]

Phrase: "avoid"

Phrase: "its apoptotic effects."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C1280500:effects [Qualitative Concept]
   827 E C2348382:Effect [Qualitative Concept]
Processing 00000000.tx.110: Gene expression patterns in these cells were evaluated by quantitative northern blotting. 

Phrase: "Gene expression patterns in these cells"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0449774:Patterns [Spatial Concept]

Phrase: "were"

Phrase: "evaluated by quantitative northern blotting."
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   806   C0005861:Northern Blotting [Molecular Biology Research Technique]
   790 E C1621557:Northern Blot [Research Device]
   760   C0220825:Evaluated [Functional Concept]
   760   C0392762:Quantitative [Quantitative Concept]
   760   C1709269:Northern [Spatial Concept]
Processing 00000000.tx.111: 20 g total RNA samples were analysed by hybridising with indicated cDNA probes. 

Phrase: "20 g total RNA samples"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   771   C0370003:Sample [Substance]
   771   C2347026:Sample [Conceptual Entity]

Phrase: "were"

Phrase: "analysed by hybridising"

Phrase: "with indicated cDNA probes."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   901   C0007512:cDNA Probes [Indicator, Reagent, or Diagnostic Aid,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0182400:Probes [Medical Device]
   793 E C1704681:Probe [Gene or Genome]
   793 E C2347609:Probe [Chemical Viewed Functionally]
   793 E C3536729:Probe [Manufactured Object]
Processing 00000000.tx.112: WT, the endogenous wild-type SREBP-1c; 

Phrase: "WT,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2700323:WT [Fish]

Phrase: "the endogenous wild-type SREBP-1c"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
   901   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   829   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   829   C2246292:sterol binding [Molecular Function]
   807   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   807   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   791   C0013879:Element [Element, Ion, or Isotope]
   791   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   791   C0038323:Sterol [Steroid]
   791   C0220905:regulatory [Regulation or Law]
   791   C0243122:binding [Functional Concept]
   791   C1145667:Binding [Activity]
   791   C1167622:Binding [Molecular Function]
   791   C1704735:Regulatory [Conceptual Entity]
   791   C1705248:Element [Conceptual Entity]

Phrase: ";"
Processing 00000000.tx.113: NA, the induced nuclear active form of SRENP-1c. 

Phrase: "NA,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597484:Na+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1272460:{NA} [Qualitative Concept]

Phrase: "the induced nuclear active form of SRENP-1c."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0348078:Form [Qualitative Concept]
   744   C0376315:Form [Manufactured Object]
   744   C1522492:Form [Functional Concept]
Processing 00000000.tx.114: The experiments were repeated two times with similar results.  

Phrase: "The experiments"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0681814:Experiments [Research Activity]
   966 E C1706386:Experiment [Conceptual Entity]
   916 E C1517586:Experimental [Qualitative Concept]

Phrase: "were"

Phrase: "repeated"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0205341:Repeated [Functional Concept]
   966 E C1547730:Repeat [Temporal Concept]
   966 E C1705914:Repeat [Conceptual Entity]

Phrase: "two times with similar results."
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   806   C1948050:Two Times [Quantitative Concept]
   760   C0040223:times [Temporal Concept]
   760   C0205448:Two [Quantitative Concept]
   760   C1632851:Times [Quantitative Concept]
   760   C2348205:Similar [Qualitative Concept]
   726   C1274040:Result [Functional Concept]
   726   C1546471:Result [Idea or Concept]
   726   C2825142:Result [Finding]
   726 E C3541383:Time [Temporal Concept]
Processing 00000000.tx.115: Induction of ChREBP in INS-1 cells did not affect glucose-stimulated insulin secretion or cell growth. 

Phrase: "Induction of ChREBP"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0205263:Induction [Functional Concept]
   748   C0857127:induction [Therapeutic or Preventive Procedure]
   731   C1826259:carbohydrate response element binding protein [Gene or Genome]

Phrase: "in"

Phrase: "INS-1 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "affect"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001721:Affect [Mental Process]

Phrase: "glucose-stimulated insulin secretion"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   875   C1719133:Glucose/Insulin [Quantitative Concept]
   861   C1256369:insulin secretion [Cell Function]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0036536:secretion [Biologic Function]
   812   C0036537:Secretion [Body Substance]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "or"

Phrase: "cell growth."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0007595:Cell Growth [Cell Function]
   861   C0018270:'growth' NOS [Organism Function]
   861   C0220844:growth [Physiologic Function]
   861   C1621966:Growth [Organ or Tissue Function]
   861   C2911660:Growth [Activity]
Processing 00000000.tx.116: In contrast to the effect of naSREBP-1c, induction of ChREBP with 500 ng/ml doxycycline for 48 hours did not alter glucose-stimulated insulin secretion or cellular insulin content. 

Phrase: "In contrast to the effect"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1280500:Effect [Qualitative Concept]
  1000   C2348382:Effect [Qualitative Concept]

Phrase: "of naSREBP-1c,"

Phrase: "induction of ChREBP"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0205263:Induction [Functional Concept]
   748   C0857127:induction [Therapeutic or Preventive Procedure]
   731   C1826259:carbohydrate response element binding protein [Gene or Genome]

Phrase: "with 500 ng/ml doxycycline"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   812   C0013090:Doxycycline [Antibiotic,Organic Chemical]
   756 E C0699957:Vibramycin [Antibiotic,Organic Chemical]

Phrase: "for 48 hours"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0439586:48 hours [Temporal Concept]
  1000   C1442464:48 Hours [Temporal Concept]
   861   C0439227:hours [Temporal Concept]
   827 E C0564385:/hour [Quantitative Concept]

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "alter"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   916   C0392747:Altered [Functional Concept]

Phrase: "glucose-stimulated insulin secretion"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   875   C1719133:Glucose/Insulin [Quantitative Concept]
   861   C1256369:insulin secretion [Cell Function]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0036536:secretion [Biologic Function]
   812   C0036537:Secretion [Body Substance]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "or"

Phrase: "cellular insulin content."
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   827   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C0423896:Content [Mental Process]
   827   C0456205:Content [Conceptual Entity]
   827   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C1579433:Insulin [Pharmacologic Substance]
   771 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   743 E C3537244:Insulins [Pharmacologic Substance]
Processing 00000000.tx.117: To assess the impact of ChREBP on INS-1 cell growth and viability, we performed the WST-1 assay (Fig. 3B). 

Phrase: "To"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "assess"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1516048:Assess [Activity]

Phrase: "the impact of ChREBP"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C1825598:IMPACT [Gene or Genome]
   703   C1826259:carbohydrate response element binding protein [Gene or Genome]

Phrase: "on"

Phrase: "INS-1 cell growth"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C0007595:Cell Growth [Cell Function]
   827   C0018270:'growth' NOS [Organism Function]
   827   C0220844:growth [Physiologic Function]
   827   C1621966:Growth [Organ or Tissue Function]
   827   C2911660:Growth [Activity]

Phrase: "and"

Phrase: "viability,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443348:viability [Qualitative Concept]

Phrase: "we"

Phrase: "performed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0884358:Performed [Functional Concept]
   966 E C2947996:Perform [Pharmacologic Substance]

Phrase: "the WST-1 assay"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0005507:Assay [Laboratory Procedure]
   827   C0243073:assay [Qualitative Concept]
   827   C1510438:Assay [Laboratory Procedure]

Phrase: "(B) SREBP-1c*233 cells were cultured in 2.5 mM glucose medium with the indicated concentrations of doxycycline for 16 hours, followed by an additional 8 hours in culture medium with 2.5, 6, 12 and 24 mM glucose and with or without doxycycline. SREBP-1c was induced for a total of 24 hours to avoid its apoptotic effects. Gene expression patterns in these cells were evaluated by quantitative northern blotting. 20 g total RNA samples were analysed by hybridising with indicated cDNA probes. WT, the endogenous wild-type SREBP-1c; NA, the induced nuclear active form of SRENP-1c. The experiments were repeated two times with similar results.  Induction of ChREBP in INS-1 cells did not affect glucose-stimulated insulin secretion or cell growth. In contrast to the effect of naSREBP-1c, induction of ChREBP with 500 ng/ml doxycycline for 48 hours did not alter glucose-stimulated insulin secretion or cellular insulin content. To assess the impact of ChREBP on INS-1 cell growth and viability, we performed the WST-1 assay (Fig. 3B"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0450365:3b [Intellectual Product]
   861   C1706097:3B [Research Activity]

Phrase: ") with 0, 75, 150 or 500 ng/ml doxycycline for 24 hours. The culture was continued in 2.5 mmol/l glucose medium with the indicated concentrations of doxycycline for 16 hours, followed by an additional 8 hours in culture medium with 2.5, 6, 12 and 24 mM glucose and with or without doxycycline. The equilibration period is necessary to see the glucose-responsiveness of gene expression. (B) SREBP-1c*233 cells were cultured in 2.5 mM glucose medium with the indicated concentrations of doxycycline for 16 hours, followed by an additional 8 hours in culture medium with 2.5, 6, 12 and 24 mM glucose and with or without doxycycline. SREBP-1c was induced for a total of 24 hours to avoid its apoptotic effects. Gene expression patterns in these cells were evaluated by quantitative northern blotting. 20 g total RNA samples were analysed by hybridising with indicated cDNA probes. WT, the endogenous wild-type SREBP-1c; NA, the induced nuclear active form of SRENP-1c. The experiments were repeated two times with similar results.  Induction of ChREBP in INS-1 cells did not affect glucose-stimulated insulin secretion or cell growth. In contrast to the effect of naSREBP-1c, induction of ChREBP with 500 ng/ml doxycycline for 48 hours did not alter glucose-stimulated insulin secretion or cellular insulin content. To assess the impact of ChREBP on INS-1 cell growth and viability, we performed the WST-1 assay (Fig. 3B)."
Processing 00000000.tx.118: This assay is based on the cleavage of a tetrazolium salt WST-1 to formazan by mitochondrial dehydrogenases. 

Phrase: "This assay"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0005507:Assay [Laboratory Procedure]
  1000   C0243073:assay [Qualitative Concept]
  1000   C1510438:Assay [Laboratory Procedure]

Phrase: "is"

Phrase: "based on the cleavage of a tetrazolium salt WST-1"
Meta Candidates (Total=14; Excluded=3; Pruned=0; Remaining=11)
   777   C0671437:WST-1 salt [Organic Chemical]
   760   C0039704:tetrazolium salt [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]
           tetrazolium
   739   C0010813:cleavage [Cell Function]
   739   C0036140:Salt [Chemical Viewed Structurally]
   739   C0037494:Salt [Biologically Active Substance,Inorganic Chemical,Pharmacologic Substance]
   739   C0206136:Salt [Food,Inorganic Chemical]
   739   C0596311:Cleavage [Phenomenon or Process]
   739   C1330957:cleavage [Cell Function]
   739   C1527178:Based [Functional Concept]
   739   C1705938:Based [Idea or Concept]
   706 E C0002055:base [Inorganic Chemical]
   706 E C0178499:Base [Chemical Viewed Functionally]
   706 E C1880279:Base [Biomedical or Dental Material]

Phrase: "to formazan"

Phrase: "by mitochondrial dehydrogenases."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030016:Dehydrogenases [Amino Acid, Peptide, or Protein,Enzyme]
Processing 00000000.tx.119: Expansion in the number of viable cells results in an increase in the overall activity of the mitochondrial dehydrogenases and subsequently an augmentation in the amount of formazan dye formed. 

Phrase: "Expansion in the number of viable cells"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   757   C0007595:cell expansion [Cell Function]

Phrase: "results in an increase"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0442805:Increase [Functional Concept]
   770   C1274040:Result [Functional Concept]
   770   C1546471:Result [Idea or Concept]
   770   C2825142:Result [Finding]

Phrase: "in the overall activity"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0205177:Activity [Functional Concept]
   861   C0439167:% activity [Quantitative Concept]
   861   C0441655:Activity [Activity]
   861   C1561536:*Activity [Idea or Concept]

Phrase: "of the mitochondrial dehydrogenases"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030016:Dehydrogenases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "and"

Phrase: "subsequently"

Phrase: "an augmentation in the amount of formazan dye"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C1293122:Augmentation [Therapeutic or Preventive Procedure]

Phrase: "formed."
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0205431:Formed [Functional Concept]
   966 E C0348078:Form [Qualitative Concept]
   966 E C0376315:Form [Manufactured Object]
   966 E C1522492:Form [Functional Concept]
Processing 00000000.tx.120: Unlike overexpression of naSREBP-1c (Wang et al., 2003), maximum induction of ChREBP for 48 hours did not cause INS-1 cell growth arrest (Fig. 3B) or apoptosis as assessed by DNA fragmentation experiments (data not shown). 

Phrase: "Unlike overexpression"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514559:Overexpression [Genetic Function]

Phrase: "of naSREBP-1c"

Phrase: "(Fig. 3B). This assay is based on the cleavage of a tetrazolium salt WST-1 to formazan by mitochondrial dehydrogenases. Expansion in the number of viable cells results in an increase in the overall activity of the mitochondrial dehydrogenases and subsequently an augmentation in the amount of formazan dye formed. Unlike overexpression of naSREBP-1c (Wang et al.,"

Phrase: "2003"

Phrase: ")"

Phrase: ","

Phrase: "maximum induction of ChREBP"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0205263:Induction [Functional Concept]
   744   C0857127:induction [Therapeutic or Preventive Procedure]
   703   C1826259:carbohydrate response element binding protein [Gene or Genome]

Phrase: "for 48 hours"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0439586:48 hours [Temporal Concept]
  1000   C1442464:48 Hours [Temporal Concept]
   861   C0439227:hours [Temporal Concept]
   827 E C0564385:/hour [Quantitative Concept]

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "cause INS-1 cell growth arrest"
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
   790   C0007595:Cell Growth [Cell Function]
   790   C0333951:Growth arrest [Pathologic Function]
   790   C1414685:INS-1 [Gene or Genome]
   790   C3538717:INS-1 [Gene or Genome]
   753   C0007634:Cell [Cell]
   753   C0015127:cause [Functional Concept]
   753   C0018270:'growth' NOS [Organism Function]
   753   C0220844:growth [Physiologic Function]
   753   C0237477:Arrest [Temporal Concept]
   753   C0392351:arrest [Governmental or Regulatory Activity]
   753   C1269647:Cell [Cell]
   753   C1524003:Cause [Conceptual Entity]
   753   C1621966:Growth [Organ or Tissue Function]
   753   C1704653:Cell [Medical Device]
   753   C1948049:Cell [Spatial Concept]
   753   C2911660:Growth [Activity]

Phrase: "(Wang et al., 2003), maximum induction of ChREBP for 48 hours did not cause INS-1 cell growth arrest (Fig. 3B"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0450365:3b [Intellectual Product]
   861   C1706097:3B [Research Activity]

Phrase: ")"

Phrase: "or"

Phrase: "apoptosis"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0162638:Apoptosis [Cell Function]
   928 E C1516044:Apoptotic [Qualitative Concept]

Phrase: "as"

Phrase: "assessed by DNA fragmentation experiments"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   806   C0376669:DNA Fragmentation [Molecular Function]
   760   C0012854:DNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   760   C0332472:Fragmentation [Anatomical Abnormality]
   760   C0681814:Experiments [Research Activity]
   760   C1516048:Assessed [Activity]
   760   C1881708:FRAGMENTATION [Phenomenon or Process]
   726 E C1706386:Experiment [Conceptual Entity]

Phrase: "(Fig. 3B) or apoptosis as assessed by DNA fragmentation experiments (data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: ") or apoptosis as assessed by DNA fragmentation experiments (data not shown)."
Processing 00000000.tx.121: We have previously shown that similar induction of SREBP-1c caused apoptosis in INS-1 cells (Wang et al., 2003). 

Phrase: "We"

Phrase: "have"

Phrase: "previously"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "that similar induction of SREBP-1c"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   739   C0205263:Induction [Functional Concept]
   739   C0857127:induction [Therapeutic or Preventive Procedure]

Phrase: "caused"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0015127:cause [Functional Concept]
   966   C1524003:Cause [Conceptual Entity]

Phrase: "apoptosis in"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   833   C0162638:Apoptosis [Cell Function]
   761 E C1516044:Apoptotic [Qualitative Concept]

Phrase: "INS-1 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "(data not shown). We have previously shown that similar induction of SREBP-1c caused apoptosis in INS-1 cells (Wang et al.,"

Phrase: "2003"

Phrase: "). We have previously shown that similar induction of SREBP-1c caused apoptosis in INS-1 cells (Wang et al., 2003)."
Processing 00000000.tx.122: View larger version (14K): [in this window] [in a new window]  Fig. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(Wang et al., 2003). View larger version (14K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Fig."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.123: 3. 

Phrase: "3."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]
Processing 00000000.tx.124: Overexpression of ChREBP did not affect glucose-stimulated insulin secretion or cell growth. 

Phrase: "Overexpression of ChREBP"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   774   C1514559:Protein Overexpression [Genetic Function]
           Overexpression
   731   C1826259:carbohydrate response element binding protein [Gene or Genome]

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "affect"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001721:Affect [Mental Process]

Phrase: "glucose-stimulated insulin secretion"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   875   C1719133:Glucose/Insulin [Quantitative Concept]
   861   C1256369:insulin secretion [Cell Function]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0036536:secretion [Biologic Function]
   812   C0036537:Secretion [Body Substance]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "or"

Phrase: "cell growth."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0007595:Cell Growth [Cell Function]
   861   C0018270:'growth' NOS [Organism Function]
   861   C0220844:growth [Physiologic Function]
   861   C1621966:Growth [Organ or Tissue Function]
   861   C2911660:Growth [Activity]
Processing 00000000.tx.125: (A) ChREBP*16 cells were cultured with (+Dox) or without (-Dox) 500 ng/ml doxycycline in standard medium (11.2 mM glucose) for 24 hours and then equilibrated in 2.5 mM glucose medium for a further 24 hours. 

Phrase: "(14K): [in this window] [in a new window]  Fig. 3. Overexpression of ChREBP did not affect glucose-stimulated insulin secretion or cell growth. (A) ChREBP"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   947   C1826259:carbohydrate response element binding protein [Gene or Genome]
   901   C3158709:carbohydrate response element binding [Genetic Function]
   895   C0038164:a protein [Amino Acid, Peptide, or Protein,Immunologic Factor,Indicator, Reagent, or Diagnostic Aid]
   885   C0108401:carbohydrate-binding protein [Amino Acid, Peptide, or Protein,Receptor]
   858   C1148582:carbohydrate binding [Molecular Function]
   827   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0243122:binding [Functional Concept]
   799   C1145667:Binding [Activity]
   799   C1167622:Binding [Molecular Function]

Phrase: "*16 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "cultured with"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   799   C0010453:Culture [Idea or Concept]
   799   C0220814:culture [Functional Concept]
   799   C0430400:Culture [Laboratory Procedure]
   799   C2242979:Culture [Laboratory Procedure]

Phrase: "(A) ChREBP*16 cells were cultured with (+Dox"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0013089:DOX [Antibiotic,Organic Chemical]

Phrase: ")"

Phrase: "or without"

Phrase: "(+Dox) or without (-Dox"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0013089:DOX [Antibiotic,Organic Chemical]

Phrase: ")"

Phrase: "500 ng/ml doxycycline in standard medium"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0013090:Doxycycline [Antibiotic,Organic Chemical]

Phrase: "(-Dox) 500 ng/ml doxycycline in standard medium (11.2 mM glucose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: ")"

Phrase: "for 24 hours"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0439584:24 hours [Temporal Concept]
  1000   C0456696:/24 hours [Temporal Concept]
  1000   C1442770:24 Hours [Temporal Concept]
   861   C0439227:hours [Temporal Concept]
   827 E C0564385:/hour [Quantitative Concept]

Phrase: "and"

Phrase: "then"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883708:Then [Temporal Concept]

Phrase: "equilibrated in 2.5 mM glucose medium"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   748   C0009458:Medium [Intellectual Product]
   748   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   748   C0439536:Medium [Quantitative Concept]
   748   C1705217:Medium [Substance]
   748   C3244283:medium [Intellectual Product]

Phrase: "for a further 24 hours."
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   901   C0439584:24 hours [Temporal Concept]
   901   C0456696:/24 hours [Temporal Concept]
   901   C1442770:24 Hours [Temporal Concept]
   827   C0439227:hours [Temporal Concept]
   793 E C0564385:/hour [Quantitative Concept]
Processing 00000000.tx.126: Insulin release from ChREBP*16 cells in KRBH buffer containing the indicated concentrations of glucose was determined by radio-immunoassay and expressed as a percentage of cellular insulin content. 

Phrase: "Insulin release from ChREBP"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   767   C1623517:insulin binding [Molecular Function]
   744   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C0030685:Release [Health Care Activity]
   744   C0391871:Release [Functional Concept]
   744   C0439180:% release [Quantitative Concept]
   744   C0680255:release [Health Care Activity]
   744   C1283071:Release [Functional Concept]
   744   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C1579433:Insulin [Pharmacologic Substance]
   744   C1963578:Release [Therapeutic or Preventive Procedure]
   703   C1826259:carbohydrate response element binding protein [Gene or Genome]

Phrase: "*16 cells in KRBH buffer"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   760   C0007634:Cells [Cell]
   760   C3282337:Cells [Cell]
   726 E C1269647:Cell [Cell]
   726 E C1704653:Cell [Medical Device]
   726 E C1948049:Cell [Spatial Concept]

Phrase: "containing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:Containing [Functional Concept]
  1000   C2700400:Containing [Activity]

Phrase: "the indicated concentrations of glucose"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   797   C0427743:concentrations glucose [Laboratory Procedure]
   797   C1287281:concentrations glucose [Laboratory or Test Result]
   760   C0086045:Concentrations [Mental Process]
   726 E C1446561:Concentration [Quantitative Concept]

Phrase: "was"

Phrase: "determined by radio-immunoassay"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0020980:Immunoassay [Laboratory Procedure]
   770   C0021060:immunoassay [Laboratory Procedure]
   770   C0034546:Radio [Intellectual Product]
   770   C1304639:Radio [Manufactured Object]

Phrase: "and"

Phrase: "expressed as a percentage of cellular insulin content."
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   744   C0007634:Cellular [Cell]
   744   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C0178539:Cellular [Functional Concept]
   744   C0423896:Content [Mental Process]
   744   C0439165:Percentage [Quantitative Concept]
   744   C0456205:Content [Conceptual Entity]
   744   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C1549488:Percentage [Idea or Concept]
   744   C1561533:Percentage [Idea or Concept]
   744   C1579433:Insulin [Pharmacologic Substance]
Processing 00000000.tx.127: Data represent six independent experiments. 

Phrase: "Data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "represent"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882932:Represent [Activity]

Phrase: "six independent experiments."
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   827   C0681814:Experiments [Research Activity]
   793 E C1706386:Experiment [Conceptual Entity]
   743 E C1517586:Experimental [Qualitative Concept]
Processing 00000000.tx.128: (B) A WST-1 assay, presented as optical density at 440 nm, showed that ChREBP*16 cell growth/survival was not affected by 48 hours treatment with 500 ng/ml doxycycline.  

Phrase: "(11.2 mM glucose) for 24 hours and then equilibrated in 2.5 mM glucose medium for a further 24 hours. Insulin release from ChREBP*16 cells in KRBH buffer containing the indicated concentrations of glucose was determined by radio-immunoassay and expressed as a percentage of cellular insulin content. Data represent six independent experiments. (B) A WST-1 assay,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   804   C0005507:Assay [Laboratory Procedure]
   804   C0243073:assay [Qualitative Concept]
   804   C1510438:Assay [Laboratory Procedure]

Phrase: "presented as optical density"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   833   C0439164:Optical density [Quantitative Concept]
   833   C1268822:Optical density [Clinical Attribute]
   770   C0178587:density [Quantitative Concept]
   770   C0449450:Presented [Idea or Concept]
   737 E C0150312:Present [Quantitative Concept]
   715   C0042789:Vision [Organism Function]
   715   C2707266:Vision [Clinical Attribute]

Phrase: "at 440 nm,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0312860:NM [Cell Function]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "that ChREBP"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C1826259:carbohydrate response element binding protein [Gene or Genome]
   937   C3158709:carbohydrate response element binding [Genetic Function]
   911   C0108401:carbohydrate-binding protein [Amino Acid, Peptide, or Protein,Receptor]
   875   C1148582:carbohydrate binding [Molecular Function]
   840   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0243122:binding [Functional Concept]
   804   C1145667:Binding [Activity]
   804   C1167622:Binding [Molecular Function]

Phrase: "*16 cell growth/survival"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   875   C0007620:Cell Survival [Cell Function]
   812   C0038952:Survival [Activity]
   812   C0220921:survival [Functional Concept]

Phrase: "was"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "affected by 48 hours treatment"
Meta Candidates (Total=13; Excluded=2; Pruned=0; Remaining=11)
   806   C0439586:48 hours [Temporal Concept]
   806   C1442464:48 Hours [Temporal Concept]
   760   C0039798:treatment [Functional Concept]
   760   C0087111:Treatment [Therapeutic or Preventive Procedure]
   760   C0392760:Affected [Functional Concept]
   760   C0439227:hours [Temporal Concept]
   760   C1314939:Affected [Functional Concept]
   760   C1522326:Treatment [Functional Concept]
   760   C1533734:Treatment [Therapeutic or Preventive Procedure]
   760   C1705169:Treatment [Conceptual Entity]
   760   C3538994:TREATMENT [Research Activity]
   726 E C0001721:Affect [Mental Process]
   726 E C0564385:/hour [Quantitative Concept]

Phrase: "with 500 ng/ml doxycycline."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   812   C0013090:Doxycycline [Antibiotic,Organic Chemical]
   756 E C0699957:Vibramycin [Antibiotic,Organic Chemical]
Processing 00000000.tx.129: Establishment of INS-1 stable cell line permitting inducible expression of DN-SREBP-1c To further substantiate the implication of SREBP-1c in chronic high-glucose-induced glucolipotoxicity, we generated an INS-1 stable cell line expressing DN-SREBP-1c, called DN-SREBP-1c*23 cells. 

Phrase: "Establishment of"

Phrase: "INS-1 stable cell line"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   923   C0598091:stable cell line [Cell]
   861   C0007600:Cell Line [Cell]
   812   C0007634:Cell [Cell]
   812   C0205132:Line [Spatial Concept]
   812   C1269647:Cell [Cell]
   812   C1550648:Line [Substance]
   812   C1552960:Line [Quantitative Concept]
   812   C1704653:Cell [Medical Device]
   812   C1948049:Cell [Spatial Concept]

Phrase: "permitting"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0023636:Permit [Regulation or Law]
   966   C0329040:Permit [Fish]

Phrase: "inducible expression of DN-SREBP-1c"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "To further"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1517331:Further [Spatial Concept]
   966 E C0205108:far [Spatial Concept]

Phrase: "substantiate"

Phrase: "the implication of SREBP-1c"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   716   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "in chronic high-glucose-induced glucolipotoxicity,"

Phrase: "we"

Phrase: "generated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3146294:Generated [Activity]

Phrase: "an INS-1 stable cell line"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
   833   C0598091:stable cell line [Cell]
   790   C0007600:Cell Line [Cell]
   790   C1414685:INS-1 [Gene or Genome]
   790   C3538717:INS-1 [Gene or Genome]
   783   C0950951:AN 1 [Organic Chemical,Pharmacologic Substance]
   753   C0007634:Cell [Cell]
   753   C0205132:Line [Spatial Concept]
   753   C0205360:Stable [Qualitative Concept]
   753   C1269647:Cell [Cell]
   753   C1547311:Stable [Intellectual Product]
   753   C1550648:Line [Substance]
   753   C1552960:Line [Quantitative Concept]
   753   C1704653:Cell [Medical Device]
   753   C1948049:Cell [Spatial Concept]

Phrase: "expressing"

Phrase: "DN-SREBP-1c,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
   753   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: "called"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0679006:Call [Mental Process]
   966   C1947967:Call [Functional Concept]

Phrase: "DN-SREBP-1c"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
   753   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: "*23 cells."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.130: This mutant protein contains an intact dimerization domain but lacks DNA-binding activity (Kim and Spiegelman, 1996). 

Phrase: "This mutant protein"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1564139:Mutant Protein [Amino Acid, Peptide, or Protein]
   861   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "contains"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:contain [Functional Concept]
  1000   C2700400:Contain [Activity]

Phrase: "an intact dimerization domain"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1880389:Domain [Functional Concept]
   827   C1883221:Domain [Conceptual Entity]
   827   C3541951:Domain [Intellectual Product]

Phrase: "but"

Phrase: "lacks"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332268:lack [Qualitative Concept]

Phrase: "DNA-binding activity"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   901   C2266866:Binding Activity [Molecular Function]
   827   C0205177:Activity [Functional Concept]
   827   C0439167:% activity [Quantitative Concept]
   827   C0441655:Activity [Activity]
   827   C1561536:*Activity [Idea or Concept]
   734   C1148673:DNA Binding [Genetic Function]

Phrase: "(B) A WST-1 assay, presented as optical density at 440 nm, showed that ChREBP*16 cell growth/survival was not affected by 48 hours treatment with 500 ng/ml doxycycline.  Establishment of INS-1 stable cell line permitting inducible expression of DN-SREBP-1c To further substantiate the implication of SREBP-1c in chronic high-glucose-induced glucolipotoxicity, we generated an INS-1 stable cell line expressing DN-SREBP-1c, called DN-SREBP-1c*23 cells. This mutant protein contains an intact dimerization domain but lacks DNA-binding activity (Kim"

Phrase: "and"

Phrase: "Spiegelman,"

Phrase: "1996"

Phrase: ") for 24 hours and then equilibrated in 2.5 mM glucose medium for a further 24 hours. Insulin release from ChREBP*16 cells in KRBH buffer containing the indicated concentrations of glucose was determined by radio-immunoassay and expressed as a percentage of cellular insulin content. Data represent six independent experiments. (B) A WST-1 assay, presented as optical density at 440 nm, showed that ChREBP*16 cell growth/survival was not affected by 48 hours treatment with 500 ng/ml doxycycline.  Establishment of INS-1 stable cell line permitting inducible expression of DN-SREBP-1c To further substantiate the implication of SREBP-1c in chronic high-glucose-induced glucolipotoxicity, we generated an INS-1 stable cell line expressing DN-SREBP-1c, called DN-SREBP-1c*23 cells. This mutant protein contains an intact dimerization domain but lacks DNA-binding activity (Kim and Spiegelman, 1996)."
Processing 00000000.tx.131: DN-SREBP-1c therefore exerts its dominant-negative function by forming non-functional heterodimers with endogenous SREBPs (Kim and Spiegelman, 1996). 

Phrase: "DN-SREBP-1c therefore"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   814   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
   748   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: "exerts"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0015264:exert [Organism Function]

Phrase: "its dominant-negative function by forming non-functional heterodimers"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   742   C0031843:function [Physiologic Function]
   742   C0542341:Function [Functional Concept]
   742   C0700205:FUNCTION [Classification]
   742   C1705273:Function [Intellectual Product]
   726   C0205300:Non-functional [Functional Concept]

Phrase: "with endogenous SREBPs"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
   947   C1566548:Sterol Regulatory Element Binding Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C0815047:regulatory proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C2246292:sterol binding [Molecular Function]
   827   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0242210:Binding Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0013879:Element [Element, Ion, or Isotope]
   799   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0038323:Sterol [Steroid]
   799   C0220905:regulatory [Regulation or Law]
   799   C0243122:binding [Functional Concept]
   799   C1145667:Binding [Activity]
   799   C1167622:Binding [Molecular Function]
   799   C1704735:Regulatory [Conceptual Entity]
   799   C1705248:Element [Conceptual Entity]

Phrase: "(Kim and Spiegelman, 1996). DN-SREBP-1c therefore exerts its dominant-negative function by forming non-functional heterodimers with endogenous SREBPs (Kim"

Phrase: "and"

Phrase: "Spiegelman,"

Phrase: "1996"

Phrase: "). DN-SREBP-1c therefore exerts its dominant-negative function by forming non-functional heterodimers with endogenous SREBPs (Kim and Spiegelman, 1996)."
Processing 00000000.tx.132: Immunofluorescence staining with an antibody against the N terminus of SREBP-1c demonstrated that DN-SREBP-1c protein was induced by doxycycline in an all-or-none manner (Fig. 4A). 

Phrase: "Immunofluorescence staining with an antibody"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0487602:Staining [Laboratory Procedure]
   760   C1704680:Staining [Finding]

Phrase: "against the N terminus"

Phrase: "of SREBP-1c"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
  1000   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C2246292:sterol binding [Molecular Function]
   827   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0013879:Element [Element, Ion, or Isotope]
   799   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0038323:Sterol [Steroid]
   799   C0220905:regulatory [Regulation or Law]
   799   C0243122:binding [Functional Concept]
   799   C1145667:Binding [Activity]
   799   C1167622:Binding [Molecular Function]
   799   C1704735:Regulatory [Conceptual Entity]
   799   C1705248:Element [Conceptual Entity]

Phrase: "demonstrated"

Phrase: "that DN-SREBP-1c protein"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   800   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
   767   C1564139:Mutant Protein [Amino Acid, Peptide, or Protein]
   744   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: "was"

Phrase: "induced by doxycycline"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0013090:Doxycycline [Antibiotic,Organic Chemical]
   790   C0205263:Induced [Functional Concept]
   734 E C0699957:Vibramycin [Antibiotic,Organic Chemical]

Phrase: "in an all-or-none manner"

Phrase: "(Kim and Spiegelman, 1996). Immunofluorescence staining with an antibody against the N terminus of SREBP-1c demonstrated that DN-SREBP-1c protein was induced by doxycycline in an all-or-none manner (Fig. 4A"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0450373:4a [Intellectual Product]
   861   C1553636:4a [Medical Device]

Phrase: "). Immunofluorescence staining with an antibody against the N terminus of SREBP-1c demonstrated that DN-SREBP-1c protein was induced by doxycycline in an all-or-none manner (Fig. 4A)."
Processing 00000000.tx.133: View larger version (63K): [in this window] [in a new window]  Fig. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(Fig. 4A). View larger version (63K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Fig."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.134: 4. 

Phrase: "4."
Processing 00000000.tx.135: Characteristics of the INS-1 stable cell line expressing DN-SREBP-1c. 

Phrase: "Characteristics of the INS-1 stable cell line"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C1521970:Characteristics [Qualitative Concept]

Phrase: "expressing"

Phrase: "DN-SREBP-1c."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
   753   C0596988:Mutant [Cell or Molecular Dysfunction]
Processing 00000000.tx.136: (A) Phase-contrast images (top) and immunofluorescence staining (bottom) with a rabbit polyclonal antibody against SREBP-1 showed that DN-SREBP-1c protein was induced by doxycycline in an all-or-none manner. 

Phrase: "(63K): [in this window] [in a new window]  Fig. 4. Characteristics of the INS-1 stable cell line expressing DN-SREBP-1c. (A) Phase-contrast images"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   779   C1704254:Image [Intellectual Product]
   779   C1704922:Image [Entity]
   779   C3542466:Image [Intellectual Product]

Phrase: "(A) Phase-contrast images (top)"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1704458:Top [Spatial Concept]

Phrase: "and"

Phrase: "immunofluorescence staining"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0487602:Staining [Laboratory Procedure]
   861   C1704680:Staining [Finding]

Phrase: "(top) and immunofluorescence staining (bottom"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511276:Bottom [Spatial Concept]
  1000   C1552825:bottom [Idea or Concept]

Phrase: ")"

Phrase: "with a rabbit polyclonal antibody"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   913   C1979003:Rabbit Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   901   C0312586:Polyclonal antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   827   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "against SREBP-1"
Meta Candidates (Total=17; Excluded=0; Pruned=0; Remaining=17)
  1000   C0217529:Sterol Regulatory Element Binding Protein 1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
  1000   C1420398:STEROL REGULATORY ELEMENT-BINDING PROTEIN 1 [Gene or Genome]
   858   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C2246292:sterol binding [Molecular Function]
   827   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0087044:protein i [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   827   C0103404:Protein I [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   827   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0013879:Element [Element, Ion, or Isotope]
   799   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0038323:Sterol [Steroid]
   799   C0220905:regulatory [Regulation or Law]
   799   C0243122:binding [Functional Concept]
   799   C1145667:Binding [Activity]
   799   C1167622:Binding [Molecular Function]
   799   C1704735:Regulatory [Conceptual Entity]
   799   C1705248:Element [Conceptual Entity]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "that DN-SREBP-1c protein"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   800   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
   767   C1564139:Mutant Protein [Amino Acid, Peptide, or Protein]
   744   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: "was"

Phrase: "induced by doxycycline"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0013090:Doxycycline [Antibiotic,Organic Chemical]
   790   C0205263:Induced [Functional Concept]
   734 E C0699957:Vibramycin [Antibiotic,Organic Chemical]

Phrase: "in an all-or-none manner."
Processing 00000000.tx.137: DN-SREBP-1c*23 cells were cultured with (+Dox) or without (-Dox) 500 ng/ml doxycycline for 48 hours. 

Phrase: "DN-SREBP-1c"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
   753   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: "*23 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "cultured with"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   799   C0010453:Culture [Idea or Concept]
   799   C0220814:culture [Functional Concept]
   799   C0430400:Culture [Laboratory Procedure]
   799   C2242979:Culture [Laboratory Procedure]

Phrase: "(bottom) with a rabbit polyclonal antibody against SREBP-1 showed that DN-SREBP-1c protein was induced by doxycycline in an all-or-none manner. DN-SREBP-1c*23 cells were cultured with (+Dox"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0013089:DOX [Antibiotic,Organic Chemical]

Phrase: ")"

Phrase: "or without"

Phrase: "(+Dox) or without (-Dox"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0013089:DOX [Antibiotic,Organic Chemical]

Phrase: ")"

Phrase: "500 ng/ml doxycycline for 48 hours."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0013090:Doxycycline [Antibiotic,Organic Chemical]
Processing 00000000.tx.138: (B) Gel-shift assay of nuclear extracts from DN-SREBP-1c*23 cells using the SRE sequence of the IRS2 promoter. 

Phrase: "(-Dox) 500 ng/ml doxycycline for 48 hours. (B) Gel-shift assay of nuclear extracts"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   814   C0949632:Gel Shift Assay [Laboratory Procedure]
   748   C0005507:Assay [Laboratory Procedure]
   748   C0017243:Gel [Biomedical or Dental Material]
   748   C0243073:assay [Qualitative Concept]
   748   C0333051:Shift [Functional Concept]
   748   C1382104:Gel [Substance]
   748   C1510438:Assay [Laboratory Procedure]
   748   C2347509:Shift [Phenomenon or Process]

Phrase: "from DN-SREBP-1c"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   845   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
           Dominant Negative
   818   C0537474:SREBP-1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   818   C1420398:SREBP-1c [Gene or Genome]
   818   C3538602:SREBP-1c [Gene or Genome]
   795   C0205160:Negative [Qualitative Concept]
   795   C0596988:Mutant [Cell or Molecular Dysfunction]
   795   C1513916:Negative [Finding]
   795   C1517320:From [Qualitative Concept]
   795   C1527180:Dominant [Functional Concept]
   795   C2825415:Negative [Conceptual Entity]
   795   C2825491:Negative [Qualitative Concept]

Phrase: "*23 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the SRE sequence of the IRS2 promoter."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   751   C0314642:Regulatory sequence [Nucleotide Sequence]
   736   C0004793:Sequence [Nucleotide Sequence]
   736   C0162326:Sequence [Nucleotide Sequence]
   736   C0162327:Sequence [Nucleotide Sequence]
   736   C1519249:Sequence [Functional Concept]
Processing 00000000.tx.139: DN-SREBP-1c*23 cells were cultured in either standard (11.2 mM) or 30 mM glucose medium for 48 hours, in the presence (+Dox) or absence (-Dox) of 500 ng/ml doxycycline. 

Phrase: "DN-SREBP-1c"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
   753   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: "*23 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "cultured in either standard"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C1442989:Standard [Qualitative Concept]
   770   C2828392:Standard [Intellectual Product]
   737   C0010453:Culture [Idea or Concept]
   737   C0220814:culture [Functional Concept]
   737   C0430400:Culture [Laboratory Procedure]
   737   C2242979:Culture [Laboratory Procedure]

Phrase: "(B) Gel-shift assay of nuclear extracts from DN-SREBP-1c*23 cells using the SRE sequence of the IRS2 promoter. DN-SREBP-1c*23 cells were cultured in either standard (11.2 mM)"

Phrase: "or"

Phrase: "30 mM glucose medium for 48 hours,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0009458:Medium [Intellectual Product]
   748   C0439536:Medium [Quantitative Concept]
   748   C1705217:Medium [Substance]
   748   C3244283:medium [Intellectual Product]

Phrase: "in the presence"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0392148:Presence [Therapeutic or Preventive Procedure]
   928 E C0150312:Present [Quantitative Concept]
   928 E C0449450:Present [Idea or Concept]

Phrase: "(11.2 mM) or 30 mM glucose medium for 48 hours, in the presence (+Dox"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0013089:DOX [Antibiotic,Organic Chemical]

Phrase: ")"

Phrase: "or"

Phrase: "absence"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0332197:absence [Quantitative Concept]
  1000   C1689985:Absence [Anatomical Abnormality]
   928 E C2699517:ABSENT [Finding]

Phrase: "(+Dox) or absence (-Dox"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0013089:DOX [Antibiotic,Organic Chemical]

Phrase: ")"

Phrase: "of 500 ng/ml doxycycline."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   812   C0013090:Doxycycline [Antibiotic,Organic Chemical]
   756 E C0699957:Vibramycin [Antibiotic,Organic Chemical]
Processing 00000000.tx.140: Monoclonal SREBP-1-specific antibody was used for the supershift experiment. 

Phrase: "Monoclonal SREBP-1-specific antibody"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   891   C0003250:Monoclonal antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   829   C1445860:Protein antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   807   C0443640:Specific antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   791   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   791   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   734   C0217529:Sterol Regulatory Element Binding Protein 1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   734   C1420398:STEROL REGULATORY ELEMENT-BINDING PROTEIN 1 [Gene or Genome]

Phrase: "was"

Phrase: "used for the supershift experiment."
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   760   C0681814:Experiment [Research Activity]
   760   C1273517:used [Finding]
   760   C1706386:Experiment [Conceptual Entity]
   726 E C0042153:use [Functional Concept]
   726 E C0457083:Use [Functional Concept]
   726 E C1947944:Use [Intellectual Product]
Processing 00000000.tx.141: Experiments were repeated two to three times with similar results. 

Phrase: "Experiments"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0681814:Experiments [Research Activity]
   966 E C1706386:Experiment [Conceptual Entity]
   916 E C1517586:Experimental [Qualitative Concept]

Phrase: "were"

Phrase: "repeated"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0205341:Repeated [Functional Concept]
   966 E C1547730:Repeat [Temporal Concept]
   966 E C1705914:Repeat [Conceptual Entity]

Phrase: "two to three times"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   819   C1948050:Two Times [Quantitative Concept]
   770   C0205448:Two [Quantitative Concept]

Phrase: "with similar results."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1274040:Result [Functional Concept]
   827   C1546471:Result [Idea or Concept]
   827   C2825142:Result [Finding]
Processing 00000000.tx.142: (C) EMSA of nuclear extracts from non-induced DN-SREBP-1c*23 cells using the SRE sequence of the IRS2 promoter. 

Phrase: "(-Dox) of 500 ng/ml doxycycline. Monoclonal SREBP-1-specific antibody was used for the supershift experiment. Experiments were repeated two to three times with similar results. (C) EMSA"
Meta Candidates (Total=15; Excluded=2; Pruned=0; Remaining=13)
   877   C0949632:Electrophoretic Mobility Shift Assay [Laboratory Procedure]
           Mobility Shift Assay
   795   C0005507:Assay [Laboratory Procedure]
   795   C0185115:Extraction [Therapeutic or Preventive Procedure]
   795   C0243073:assay [Qualitative Concept]
   795   C0333051:Shift [Functional Concept]
   795   C0425245:Mobility [Finding]
   795   C0449580:Mobility [Qualitative Concept]
   795   C0684295:extraction [Laboratory Procedure]
   795   C1510438:Assay [Laboratory Procedure]
   795   C1553033:[c] [Quantitative Concept]
   795   C2347509:Shift [Phenomenon or Process]
   724   C0013855:Electrophoreses [Laboratory Procedure]
   724 E C0231435:Mobile [Functional Concept]
   724 E C1552449:Mobile [Health Care Related Organization,Manufactured Object]

Phrase: "of nuclear extracts"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1518434:Nuclear Extract [Biomedical or Dental Material]
   861   C0521447:Nuclear [Spatial Concept]
   827   C2828366:Extract [Substance]

Phrase: "from non-induced DN-SREBP-1c"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
   827   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
           Dominant Negative
   807   C0537474:SREBP-1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   807   C1420398:SREBP-1c [Gene or Genome]
   807   C3538602:SREBP-1c [Gene or Genome]
   791   C0205160:Negative [Qualitative Concept]
   791   C0205263:Induced [Functional Concept]
   791   C0596988:Mutant [Cell or Molecular Dysfunction]
   791   C1513916:Negative [Finding]
   791   C1517320:From [Qualitative Concept]
   791   C1518422:Non [Functional Concept]
   791   C1527180:Dominant [Functional Concept]
   791   C2825415:Negative [Conceptual Entity]
   791   C2825491:Negative [Qualitative Concept]

Phrase: "*23 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the SRE sequence of the IRS2 promoter."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   751   C0314642:Regulatory sequence [Nucleotide Sequence]
   736   C0004793:Sequence [Nucleotide Sequence]
   736   C0162326:Sequence [Nucleotide Sequence]
   736   C0162327:Sequence [Nucleotide Sequence]
   736   C1519249:Sequence [Functional Concept]
Processing 00000000.tx.143: DN-SREBP-1c*23 cells were cultured in either standard (11.2 mM) or 30 mM glucose medium for 48 hours. 

Phrase: "DN-SREBP-1c"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
   753   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: "*23 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "cultured in either standard"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C1442989:Standard [Qualitative Concept]
   770   C2828392:Standard [Intellectual Product]
   737   C0010453:Culture [Idea or Concept]
   737   C0220814:culture [Functional Concept]
   737   C0430400:Culture [Laboratory Procedure]
   737   C2242979:Culture [Laboratory Procedure]

Phrase: "(C) EMSA of nuclear extracts from non-induced DN-SREBP-1c*23 cells using the SRE sequence of the IRS2 promoter. DN-SREBP-1c*23 cells were cultured in either standard (11.2 mM)"

Phrase: "or"

Phrase: "30 mM glucose medium for 48 hours."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0009458:Medium [Intellectual Product]
   748   C0439536:Medium [Quantitative Concept]
   748   C1705217:Medium [Substance]
   748   C3244283:medium [Intellectual Product]
Processing 00000000.tx.144: Monoclonal SREBP-2-specific antibody was used for the supershift experiment. 

Phrase: "Monoclonal SREBP-2-specific antibody"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   891   C0003250:Monoclonal antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   829   C1445860:Protein antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   807   C0443640:Specific antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   791   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   791   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   734   C0250036:Sterol Regulatory Element Binding Protein 2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   734   C1420399:STEROL REGULATORY ELEMENT-BINDING PROTEIN 2 [Gene or Genome]

Phrase: "was"

Phrase: "used for the supershift experiment."
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   760   C0681814:Experiment [Research Activity]
   760   C1273517:used [Finding]
   760   C1706386:Experiment [Conceptual Entity]
   726 E C0042153:use [Functional Concept]
   726 E C0457083:Use [Functional Concept]
   726 E C1947944:Use [Intellectual Product]
Processing 00000000.tx.145: Experiments were repeated twice with similar results.  

Phrase: "Experiments"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0681814:Experiments [Research Activity]
   966 E C1706386:Experiment [Conceptual Entity]
   916 E C1517586:Experimental [Qualitative Concept]

Phrase: "were"

Phrase: "repeated"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0205341:Repeated [Functional Concept]
   966 E C1547730:Repeat [Temporal Concept]
   966 E C1705914:Repeat [Conceptual Entity]

Phrase: "twice with similar results."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C1720725:Twice [Intellectual Product]
   770   C1948050:Twice [Quantitative Concept]
   770   C2348205:Similar [Qualitative Concept]
   737   C1274040:Result [Functional Concept]
   737   C1546471:Result [Idea or Concept]
   737   C2825142:Result [Finding]
Processing 00000000.tx.146: Effects of DN-SREBP-1c on chronic high-glucose-induced glucolipotoxicity in INS-1 cells Induction of DN-SREBP-1c abolished chronic high-glucose-induced SREBP-1 binding to the IRS2 promoter. 

Phrase: "Effects of DN-SREBP-1c"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   744   C1280500:effects [Qualitative Concept]
   711 E C2348382:Effect [Qualitative Concept]

Phrase: "on chronic high-glucose-induced glucolipotoxicity"

Phrase: "in"

Phrase: "INS-1 cells Induction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0205263:Induction [Functional Concept]
   827   C0857127:induction [Therapeutic or Preventive Procedure]

Phrase: "of DN-SREBP-1c"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   845   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
           Dominant Negative
   818   C0537474:SREBP-1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   818   C1420398:SREBP-1c [Gene or Genome]
   818   C3538602:SREBP-1c [Gene or Genome]
   795   C0205160:Negative [Qualitative Concept]
   795   C0332285:Of [Spatial Concept]
   795   C0596988:Mutant [Cell or Molecular Dysfunction]
   795   C1513916:Negative [Finding]
   795   C1527180:Dominant [Functional Concept]
   795   C2825415:Negative [Conceptual Entity]
   795   C2825491:Negative [Qualitative Concept]

Phrase: "abolished"

Phrase: "chronic high-glucose-induced SREBP-1 binding"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   704   C0217529:Sterol Regulatory Element Binding Protein 1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   704   C1420398:STEROL REGULATORY ELEMENT-BINDING PROTEIN 1 [Gene or Genome]

Phrase: "to the IRS2 promoter."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0086860:Promoter [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   771   C0381451:Insulin Receptor Substrate-2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   771   C1334141:INSULIN RECEPTOR SUBSTRATE 2 [Gene or Genome]
   771   C1334191:Insulin Receptor Substrate 2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
Processing 00000000.tx.147: DN-SREBP-1c*23 cells were cultured in either standard (11.2 mM) or 30 mM glucose medium for 48 hours, in the presence (+Dox) or absence (-Dox) of 500 ng/ml doxycycline. 

Phrase: "DN-SREBP-1c"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
   753   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: "*23 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "cultured in either standard"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C1442989:Standard [Qualitative Concept]
   770   C2828392:Standard [Intellectual Product]
   737   C0010453:Culture [Idea or Concept]
   737   C0220814:culture [Functional Concept]
   737   C0430400:Culture [Laboratory Procedure]
   737   C2242979:Culture [Laboratory Procedure]

Phrase: "(11.2 mM) or 30 mM glucose medium for 48 hours. Monoclonal SREBP-2-specific antibody was used for the supershift experiment. Experiments were repeated twice with similar results.  Effects of DN-SREBP-1c on chronic high-glucose-induced glucolipotoxicity in INS-1 cells Induction of DN-SREBP-1c abolished chronic high-glucose-induced SREBP-1 binding to the IRS2 promoter. DN-SREBP-1c*23 cells were cultured in either standard (11.2 mM)"

Phrase: "or"

Phrase: "30 mM glucose medium for 48 hours,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0009458:Medium [Intellectual Product]
   748   C0439536:Medium [Quantitative Concept]
   748   C1705217:Medium [Substance]
   748   C3244283:medium [Intellectual Product]

Phrase: "in the presence"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0392148:Presence [Therapeutic or Preventive Procedure]
   928 E C0150312:Present [Quantitative Concept]
   928 E C0449450:Present [Idea or Concept]

Phrase: "(11.2 mM) or 30 mM glucose medium for 48 hours, in the presence (+Dox"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0013089:DOX [Antibiotic,Organic Chemical]

Phrase: ")"

Phrase: "or"

Phrase: "absence"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0332197:absence [Quantitative Concept]
  1000   C1689985:Absence [Anatomical Abnormality]
   928 E C2699517:ABSENT [Finding]

Phrase: "(+Dox) or absence (-Dox"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0013089:DOX [Antibiotic,Organic Chemical]

Phrase: ")"

Phrase: "of 500 ng/ml doxycycline."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   812   C0013090:Doxycycline [Antibiotic,Organic Chemical]
   756 E C0699957:Vibramycin [Antibiotic,Organic Chemical]
Processing 00000000.tx.148: EMSA with the SRE element of the human IRS2 promoter (Ide et al., 2004) showed that SREBP protein binding was increased 10-fold by 48 hours treatment with 30 mM glucose, which was diminished by 80% after induction of DN-SREBP-1c (Fig. 4B). 

Phrase: "EMSA"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   799   C0185115:Extraction [Therapeutic or Preventive Procedure]
   799   C0684295:extraction [Laboratory Procedure]
   734   C0949632:Electrophoretic Mobility Shift Assay [Laboratory Procedure]

Phrase: "with the SRE element"

Phrase: "of the human IRS2 promoter"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   799   C0086860:Promoter [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   780   C1334191:insulin receptor substrate 2, human [Amino Acid, Peptide, or Protein,Biologically Active Substance]
           Insulin Receptor Substrate 2
   734   C0381451:Insulin Receptor Substrate-2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   734   C1334141:INSULIN RECEPTOR SUBSTRATE 2 [Gene or Genome]

Phrase: "(-Dox) of 500 ng/ml doxycycline. EMSA with the SRE element of the human IRS2 promoter (Ide et al.,"

Phrase: "2004"

Phrase: ")"

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "that SREBP protein binding"

Phrase: "was"

Phrase: "increased"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
  1000   C0205217:Increased [Quantitative Concept]
  1000   C0442805:Increased [Functional Concept]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C1301820:Obtain [Functional Concept]
   907 E C1706701:Acquire [Activity]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "10-fold by 48 hours treatment"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   783   C1442445:10 Hours [Temporal Concept]
   753   C0332462:Fold [Spatial Concept]
   753   C1880834:FOLD [Phenomenon or Process]

Phrase: "with 30 mM glucose,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "which"

Phrase: "was"

Phrase: "diminished by 80%"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0205216:Diminished [Quantitative Concept]

Phrase: "after induction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205263:Induction [Functional Concept]
  1000   C0857127:induction [Therapeutic or Preventive Procedure]

Phrase: "of DN-SREBP-1c"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   845   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
           Dominant Negative
   818   C0537474:SREBP-1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   818   C1420398:SREBP-1c [Gene or Genome]
   818   C3538602:SREBP-1c [Gene or Genome]
   795   C0205160:Negative [Qualitative Concept]
   795   C0332285:Of [Spatial Concept]
   795   C0596988:Mutant [Cell or Molecular Dysfunction]
   795   C1513916:Negative [Finding]
   795   C1527180:Dominant [Functional Concept]
   795   C2825415:Negative [Conceptual Entity]
   795   C2825491:Negative [Qualitative Concept]

Phrase: "(Ide et al., 2004) showed that SREBP protein binding was increased 10-fold by 48 hours treatment with 30 mM glucose, which was diminished by 80% after induction of DN-SREBP-1c (Fig. 4B"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0450375:4b [Intellectual Product]

Phrase: ") showed that SREBP protein binding was increased 10-fold by 48 hours treatment with 30 mM glucose, which was diminished by 80% after induction of DN-SREBP-1c (Fig. 4B)."
Processing 00000000.tx.149: The specificity of SREBP-1 binding complexes was confirmed by the observed supershift with a monoclonal anti-SREBP-1 antibody (Fig. 4B). 

Phrase: "The specificity of SREBP-1 binding complexes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   772   C1335858:SPECIFICITY PROTEIN 1 [Gene or Genome]
   738   C0037791:Specificity [Quantitative Concept]
   738   C1511884:Specificity [Quantitative Concept]

Phrase: "was"

Phrase: "confirmed by the observed supershift"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   806   C0521093:Confirmed by [Qualitative Concept]
           confirmed
   760   C0750484:Confirmed [Idea or Concept]
   760   C1441672:Observed [Functional Concept]
   726 E C1456348:Confirm [Qualitative Concept]

Phrase: "with a monoclonal anti-SREBP-1 antibody"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   891   C0003250:Monoclonal antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   879   C0003242:anti antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   817   C1445860:Protein antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   791   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   791   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   734   C0217529:Sterol Regulatory Element Binding Protein 1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   734   C1420398:STEROL REGULATORY ELEMENT-BINDING PROTEIN 1 [Gene or Genome]
   700   C0443737:Monoclonal protein [Amino Acid, Peptide, or Protein,Immunologic Factor]
   700   C0700271:monoclonal protein [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "(Fig. 4B). The specificity of SREBP-1 binding complexes was confirmed by the observed supershift with a monoclonal anti-SREBP-1 antibody (Fig. 4B"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0450375:4b [Intellectual Product]

Phrase: "). The specificity of SREBP-1 binding complexes was confirmed by the observed supershift with a monoclonal anti-SREBP-1 antibody (Fig. 4B)."
Processing 00000000.tx.150: However, we could not exclude binding activity of SREBP-2 to the IRS2-SRE-element, since it would also be inhibited by DN-SREBP-1c (Rishi et al., 2004). 

Phrase: "However,"

Phrase: "we"

Phrase: "could"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "exclude"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332196:Exclude [Functional Concept]
  1000   C2828389:Exclude [Activity]

Phrase: "binding activity of SREBP-2"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   764   C2266866:Binding Activity [Molecular Function]
   762   C1537044:protein activity [Molecular Function]
   742   C0205177:Activity [Functional Concept]
   742   C0439167:% activity [Quantitative Concept]
   742   C0441655:Activity [Activity]
   742   C1561536:*Activity [Idea or Concept]
   716   C0250036:Sterol Regulatory Element Binding Protein 2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   716   C1420399:STEROL REGULATORY ELEMENT-BINDING PROTEIN 2 [Gene or Genome]

Phrase: "to the IRS2-SRE-element,"

Phrase: "since"

Phrase: "it"

Phrase: "would"

Phrase: "also"

Phrase: "be"

Phrase: "inhibited by DN-SREBP-1c"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   800   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
           Dominant Negative
   770   C0537474:SREBP-1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   770   C1420398:SREBP-1c [Gene or Genome]
   770   C3538602:SREBP-1c [Gene or Genome]
   744   C0205160:Negative [Qualitative Concept]
   744   C0311403:Inhibited [Qualitative Concept]
   744   C0596988:Mutant [Cell or Molecular Dysfunction]
   744   C1513916:Negative [Finding]
   744   C1527180:Dominant [Functional Concept]
   744   C2825415:Negative [Conceptual Entity]
   744   C2825491:Negative [Qualitative Concept]

Phrase: "(Fig. 4B). However, we could not exclude binding activity of SREBP-2 to the IRS2-SRE-element, since it would also be inhibited by DN-SREBP-1c (Rishi et al.,"

Phrase: "2004"

Phrase: "). However, we could not exclude binding activity of SREBP-2 to the IRS2-SRE-element, since it would also be inhibited by DN-SREBP-1c (Rishi et al., 2004)."
Processing 00000000.tx.151: Indeed, monoclonal anti-SREBP-2 antibody also caused a supershift of the retarded complex but to a much lesser extent than the SREBP-1-specific antibody (Fig. 4C). 

Phrase: "Indeed,"

Phrase: "monoclonal anti-SREBP-2 antibody also"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   880   C0003250:Monoclonal antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   868   C0003242:anti antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   813   C1445860:Protein antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   790   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   790   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   717   C0250036:Sterol Regulatory Element Binding Protein 2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   717   C1420399:STEROL REGULATORY ELEMENT-BINDING PROTEIN 2 [Gene or Genome]

Phrase: "caused"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0015127:cause [Functional Concept]
   966   C1524003:Cause [Conceptual Entity]

Phrase: "a supershift of the retarded complex"

Phrase: "but to a much lesser extent"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0233535:but [Mental or Behavioral Dysfunction]
   753   C0439792:Extent [Spatial Concept]
   753   C0547044:Lesser [Qualitative Concept]

Phrase: "than the SREBP-1-specific antibody"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   836   C1445860:Protein antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   812   C0443640:Specific antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   793   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   793   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   756   C0217529:Sterol Regulatory Element Binding Protein 1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   756   C1420398:STEROL REGULATORY ELEMENT-BINDING PROTEIN 1 [Gene or Genome]

Phrase: "(Rishi et al., 2004). Indeed, monoclonal anti-SREBP-2 antibody also caused a supershift of the retarded complex but to a much lesser extent than the SREBP-1-specific antibody (Fig. 4C"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0450376:4c [Intellectual Product]

Phrase: "). Indeed, monoclonal anti-SREBP-2 antibody also caused a supershift of the retarded complex but to a much lesser extent than the SREBP-1-specific antibody (Fig. 4C)."
Processing 00000000.tx.152: These results suggest that SREBP-1 accounts for the majority of the glucose-induced binding activity to the IRS2 promoter. 

Phrase: "These results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "suggest"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that SREBP-1 accounts for the majority"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   704   C1551359:account [Idea or Concept]
   704   C2741673:Account # [Clinical Attribute]
   704   C2981730:Account [Classification]

Phrase: "of the glucose-induced binding activity"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C2266866:Binding Activity [Molecular Function]
   812   C0205177:Activity [Functional Concept]
   812   C0439167:% activity [Quantitative Concept]
   812   C0441655:Activity [Activity]
   812   C1561536:*Activity [Idea or Concept]
   708   C1148590:glucose binding [Molecular Function]

Phrase: "to the IRS2 promoter."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0086860:Promoter [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   771   C0381451:Insulin Receptor Substrate-2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   771   C1334141:INSULIN RECEPTOR SUBSTRATE 2 [Gene or Genome]
   771   C1334191:Insulin Receptor Substrate 2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
Processing 00000000.tx.153: Induction of DN-SREBP-1c diminished chronic high-glucose-induced lipid accumulation, apoptosis and impaired insulin secretion in INS-1 cells. 

Phrase: "Induction of DN-SREBP-1c"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0205263:Induction [Functional Concept]
   744   C0857127:induction [Therapeutic or Preventive Procedure]

Phrase: "diminished"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205216:Diminished [Quantitative Concept]

Phrase: "chronic high-glucose-induced lipid accumulation,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0333574:Lipid accumulation [Finding]

Phrase: "apoptosis"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0162638:Apoptosis [Cell Function]
   928 E C1516044:Apoptotic [Qualitative Concept]

Phrase: "and"

Phrase: "impaired insulin secretion in"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   833   C1256369:insulin secretion [Cell Function]
   770   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   770   C0036536:secretion [Biologic Function]
   770   C0036537:Secretion [Body Substance]
   770   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   770   C1579433:Insulin [Pharmacologic Substance]
   715 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]

Phrase: "INS-1 cells."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.154: As shown by Oil-Red-O staining (Fig. 5A), 30 mM glucose treatment of DN-SREBP-1c*23 cells for 48 hours resulted in massive lipid accumulation, which was largely prevented by induction of DN-SREBP-1c. 

Phrase: "As"

Phrase: "shown by Oil-Red-O staining"
Meta Candidates (Total=11; Excluded=1; Pruned=0; Remaining=10)
   866   C0069388:Oil red O stain [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]
           oil red O
   866   C1294000:Oil red-O stain [Laboratory Procedure]
   753   C0028908:Oil [Lipid]
   753   C0332575:Red [Finding]
   753   C0487602:Staining [Laboratory Procedure]
   753   C1260956:Red [Qualitative Concept]
   753   C1517288:Oil [Food,Lipid]
   753   C1704680:Staining [Finding]
   719 E C0038128:Stain [Indicator, Reagent, or Diagnostic Aid]
   719   C1547282:Show [Intellectual Product]

Phrase: "(Fig. 4C). These results suggest that SREBP-1 accounts for the majority of the glucose-induced binding activity to the IRS2 promoter. Induction of DN-SREBP-1c diminished chronic high-glucose-induced lipid accumulation, apoptosis and impaired insulin secretion in INS-1 cells. As shown by Oil-Red-O staining (Fig. 5A"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1553637:5a [Medical Device]

Phrase: ")"

Phrase: ","

Phrase: "30 mM glucose treatment of DN-SREBP-1c"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   738   C0039798:treatment [Functional Concept]
   738   C0087111:Treatment [Therapeutic or Preventive Procedure]
   738   C1522326:Treatment [Functional Concept]
   738   C1533734:Treatment [Therapeutic or Preventive Procedure]
   738   C1705169:Treatment [Conceptual Entity]
   738   C3538994:TREATMENT [Research Activity]

Phrase: "*23 cells for 48 hours"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   760   C0007634:Cells [Cell]
   760   C3282337:Cells [Cell]
   726 E C1269647:Cell [Cell]
   726 E C1704653:Cell [Medical Device]
   726 E C1948049:Cell [Spatial Concept]

Phrase: "resulted in massive lipid accumulation,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   806   C0333574:Lipid accumulation [Finding]
   760   C0023779:Lipid [Lipid]
   760   C0522501:Massive [Qualitative Concept]
   726   C1274040:Result [Functional Concept]
   726   C1546471:Result [Idea or Concept]
   726   C2825142:Result [Finding]

Phrase: "which"

Phrase: "was"

Phrase: "largely"

Phrase: "prevented by induction of DN-SREBP-1c."
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
   782   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
           Dominant Negative
   760   C0537474:SREBP-1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   760   C1420398:SREBP-1c [Gene or Genome]
   760   C3538602:SREBP-1c [Gene or Genome]
   739   C0205160:Negative [Qualitative Concept]
   739   C0205263:Induction [Functional Concept]
   739   C0596988:Mutant [Cell or Molecular Dysfunction]
   739   C0857127:induction [Therapeutic or Preventive Procedure]
   739   C1513916:Negative [Finding]
   739   C1527180:Dominant [Functional Concept]
   739   C2825415:Negative [Conceptual Entity]
   739   C2825491:Negative [Qualitative Concept]
   706   C0309872:PREVENT [Pharmacologic Substance]
Processing 00000000.tx.155: Similarly, treatment of DN-SREBP-1c*23 cells for 48 and 72 hours with 30 mM glucose caused typical DNA fragmentation (Fig. 5B), a characteristic hallmark of cells undergoing apoptosis. 

Phrase: "Similarly,"

Phrase: "treatment of DN-SREBP-1c"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   744   C0039798:treatment [Functional Concept]
   744   C0087111:Treatment [Therapeutic or Preventive Procedure]
   744   C1522326:Treatment [Functional Concept]
   744   C1533734:Treatment [Therapeutic or Preventive Procedure]
   744   C1705169:Treatment [Conceptual Entity]
   744   C3538994:TREATMENT [Research Activity]

Phrase: "*23 cells for 48"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   770   C0007634:Cells [Cell]
   770   C3282337:Cells [Cell]
   737 E C1269647:Cell [Cell]
   737 E C1704653:Cell [Medical Device]
   737 E C1948049:Cell [Spatial Concept]

Phrase: "and"

Phrase: "72 hours with 30 mM glucose"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C1292423:72 Hours [Temporal Concept]
   753   C0439227:hours [Temporal Concept]
   719 E C0564385:/hour [Quantitative Concept]

Phrase: "caused"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0015127:cause [Functional Concept]
   966   C1524003:Cause [Conceptual Entity]

Phrase: "typical DNA fragmentation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0376669:DNA Fragmentation [Molecular Function]
   827   C0332472:Fragmentation [Anatomical Abnormality]
   827   C1881708:FRAGMENTATION [Phenomenon or Process]

Phrase: "(Fig. 5A), 30 mM glucose treatment of DN-SREBP-1c*23 cells for 48 hours resulted in massive lipid accumulation, which was largely prevented by induction of DN-SREBP-1c. Similarly, treatment of DN-SREBP-1c*23 cells for 48 and 72 hours with 30 mM glucose caused typical DNA fragmentation (Fig. 5B"

Phrase: ")"

Phrase: ","

Phrase: "a characteristic hallmark of cells"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   781   C1512330:Hallmark Cell [Cell]

Phrase: "undergoing"

Phrase: "apoptosis."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0162638:Apoptosis [Cell Function]
   928 E C1516044:Apoptotic [Qualitative Concept]
Processing 00000000.tx.156: DN-SREBP-1c largely protected INS-1 cells from apoptosis (Fig. 5B). 

Phrase: "DN-SREBP-1c"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
   753   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: "largely protected INS-1 cells"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   745   C0524828:Cell Protection [Physiologic Function]

Phrase: "from apoptosis"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0162638:Apoptosis [Cell Function]
   928 E C1516044:Apoptotic [Qualitative Concept]

Phrase: "(Fig. 5B), a characteristic hallmark of cells undergoing apoptosis. DN-SREBP-1c largely protected INS-1 cells from apoptosis (Fig. 5B"

Phrase: "), a characteristic hallmark of cells undergoing apoptosis. DN-SREBP-1c largely protected INS-1 cells from apoptosis (Fig. 5B)."
Processing 00000000.tx.157: View larger version (48K): [in this window] [in a new window]  Fig. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(Fig. 5B). View larger version (48K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Fig."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.158: 5. 

Phrase: "5."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439084:>5 [Quantitative Concept]
  1000   C0728893:+5 [Quantitative Concept]
Processing 00000000.tx.159: Induction of DN-SREBP-1c largely prevented chronic high-glucose-induced glucolipotoxicity in INS-1 cells. 

Phrase: "Induction of DN-SREBP-1c largely"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C0205263:Induction [Functional Concept]
   742   C0857127:induction [Therapeutic or Preventive Procedure]

Phrase: "prevented"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0309872:PREVENT [Pharmacologic Substance]

Phrase: "chronic high-glucose-induced glucolipotoxicity in"

Phrase: "INS-1 cells."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.160: (A) DN-SREBP-1c diminished lipid droplets accumulation, as seen by staining with Oil Red-O. 

Phrase: "(48K): [in this window] [in a new window]  Fig. 5. Induction of DN-SREBP-1c largely prevented chronic high-glucose-induced glucolipotoxicity in INS-1 cells. (A) DN-SREBP-1c"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   814   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
   748   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: "diminished"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205216:Diminished [Quantitative Concept]

Phrase: "lipid droplets accumulation,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   988   C3278535:Lipid droplet accumulation [Finding]
   913   C0333574:Lipid accumulation [Finding]
   734   C0230704:Lipid droplets [Cell Component]

Phrase: "as"

Phrase: "seen by staining"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   790   C0205397:Seen [Qualitative Concept]
   790   C0487602:Staining [Laboratory Procedure]
   790   C1704680:Staining [Finding]
   756 E C0042789:see [Organism Function]
   756 E C1947903:See [Activity]

Phrase: "with Oil Red-O."
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
  1000   C0069388:oil red O [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]
   827   C0028908:Oil [Lipid]
   827   C0332575:Red [Finding]
   827   C1260956:Red [Qualitative Concept]
   827   C1517288:Oil [Food,Lipid]
   771 E C0996956:Olea [Plant]
   755 E C0234925:OILY [Finding]
Processing 00000000.tx.161: DN-SREBP-1c*23 cells were cultured in either standard (11.2 mM; Control) or 30 mM glucose (High glucose) medium for 48 hours, in the presence (+Dox) or absence (-Dox) of 500 ng/ml doxycycline. 

Phrase: "DN-SREBP-1c"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
   753   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: "*23 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "cultured in either standard"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C1442989:Standard [Qualitative Concept]
   770   C2828392:Standard [Intellectual Product]
   737   C0010453:Culture [Idea or Concept]
   737   C0220814:culture [Functional Concept]
   737   C0430400:Culture [Laboratory Procedure]
   737   C2242979:Culture [Laboratory Procedure]

Phrase: "(A) DN-SREBP-1c diminished lipid droplets accumulation, as seen by staining with Oil Red-O. DN-SREBP-1c*23 cells were cultured in either standard (11.2 mM"

Phrase: "; Control"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0243148:control [Qualitative Concept]
  1000   C1550141:Control [Substance]
  1000   C1882979:Control [Conceptual Entity]
  1000   C2587213:Control [Functional Concept]
  1000   C3274648:Control [Qualitative Concept]

Phrase: ")"

Phrase: "or"

Phrase: "30 mM glucose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "(11.2 mM; Control) or 30 mM glucose (High glucose"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0860803:high glucose [Finding]
   861   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: ")"

Phrase: "medium for 48 hours,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0009458:Medium [Intellectual Product]
   770   C0439536:Medium [Quantitative Concept]
   770   C1705217:Medium [Substance]
   770   C3244283:medium [Intellectual Product]

Phrase: "in the presence"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0392148:Presence [Therapeutic or Preventive Procedure]
   928 E C0150312:Present [Quantitative Concept]
   928 E C0449450:Present [Idea or Concept]

Phrase: "(High glucose) medium for 48 hours, in the presence (+Dox"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0013089:DOX [Antibiotic,Organic Chemical]

Phrase: ")"

Phrase: "or"

Phrase: "absence"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0332197:absence [Quantitative Concept]
  1000   C1689985:Absence [Anatomical Abnormality]
   928 E C2699517:ABSENT [Finding]

Phrase: "(+Dox) or absence (-Dox"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0013089:DOX [Antibiotic,Organic Chemical]

Phrase: ")"

Phrase: "of 500 ng/ml doxycycline."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   812   C0013090:Doxycycline [Antibiotic,Organic Chemical]
   756 E C0699957:Vibramycin [Antibiotic,Organic Chemical]
Processing 00000000.tx.162: (B) DN-SREBP-1c prevented apoptosis. 

Phrase: "(-Dox) of 500 ng/ml doxycycline. (B) DN-SREBP-1c"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   814   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
   748   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: "prevented"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0309872:PREVENT [Pharmacologic Substance]

Phrase: "apoptosis."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0162638:Apoptosis [Cell Function]
   928 E C1516044:Apoptotic [Qualitative Concept]
Processing 00000000.tx.163: DNA fragmentation was assessed in DN-SREBP-1c*23 cells cultured in 30 mM glucose medium for 0, 24, 48, and 72 hours, in the presence (+Dox) or absence (-Dox) of 500 ng/ml doxycycline. 

Phrase: "DNA fragmentation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0376669:DNA Fragmentation [Molecular Function]
   861   C0332472:Fragmentation [Anatomical Abnormality]
   861   C1881708:FRAGMENTATION [Phenomenon or Process]

Phrase: "was"

Phrase: "assessed in DN-SREBP-1c"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   800   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
           Dominant Negative
   770   C0537474:SREBP-1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   770   C1420398:SREBP-1c [Gene or Genome]
   770   C3538602:SREBP-1c [Gene or Genome]
   744   C0205160:Negative [Qualitative Concept]
   744   C0596988:Mutant [Cell or Molecular Dysfunction]
   744   C1513916:Negative [Finding]
   744   C1516048:Assessed [Activity]
   744   C1527180:Dominant [Functional Concept]
   744   C2825415:Negative [Conceptual Entity]
   744   C2825491:Negative [Qualitative Concept]

Phrase: "*23 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "cultured in 30 mM glucose medium"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   767   C0010454:Culture medium [Indicator, Reagent, or Diagnostic Aid]
   753   C0009458:Medium [Intellectual Product]
   753   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   753   C0439536:Medium [Quantitative Concept]
   753   C1705217:Medium [Substance]
   753   C3244283:medium [Intellectual Product]
   719   C0010453:Culture [Idea or Concept]
   719   C0220814:culture [Functional Concept]
   719   C0430400:Culture [Laboratory Procedure]
   719   C2242979:Culture [Laboratory Procedure]

Phrase: "for 0,"

Phrase: "24,"

Phrase: "48,"

Phrase: "and"

Phrase: "72 hours,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1292423:72 Hours [Temporal Concept]
   861   C0439227:hours [Temporal Concept]
   827 E C0564385:/hour [Quantitative Concept]

Phrase: "in the presence"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0392148:Presence [Therapeutic or Preventive Procedure]
   928 E C0150312:Present [Quantitative Concept]
   928 E C0449450:Present [Idea or Concept]

Phrase: "(B) DN-SREBP-1c prevented apoptosis. DNA fragmentation was assessed in DN-SREBP-1c*23 cells cultured in 30 mM glucose medium for 0, 24, 48, and 72 hours, in the presence (+Dox"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0013089:DOX [Antibiotic,Organic Chemical]

Phrase: ")"

Phrase: "or"

Phrase: "absence"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0332197:absence [Quantitative Concept]
  1000   C1689985:Absence [Anatomical Abnormality]
   928 E C2699517:ABSENT [Finding]

Phrase: "(+Dox) or absence (-Dox"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0013089:DOX [Antibiotic,Organic Chemical]

Phrase: ")"

Phrase: "of 500 ng/ml doxycycline."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   812   C0013090:Doxycycline [Antibiotic,Organic Chemical]
   756 E C0699957:Vibramycin [Antibiotic,Organic Chemical]
Processing 00000000.tx.164: (C) DN-SREBP-1c partially restored glucose-stimulated insulin secretion. 

Phrase: "(-Dox) of 500 ng/ml doxycycline. (C) DN-SREBP-1c partially restored glucose-stimulated insulin secretion."
Meta Candidates (Total=23; Excluded=2; Pruned=0; Remaining=21)
   809   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
           Dominant Negative
   804   C1719133:Glucose/Insulin [Quantitative Concept]
   797   C0537474:SREBP-1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   797   C1256369:insulin secretion [Cell Function]
   797   C1420398:SREBP-1c [Gene or Genome]
   797   C3538602:SREBP-1c [Gene or Genome]
   786   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   786   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   786   C0036536:secretion [Biologic Function]
   786   C0036537:Secretion [Body Substance]
   786   C0205160:Negative [Qualitative Concept]
   786   C0596988:Mutant [Cell or Molecular Dysfunction]
   786   C1513916:Negative [Finding]
   786   C1527180:Dominant [Functional Concept]
   786   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   786   C1553033:[c] [Quantitative Concept]
   786   C1579433:Insulin [Pharmacologic Substance]
   786   C1948023:Stimulated [Natural Phenomenon or Process]
   786   C2825415:Negative [Conceptual Entity]
   786   C2825491:Negative [Qualitative Concept]
   731 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   703 E C3537244:Insulins [Pharmacologic Substance]
Processing 00000000.tx.165: DN-SREBP-1c*23 cells in 24-well dishes were cultured in either standard (11.2 mM; Control) or 30 mM glucose (High Glucose) medium for 48 hours. 

Phrase: "DN-SREBP-1c"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
   753   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: "*23 cells in 24-well dishes"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   783   C2347578:Cells/well [Quantitative Concept]
   767   C2347576:Cells/dish [Quantitative Concept]
   753   C0007634:Cells [Cell]
   753   C3282337:Cells [Cell]
   719 E C1269647:Cell [Cell]
   719 E C1704653:Cell [Medical Device]
   719 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "cultured in either standard"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C1442989:Standard [Qualitative Concept]
   770   C2828392:Standard [Intellectual Product]
   737   C0010453:Culture [Idea or Concept]
   737   C0220814:culture [Functional Concept]
   737   C0430400:Culture [Laboratory Procedure]
   737   C2242979:Culture [Laboratory Procedure]

Phrase: "(C) DN-SREBP-1c partially restored glucose-stimulated insulin secretion. DN-SREBP-1c*23 cells in 24-well dishes were cultured in either standard (11.2 mM"

Phrase: "; Control"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0243148:control [Qualitative Concept]
  1000   C1550141:Control [Substance]
  1000   C1882979:Control [Conceptual Entity]
  1000   C2587213:Control [Functional Concept]
  1000   C3274648:Control [Qualitative Concept]

Phrase: ")"

Phrase: "or"

Phrase: "30 mM glucose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "(11.2 mM; Control) or 30 mM glucose (High Glucose"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0860803:high glucose [Finding]
   861   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: ")"

Phrase: "medium for 48 hours."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0009458:Medium [Intellectual Product]
   770   C0439536:Medium [Quantitative Concept]
   770   C1705217:Medium [Substance]
   770   C3244283:medium [Intellectual Product]
Processing 00000000.tx.166: After 5 hours equilibration in 2.5 mM glucose medium, cells were washed twice with KRBH. 

Phrase: "After 5 hours equilibration"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   734   C1442467:5 Hours [Temporal Concept]

Phrase: "in 2.5 mM glucose medium,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0009458:Medium [Intellectual Product]
   804   C0439536:Medium [Quantitative Concept]
   804   C1705217:Medium [Substance]
   804   C3244283:medium [Intellectual Product]

Phrase: "cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "washed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1548982:Washed [Idea or Concept]
   966 E C0441648:Wash [Activity]

Phrase: "twice with KRBH."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C1720725:Twice [Intellectual Product]
   790   C1948050:Twice [Quantitative Concept]
Processing 00000000.tx.167: Insulin release from DN-SREBP-1c*23 cells stimulated with either 2.5 (Basal) or 20 mM glucose was determined by radio-immunoassay and expressed as a percentage of cellular insulin content. 

Phrase: "Insulin release from DN-SREBP-1c"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   742   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   742   C0030685:Release [Health Care Activity]
   742   C0391871:Release [Functional Concept]
   742   C0439180:% release [Quantitative Concept]
   742   C0680255:release [Health Care Activity]
   742   C1283071:Release [Functional Concept]
   742   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   742   C1579433:Insulin [Pharmacologic Substance]
   742   C1963578:Release [Therapeutic or Preventive Procedure]

Phrase: "*23 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "stimulated with either 2.5"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1948023:Stimulated [Natural Phenomenon or Process]

Phrase: "(High Glucose) medium for 48 hours. After 5 hours equilibration in 2.5 mM glucose medium, cells were washed twice with KRBH. Insulin release from DN-SREBP-1c*23 cells stimulated with either 2.5 (Basal"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205112:Basal [Spatial Concept]

Phrase: ")"

Phrase: "or"

Phrase: "20 mM glucose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "was"

Phrase: "determined by radio-immunoassay"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0020980:Immunoassay [Laboratory Procedure]
   770   C0021060:immunoassay [Laboratory Procedure]
   770   C0034546:Radio [Intellectual Product]
   770   C1304639:Radio [Manufactured Object]

Phrase: "and"

Phrase: "expressed as a percentage of cellular insulin content."
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   744   C0007634:Cellular [Cell]
   744   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C0178539:Cellular [Functional Concept]
   744   C0423896:Content [Mental Process]
   744   C0439165:Percentage [Quantitative Concept]
   744   C0456205:Content [Conceptual Entity]
   744   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C1549488:Percentage [Idea or Concept]
   744   C1561533:Percentage [Idea or Concept]
   744   C1579433:Insulin [Pharmacologic Substance]
Processing 00000000.tx.168: Data represent mean  s.e.m. of six independent experiments. 

Phrase: "Data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "represent"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882932:Represent [Activity]

Phrase: "mean"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0444504:Mean [Quantitative Concept]
  1000   C2347634:Mean [Quantitative Concept]
  1000   C2348143:Mean [Quantitative Concept]

Phrase: "s."

Phrase: "e.m."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "of six independent experiments."
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   827   C0681814:Experiments [Research Activity]
   793 E C1706386:Experiment [Conceptual Entity]
   743 E C1517586:Experimental [Qualitative Concept]
Processing 00000000.tx.169: *P<0.01; 

Phrase: "*P<0.01"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: ";"
Processing 00000000.tx.170: **P<0.001.  

Phrase: "*"

Phrase: "*P<0.001."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]
Processing 00000000.tx.171: In agreement with the results obtained in INS-1E (Fig. 1A), treatment of DN-SREBP-1c*23 cells with 30 mM glucose for 48 hours also led to reduced glucose-stimulated insulin secretion (Fig. 5C). 

Phrase: "In agreement"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0680240:Agreement [Social Behavior]

Phrase: "with the results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "obtained in"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
   833   C1301820:Obtained [Functional Concept]
   799 E C1706701:Obtain [Activity]
   761 E C1517378:Gain [Quantitative Concept]
   740 E C0205217:Increased [Quantitative Concept]
   740 E C0439661:Acquired [Temporal Concept]
   740 E C0442805:Increase [Functional Concept]
   740 E C0442808:Increasing [Functional Concept]
   740 E C3245488:acquired [Intellectual Product]

Phrase: "INS-1E"

Phrase: "(Basal) or 20 mM glucose was determined by radio-immunoassay and expressed as a percentage of cellular insulin content. Data represent mean  s.e.m. of six independent experiments. *P<0.01; **P<0.001.  In agreement with the results obtained in INS-1E (Fig. 1A"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0450344:1A [Intellectual Product]
   861   C1553633:1a [Medical Device]

Phrase: ")"

Phrase: ","

Phrase: "treatment of DN-SREBP-1c"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   744   C0039798:treatment [Functional Concept]
   744   C0087111:Treatment [Therapeutic or Preventive Procedure]
   744   C1522326:Treatment [Functional Concept]
   744   C1533734:Treatment [Therapeutic or Preventive Procedure]
   744   C1705169:Treatment [Conceptual Entity]
   744   C3538994:TREATMENT [Research Activity]

Phrase: "*23 cells with 30 mM glucose"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   753   C0007634:Cells [Cell]
   753   C3282337:Cells [Cell]
   719 E C1269647:Cell [Cell]
   719 E C1704653:Cell [Medical Device]
   719 E C1948049:Cell [Spatial Concept]

Phrase: "for 48 hours also"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   901   C0439586:48 hours [Temporal Concept]
   901   C1442464:48 Hours [Temporal Concept]
   827   C0439227:hours [Temporal Concept]
   793 E C0564385:/hour [Quantitative Concept]

Phrase: "led to reduced glucose-stimulated insulin secretion"
Meta Candidates (Total=16; Excluded=5; Pruned=0; Remaining=11)
   778   C1256369:insulin secretion [Cell Function]
   774   C1719133:Glucose/Insulin [Quantitative Concept]
   748   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   748   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   748   C0036536:secretion [Biologic Function]
   748   C0036537:Secretion [Body Substance]
   748   C0392756:Reduced [Qualitative Concept]
   748   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   748   C1579433:Insulin [Pharmacologic Substance]
   748   C1708698:LED [Manufactured Object]
   748   C1948023:Stimulated [Natural Phenomenon or Process]
   714 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   714 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   714 E C1522538:Lead [Functional Concept]
   714 E C2348269:Lead [Element, Ion, or Isotope]
   714 E C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "(Fig. 1A), treatment of DN-SREBP-1c*23 cells with 30 mM glucose for 48 hours also led to reduced glucose-stimulated insulin secretion (Fig. 5C"

Phrase: "), treatment of DN-SREBP-1c*23 cells with 30 mM glucose for 48 hours also led to reduced glucose-stimulated insulin secretion (Fig. 5C)."
Processing 00000000.tx.172: The glucose-stimulated insulin secretion was partially restored by expression of DN-SREBP-1c (Fig. 5C). 

Phrase: "The glucose-stimulated insulin secretion"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   875   C1719133:Glucose/Insulin [Quantitative Concept]
   861   C1256369:insulin secretion [Cell Function]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0036536:secretion [Biologic Function]
   812   C0036537:Secretion [Body Substance]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "was"

Phrase: "partially"

Phrase: "restored by expression of DN-SREBP-1c"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   782   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
           Dominant Negative
   760   C0537474:SREBP-1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   760   C1420398:SREBP-1c [Gene or Genome]
   760   C3538602:SREBP-1c [Gene or Genome]
   739   C0185117:Expression [Therapeutic or Preventive Procedure]
   739   C0205160:Negative [Qualitative Concept]
   739   C0596988:Mutant [Cell or Molecular Dysfunction]
   739   C1513916:Negative [Finding]
   739   C1527180:Dominant [Functional Concept]
   739   C2825415:Negative [Conceptual Entity]
   739   C2825491:Negative [Qualitative Concept]

Phrase: "(Fig. 5C). The glucose-stimulated insulin secretion was partially restored by expression of DN-SREBP-1c (Fig. 5C"

Phrase: "). The glucose-stimulated insulin secretion was partially restored by expression of DN-SREBP-1c (Fig. 5C)."
Processing 00000000.tx.173: Unexpectedly, induction of DN-SREBP-1c slightly increased basal (2.5 mM) insulin release in control cells (Fig. 5C). 

Phrase: "Unexpectedly,"

Phrase: "induction of DN-SREBP-1c slightly"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C0205263:Induction [Functional Concept]
   742   C0857127:induction [Therapeutic or Preventive Procedure]

Phrase: "increased"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
  1000   C0205217:Increased [Quantitative Concept]
  1000   C0442805:Increased [Functional Concept]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C1301820:Obtain [Functional Concept]
   907 E C1706701:Acquire [Activity]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "basal"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205112:Basal [Spatial Concept]

Phrase: "(Fig. 5C). Unexpectedly, induction of DN-SREBP-1c slightly increased basal (2.5 mM) insulin release in control cells"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   793   C1548189:Release 2.5 [Intellectual Product]
   750   C0030281:Insulin Cell [Cell]
   744   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C0030685:Release [Health Care Activity]
   744   C0391871:Release [Functional Concept]
   744   C0439180:% release [Quantitative Concept]
   744   C0680255:release [Health Care Activity]
   744   C1283071:Release [Functional Concept]
   744   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C1579433:Insulin [Pharmacologic Substance]
   744   C1963578:Release [Therapeutic or Preventive Procedure]

Phrase: "(2.5 mM) insulin release in control cells (Fig. 5C"

Phrase: "). Unexpectedly, induction of DN-SREBP-1c slightly increased basal (2.5 mM) insulin release in control cells (Fig. 5C)."
Processing 00000000.tx.174: DN-SREBP-1c corrected defective gene expression in INS-1 cells treated with chronic high glucose As demonstrated in Fig. 

Phrase: "DN-SREBP-1c"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
   753   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: "corrected"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0205202:Corrected [Qualitative Concept]
   966 E C2349182:Correct [Qualitative Concept]

Phrase: "defective gene expression in"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   833   C0017262:Gene Expression [Genetic Function]
   770   C0017337:Gene [Gene or Genome]
   770   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "INS-1 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "treated with chronic high glucose"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   806   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   806   C0860803:high glucose [Finding]
   760   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   760   C0205191:chronic [Temporal Concept]
   760   C0205250:High [Qualitative Concept]
   760   C1299351:High [Qualitative Concept]
   760   C1522326:Treated [Functional Concept]
   760   C2700149:HIGH [Intellectual Product]
   726 E C1292734:TREAT [Functional Concept]

Phrase: "As"

Phrase: "demonstrated in Fig."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0349966:Fig [Food]
   790   C1337208:FIG [Food]
Processing 00000000.tx.175: 6, treatment of DN-SREBP-1c*23 cells with 30 mM glucose for 48 hours increased the mRNA levels of L-PK, aldolase B and ChREBP, which were not affected by induction of DN-SREBP-1c. 

Phrase: "6,"

Phrase: "treatment of DN-SREBP-1c"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   744   C0039798:treatment [Functional Concept]
   744   C0087111:Treatment [Therapeutic or Preventive Procedure]
   744   C1522326:Treatment [Functional Concept]
   744   C1533734:Treatment [Therapeutic or Preventive Procedure]
   744   C1705169:Treatment [Conceptual Entity]
   744   C3538994:TREATMENT [Research Activity]

Phrase: "*23 cells with 30 mM glucose"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   753   C0007634:Cells [Cell]
   753   C3282337:Cells [Cell]
   719 E C1269647:Cell [Cell]
   719 E C1704653:Cell [Medical Device]
   719 E C1948049:Cell [Spatial Concept]

Phrase: "for 48 hours"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0439586:48 hours [Temporal Concept]
  1000   C1442464:48 Hours [Temporal Concept]
   861   C0439227:hours [Temporal Concept]
   827 E C0564385:/hour [Quantitative Concept]

Phrase: "increased"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
  1000   C0205217:Increased [Quantitative Concept]
  1000   C0442805:Increased [Functional Concept]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C1301820:Obtain [Functional Concept]
   907 E C1706701:Acquire [Activity]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "the mRNA levels of L-PK,"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   753   C0035696:mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   753   C0441889:Levels [Qualitative Concept]
   719 E C0456079:Level [Classification]
   719 E C1547707:Level [Geographic Area]
   719 E C2946261:Level [Pharmacologic Substance]

Phrase: "aldolase B"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0001999:Aldolase B [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1412347:ALDOLASE B [Gene or Genome]
   861   C0016762:Aldolase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "and"

Phrase: "ChREBP,"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C1826259:carbohydrate response element binding protein [Gene or Genome]
   937   C3158709:carbohydrate response element binding [Genetic Function]
   911   C0108401:carbohydrate-binding protein [Amino Acid, Peptide, or Protein,Receptor]
   875   C1148582:carbohydrate binding [Molecular Function]
   840   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0243122:binding [Functional Concept]
   804   C1145667:Binding [Activity]
   804   C1167622:Binding [Molecular Function]

Phrase: "which"

Phrase: "were"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "affected by induction of DN-SREBP-1c."
Meta Candidates (Total=16; Excluded=1; Pruned=0; Remaining=15)
   782   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
           Dominant Negative
   760   C0537474:SREBP-1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   760   C1420398:SREBP-1c [Gene or Genome]
   760   C3538602:SREBP-1c [Gene or Genome]
   739   C0205160:Negative [Qualitative Concept]
   739   C0205263:Induction [Functional Concept]
   739   C0392760:Affected [Functional Concept]
   739   C0596988:Mutant [Cell or Molecular Dysfunction]
   739   C0857127:induction [Therapeutic or Preventive Procedure]
   739   C1314939:Affected [Functional Concept]
   739   C1513916:Negative [Finding]
   739   C1527180:Dominant [Functional Concept]
   739   C2825415:Negative [Conceptual Entity]
   739   C2825491:Negative [Qualitative Concept]
   706 E C0001721:Affect [Mental Process]
Processing 00000000.tx.176: These results suggest that high glucose may promote the expression of L-PK and aldolase B through a SREBP-1c-independent but ChREBP-dependent pathway. 

Phrase: "These results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "suggest"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that high glucose"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0860803:high glucose [Finding]
   861   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "may"

Phrase: "promote"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033414:Promote [Activity]

Phrase: "the expression of L-PK"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "and"

Phrase: "aldolase B through a SREBP-1c-independent"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   756   C0001999:Aldolase B [Amino Acid, Peptide, or Protein,Enzyme]
   756   C1412347:ALDOLASE B [Gene or Genome]
   754   C0001998:Aldolase A [Amino Acid, Peptide, or Protein,Enzyme]
   754   C0377800:protein B [Amino Acid, Peptide, or Protein,Receptor]
   754   C1412344:ALDOLASE A [Gene or Genome]
   738   C0016762:Aldolase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "but"

Phrase: "ChREBP-dependent pathway."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   795   C1704259:Pathway [Molecular Function]
   795   C1705987:Pathway [Conceptual Entity]
   747   C1826259:carbohydrate response element binding protein [Gene or Genome]
   710   C3158709:carbohydrate response element binding [Genetic Function]
   701   C0108401:carbohydrate-binding protein [Amino Acid, Peptide, or Protein,Receptor]
Processing 00000000.tx.177: In contrast, the protective effects of DNSREBP-1c in high-glucose-treated DN-SREBP-1c*23 cells revealed the SREBP-1c-dependent gene expression patterns, including upregulation of fatty acid synthase, HMG-CoA reductase, LDLR and P21, as well as downregulation of GLUT2, glucokinase, PDX1, IRS2 and BCLXL (Fig. 6). 

Phrase: "In contrast,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1979874:Contrast [Qualitative Concept]

Phrase: "the protective effects of DNSREBP-1c"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C1280500:effects [Qualitative Concept]
   719 E C2348382:Effect [Qualitative Concept]

Phrase: "in high-glucose-treated DN-SREBP-1c"
Meta Candidates (Total=21; Excluded=1; Pruned=0; Remaining=20)
   821   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
           Dominant Negative
   804   C0537474:SREBP-1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0860803:high glucose [Finding]
   804   C1420398:SREBP-1c [Gene or Genome]
   804   C3538602:SREBP-1c [Gene or Genome]
   790   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   790   C0150312:In [Quantitative Concept]
   790   C0205160:Negative [Qualitative Concept]
   790   C0205250:High [Qualitative Concept]
   790   C0332285:In [Spatial Concept]
   790   C0332293:treated [Therapeutic or Preventive Procedure]
   790   C0596988:Mutant [Cell or Molecular Dysfunction]
   790   C1299351:High [Qualitative Concept]
   790   C1513916:Negative [Finding]
   790   C1522326:Treated [Functional Concept]
   790   C1527180:Dominant [Functional Concept]
   790   C2700149:HIGH [Intellectual Product]
   790   C2825415:Negative [Conceptual Entity]
   790   C2825491:Negative [Qualitative Concept]
   756 E C1292734:TREAT [Functional Concept]

Phrase: "*23 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "revealed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443289:Revealed [Qualitative Concept]

Phrase: "the SREBP-1c-dependent gene expression patterns,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   830   C1317658:Protein pattern [Clinical Attribute]
   790   C0449774:Patterns [Spatial Concept]
   717   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "upregulation of fatty acid synthase,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0041904:Up-Regulation [Cell Function,Molecular Function]
   760   C0162493:Up-Regulation [Genetic Function]

Phrase: "HMG-CoA reductase,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0020374:HMG CoA Reductase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C0063164:HMG-CoA reductase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1415615:HMG-CoA REDUCTASE [Gene or Genome]
   901   C0047420:HMG-CoA [Biologically Active Substance,Organic Chemical]
   827   C0030016:Reductase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "LDLR"
Meta Candidates (Total=11; Excluded=1; Pruned=0; Remaining=10)
  1000   C0034821:Low Density Lipoprotein Receptor [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1366529:LOW DENSITY LIPOPROTEIN RECEPTOR [Gene or Genome]
   923   C0023823:Low density lipoprotein [Amino Acid, Peptide, or Protein,Biologically Active Substance,Lipid]
   861   C0065059:Lipoprotein Receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C0023820:Lipoprotein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   812   C0178587:density [Quantitative Concept]
   812   C0205251:low [Qualitative Concept]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C1299352:Low [Qualitative Concept]
   812   C1550472:low [Idea or Concept]
   741 E C0439794:Dense [Qualitative Concept]

Phrase: "and"

Phrase: "P21,"

Phrase: "as well as"

Phrase: "downregulation of GLUT2,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0013081:Down-Regulation [Cell Function,Molecular Function]

Phrase: "glucokinase,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0017713:Glucokinase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1415014:GLUCOKINASE [Gene or Genome]

Phrase: "PDX1,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1427500:PDX1 [Gene or Genome]
  1000   C1826562:PDX1 [Gene or Genome]

Phrase: "IRS2"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
  1000   C0381451:Insulin Receptor Substrate-2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
  1000   C1334141:INSULIN RECEPTOR SUBSTRATE 2 [Gene or Genome]
  1000   C1334191:Insulin Receptor Substrate 2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C0034818:Insulin Receptor [Amino Acid, Peptide, or Protein,Enzyme,Receptor]
   861   C1334133:INSULIN RECEPTOR [Gene or Genome]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   812   C1710236:Substrate [Manufactured Object]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "BCLXL"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1332397:BCLXL [Gene or Genome]

Phrase: "(Fig. 5C). DN-SREBP-1c corrected defective gene expression in INS-1 cells treated with chronic high glucose As demonstrated in Fig. 6, treatment of DN-SREBP-1c*23 cells with 30 mM glucose for 48 hours increased the mRNA levels of L-PK, aldolase B and ChREBP, which were not affected by induction of DN-SREBP-1c. These results suggest that high glucose may promote the expression of L-PK and aldolase B through a SREBP-1c-independent but ChREBP-dependent pathway. In contrast, the protective effects of DNSREBP-1c in high-glucose-treated DN-SREBP-1c*23 cells revealed the SREBP-1c-dependent gene expression patterns, including upregulation of fatty acid synthase, HMG-CoA reductase, LDLR and P21, as well as downregulation of GLUT2, glucokinase, PDX1, IRS2 and BCLXL (Fig. 6"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: "). DN-SREBP-1c corrected defective gene expression in INS-1 cells treated with chronic high glucose As demonstrated in Fig. 6, treatment of DN-SREBP-1c*23 cells with 30 mM glucose for 48 hours increased the mRNA levels of L-PK, aldolase B and ChREBP, which were not affected by induction of DN-SREBP-1c. These results suggest that high glucose may promote the expression of L-PK and aldolase B through a SREBP-1c-independent but ChREBP-dependent pathway. In contrast, the protective effects of DNSREBP-1c in high-glucose-treated DN-SREBP-1c*23 cells revealed the SREBP-1c-dependent gene expression patterns, including upregulation of fatty acid synthase, HMG-CoA reductase, LDLR and P21, as well as downregulation of GLUT2, glucokinase, PDX1, IRS2 and BCLXL (Fig. 6)."
Processing 00000000.tx.178: These data further substantiate the notion that SREBP-1c-target genes are implicated in chronic high-glucose-mediated -cell glucolipotoxicity. 

Phrase: "These data further"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1511726:Data [Idea or Concept]
   861   C3245479:data [Medical Device]

Phrase: "substantiate"

Phrase: "the notion"

Phrase: "that SREBP-1c-target genes"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   878   C0017362:Regulatory Genes [Gene or Genome]
   820   C0751455:protein gene [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   795   C1332838:Target Gene [Gene or Genome]
   793   C0017337:Genes [Gene or Genome]
   756   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "are"

Phrase: "implicated in chronic high-glucose-"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   806   C0860803:high glucose [Finding]
   760   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   760   C0205191:chronic [Temporal Concept]
   760   C0205250:High [Qualitative Concept]
   760   C1299351:High [Qualitative Concept]
   760   C2700149:HIGH [Intellectual Product]

Phrase: "mediated -"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0086597:mediated [Social Behavior]
  1000   C0127400:Mediated [Organic Chemical,Pharmacologic Substance]

Phrase: "cell glucolipotoxicity."
Processing 00000000.tx.179: Ucp2 is also a downstream target gene of SREBP-1c in INS-1 cells (Wang et al., 2003; Yamashita et al., 2004). 

Phrase: "Ucp2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1421314:UCP2 [Gene or Genome]

Phrase: "is"

Phrase: "also"

Phrase: "a downstream target gene of SREBP-1c"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   756   C1332838:Target Gene [Gene or Genome]
   754   C0017362:Regulatory Gene [Gene or Genome]
   754   C0079429:A Gene [Gene or Genome]
   754   C0751455:gene protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   738   C0017337:Gene [Gene or Genome]

Phrase: "in"

Phrase: "INS-1 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "(Fig. 6). These data further substantiate the notion that SREBP-1c-target genes are implicated in chronic high-glucose-mediated -cell glucolipotoxicity. Ucp2 is also a downstream target gene of SREBP-1c in INS-1 cells (Wang et al.,"

Phrase: "2003"

Phrase: "; Yamashita et al.,"

Phrase: "2004"

Phrase: "). These data further substantiate the notion that SREBP-1c-target genes are implicated in chronic high-glucose-mediated -cell glucolipotoxicity. Ucp2 is also a downstream target gene of SREBP-1c in INS-1 cells (Wang et al., 2003; Yamashita et al., 2004)."
Processing 00000000.tx.180: Interestingly, induction of DN-SREBP-1c suppressed UCP2, which may account for the increased basal insulin secretion observed (Fig. 5C). 

Phrase: "Interestingly,"

Phrase: "induction of DN-SREBP-1c"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0205263:Induction [Functional Concept]
   744   C0857127:induction [Therapeutic or Preventive Procedure]

Phrase: "suppressed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1260953:Suppressed [Functional Concept]

Phrase: "UCP2,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0536847:uncoupling protein-2 [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
  1000   C1421314:UNCOUPLING PROTEIN 2 [Gene or Genome]
   827   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "which"

Phrase: "may"

Phrase: "account for the increased basal insulin secretion"
Meta Candidates (Total=15; Excluded=0; Pruned=0; Remaining=15)
   804   C1372360:Increased Insulin Secretion [Organ or Tissue Function]
   778   C0650607:Basal insulin [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   778   C1256369:insulin secretion [Cell Function]
   774   C0020459:increased insulin [Disease or Syndrome]
   748   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   748   C0036536:secretion [Biologic Function]
   748   C0036537:Secretion [Body Substance]
   748   C0205112:Basal [Spatial Concept]
   748   C0205217:Increased [Quantitative Concept]
   748   C0442805:Increased [Functional Concept]
   748   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   748   C1551359:account [Idea or Concept]
   748   C1579433:Insulin [Pharmacologic Substance]
   748   C2741673:Account # [Clinical Attribute]
   748   C2981730:Account [Classification]

Phrase: "observed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1441672:Observed [Functional Concept]

Phrase: "(Wang et al., 2003; Yamashita et al., 2004). Interestingly, induction of DN-SREBP-1c suppressed UCP2, which may account for the increased basal insulin secretion observed (Fig. 5C"

Phrase: "). Interestingly, induction of DN-SREBP-1c suppressed UCP2, which may account for the increased basal insulin secretion observed (Fig. 5C)."
Processing 00000000.tx.181: View larger version (66K): [in this window] [in a new window]  Fig. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(Fig. 5C). View larger version (66K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Fig."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.182: 6. 

Phrase: "6."
Processing 00000000.tx.183: Effects of DN-SREBP-1c on gene expression patterns induced by chronic high-glucose in INS-1 cells. 

Phrase: "Effects of DN-SREBP-1c"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   744   C1280500:effects [Qualitative Concept]
   711 E C2348382:Effect [Qualitative Concept]

Phrase: "on gene expression patterns"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0449774:Patterns [Spatial Concept]
   734   C0017262:Gene Expression [Genetic Function]

Phrase: "induced by chronic high-glucose"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   806   C0860803:high glucose [Finding]
   760   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   760   C0205191:chronic [Temporal Concept]
   760   C0205250:High [Qualitative Concept]
   760   C0205263:Induced [Functional Concept]
   760   C1299351:High [Qualitative Concept]
   760   C2700149:HIGH [Intellectual Product]

Phrase: "in"

Phrase: "INS-1 cells."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.184: DN-SREBP-1c*23 cells were cultured in either standard (11.2 mM; -) or 30 mM (+) glucose medium for 48 hours, in the presence (+Dox) or absence (-Dox) of 500 ng/ml doxycycline. 

Phrase: "DN-SREBP-1c"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
   753   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: "*23 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "cultured in either standard"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C1442989:Standard [Qualitative Concept]
   770   C2828392:Standard [Intellectual Product]
   737   C0010453:Culture [Idea or Concept]
   737   C0220814:culture [Functional Concept]
   737   C0430400:Culture [Laboratory Procedure]
   737   C2242979:Culture [Laboratory Procedure]

Phrase: "(66K): [in this window] [in a new window]  Fig. 6. Effects of DN-SREBP-1c on gene expression patterns induced by chronic high-glucose in INS-1 cells. DN-SREBP-1c*23 cells were cultured in either standard (11.2 mM"

Phrase: "; -"

Phrase: ")"

Phrase: "or"

Phrase: "30 mM (+) glucose medium for 48 hours,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0009458:Medium [Intellectual Product]
   748   C0439536:Medium [Quantitative Concept]
   748   C1705217:Medium [Substance]
   748   C3244283:medium [Intellectual Product]

Phrase: "in the presence"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0392148:Presence [Therapeutic or Preventive Procedure]
   928 E C0150312:Present [Quantitative Concept]
   928 E C0449450:Present [Idea or Concept]

Phrase: "(11.2 mM; -) or 30 mM (+) glucose medium for 48 hours, in the presence (+Dox"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0013089:DOX [Antibiotic,Organic Chemical]

Phrase: ")"

Phrase: "or"

Phrase: "absence"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0332197:absence [Quantitative Concept]
  1000   C1689985:Absence [Anatomical Abnormality]
   928 E C2699517:ABSENT [Finding]

Phrase: "(+Dox) or absence (-Dox"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0013089:DOX [Antibiotic,Organic Chemical]

Phrase: ")"

Phrase: "of 500 ng/ml doxycycline."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   812   C0013090:Doxycycline [Antibiotic,Organic Chemical]
   756 E C0699957:Vibramycin [Antibiotic,Organic Chemical]
Processing 00000000.tx.185: The gene expression pattern in these cells was quantitatively evaluated by northern blotting. 

Phrase: "The gene expression pattern in these cells"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0449774:Pattern [Spatial Concept]

Phrase: "was"

Phrase: "quantitatively"

Phrase: "evaluated by northern blotting."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   833   C0005861:Northern Blotting [Molecular Biology Research Technique]
   816 E C1621557:Northern Blot [Research Device]
   770   C0220825:Evaluated [Functional Concept]
   770   C1709269:Northern [Spatial Concept]
Processing 00000000.tx.186: 20 g total RNA samples were analysed by hybridising with the indicated cDNA probes. 

Phrase: "20 g total RNA samples"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   771   C0370003:Sample [Substance]
   771   C2347026:Sample [Conceptual Entity]

Phrase: "were"

Phrase: "analysed by hybridising"

Phrase: "with the indicated cDNA probes."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   901   C0007512:cDNA Probes [Indicator, Reagent, or Diagnostic Aid,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0182400:Probes [Medical Device]
   793 E C1704681:Probe [Gene or Genome]
   793 E C2347609:Probe [Chemical Viewed Functionally]
   793 E C3536729:Probe [Manufactured Object]
Processing 00000000.tx.187: The experiments were repeated twice with similar results.  

Phrase: "The experiments"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0681814:Experiments [Research Activity]
   966 E C1706386:Experiment [Conceptual Entity]
   916 E C1517586:Experimental [Qualitative Concept]

Phrase: "were"

Phrase: "repeated"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0205341:Repeated [Functional Concept]
   966 E C1547730:Repeat [Temporal Concept]
   966 E C1705914:Repeat [Conceptual Entity]

Phrase: "twice with similar results."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C1720725:Twice [Intellectual Product]
   770   C1948050:Twice [Quantitative Concept]
   770   C2348205:Similar [Qualitative Concept]
   737   C1274040:Result [Functional Concept]
   737   C1546471:Result [Idea or Concept]
   737   C2825142:Result [Finding]
Processing 00000000.tx.188: ER-stress and SREBP-1 activation could be the molecular mechanisms underlying -cell glucolipotoxicity Increased expression of GADD153/CHOP10 and BIP are characteristics of ER stress response in many cell types. 

Phrase: "ER-stress"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C3178870:Endoplasmic Reticulum Stress [Cell or Molecular Dysfunction]
   901   C0014239:Endoplasmic Reticulum [Cell Component]
   827   C0035295:Reticulum [Body Part, Organ, or Organ Component]
   827   C0038435:Stress [Finding]
   755 E C0231297:Stressful [Functional Concept]
   755   C0598268:Endoplasm [Cell Component]

Phrase: "and"

Phrase: "SREBP-1 activation"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   829   C0599177:protein activation [Genetic Function]
   795   C1879547:Activation [Activity]
   787   C0217529:Sterol Regulatory Element Binding Protein 1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   787   C1420398:STEROL REGULATORY ELEMENT-BINDING PROTEIN 1 [Gene or Genome]

Phrase: "could"

Phrase: "be"

Phrase: "the molecular mechanisms"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0441712:Mechanisms [Functional Concept]
   827 E C1706376:Mechanism [Manufactured Object]

Phrase: "underlying -"

Phrase: "cell glucolipotoxicity"

Phrase: "Increased"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
  1000   C0205217:Increased [Quantitative Concept]
  1000   C0442805:Increased [Functional Concept]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C1301820:Obtain [Functional Concept]
   907 E C1706701:Acquire [Activity]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "expression of GADD153/CHOP10"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "and"

Phrase: "BIP"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0063423:BiP [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1415761:BIP [Gene or Genome]

Phrase: "are"

Phrase: "characteristics of ER stress response"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1521970:Characteristics [Qualitative Concept]

Phrase: "in many cell types."
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C0449475:Cell types [Intellectual Product]
   966 E C0007634:Cell Type [Cell]
           Cell
   861   C0332307:Types [Qualitative Concept]
   861   C1269647:Cell [Cell]
   861   C1704653:Cell [Medical Device]
   861   C1948049:Cell [Spatial Concept]
   827 E C1547052:*Type [Quantitative Concept]
Processing 00000000.tx.189: We found that treatment of INS-1E cells for 48 hours with 30 mM glucose markedly induced these ER stress marker genes (Fig. 7A). 

Phrase: "We"

Phrase: "found"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0150312:Found [Quantitative Concept]
   966 E C0243095:Find [Finding]

Phrase: "that treatment of"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0039798:treatment [Functional Concept]
   790   C0087111:Treatment [Therapeutic or Preventive Procedure]
   790   C1522326:Treatment [Functional Concept]
   790   C1533734:Treatment [Therapeutic or Preventive Procedure]
   790   C1705169:Treatment [Conceptual Entity]
   790   C3538994:TREATMENT [Research Activity]

Phrase: "INS-1E cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "for 48 hours"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0439586:48 hours [Temporal Concept]
  1000   C1442464:48 Hours [Temporal Concept]
   861   C0439227:hours [Temporal Concept]
   827 E C0564385:/hour [Quantitative Concept]

Phrase: "with 30 mM glucose markedly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "induced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induced [Functional Concept]

Phrase: "these ER stress marker genes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   804   C0017337:Genes [Gene or Genome]
   717   C3178870:Endoplasmic Reticulum Stress [Cell or Molecular Dysfunction]

Phrase: "(-Dox) of 500 ng/ml doxycycline. The gene expression pattern in these cells was quantitatively evaluated by northern blotting. 20 g total RNA samples were analysed by hybridising with the indicated cDNA probes. The experiments were repeated twice with similar results.  ER-stress and SREBP-1 activation could be the molecular mechanisms underlying -cell glucolipotoxicity Increased expression of GADD153/CHOP10 and BIP are characteristics of ER stress response in many cell types. We found that treatment of INS-1E cells for 48 hours with 30 mM glucose markedly induced these ER stress marker genes (Fig. 7A"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1571602:7a [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: ") of 500 ng/ml doxycycline. The gene expression pattern in these cells was quantitatively evaluated by northern blotting. 20 g total RNA samples were analysed by hybridising with the indicated cDNA probes. The experiments were repeated twice with similar results.  ER-stress and SREBP-1 activation could be the molecular mechanisms underlying -cell glucolipotoxicity Increased expression of GADD153/CHOP10 and BIP are characteristics of ER stress response in many cell types. We found that treatment of INS-1E cells for 48 hours with 30 mM glucose markedly induced these ER stress marker genes (Fig. 7A)."
Processing 00000000.tx.190: Therefore, chronic high-glucose-induced ER stress could be the underlying mechanism involved in SREBP-1 activation and subsequently INS-1 cell glucolipotoxicity, since it has been well documented that ER stress causes SREBP processing through S1P and S2P (Werstuck et al., 2001; Ye et al., 2000). 

Phrase: "Therefore,"

Phrase: "chronic high-glucose-induced ER stress"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   845   C3178870:Endoplasmic Reticulum Stress [Cell or Molecular Dysfunction]
   818   C0014239:Endoplasmic Reticulum [Cell Component]
   795   C0035295:Reticulum [Body Part, Organ, or Organ Component]
   795   C0038435:Stress [Finding]
   724 E C0231297:Stressful [Functional Concept]
   724   C0598268:Endoplasm [Cell Component]

Phrase: "could"

Phrase: "be"

Phrase: "the underlying mechanism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0441712:Mechanism [Functional Concept]
   861   C1706376:Mechanism [Manufactured Object]

Phrase: "involved in SREBP-1 activation"
Meta Candidates (Total=21; Excluded=1; Pruned=0; Remaining=20)
   882   C0217529:Sterol Regulatory Element Binding Protein 1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   882   C1420398:STEROL REGULATORY ELEMENT-BINDING PROTEIN 1 [Gene or Genome]
   764   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   764   C0087044:protein i [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   764   C0103404:Protein I [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   764   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   762 E C0033618:Protein Binding [Molecular Function]
   762   C0599177:protein activation [Genetic Function]
   762   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   762   C2246292:sterol binding [Molecular Function]
   742   C0013879:Element [Element, Ion, or Isotope]
   742   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   742   C0038323:Sterol [Steroid]
   742   C0220905:regulatory [Regulation or Law]
   742   C0243122:binding [Functional Concept]
   742   C1145667:Binding [Activity]
   742   C1167622:Binding [Molecular Function]
   742   C1314939:Involved [Functional Concept]
   742   C1704735:Regulatory [Conceptual Entity]
   742   C1705248:Element [Conceptual Entity]
   742   C1879547:Activation [Activity]

Phrase: "and"

Phrase: "subsequently INS-1 cell glucolipotoxicity,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   806   C1414685:INS-1 [Gene or Genome]
   806   C3538717:INS-1 [Gene or Genome]
   760   C0007634:Cell [Cell]
   760   C1269647:Cell [Cell]
   760   C1704653:Cell [Medical Device]
   760   C1948049:Cell [Spatial Concept]

Phrase: "since"

Phrase: "it"

Phrase: "has"

Phrase: "been"

Phrase: "well documented"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   861   C0205170:Well [Qualitative Concept]
   861   C1301725:Documented [Health Care Activity]
   861   C1609436:documented [Idea or Concept]
   861   C3146287:Well [Manufactured Object]
   827 E C1301746:document [Intellectual Product]
   827 E C1547673:Document [Intellectual Product]

Phrase: "that ER stress"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C3178870:Endoplasmic Reticulum Stress [Cell or Molecular Dysfunction]
   901   C0014239:Endoplasmic Reticulum [Cell Component]
   827   C0035295:Reticulum [Body Part, Organ, or Organ Component]
   827   C0038435:Stress [Finding]
   755 E C0231297:Stressful [Functional Concept]
   755   C0598268:Endoplasm [Cell Component]

Phrase: "causes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0015127:cause [Functional Concept]
  1000   C1314792:Causes [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]

Phrase: "SREBP processing through S1P"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0033666:protein processing [Molecular Function]
   757   C2985687:Processing Site [Spatial Concept]
   739   C1709694:Processing [Activity]

Phrase: "and"

Phrase: "S2P"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1423501:SITE-2 PROTEASE [Gene or Genome]
   827   C0030946:Protease [Amino Acid, Peptide, or Protein,Enzyme,Pharmacologic Substance]
   827   C1947941:Protease [Enzyme]

Phrase: "(Fig. 7A). Therefore, chronic high-glucose-induced ER stress could be the underlying mechanism involved in SREBP-1 activation and subsequently INS-1 cell glucolipotoxicity, since it has been well documented that ER stress causes SREBP processing through S1P and S2P (Werstuck et al.,"

Phrase: "2001"

Phrase: "; Ye et al.,"

Phrase: "2000"

Phrase: "). Therefore, chronic high-glucose-induced ER stress could be the underlying mechanism involved in SREBP-1 activation and subsequently INS-1 cell glucolipotoxicity, since it has been well documented that ER stress causes SREBP processing through S1P and S2P (Werstuck et al., 2001; Ye et al., 2000)."
Processing 00000000.tx.191: View larger version (27K): [in this window] [in a new window]  Fig. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(Werstuck et al., 2001; Ye et al., 2000). View larger version (27K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Fig."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.192: 7. 

Phrase: "7."
Processing 00000000.tx.193: ER stress and SREBP-1 activation are implicated in -cell glucolipotoxicity. 

Phrase: "ER stress"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C3178870:Endoplasmic Reticulum Stress [Cell or Molecular Dysfunction]
   901   C0014239:Endoplasmic Reticulum [Cell Component]
   827   C0035295:Reticulum [Body Part, Organ, or Organ Component]
   827   C0038435:Stress [Finding]
   755 E C0231297:Stressful [Functional Concept]
   755   C0598268:Endoplasm [Cell Component]

Phrase: "and"

Phrase: "SREBP-1 activation"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   829   C0599177:protein activation [Genetic Function]
   795   C1879547:Activation [Activity]
   787   C0217529:Sterol Regulatory Element Binding Protein 1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   787   C1420398:STEROL REGULATORY ELEMENT-BINDING PROTEIN 1 [Gene or Genome]

Phrase: "are"

Phrase: "implicated"

Phrase: "in -cell glucolipotoxicity."
Processing 00000000.tx.194: (A) The gene expression patterns in INS-1E cells cultured in either standard (11.2 mM; -) or 30 mM (+) glucose medium for 48 hours were quantified by northern blotting. 

Phrase: "(27K): [in this window] [in a new window]  Fig. 7. ER stress and SREBP-1 activation are implicated in -cell glucolipotoxicity. (A)"

Phrase: "The gene expression patterns in"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0449774:Patterns [Spatial Concept]

Phrase: "INS-1E cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "cultured in either standard"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C1442989:Standard [Qualitative Concept]
   770   C2828392:Standard [Intellectual Product]
   737   C0010453:Culture [Idea or Concept]
   737   C0220814:culture [Functional Concept]
   737   C0430400:Culture [Laboratory Procedure]
   737   C2242979:Culture [Laboratory Procedure]

Phrase: "(A) The gene expression patterns in INS-1E cells cultured in either standard (11.2 mM"

Phrase: "; -"

Phrase: ")"

Phrase: "or"

Phrase: "30 mM (+) glucose medium for 48 hours"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0009458:Medium [Intellectual Product]
   748   C0439536:Medium [Quantitative Concept]
   748   C1705217:Medium [Substance]
   748   C3244283:medium [Intellectual Product]

Phrase: "were"

Phrase: "quantified by northern blotting."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   833   C0005861:Northern Blotting [Molecular Biology Research Technique]
   816 E C1621557:Northern Blot [Research Device]
   770   C1709269:Northern [Spatial Concept]
   737   C1709793:Quantify [Quantitative Concept]
Processing 00000000.tx.195: Total RNA samples (20 g/lane) were analysed by hybridizing with the indicated cDNA probes. 

Phrase: "Total RNA samples"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   793   C0370003:Sample [Substance]
   793   C2347026:Sample [Conceptual Entity]

Phrase: "(11.2 mM; -) or 30 mM (+) glucose medium for 48 hours were quantified by northern blotting. Total RNA samples (20 g/lane"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1708639:Lane [Spatial Concept]

Phrase: ")"

Phrase: "were"

Phrase: "analysed by hybridizing"

Phrase: "with the indicated cDNA probes."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   901   C0007512:cDNA Probes [Indicator, Reagent, or Diagnostic Aid,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0182400:Probes [Medical Device]
   793 E C1704681:Probe [Gene or Genome]
   793 E C2347609:Probe [Chemical Viewed Functionally]
   793 E C3536729:Probe [Manufactured Object]
Processing 00000000.tx.196: Four independent experiments are shown side by side to demonstrate the consistency of the results. 

Phrase: "Four independent experiments"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   827   C0681814:Experiments [Research Activity]
   793 E C1706386:Experiment [Conceptual Entity]
   743 E C1517586:Experimental [Qualitative Concept]

Phrase: "are"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "side by side to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0441987:Side [Spatial Concept]

Phrase: "demonstrate"

Phrase: "the consistency of the results."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0332529:Consistency [Qualitative Concept]
   760   C1547017:Consistency [Quantitative Concept]
Processing 00000000.tx.197: (B) Gel-shift assay of nuclear extracts from isolated rat islets using the SRE sequence of the IRS2 promoter. 

Phrase: "(20 g/lane) were analysed by hybridizing with the indicated cDNA probes. Four independent experiments are shown side by side to demonstrate the consistency of the results. (B) Gel-shift assay of nuclear extracts"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   814   C0949632:Gel Shift Assay [Laboratory Procedure]
   748   C0005507:Assay [Laboratory Procedure]
   748   C0017243:Gel [Biomedical or Dental Material]
   748   C0243073:assay [Qualitative Concept]
   748   C0333051:Shift [Functional Concept]
   748   C1382104:Gel [Substance]
   748   C1510438:Assay [Laboratory Procedure]
   748   C2347509:Shift [Phenomenon or Process]

Phrase: "from isolated rat islets"

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the SRE sequence of the IRS2 promoter."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   751   C0314642:Regulatory sequence [Nucleotide Sequence]
   736   C0004793:Sequence [Nucleotide Sequence]
   736   C0162326:Sequence [Nucleotide Sequence]
   736   C0162327:Sequence [Nucleotide Sequence]
   736   C1519249:Sequence [Functional Concept]
Processing 00000000.tx.198: SREBP-1 protein binding activity was assessed in rat islets treated with 30 mM glucose for 0 (freshly isolated), 1, 2, 3, 4, and 5 days or alternatively with two ER stress inducers, thapsigargin (1 M) and tunicamycin (10 g/ml) for 1 day. 

Phrase: "SREBP-1 protein binding activity"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   854   C2266866:Binding Activity [Molecular Function]
   842   C1537044:protein activity [Molecular Function]
   791   C0205177:Activity [Functional Concept]
   791   C0439167:% activity [Quantitative Concept]
   791   C0441655:Activity [Activity]
   791   C1561536:*Activity [Idea or Concept]
   734   C0217529:Sterol Regulatory Element Binding Protein 1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   734   C1420398:STEROL REGULATORY ELEMENT-BINDING PROTEIN 1 [Gene or Genome]

Phrase: "was"

Phrase: "assessed in rat islets"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0034693:Rat, NOS [Mammal]
   770   C0034721:Rat [Mammal]
   770   C1516048:Assessed [Activity]

Phrase: "treated with 30 mM glucose"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   806   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   760   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   760   C1522326:Treated [Functional Concept]
   726 E C1292734:TREAT [Functional Concept]

Phrase: "for 0"

Phrase: "(B) Gel-shift assay of nuclear extracts from isolated rat islets using the SRE sequence of the IRS2 promoter. SREBP-1 protein binding activity was assessed in rat islets treated with 30 mM glucose for 0 (freshly"

Phrase: "isolated"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0205409:Isolated [Functional Concept]
  1000   C1548221:Isolated [Idea or Concept]
   966 E C0370215:Isolate [Substance]
   966 E C1875400:ISOLATE [Pharmacologic Substance]

Phrase: ")"

Phrase: ","

Phrase: "1,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: "2,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: "3,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: "4,"

Phrase: "and"

Phrase: "5 days"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C1442466:5 Days [Temporal Concept]
   861   C0439228:days [Temporal Concept]
   827 E C0332173:/day [Temporal Concept]
   827 E C0439505:/day [Temporal Concept]

Phrase: "or"

Phrase: "alternatively with two ER stress inducers,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   814   C3178870:Endoplasmic Reticulum Stress [Cell or Molecular Dysfunction]
   778   C0014239:Endoplasmic Reticulum [Cell Component]
   748   C0035295:Reticulum [Body Part, Organ, or Organ Component]
   748   C0038435:Stress [Finding]
   748   C0205448:Two [Quantitative Concept]

Phrase: "thapsigargin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0076374:Thapsigargin [Hazardous or Poisonous Substance,Organic Chemical]

Phrase: "(freshly isolated), 1, 2, 3, 4, and 5 days or alternatively with two ER stress inducers, thapsigargin (1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: "M)"

Phrase: "and"

Phrase: "tunicamycin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0041385:Tunicamycin [Antibiotic,Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "(1 M) and tunicamycin (10 g/"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "ml) for 1 day."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   819   C0439446:mL/day [Quantitative Concept]
   770   C0439526:/mL [Quantitative Concept]
Processing 00000000.tx.199: The mouse monoconal antibody against SREBP-1 was used for supershift experiments.  

Phrase: "The mouse monoconal antibody against SREBP-1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   754   C1445860:Protein antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   738   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   738   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "was"

Phrase: "used for supershift experiments."
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
   770   C0681814:Experiments [Research Activity]
   770   C1273517:used [Finding]
   737 E C0042153:use [Functional Concept]
   737 E C0457083:Use [Functional Concept]
   737 E C1706386:Experiment [Conceptual Entity]
   737 E C1947944:Use [Intellectual Product]
Processing 00000000.tx.200: A similar mechanism may also apply to islet  cells. 

Phrase: "A similar mechanism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0441712:Mechanism [Functional Concept]
   861   C1706376:Mechanism [Manufactured Object]

Phrase: "may"

Phrase: "also"

Phrase: "apply to islet  cells."
Meta Candidates (Total=10; Excluded=4; Pruned=0; Remaining=6)
   833   C0022131:Islet Cells [Body Part, Organ, or Organ Component]
   799 E C1522529:Islet Cell [Cell]
   770   C0007634:Cells [Cell]
   770   C0185125:Apply [Health Care Activity]
   770   C1632850:Apply [Functional Concept]
   770   C1879355:Apply [Functional Concept]
   770   C3282337:Cells [Cell]
   737 E C1269647:Cell [Cell]
   737 E C1704653:Cell [Medical Device]
   737 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.201: The EMSA shown in Fig. 

Phrase: "The EMSA"
Meta Candidates (Total=14; Excluded=2; Pruned=0; Remaining=12)
   877   C0949632:Electrophoretic Mobility Shift Assay [Laboratory Procedure]
           Mobility Shift Assay
   795   C0005507:Assay [Laboratory Procedure]
   795   C0185115:Extraction [Therapeutic or Preventive Procedure]
   795   C0243073:assay [Qualitative Concept]
   795   C0333051:Shift [Functional Concept]
   795   C0425245:Mobility [Finding]
   795   C0449580:Mobility [Qualitative Concept]
   795   C0684295:extraction [Laboratory Procedure]
   795   C1510438:Assay [Laboratory Procedure]
   795   C2347509:Shift [Phenomenon or Process]
   724   C0013855:Electrophoreses [Laboratory Procedure]
   724 E C0231435:Mobile [Functional Concept]
   724 E C1552449:Mobile [Health Care Related Organization,Manufactured Object]

Phrase: "shown in Fig."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0349966:Fig [Food]
   790   C1337208:FIG [Food]
   756   C1547282:Show [Intellectual Product]
Processing 00000000.tx.202: 7B indicates that treatment of isolated rat islets with either chronic high glucose or two ER stress inducers, thapsigargin and tunicamycin, drastically enhanced SREBP-1 binding to the SRE sequence of the IRS2 promoter. 

Phrase: "7B"

Phrase: "indicates"

Phrase: "that treatment of isolated rat islets"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   753   C0039798:treatment [Functional Concept]
   753   C0087111:Treatment [Therapeutic or Preventive Procedure]
   753   C1522326:Treatment [Functional Concept]
   753   C1533734:Treatment [Therapeutic or Preventive Procedure]
   753   C1705169:Treatment [Conceptual Entity]
   753   C3538994:TREATMENT [Research Activity]

Phrase: "with either chronic high glucose"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0860803:high glucose [Finding]
   812   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "or"

Phrase: "two ER stress inducers,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   717   C3178870:Endoplasmic Reticulum Stress [Cell or Molecular Dysfunction]

Phrase: "thapsigargin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0076374:Thapsigargin [Hazardous or Poisonous Substance,Organic Chemical]

Phrase: "and"

Phrase: "tunicamycin,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0041385:Tunicamycin [Antibiotic,Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "drastically enhanced SREBP-1 binding"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   734   C0217529:Sterol Regulatory Element Binding Protein 1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   734   C1420398:STEROL REGULATORY ELEMENT-BINDING PROTEIN 1 [Gene or Genome]

Phrase: "to the SRE sequence"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   875   C0314642:Regulatory sequence [Nucleotide Sequence]
   812   C0004793:Sequence [Nucleotide Sequence]
   812   C0162326:Sequence [Nucleotide Sequence]
   812   C0162327:Sequence [Nucleotide Sequence]
   812   C1519249:Sequence [Functional Concept]
   741 E C1548958:Sequential [Idea or Concept]
   741 E C1705294:Sequential [Qualitative Concept]

Phrase: "of the IRS2 promoter."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0086860:Promoter [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   771   C0381451:Insulin Receptor Substrate-2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   771   C1334141:INSULIN RECEPTOR SUBSTRATE 2 [Gene or Genome]
   771   C1334191:Insulin Receptor Substrate 2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
Processing 00000000.tx.203: The specificity of retarded SREBP-1 complexes was confirmed by the supershift in the presence of the monoclonal antibody against SREBP-1 (Fig. 7B).  

Phrase: "The specificity of retarded SREBP-1 complexes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   772   C1335858:SPECIFICITY PROTEIN 1 [Gene or Genome]
   738   C0037791:Specificity [Quantitative Concept]
   738   C1511884:Specificity [Quantitative Concept]

Phrase: "was"

Phrase: "confirmed by the supershift"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   833   C0521093:Confirmed by [Qualitative Concept]
           confirmed
   770   C0750484:Confirmed [Idea or Concept]
   737 E C1456348:Confirm [Qualitative Concept]

Phrase: "in the presence"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0392148:Presence [Therapeutic or Preventive Procedure]
   928 E C0150312:Present [Quantitative Concept]
   928 E C0449450:Present [Idea or Concept]

Phrase: "of the monoclonal antibody"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0003250:Monoclonal antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   861   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0746619:monoclonal [Finding]

Phrase: "against SREBP-1"
Meta Candidates (Total=17; Excluded=0; Pruned=0; Remaining=17)
  1000   C0217529:Sterol Regulatory Element Binding Protein 1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
  1000   C1420398:STEROL REGULATORY ELEMENT-BINDING PROTEIN 1 [Gene or Genome]
   858   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C2246292:sterol binding [Molecular Function]
   827   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0087044:protein i [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   827   C0103404:Protein I [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   827   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0013879:Element [Element, Ion, or Isotope]
   799   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0038323:Sterol [Steroid]
   799   C0220905:regulatory [Regulation or Law]
   799   C0243122:binding [Functional Concept]
   799   C1145667:Binding [Activity]
   799   C1167622:Binding [Molecular Function]
   799   C1704735:Regulatory [Conceptual Entity]
   799   C1705248:Element [Conceptual Entity]

Phrase: "(10 g/ml) for 1 day. The mouse monoconal antibody against SREBP-1 was used for supershift experiments.  A similar mechanism may also apply to islet  cells. The EMSA shown in Fig. 7B indicates that treatment of isolated rat islets with either chronic high glucose or two ER stress inducers, thapsigargin and tunicamycin, drastically enhanced SREBP-1 binding to the SRE sequence of the IRS2 promoter. The specificity of retarded SREBP-1 complexes was confirmed by the supershift in the presence of the monoclonal antibody against SREBP-1 (Fig. 7B"

Phrase: "), 1, 2, 3, 4, and 5 days or alternatively with two ER stress inducers, thapsigargin (1 M) and tunicamycin (10 g/ml) for 1 day. The mouse monoconal antibody against SREBP-1 was used for supershift experiments.  A similar mechanism may also apply to islet  cells. The EMSA shown in Fig. 7B indicates that treatment of isolated rat islets with either chronic high glucose or two ER stress inducers, thapsigargin and tunicamycin, drastically enhanced SREBP-1 binding to the SRE sequence of the IRS2 promoter. The specificity of retarded SREBP-1 complexes was confirmed by the supershift in the presence of the monoclonal antibody against SREBP-1 (Fig. 7B)."
Processing 00000000.tx.204: Discussion Top Summary Introduction Materials and Methods Results Discussion References  It is well known that chronic high-glucose treatment in vitro causes -cell glucolipotoxicity, including lipid accumulation, impaired glucose-stimulated insulin secretion and apoptosis (Efanova et al., 1998; Roche et al., 1998). 

Phrase: "Discussion Top Summary Introduction Materials"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0520510:Materials [Substance]

Phrase: "and"

Phrase: "Methods Results Discussion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "References"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "It"

Phrase: "is"

Phrase: "well known"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205170:Well [Qualitative Concept]
   861   C0205309:Known [Qualitative Concept]
   861   C3146287:Well [Manufactured Object]

Phrase: "that chronic high-glucose treatment in vitro causes -cell glucolipotoxicity,"

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "lipid accumulation,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0333574:Lipid accumulation [Finding]

Phrase: "impaired glucose-stimulated insulin secretion"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   853   C1719133:Glucose/Insulin [Quantitative Concept]
   840   C1256369:insulin secretion [Cell Function]
   804   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   804   C0036536:secretion [Biologic Function]
   804   C0036537:Secretion [Body Substance]
   804   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   804   C1579433:Insulin [Pharmacologic Substance]
   748 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   721 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "apoptosis"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0162638:Apoptosis [Cell Function]
   928 E C1516044:Apoptotic [Qualitative Concept]

Phrase: "(Fig. 7B).  Discussion Top Summary Introduction Materials and Methods Results Discussion References  It is well known that chronic high-glucose treatment in vitro causes -cell glucolipotoxicity, including lipid accumulation, impaired glucose-stimulated insulin secretion and apoptosis (Efanova et al.,"

Phrase: "1998"

Phrase: "; Roche et al.,"

Phrase: "1998"

Phrase: ").  Discussion Top Summary Introduction Materials and Methods Results Discussion References  It is well known that chronic high-glucose treatment in vitro causes -cell glucolipotoxicity, including lipid accumulation, impaired glucose-stimulated insulin secretion and apoptosis (Efanova et al., 1998; Roche et al., 1998)."
Processing 00000000.tx.205: These characteristics resemble the description of -cell lipotoxicity in ob/ob mice and Zucker Diabetic Fatty (ZDF) rats (Unger, 2002; Unger and Zhou, 2001). 

Phrase: "These characteristics"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1521970:Characteristics [Qualitative Concept]

Phrase: "resemble"

Phrase: "the description of -cell lipotoxicity in ob/ob mice"

Phrase: "and"

Phrase: "Zucker Diabetic Fatty (ZDF) rats"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   902   C0034719:Rats, Zucker [Mammal]
   812   C0034693:rats [Mammal]
   812   C0034721:Rats [Mammal]

Phrase: "(Efanova et al., 1998; Roche et al., 1998). These characteristics resemble the description of -cell lipotoxicity in ob/ob mice and Zucker Diabetic Fatty (ZDF) rats (Unger,"

Phrase: "2002"

Phrase: "; Unger"

Phrase: "and"

Phrase: "Zhou,"

Phrase: "2001"

Phrase: "). These characteristics resemble the description of -cell lipotoxicity in ob/ob mice and Zucker Diabetic Fatty (ZDF) rats (Unger, 2002; Unger and Zhou, 2001)."
Processing 00000000.tx.206: Overexpression or overactivation of SREBP-1c in the islets of these animals has been proposed as the causal factor (Unger, 2002; Unger and Zhou, 2001). 

Phrase: "Overexpression"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514559:Overexpression [Genetic Function]

Phrase: "or"

Phrase: "overactivation of SREBP-1c"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   743   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "in the islets"

Phrase: "of these animals"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0003062:Animals [Animal]

Phrase: "has"

Phrase: "been"

Phrase: "proposed as the causal factor"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C1441414:PROPOSED [Idea or Concept]
   760   C1521761:Factor [Functional Concept]
   760   C1553874:Proposed [Qualitative Concept]
   760   C1578820:Proposed [Idea or Concept]
   760   C2827422:Factor [Conceptual Entity]

Phrase: "(Unger, 2002; Unger and Zhou, 2001). Overexpression or overactivation of SREBP-1c in the islets of these animals has been proposed as the causal factor (Unger,"

Phrase: "2002"

Phrase: "; Unger"

Phrase: "and"

Phrase: "Zhou,"

Phrase: "2001"

Phrase: "). Overexpression or overactivation of SREBP-1c in the islets of these animals has been proposed as the causal factor (Unger, 2002; Unger and Zhou, 2001)."
Processing 00000000.tx.207: Consistently, overexpression of a nuclear active form of SREBP-1c in insulinoma cells (INS-1 and MIN6) and isolated rat islets results in typical characteristics of -cell glucolipotoxicity (Andreolas et al., 2002; Diraison et al., 2004; Wang et al., 2003; Yamashita et al., 2004). 

Phrase: "Consistently,"

Phrase: "overexpression of a nuclear active form"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1514559:Overexpression [Genetic Function]

Phrase: "of SREBP-1c"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
  1000   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C2246292:sterol binding [Molecular Function]
   827   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0013879:Element [Element, Ion, or Isotope]
   799   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0038323:Sterol [Steroid]
   799   C0220905:regulatory [Regulation or Law]
   799   C0243122:binding [Functional Concept]
   799   C1145667:Binding [Activity]
   799   C1167622:Binding [Molecular Function]
   799   C1704735:Regulatory [Conceptual Entity]
   799   C1705248:Element [Conceptual Entity]

Phrase: "in insulinoma cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "("

Phrase: "INS-1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: "and"

Phrase: "MIN6"

Phrase: ")"

Phrase: "and"

Phrase: "isolated rat islets"

Phrase: "results in typical characteristics of -cell glucolipotoxicity"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   748   C0007634:Cell [Cell]
   748   C1269647:Cell [Cell]
   748   C1274040:Result [Functional Concept]
   748   C1521970:Characteristics [Qualitative Concept]
   748   C1546471:Result [Idea or Concept]
   748   C1704653:Cell [Medical Device]
   748   C1948049:Cell [Spatial Concept]
   748   C2825142:Result [Finding]
   748   C3538928:Typical [Qualitative Concept]

Phrase: "(INS-1 and MIN6) and isolated rat islets results in typical characteristics of -cell glucolipotoxicity (Andreolas et al.,"

Phrase: "2002"

Phrase: "; Diraison et al.,"

Phrase: "2004"

Phrase: "; Wang et al.,"

Phrase: "2003"

Phrase: "; Yamashita et al.,"

Phrase: "2004"

Phrase: ") and isolated rat islets results in typical characteristics of -cell glucolipotoxicity (Andreolas et al., 2002; Diraison et al., 2004; Wang et al., 2003; Yamashita et al., 2004)."
Processing 00000000.tx.208: Some investigators refer to lipotoxicity as the consequence of increased circulating free fatty acids and cellular lipid accumulation (Unger, 2002; Unger and Zhou, 2001; Unger et al., 1999), whereas others suggest that glucotoxicity is the prerequisite for lipotoxicity, at least in  cells (Bonner-Weir et al., 1983; Harmon et al., 2001; Poitout and Robertson, 2002; Roche et al., 1998; Weir, 1982; Weir et al., 2001). 

Phrase: "Some investigators"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0035173:Investigators [Professional or Occupational Group]

Phrase: "refer to lipotoxicity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0205543:refer [Functional Concept]

Phrase: "as the consequence"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0686907:Consequence [Functional Concept]

Phrase: "of increased circulating free fatty acids"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   884   C0015688:Free Fatty Acids [Lipid]
   851 E C2698488:Free Fatty Acid [Laboratory Procedure]
   840   C0015684:Fatty Acids [Lipid]
   804   C0001128:Acids [Chemical]
   804   C0332296:free [Functional Concept]
   804   C1880497:Free [Qualitative Concept]
   804   C1996904:Free [Qualitative Concept]
   771 E C0202406:Acid [Laboratory Procedure]

Phrase: "and"

Phrase: "cellular lipid accumulation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   901   C0333574:Lipid accumulation [Finding]

Phrase: "(Andreolas et al., 2002; Diraison et al., 2004; Wang et al., 2003; Yamashita et al., 2004). Some investigators refer to lipotoxicity as the consequence of increased circulating free fatty acids and cellular lipid accumulation (Unger,"

Phrase: "2002"

Phrase: "; Unger"

Phrase: "and"

Phrase: "Zhou,"

Phrase: "2001"

Phrase: "; Unger et al.,"

Phrase: "1999"

Phrase: ")"

Phrase: ","

Phrase: "whereas"

Phrase: "others"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1955473:Others [Finding]
   966 E C0205394:Other [Qualitative Concept]

Phrase: "suggest"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that glucotoxicity"

Phrase: "is"

Phrase: "the prerequisite for lipotoxicity,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0679209:prerequisite [Idea or Concept]

Phrase: "at least"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0439092:less [Intellectual Product]
   966   C0547044:Less [Qualitative Concept]

Phrase: "in  cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "(Unger, 2002; Unger and Zhou, 2001; Unger et al., 1999), whereas others suggest that glucotoxicity is the prerequisite for lipotoxicity, at least in  cells (Bonner-Weir et al.,"

Phrase: "1983"

Phrase: "; Harmon et al.,"

Phrase: "2001"

Phrase: "; Poitout"

Phrase: "and"

Phrase: "Robertson,"

Phrase: "2002"

Phrase: "; Roche et al.,"

Phrase: "1998"

Phrase: "; Weir,"

Phrase: "1982"

Phrase: "; Weir et al.,"

Phrase: "2001"

Phrase: "), whereas others suggest that glucotoxicity is the prerequisite for lipotoxicity, at least in  cells (Bonner-Weir et al., 1983; Harmon et al., 2001; Poitout and Robertson, 2002; Roche et al., 1998; Weir, 1982; Weir et al., 2001)."
Processing 00000000.tx.209: Therefore, glucolipotoxicity is a more proper term to describe  cell dysfunction in type 2 diabetes. 

Phrase: "Therefore,"

Phrase: "glucolipotoxicity"

Phrase: "is"

Phrase: "a more proper term to"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C1515273:Term [Temporal Concept]
   812   C1705313:Term [Idea or Concept]
   812   C2826302:TERM [Intellectual Product]

Phrase: "describe"

Phrase: "cell dysfunction in type 2 diabetes."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0031847:dysfunction [Functional Concept]
   753   C0277785:Dysfunction, NOS [Qualitative Concept]
Processing 00000000.tx.210: To elucidate the molecular mechanisms underlying -cell glucolipotoxicity, we first investigated the quantitative gene expression patterns in INS-1 cells treated chronically with high-glucose. 

Phrase: "To"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "elucidate"

Phrase: "the molecular mechanisms"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0441712:Mechanisms [Functional Concept]
   827 E C1706376:Mechanism [Manufactured Object]

Phrase: "underlying -"

Phrase: "cell glucolipotoxicity,"

Phrase: "we first"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205435:First [Quantitative Concept]
  1000   C1279901:First [Qualitative Concept]

Phrase: "investigated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1292732:investigated [Functional Concept]

Phrase: "the quantitative gene expression patterns in"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0449774:Patterns [Spatial Concept]

Phrase: "INS-1 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "treated"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0332293:treated [Therapeutic or Preventive Procedure]
  1000   C1522326:Treated [Functional Concept]
   966 E C1292734:TREAT [Functional Concept]

Phrase: "chronically with high-glucose."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   833   C0860803:high glucose [Finding]
   770   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   770   C0205250:High [Qualitative Concept]
   770   C1299351:High [Qualitative Concept]
   770   C2700149:HIGH [Intellectual Product]
Processing 00000000.tx.211: The drastically reduced expression of essential -cell genes such as IRS2, insulin, Pdx1, Glut2, glucokinase and Bclxl, and markedly increased mRNA levels of lipogenic and proapoptotic genes should contribute to the glucolipotoxicity. 

Phrase: "The drastically reduced expression of essential -cell genes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   750   C0017262:Gene Expression [Genetic Function]
   744   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "such as IRS2,"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
  1000   C0381451:Insulin Receptor Substrate-2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
  1000   C1334141:INSULIN RECEPTOR SUBSTRATE 2 [Gene or Genome]
  1000   C1334191:Insulin Receptor Substrate 2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C0034818:Insulin Receptor [Amino Acid, Peptide, or Protein,Enzyme,Receptor]
   861   C1334133:INSULIN RECEPTOR [Gene or Genome]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   812   C1710236:Substrate [Manufactured Object]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "insulin,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1579433:Insulin [Pharmacologic Substance]
   944 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   916 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "Pdx1,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1427500:PDX1 [Gene or Genome]
  1000   C1826562:PDX1 [Gene or Genome]

Phrase: "Glut2,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1420172:GLUT2 [Gene or Genome]

Phrase: "glucokinase"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0017713:Glucokinase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1415014:GLUCOKINASE [Gene or Genome]

Phrase: "and"

Phrase: "Bclxl,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1332397:BCLXL [Gene or Genome]

Phrase: "and"

Phrase: "markedly increased mRNA levels of lipogenic"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   753   C0035696:mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   753   C0441889:Levels [Qualitative Concept]
   719 E C0456079:Level [Classification]
   719 E C1547707:Level [Geographic Area]
   719 E C2946261:Level [Pharmacologic Substance]

Phrase: "and"

Phrase: "proapoptotic genes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0017337:Genes [Gene or Genome]

Phrase: "should"

Phrase: "contribute to the glucolipotoxicity."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1880177:Contribute [Activity]
Processing 00000000.tx.212: Interestingly, this gene expression profile is strikingly similar to what we have reported in the INS-1 cell line expressing naSREBP-1c (Wang et al., 2003). 

Phrase: "Interestingly,"

Phrase: "this gene expression profile"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C1449575:gene expression profile [Laboratory Procedure]
  1000   C1956267:Profile, Gene Expression [Quantitative Concept]
   827   C1979963:Profile [Laboratory Procedure]
   827   C2003903:Profile [Functional Concept]
   734   C0017262:Gene Expression [Genetic Function]

Phrase: "is"

Phrase: "strikingly similar to what"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C2348205:Similar [Qualitative Concept]

Phrase: "we"

Phrase: "have"

Phrase: "reported in the INS-1 cell line expressing naSREBP-1c"
Meta Candidates (Total=14; Excluded=1; Pruned=0; Remaining=13)
   760   C0007600:Cell Line [Cell]
   760   C1414685:INS-1 [Gene or Genome]
   760   C3538717:INS-1 [Gene or Genome]
   739   C0007634:Cell [Cell]
   739   C0205132:Line [Spatial Concept]
   739   C0684224:Reported [Intellectual Product]
   739   C0700287:Reported [Health Care Activity]
   739   C1269647:Cell [Cell]
   739   C1550648:Line [Substance]
   739   C1552960:Line [Quantitative Concept]
   739   C1704653:Cell [Medical Device]
   739   C1948049:Cell [Spatial Concept]
   739   C3496591:Reported [Clinical Attribute]
   706 E C3273238:Report [Intellectual Product]

Phrase: "(Bonner-Weir et al., 1983; Harmon et al., 2001; Poitout and Robertson, 2002; Roche et al., 1998; Weir, 1982; Weir et al., 2001). Therefore, glucolipotoxicity is a more proper term to describe  cell dysfunction in type 2 diabetes. To elucidate the molecular mechanisms underlying -cell glucolipotoxicity, we first investigated the quantitative gene expression patterns in INS-1 cells treated chronically with high-glucose. The drastically reduced expression of essential -cell genes such as IRS2, insulin, Pdx1, Glut2, glucokinase and Bclxl, and markedly increased mRNA levels of lipogenic and proapoptotic genes should contribute to the glucolipotoxicity. Interestingly, this gene expression profile is strikingly similar to what we have reported in the INS-1 cell line expressing naSREBP-1c (Wang et al.,"

Phrase: "2003"

Phrase: "). Therefore, glucolipotoxicity is a more proper term to describe  cell dysfunction in type 2 diabetes. To elucidate the molecular mechanisms underlying -cell glucolipotoxicity, we first investigated the quantitative gene expression patterns in INS-1 cells treated chronically with high-glucose. The drastically reduced expression of essential -cell genes such as IRS2, insulin, Pdx1, Glut2, glucokinase and Bclxl, and markedly increased mRNA levels of lipogenic and proapoptotic genes should contribute to the glucolipotoxicity. Interestingly, this gene expression profile is strikingly similar to what we have reported in the INS-1 cell line expressing naSREBP-1c (Wang et al., 2003)."
Processing 00000000.tx.213: In contrast, the characteristics of these gene expression patterns as well as typical glucolipotoxicity were not observed in the INS-1 cell line overexpressing another lipogenic transcription factor ChREBP. 

Phrase: "In contrast,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1979874:Contrast [Qualitative Concept]

Phrase: "the characteristics of these gene expression patterns"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1521970:Characteristics [Qualitative Concept]

Phrase: "as well as"

Phrase: "typical glucolipotoxicity"

Phrase: "were"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "observed in the INS-1 cell line"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   778   C0007600:Cell Line [Cell]
   778   C1414685:INS-1 [Gene or Genome]
   778   C3538717:INS-1 [Gene or Genome]
   748   C0007634:Cell [Cell]
   748   C0205132:Line [Spatial Concept]
   748   C1269647:Cell [Cell]
   748   C1441672:Observed [Functional Concept]
   748   C1550648:Line [Substance]
   748   C1552960:Line [Quantitative Concept]
   748   C1704653:Cell [Medical Device]
   748   C1948049:Cell [Spatial Concept]

Phrase: "overexpressing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1514559:overexpress [Genetic Function]

Phrase: "another lipogenic transcription factor ChREBP."
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   890   C1826259:carbohydrate response element binding protein [Gene or Genome]
   869   C1149367:transcription factor binding [Genetic Function]
   861   C3158709:carbohydrate response element binding [Genetic Function]
   855   C0108401:carbohydrate-binding protein [Amino Acid, Peptide, or Protein,Receptor]
   836   C1148582:carbohydrate binding [Molecular Function]
   812   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   793   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   793   C0243122:binding [Functional Concept]
   793   C1145667:Binding [Activity]
   793   C1167622:Binding [Molecular Function]
Processing 00000000.tx.214: Similar negative results were obtained in INS-1 cells expressing, PPAR or C/EBP (H.W. and C.B.W., unpublished data), suggesting that SREBP-1c is the predominant transcription factor responsible for -cell glucolipotoxicity. 

Phrase: "Similar negative results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   793   C1274040:Result [Functional Concept]
   793   C1546471:Result [Idea or Concept]
   793   C2825142:Result [Finding]

Phrase: "were"

Phrase: "obtained in"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
   833   C1301820:Obtained [Functional Concept]
   799 E C1706701:Obtain [Activity]
   761 E C1517378:Gain [Quantitative Concept]
   740 E C0205217:Increased [Quantitative Concept]
   740 E C0439661:Acquired [Temporal Concept]
   740 E C0442805:Increase [Functional Concept]
   740 E C0442808:Increasing [Functional Concept]
   740 E C3245488:acquired [Intellectual Product]

Phrase: "INS-1 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "expressing"

Phrase: ","

Phrase: "PPAR"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
  1000   C0166418:Peroxisome Proliferator-Activated Receptors [Amino Acid, Peptide, or Protein,Receptor]
   988 E C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   861   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   812   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   812   C0752063:Peroxysome [Cell Component]
   812   C1879547:Activated [Activity]
   812   C2984308:Peroxisome [Functional Concept]
   779 E C1515877:Activate [Functional Concept]
   741 E C3546463:peroxisomal [Cell Component]

Phrase: "or"

Phrase: "C/EBP"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C0108685:CCAAT-Enhancer-Binding Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   906   C0597716:Enhancer Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C0242210:Binding Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C2752241:enhancer binding [Genetic Function]
   812   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   812   C0086222:Enhancer [Nucleic Acid, Nucleoside, or Nucleotide]
   812   C0243122:binding [Functional Concept]
   812   C1145667:Binding [Activity]
   812   C1167622:Binding [Molecular Function]

Phrase: "(Wang et al., 2003). In contrast, the characteristics of these gene expression patterns as well as typical glucolipotoxicity were not observed in the INS-1 cell line overexpressing another lipogenic transcription factor ChREBP. Similar negative results were obtained in INS-1 cells expressing, PPAR or C/EBP (H.W."

Phrase: "and"

Phrase: "C.B.W., unpublished data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   804   C1511726:Data [Idea or Concept]
   804   C3245479:data [Medical Device]

Phrase: ")"

Phrase: ","

Phrase: "suggesting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "that SREBP-1c"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
  1000   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C2246292:sterol binding [Molecular Function]
   827   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0013879:Element [Element, Ion, or Isotope]
   799   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0038323:Sterol [Steroid]
   799   C0220905:regulatory [Regulation or Law]
   799   C0243122:binding [Functional Concept]
   799   C1145667:Binding [Activity]
   799   C1167622:Binding [Molecular Function]
   799   C1704735:Regulatory [Conceptual Entity]
   799   C1705248:Element [Conceptual Entity]

Phrase: "is"

Phrase: "the predominant transcription factor"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0040648:TRANSCRIPTION FACTOR [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   827   C0040649:Transcription [Genetic Function]
   827   C1521761:Factor [Functional Concept]
   827   C2827422:Factor [Conceptual Entity]

Phrase: "responsible for -cell glucolipotoxicity."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1273518:Responsible [Finding]
Processing 00000000.tx.215: To further substantiate this hypothesis, we established an INS-1 stable cell line with inducible expression of DN-SREBP-1c. 

Phrase: "To further"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C1517331:Further [Spatial Concept]
   861   C1883351:To [Qualitative Concept]
   827 E C0205108:far [Spatial Concept]

Phrase: "substantiate"

Phrase: "this hypothesis,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1512571:Hypothesis [Idea or Concept]

Phrase: "we"

Phrase: "established"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0443211:Established [Qualitative Concept]
  1000   C1272684:Established [Qualitative Concept]

Phrase: "an INS-1 stable cell line"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
   833   C0598091:stable cell line [Cell]
   790   C0007600:Cell Line [Cell]
   790   C1414685:INS-1 [Gene or Genome]
   790   C3538717:INS-1 [Gene or Genome]
   783   C0950951:AN 1 [Organic Chemical,Pharmacologic Substance]
   753   C0007634:Cell [Cell]
   753   C0205132:Line [Spatial Concept]
   753   C0205360:Stable [Qualitative Concept]
   753   C1269647:Cell [Cell]
   753   C1547311:Stable [Intellectual Product]
   753   C1550648:Line [Substance]
   753   C1552960:Line [Quantitative Concept]
   753   C1704653:Cell [Medical Device]
   753   C1948049:Cell [Spatial Concept]

Phrase: "with inducible expression"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "of DN-SREBP-1c."
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   845   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
           Dominant Negative
   818   C0537474:SREBP-1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   818   C1420398:SREBP-1c [Gene or Genome]
   818   C3538602:SREBP-1c [Gene or Genome]
   795   C0205160:Negative [Qualitative Concept]
   795   C0332285:Of [Spatial Concept]
   795   C0596988:Mutant [Cell or Molecular Dysfunction]
   795   C1513916:Negative [Finding]
   795   C1527180:Dominant [Functional Concept]
   795   C2825415:Negative [Conceptual Entity]
   795   C2825491:Negative [Qualitative Concept]
Processing 00000000.tx.216: Induction of DN-SREBP-1c diminished the chronic high-glucose-induced SREBP-1 binding to the SRE fragment of the IRS2 promoter. 

Phrase: "Induction of DN-SREBP-1c"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0205263:Induction [Functional Concept]
   744   C0857127:induction [Therapeutic or Preventive Procedure]

Phrase: "diminished"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205216:Diminished [Quantitative Concept]

Phrase: "the chronic high-glucose-induced SREBP-1 binding"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   704   C0217529:Sterol Regulatory Element Binding Protein 1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   704   C1420398:STEROL REGULATORY ELEMENT-BINDING PROTEIN 1 [Gene or Genome]

Phrase: "to the SRE fragment"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0332255:fragment [Functional Concept]
   812   C1708096:Fragment [Qualitative Concept]

Phrase: "of the IRS2 promoter."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0086860:Promoter [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   771   C0381451:Insulin Receptor Substrate-2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   771   C1334141:INSULIN RECEPTOR SUBSTRATE 2 [Gene or Genome]
   771   C1334191:Insulin Receptor Substrate 2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
Processing 00000000.tx.217: Consequently, the inhibitory effects of chronic high glucose on IRS2 expression were largely attenuated by DN-SREBP-1c. 

Phrase: "Consequently,"

Phrase: "the inhibitory effects of chronic high glucose"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   757   C1158774:glucose effect [Genetic Function]
   748   C1280500:effects [Qualitative Concept]
   714 E C2348382:Effect [Qualitative Concept]

Phrase: "on IRS2 expression"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   875   C0597360:receptor expression [Genetic Function]
   804   C0185117:Expression [Therapeutic or Preventive Procedure]
   771   C0381451:Insulin Receptor Substrate-2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   771   C1334141:INSULIN RECEPTOR SUBSTRATE 2 [Gene or Genome]
   771   C1334191:Insulin Receptor Substrate 2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "were"

Phrase: "largely"

Phrase: "attenuated by DN-SREBP-1c."
Meta Candidates (Total=13; Excluded=0; Pruned=0; Remaining=13)
   800   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
           Dominant Negative
   770   C0537474:SREBP-1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   770   C1420398:SREBP-1c [Gene or Genome]
   770   C3538602:SREBP-1c [Gene or Genome]
   744   C0205160:Negative [Qualitative Concept]
   744   C0332161:Attenuated [Qualitative Concept]
   744   C0596988:Mutant [Cell or Molecular Dysfunction]
   744   C0599946:Attenuated [Activity]
   744   C1513916:Negative [Finding]
   744   C1527180:Dominant [Functional Concept]
   744   C2825415:Negative [Conceptual Entity]
   744   C2825491:Negative [Qualitative Concept]
Processing 00000000.tx.218: It has been reported that SREBP-1c binds to the IRS2 promoter and suppresses IRS2 expression in rodent hepatocytes (Ide et al., 2004). 

Phrase: "It"

Phrase: "has"

Phrase: "been"

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "that SREBP-1c"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
  1000   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C2246292:sterol binding [Molecular Function]
   827   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0013879:Element [Element, Ion, or Isotope]
   799   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0038323:Sterol [Steroid]
   799   C0220905:regulatory [Regulation or Law]
   799   C0243122:binding [Functional Concept]
   799   C1145667:Binding [Activity]
   799   C1167622:Binding [Molecular Function]
   799   C1704735:Regulatory [Conceptual Entity]
   799   C1705248:Element [Conceptual Entity]

Phrase: "binds to the IRS2 promoter"
Meta Candidates (Total=13; Excluded=0; Pruned=0; Remaining=13)
   833   C0381451:Insulin Receptor Substrate-2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   833   C1334141:INSULIN RECEPTOR SUBSTRATE 2 [Gene or Genome]
   833   C1334191:Insulin Receptor Substrate 2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   770   C0034818:Insulin Receptor [Amino Acid, Peptide, or Protein,Enzyme,Receptor]
   770   C1334133:INSULIN RECEPTOR [Gene or Genome]
   744   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C0086860:Promoter [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   744   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   744   C1145667:Bind [Activity]
   744   C1167622:bind [Molecular Function]
   744   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C1579433:Insulin [Pharmacologic Substance]
   744   C1710236:Substrate [Manufactured Object]

Phrase: "and"

Phrase: "suppresses"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1260953:suppress [Functional Concept]

Phrase: "IRS2 expression in rodent hepatocytes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   767   C0597360:receptor expression [Genetic Function]
   744   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "(H.W. and C.B.W., unpublished data), suggesting that SREBP-1c is the predominant transcription factor responsible for -cell glucolipotoxicity. To further substantiate this hypothesis, we established an INS-1 stable cell line with inducible expression of DN-SREBP-1c. Induction of DN-SREBP-1c diminished the chronic high-glucose-induced SREBP-1 binding to the SRE fragment of the IRS2 promoter. Consequently, the inhibitory effects of chronic high glucose on IRS2 expression were largely attenuated by DN-SREBP-1c. It has been reported that SREBP-1c binds to the IRS2 promoter and suppresses IRS2 expression in rodent hepatocytes (Ide et al.,"

Phrase: "2004"

Phrase: "), suggesting that SREBP-1c is the predominant transcription factor responsible for -cell glucolipotoxicity. To further substantiate this hypothesis, we established an INS-1 stable cell line with inducible expression of DN-SREBP-1c. Induction of DN-SREBP-1c diminished the chronic high-glucose-induced SREBP-1 binding to the SRE fragment of the IRS2 promoter. Consequently, the inhibitory effects of chronic high glucose on IRS2 expression were largely attenuated by DN-SREBP-1c. It has been reported that SREBP-1c binds to the IRS2 promoter and suppresses IRS2 expression in rodent hepatocytes (Ide et al., 2004)."
Processing 00000000.tx.219: Our results suggest a similar mechanism in pancreatic  cells. 

Phrase: "Our results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "suggest"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "a similar mechanism in pancreatic  cells."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0441712:Mechanism [Functional Concept]
   753   C1706376:Mechanism [Manufactured Object]
Processing 00000000.tx.220: Deletion of IRS2 in mouse hypothalamus and  cells has recently been shown to cause a type 2 diabetes-like syndrome (Kubota et al., 2004; Lin et al., 2004). 

Phrase: "Deletion of IRS2"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   753   C1442161:Deletion [Cell or Molecular Dysfunction]
   753   C1511760:Deletion [Genetic Function]
   753   C1880274:Deletion [Activity]
   716   C0381451:Insulin Receptor Substrate-2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   716   C1334141:INSULIN RECEPTOR SUBSTRATE 2 [Gene or Genome]
   716   C1334191:Insulin Receptor Substrate 2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "in mouse hypothalamus"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1522183:Mouse Hypothalamus [Tissue]
   861   C0020663:Hypothalamus [Body Part, Organ, or Organ Component]
   861   C1280712:Hypothalamus [Body Part, Organ, or Organ Component]

Phrase: "and"

Phrase: "cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "has"

Phrase: "recently"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332185:Recently [Temporal Concept]

Phrase: "been"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "cause"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0015127:cause [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]

Phrase: "a type 2 diabetes-"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]

Phrase: "like syndrome"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0039082:Syndrome [Disease or Syndrome]

Phrase: "(Ide et al., 2004). Our results suggest a similar mechanism in pancreatic  cells. Deletion of IRS2 in mouse hypothalamus and  cells has recently been shown to cause a type 2 diabetes-like syndrome (Kubota et al.,"

Phrase: "2004"

Phrase: "; Lin et al.,"

Phrase: "2004"

Phrase: "). Our results suggest a similar mechanism in pancreatic  cells. Deletion of IRS2 in mouse hypothalamus and  cells has recently been shown to cause a type 2 diabetes-like syndrome (Kubota et al., 2004; Lin et al., 2004)."
Processing 00000000.tx.221: IRS2 is also known to promote  cell growth/survival (Withers et al., 1998). 

Phrase: "IRS2"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
  1000   C0381451:Insulin Receptor Substrate-2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
  1000   C1334141:INSULIN RECEPTOR SUBSTRATE 2 [Gene or Genome]
  1000   C1334191:Insulin Receptor Substrate 2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C0034818:Insulin Receptor [Amino Acid, Peptide, or Protein,Enzyme,Receptor]
   861   C1334133:INSULIN RECEPTOR [Gene or Genome]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   812   C1710236:Substrate [Manufactured Object]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "is"

Phrase: "also"

Phrase: "known"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205309:Known [Qualitative Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "promote"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033414:Promote [Activity]

Phrase: "cell growth/survival"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   913   C0007620:Cell Survival [Cell Function]
   827   C0038952:Survival [Activity]
   827   C0220921:survival [Functional Concept]
   734   C0007595:Cell Growth [Cell Function]

Phrase: "("

Phrase: "Withers"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0230107:Withers [Body Part, Organ, or Organ Component]

Phrase: "et al.,"

Phrase: "1998"

Phrase: "). IRS2 is also known to promote  cell growth/survival (Withers et al., 1998)."
Processing 00000000.tx.222: We therefore propose that suppression of IRS2 expression by SREBP-1c should contribute, at least in part, to -cell glucolipotoxicity. 

Phrase: "We therefore"

Phrase: "propose"

Phrase: "that suppression of IRS2 expression"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   744   C0221103:Suppression [Pathologic Function]
   744   C0301625:Suppression [Organism Function]
   744   C0439181:% suppression [Quantitative Concept]
   744   C0728721:suppression [Mental Process]

Phrase: "by SREBP-1c"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
  1000   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C2246292:sterol binding [Molecular Function]
   827   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0013879:Element [Element, Ion, or Isotope]
   799   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0038323:Sterol [Steroid]
   799   C0220905:regulatory [Regulation or Law]
   799   C0243122:binding [Functional Concept]
   799   C1145667:Binding [Activity]
   799   C1167622:Binding [Molecular Function]
   799   C1704735:Regulatory [Conceptual Entity]
   799   C1705248:Element [Conceptual Entity]

Phrase: "should"

Phrase: "contribute"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1880177:Contribute [Activity]

Phrase: ","

Phrase: "at least"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0439092:less [Intellectual Product]
   966   C0547044:Less [Qualitative Concept]

Phrase: "in part,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0449719:Part [Spatial Concept]
  1000   C1709471:Part [Quantitative Concept]

Phrase: "to -cell glucolipotoxicity."
Processing 00000000.tx.223: We also demonstrated that dominant-negative suppression of SREBP-1c activation largely prevented glucolipotoxicity in INS-1 cells, including lipid accumulation, impaired glucose-stimulated insulin secretion and apoptosis. 

Phrase: "We also"

Phrase: "demonstrated"

Phrase: "that dominant-negative suppression"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   827   C0221103:Suppression [Pathologic Function]
   827   C0301625:Suppression [Organism Function]
   827   C0439181:% suppression [Quantitative Concept]
   827   C0728721:suppression [Mental Process]
   734   C1512032:Dominant Negative [Cell or Molecular Dysfunction]

Phrase: "of SREBP-1c activation largely prevented glucolipotoxicity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   717   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "in"

Phrase: "INS-1 cells,"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "lipid accumulation,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0333574:Lipid accumulation [Finding]

Phrase: "impaired glucose-stimulated insulin secretion"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   853   C1719133:Glucose/Insulin [Quantitative Concept]
   840   C1256369:insulin secretion [Cell Function]
   804   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   804   C0036536:secretion [Biologic Function]
   804   C0036537:Secretion [Body Substance]
   804   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   804   C1579433:Insulin [Pharmacologic Substance]
   748 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   721 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "apoptosis."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0162638:Apoptosis [Cell Function]
   928 E C1516044:Apoptotic [Qualitative Concept]
Processing 00000000.tx.224: The protective effects of DN-SREBP-1c could be explained by nomalized expression of fatty acid synthase, HMG-CoA reductase, LDLR, P21, GLUT2, glucokinase, PDX1, IRS2 and BCLXL. 

Phrase: "The protective effects of DN-SREBP-1c"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   739   C1280500:effects [Qualitative Concept]
   706 E C2348382:Effect [Qualitative Concept]

Phrase: "could"

Phrase: "be"

Phrase: "explained by nomalized expression of fatty acid synthase,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   800   C0015683:Fatty-acid synthase [Amino Acid, Peptide, or Protein,Enzyme]
   800   C1367441:FATTY ACID SYNTHASE [Gene or Genome]
   770   C0015684:Fatty acid [Lipid]
   744   C0001128:Acid [Chemical]
   744   C0132555:synthase [Amino Acid, Peptide, or Protein,Enzyme]
   744   C0185117:Expression [Therapeutic or Preventive Procedure]
   744   C0202406:Acid [Laboratory Procedure]

Phrase: "HMG-CoA reductase,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0020374:HMG CoA Reductase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C0063164:HMG-CoA reductase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1415615:HMG-CoA REDUCTASE [Gene or Genome]
   901   C0047420:HMG-CoA [Biologically Active Substance,Organic Chemical]
   827   C0030016:Reductase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "LDLR,"
Meta Candidates (Total=11; Excluded=1; Pruned=0; Remaining=10)
  1000   C0034821:Low Density Lipoprotein Receptor [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1366529:LOW DENSITY LIPOPROTEIN RECEPTOR [Gene or Genome]
   923   C0023823:Low density lipoprotein [Amino Acid, Peptide, or Protein,Biologically Active Substance,Lipid]
   861   C0065059:Lipoprotein Receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C0023820:Lipoprotein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   812   C0178587:density [Quantitative Concept]
   812   C0205251:low [Qualitative Concept]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C1299352:Low [Qualitative Concept]
   812   C1550472:low [Idea or Concept]
   741 E C0439794:Dense [Qualitative Concept]

Phrase: "P21,"

Phrase: "GLUT2,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1420172:GLUT2 [Gene or Genome]

Phrase: "glucokinase,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0017713:Glucokinase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1415014:GLUCOKINASE [Gene or Genome]

Phrase: "PDX1,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1427500:PDX1 [Gene or Genome]
  1000   C1826562:PDX1 [Gene or Genome]

Phrase: "IRS2"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
  1000   C0381451:Insulin Receptor Substrate-2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
  1000   C1334141:INSULIN RECEPTOR SUBSTRATE 2 [Gene or Genome]
  1000   C1334191:Insulin Receptor Substrate 2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C0034818:Insulin Receptor [Amino Acid, Peptide, or Protein,Enzyme,Receptor]
   861   C1334133:INSULIN RECEPTOR [Gene or Genome]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   812   C1710236:Substrate [Manufactured Object]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "BCLXL."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1332397:BCLXL [Gene or Genome]
Processing 00000000.tx.225: In addition, DN-SREBP-1c also suppressed the expression of UCP2. 

Phrase: "In addition,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1883712:Addition [Functional Concept]
   928 E C1524062:Additional [Functional Concept]

Phrase: "DN-SREBP-1c also"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   814   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
   748   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: "suppressed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1260953:Suppressed [Functional Concept]

Phrase: "the expression of UCP2."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   783   C1171362:expression protein [Genetic Function]
   753   C0185117:Expression [Therapeutic or Preventive Procedure]
Processing 00000000.tx.226: In contrast, DN-SREBP-1c did not affect the expression of L-PK and aldolase B, which were targeted by ChREBP. 

Phrase: "In contrast,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1979874:Contrast [Qualitative Concept]

Phrase: "DN-SREBP-1c"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
   753   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "affect"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001721:Affect [Mental Process]

Phrase: "the expression of L-PK"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "and"

Phrase: "aldolase B,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0001999:Aldolase B [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1412347:ALDOLASE B [Gene or Genome]
   861   C0016762:Aldolase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "which"

Phrase: "were"

Phrase: "targeted by ChREBP."
Meta Candidates (Total=22; Excluded=2; Pruned=0; Remaining=20)
   897   C1826259:carbohydrate response element binding protein [Gene or Genome]
   853   C3158709:carbohydrate response element binding [Genetic Function]
   804   C0108401:carbohydrate-binding protein [Amino Acid, Peptide, or Protein,Receptor]
   778   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   778   C0600508:Response Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   774 E C0033618:Protein Binding [Molecular Function]
   774   C1148582:carbohydrate binding [Molecular Function]
   757   C1159372:protein target [Molecular Function]
   757   C3272920:Target Response [Finding]
   748   C0007004:Carbohydrate [Carbohydrate]
   748   C0013879:Element [Element, Ion, or Isotope]
   748   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   748   C0243122:binding [Functional Concept]
   748   C0871261:Response [Organism Attribute]
   748   C1145667:Binding [Activity]
   748   C1167622:Binding [Molecular Function]
   748   C1521840:Targeted [Functional Concept]
   748   C1704632:Response [Finding]
   748   C1705248:Element [Conceptual Entity]
   748   C1706817:Response [Intellectual Product]
   748   C2911692:Response [Mental Process]
   714 E C2986546:TARGET [Diagnostic Procedure]
Processing 00000000.tx.227: Glucokinase is the rate-limiting enzyme for glycolysis and serves as the -cell glucose sensor (Wang and Iynedjian, 1997). 

Phrase: "Glucokinase"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0017713:Glucokinase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1415014:GLUCOKINASE [Gene or Genome]

Phrase: "is"

Phrase: "the rate-limiting enzyme for glycolysis"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0014442:Enzyme [Enzyme,Organic Chemical]

Phrase: "and"

Phrase: "serves as the -cell glucose sensor"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   790   C0872382:GLUCOSE SENSOR [Medical Device]
   790   C1625163:glucose sensor [Molecular Function]
   753   C0007634:Cell [Cell]
   753   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   753   C0183210:Sensor [Medical Device]
   753   C1269647:Cell [Cell]
   753   C1704653:Cell [Medical Device]
   753   C1705193:Sensor [Manufactured Object]
   753   C1948049:Cell [Spatial Concept]

Phrase: "(Withers et al., 1998). We therefore propose that suppression of IRS2 expression by SREBP-1c should contribute, at least in part, to -cell glucolipotoxicity. We also demonstrated that dominant-negative suppression of SREBP-1c activation largely prevented glucolipotoxicity in INS-1 cells, including lipid accumulation, impaired glucose-stimulated insulin secretion and apoptosis. The protective effects of DN-SREBP-1c could be explained by nomalized expression of fatty acid synthase, HMG-CoA reductase, LDLR, P21, GLUT2, glucokinase, PDX1, IRS2 and BCLXL. In addition, DN-SREBP-1c also suppressed the expression of UCP2. In contrast, DN-SREBP-1c did not affect the expression of L-PK and aldolase B, which were targeted by ChREBP. Glucokinase is the rate-limiting enzyme for glycolysis and serves as the -cell glucose sensor (Wang"

Phrase: "and"

Phrase: "Iynedjian,"

Phrase: "1997"

Phrase: "). We therefore propose that suppression of IRS2 expression by SREBP-1c should contribute, at least in part, to -cell glucolipotoxicity. We also demonstrated that dominant-negative suppression of SREBP-1c activation largely prevented glucolipotoxicity in INS-1 cells, including lipid accumulation, impaired glucose-stimulated insulin secretion and apoptosis. The protective effects of DN-SREBP-1c could be explained by nomalized expression of fatty acid synthase, HMG-CoA reductase, LDLR, P21, GLUT2, glucokinase, PDX1, IRS2 and BCLXL. In addition, DN-SREBP-1c also suppressed the expression of UCP2. In contrast, DN-SREBP-1c did not affect the expression of L-PK and aldolase B, which were targeted by ChREBP. Glucokinase is the rate-limiting enzyme for glycolysis and serves as the -cell glucose sensor (Wang and Iynedjian, 1997)."
Processing 00000000.tx.228: PDX1 is required for maintaining -cell-specific gene expression and the -cell phenotype (Ahlgren et al., 1998; Wang et al., 2001). 

Phrase: "PDX1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1427500:PDX1 [Gene or Genome]
  1000   C1826562:PDX1 [Gene or Genome]

Phrase: "is"

Phrase: "required for maintaining -cell-specific gene expression"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   778   C0017262:Gene Expression [Genetic Function]
   774   C1861886:CELL Gene [Gene or Genome]
   748   C0007634:Cell [Cell]
   748   C0017337:Gene [Gene or Genome]
   748   C0185117:Expression [Therapeutic or Preventive Procedure]
   748   C0205369:Specific [Qualitative Concept]
   748   C1269647:Cell [Cell]
   748   C1514873:Required [Functional Concept]
   748   C1552740:specific [Intellectual Product]
   748   C1704653:Cell [Medical Device]
   748   C1948049:Cell [Spatial Concept]
   714   C0024501:Maintain [Activity]

Phrase: "and"

Phrase: "the -cell phenotype"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0427385:Cell phenotype [Laboratory Procedure]
  1000   C1318444:Cell phenotype [Organism Attribute]
   861   C0031437:Phenotype [Organism Attribute]
   861   C1285572:Phenotype [Laboratory Procedure]

Phrase: "(Wang and Iynedjian, 1997). PDX1 is required for maintaining -cell-specific gene expression and the -cell phenotype (Ahlgren et al.,"

Phrase: "1998"

Phrase: "; Wang et al.,"

Phrase: "2001"

Phrase: "). PDX1 is required for maintaining -cell-specific gene expression and the -cell phenotype (Ahlgren et al., 1998; Wang et al., 2001)."
Processing 00000000.tx.229: Mouse islets deficient in LDLR have been shown to be resistant to LDL-induced apoptosis (Roehrich et al., 2003). 

Phrase: "Mouse islets"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1522528:Mouse Islets [Tissue]

Phrase: "deficient in LDLR"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0011155:Deficient [Functional Concept]
   753   C1636779:% deficient [Quantitative Concept]
   716   C0034821:Low Density Lipoprotein Receptor [Amino Acid, Peptide, or Protein,Receptor]
   716   C1366529:LOW DENSITY LIPOPROTEIN RECEPTOR [Gene or Genome]

Phrase: "have"

Phrase: "been"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "resistant to LDL-induced apoptosis"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   806   C0332325:Resistant to [Functional Concept]
           Resistant
   760   C2827757:RESISTANT [Laboratory or Test Result]

Phrase: "(Ahlgren et al., 1998; Wang et al., 2001). Mouse islets deficient in LDLR have been shown to be resistant to LDL-induced apoptosis (Roehrich et al.,"

Phrase: "2003"

Phrase: "). Mouse islets deficient in LDLR have been shown to be resistant to LDL-induced apoptosis (Roehrich et al., 2003)."
Processing 00000000.tx.230: Deletion of Ucp2 restores -cell function in ob/ob mice and in animals fed a high-fat diet (Chan et al., 2004; Joseph et al., 2002; Zhang et al., 2001). 

Phrase: "Deletion of Ucp2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C1442161:Deletion [Cell or Molecular Dysfunction]
   790   C1511760:Deletion [Genetic Function]
   790   C1880274:Deletion [Activity]

Phrase: "restores -"

Phrase: "cell function in ob/ob mice"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   790   C0007613:Cell Function [Cell Function]
   753   C0007634:Cell [Cell]
   753   C0031843:function [Physiologic Function]
   753   C0542341:Function [Functional Concept]
   753   C0700205:FUNCTION [Classification]
   753   C1269647:Cell [Cell]
   753   C1704653:Cell [Medical Device]
   753   C1705273:Function [Intellectual Product]
   753   C1948049:Cell [Spatial Concept]

Phrase: "and in animals"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0003062:Animals [Animal]
   790   C1515981:And [Idea or Concept]

Phrase: "fed"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0342895:FED [Disease or Syndrome]
   966 E C0204695:Feed [Health Care Activity]
   966 E C2987508:Feed [Activity]

Phrase: "a high-fat diet"
Meta Candidates (Total=11; Excluded=1; Pruned=0; Remaining=10)
  1000   C0521974:Diet, High-Fat [Therapeutic or Preventive Procedure]
   901   C0301585:Fat diet [Therapeutic or Preventive Procedure]
   827   C0012155:Diet [Food]
   827   C0205250:High [Qualitative Concept]
   827   C0424612:FAT [Organism Attribute]
   827   C1299351:High [Qualitative Concept]
   827   C1442959:Diet [Organism Function]
   827   C1519433:DIET [Therapeutic or Preventive Procedure]
   827   C2700149:HIGH [Intellectual Product]
   827   C2983588:DIET [Food]
   755 E C2699635:DIETARY [Functional Concept]

Phrase: "(Roehrich et al., 2003). Deletion of Ucp2 restores -cell function in ob/ob mice and in animals fed a high-fat diet (Chan et al.,"

Phrase: "2004"

Phrase: "; Joseph et al.,"

Phrase: "2002"

Phrase: "; Zhang et al.,"

Phrase: "2001"

Phrase: "). Deletion of Ucp2 restores -cell function in ob/ob mice and in animals fed a high-fat diet (Chan et al., 2004; Joseph et al., 2002; Zhang et al., 2001)."
Processing 00000000.tx.231: In addition, mouse islets deficient in UCP2 are protected from fatty acid-induced lipotoxicity (Joseph et al., 2004), whereas its overexpression leads to impaired glucose-stimulated insulin secretion (Lameloise et al., 2001; Yamashita et al., 2004). 

Phrase: "In addition,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1883712:Addition [Functional Concept]
   928 E C1524062:Additional [Functional Concept]

Phrase: "mouse islets"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1522528:Mouse Islets [Tissue]

Phrase: "deficient in UCP2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0011155:Deficient [Functional Concept]
   760   C1636779:% deficient [Quantitative Concept]

Phrase: "are"

Phrase: "protected from fatty acid-induced lipotoxicity"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0015684:Fatty acid [Lipid]
   753   C0001128:Acid [Chemical]
   753   C0202406:Acid [Laboratory Procedure]
   753   C0205263:Induced [Functional Concept]

Phrase: "(Chan et al., 2004; Joseph et al., 2002; Zhang et al., 2001). In addition, mouse islets deficient in UCP2 are protected from fatty acid-induced lipotoxicity (Joseph et al.,"

Phrase: "2004"

Phrase: ")"

Phrase: ","

Phrase: "whereas"

Phrase: "its overexpression"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514559:Overexpression [Genetic Function]

Phrase: "leads to impaired glucose-stimulated insulin secretion"
Meta Candidates (Total=17; Excluded=0; Pruned=0; Remaining=17)
   778   C1256369:insulin secretion [Cell Function]
   774   C1719133:Glucose/Insulin [Quantitative Concept]
   748   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   748   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   748   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   748   C0036536:secretion [Biologic Function]
   748   C0036537:Secretion [Body Substance]
   748   C0181586:leads [Medical Device]
   748   C0221099:Impaired [Functional Concept]
   748   C0684336:Impaired [Pathologic Function]
   748   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   748   C1522538:Lead [Functional Concept]
   748   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   748   C1579433:Insulin [Pharmacologic Substance]
   748   C1948023:Stimulated [Natural Phenomenon or Process]
   748   C2348269:Lead [Element, Ion, or Isotope]
   748   C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "(Joseph et al., 2004), whereas its overexpression leads to impaired glucose-stimulated insulin secretion (Lameloise et al.,"

Phrase: "2001"

Phrase: "; Yamashita et al.,"

Phrase: "2004"

Phrase: "), whereas its overexpression leads to impaired glucose-stimulated insulin secretion (Lameloise et al., 2001; Yamashita et al., 2004)."
Processing 00000000.tx.232: Therefore, chronic high glucose may act through SREBP-1 to target multiple genes, causing -cell glucolipotoxicity. 

Phrase: "Therefore,"

Phrase: "chronic high glucose"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C0860803:high glucose [Finding]
   827   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "may"

Phrase: "act through SREBP-1 to"
Meta Candidates (Total=19; Excluded=1; Pruned=0; Remaining=18)
   882   C0217529:Sterol Regulatory Element Binding Protein 1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   882   C1420398:STEROL REGULATORY ELEMENT-BINDING PROTEIN 1 [Gene or Genome]
   764   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   764   C0087044:protein i [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   764   C0103404:Protein I [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   764   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   762 E C0033618:Protein Binding [Molecular Function]
   762   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   762   C2246292:sterol binding [Molecular Function]
   742   C0013879:Element [Element, Ion, or Isotope]
   742   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   742   C0038323:Sterol [Steroid]
   742   C0079613:ACT [Therapeutic or Preventive Procedure]
   742   C0220905:regulatory [Regulation or Law]
   742   C0243122:binding [Functional Concept]
   742   C1145667:Binding [Activity]
   742   C1167622:Binding [Molecular Function]
   742   C1704735:Regulatory [Conceptual Entity]
   742   C1705248:Element [Conceptual Entity]

Phrase: "target"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1521840:Target [Functional Concept]
  1000   C2986546:TARGET [Diagnostic Procedure]

Phrase: "multiple genes,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0017337:Genes [Gene or Genome]

Phrase: "causing -"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0678227:Causing [Functional Concept]
   966 E C0015127:cause [Functional Concept]
   966 E C1524003:Cause [Conceptual Entity]

Phrase: "cell glucolipotoxicity."
Processing 00000000.tx.233: Most intriguingly, we found that chronic high glucose treatment caused ER stress response in INS-1 cells, evidenced by elevated expression of two characteristic genes, CHOP and BIP. 

Phrase: "Most intriguingly,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0205393:Most [Quantitative Concept]

Phrase: "we"

Phrase: "found"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0150312:Found [Quantitative Concept]
   966 E C0243095:Find [Finding]

Phrase: "that chronic high glucose treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   812   C0039798:treatment [Functional Concept]
   812   C0087111:Treatment [Therapeutic or Preventive Procedure]
   812   C1522326:Treatment [Functional Concept]
   812   C1533734:Treatment [Therapeutic or Preventive Procedure]
   812   C1705169:Treatment [Conceptual Entity]
   812   C3538994:TREATMENT [Research Activity]

Phrase: "caused"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0015127:cause [Functional Concept]
   966   C1524003:Cause [Conceptual Entity]

Phrase: "ER stress response in"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   806   C0149784:stress response [Physiologic Function]
   760   C0871261:Response [Organism Attribute]
   760   C1704632:Response [Finding]
   760   C1706817:Response [Intellectual Product]
   760   C2911692:Response [Mental Process]

Phrase: "INS-1 cells,"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "evidenced by elevated expression of two characteristic genes,"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   750   C0017262:Gene Expression [Genetic Function]
   750   C0332120:Evidence of [Functional Concept]
           Evidence
   744   C0017337:Genes [Gene or Genome]
   744   C0185117:Expression [Therapeutic or Preventive Procedure]
   744   C0205250:Elevated [Qualitative Concept]
   744   C0205448:Two [Quantitative Concept]
   744   C1521970:Characteristic [Qualitative Concept]
   744   C3163633:Elevated [Qualitative Concept]

Phrase: "CHOP"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2945739:chop [Activity]

Phrase: "and"

Phrase: "BIP."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0063423:BiP [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1415761:BIP [Gene or Genome]
Processing 00000000.tx.234: It has been reported that glucose stimulates protein synthesis in pancreatic  cells through dephosphorylation of the eukaryotic elongation factor (eEF2) (Yan et al., 2003) and initiation factor (eIF2) (Gomez et al., 2004) and activation of the guanine nucleotide exchange factor eIF2B (Gilligan et al., 1996). 

Phrase: "It"

Phrase: "has"

Phrase: "been"

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "that glucose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "stimulates"

Phrase: "SCAP) escorts SREBPs from the ER to the Golgi, where SREBPs are sequentially cleaved by site-1 protease (S1P) and site-2 protease (S2P). The processed mature SREBPs enter the nucleus and transactivate target genes (Brown and Goldstein, 1997). Three SREBP isoforms have been identified: SREBP-1a and -1c (alternatively known as adipocyte determination and differentiation factor-1; ADD-1) (Tontonoz et al., 1993) that are derived from the same gene through alternative splicing, and SREBP-2 that is encoded by a distinct gene (Brown and Goldstein, 1997). SREBPs are expressed ubiquitously, play an essential role in regulation of lipid homeostasis in animals and have been shown to directly activate the expression of more than 30 genes dedicated to the biosynthesis of cholesterol, fatty acids, triglycerides and phospholipids (Horton et al., 2002). Elevated expression of SREBP-1c has been demonstrated in islets and liver of many animal models of diabetes (Kakuma et al., 2000; Lin et al., 2000; Matsuzaka et al., 2004; Riddle et al., 2001; Shimomura et al., 1999a; Shimomura et al., 1999b; Shimomura et al., 1999c; Shimomura et al., 2000; Sun et al., 2002; Takaishi et al., 2004; Tobe et al., 2001; Ueki et al., 2004; Unger and Zhou, 2001; Unger et al., 1999; Werstuck et al., 2001; Xu et al., 2004; Yahagi et al., 2002; You et al., 2002) and patients with severe lipodystrophy (Bastard et al., 2002; Petersen et al., 2002). Lipid accumulation, impaired glucose-stimulated insulin secretion, defective -cell gene expression (insulin, Pdx1, glucokinase and Glut2), disorganized mitochondrial ultrastructure and `lipoapoptosis' have been reported in the  cells of diabetic animals (Unger and Zhou, 2001; Unger et al., 1999). Moreover, preventing SREBP-1c overexpression and activation is common to leptin, metformin, adiponectin and PPAR agonists. Thus there is a good correlation between suppression of SREBP-1c function and antidiabetic effects of these agents (Kakuma et al., 2000; Lin et al., 2000; Petersen et al., 2002; Shimomura et al., 1999a; Shimomura et al., 1999b; Shimomura et al., 1999c; Tobe et al., 2001; Unger and Zhou, 2001; Unger et al., 1999; Wang, M. Y. et al., 1998; Xu et al., 2004; Zhou et al., 2001). We and others have demonstrated that overexpression of a nuclear active form of SREBP-1c (naSREBP-1c) in insulinoma (INS-1 and MIN6) cells and isolated rat islets results in -cell lipotoxicity (Andreolas et al., 2002; Diraison et al., 2004; Wang et al., 2003; Yamashita et al., 2004). We have previously shown that long-term exposure of INS-1 cells to 30 mM glucose generated the mature nuclear form of SREBP-1c (Wang et al., 2003). Glucose also raises SREBP-1c mRNA levels in rat  cells (Flamez et al., 2002). It is well known that chronic high glucose treatment causes glucolipotoxicity in both insulinoma cells and rat islets (Efanova et al., 1998; Roche et al., 1998). We hypothesise that SREBP-1c activation could play an essential role in development of -cell glucolipotoxicity. To further substantiate this notion we established an INS-1 stable cell line that allowed suppression of SREBP-1c function through induction of a dominant-negative mutant of SREBP-1c (DN-SREBP-1c) (Kim and Spiegelman, 1996). Strong experimental evidence demonstrated that dominant-negative suppression of SREBP-1c activity markedly prevented -cell glucolipotoxicity. In addition, we found that ER-stress-generated SREBP-1c processing and activation could be the underlying mechanism in -cell glucolipotoxicity.  Materials and Methods Top Summary Introduction Materials and Methods Results Discussion References  Cell culture The standard rat insulinoma INS-1E cells and two previously established INS-1-derived stable cell lines, ChREBP*16 (Wang and Wollheim, 2002) and naSREBP-1c*233 (Wang et al., 2003), allowing inducible expression, respectively, of ChREBP and a nuclear active form of SREBP-1c, were cultured in RPMI1640 containing 11.2 mM glucose (Asfari et al., 1992), unless otherwise indicated. Establishment of INS-1 cells permitting inducible expression of DN-SREBP-1c The first step stable INS-r (also refer to as r9) cell line, which carries the reverse tetracycline/doxycycline-dependent transactivator (Gossen et al., 1995), was described previously (Wang and Iynedjian, 1997; Wang et al., 2001). The plasmid used in the secondary stable transfection was constructed by subcloning the cDNA encoding the dominant-negative form of SREBP-1c (DN-SREBP-1c/ADD1 1-403(Y320A) [(Kim and Spiegelman, 1996) kindly supplied by B.M. Spiegelman] into the expression vector PUHD10-3 [(Gossen et al., 1995) a generous gift from H. Bujard]. The procedures for stable transfection, clone selection and screening were described previously (Wang and Iynedjian, 1997). Immunofluorescence Cells grown on polyornithine-treated glass coverslips were treated for 24 hours with or without 500 ng/ml doxycycline. Cells were then washed, fixed in 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 in phosphate-buffered saline containing 1% BSA (PBS-BSA). The preparation was then blocked with PBS-BSA before incubating with the first antibody, anti-SREBP-1 (Santa Cruz, Basel, Switzerland; 1:100 dilution), followed by the second antibody labelling. Nuclear protein extraction and electrophoretic mobility-shift assay (EMSA) Nuclear extracts from INS-1 cells were prepared according to the method of Schreiber et al. (Schreiber et al., 1988). Rat islets were isolated by collagenase digestion as described previously (Rubi et al., 2001) and their nuclear proteins were extracted as previously reported (Schreiber et al., 1988). The double-stranded oligonucleotides corresponding to the sterol regulatory element (SRE) in the human insulin receptor substrate 2 (IRS2) promoter (Ide et al., 2004), 5'cctgcgtaacgccgagtcacatgttgtt3', was used as a probe. EMSA procedures, including conditions for probe labelling and binding reactions were performed as in Wang et al. (Wang, H. et al., 1998). Mouse monoclonal antibodies against SREBP-1 (NeoMarkers, Fremont CA, USA) and SREBP-2 (purified from the supernatant of the hybridoma cell line CRL2121, American Tissue Culture Collection, Rockville, MD, USA) were used for supershift experiments. Staining of lipid accumulation by Oil Red O Cells were cultured in standard (11.2 mM) or 30 mM glucose medium in the presence or absence of 500 ng/ml doxycycline for 48 hours. Cells were fixed and stained as previously reported (Kim and Spiegelman, 1996). Lipid droplets were visualized using phase-contrast microscopy (Nikon Diaphot). Measurements of insulin secretion and cellular insulin content Insulin secretion in INS-1E or DN-SREBP-1c#23 cells was measured in 24-well plates over a period of 30 minutes, in Krebs-Ringer-bicarbonate-Hepes buffer (KRBH, 140 mM NaCl, 3.6 mM KCl, 0.5 mM NaH2PO4, 0.5 mM MgSO4, 1.5 mM CaCl2, 2 mM NaHCO3, 10 mM Hepes, 0.1% BSA) containing the indicated concentrations of glucose. Cellular insulin content was determined after extraction with acid ethanol following the procedures of Wang et al. (Wang, H. et al., 1998). Insulin was detected by radio-immunoassay using rat insulin as a standard (Wang, H. et al., 1998). Total RNA isolation and northern blotting Total RNA was extracted and blotted to nylon membranes as described previously (Wang and Iynedjian, 1997). The membrane was prehybridized and then hybridized to 32P-labelled random primer cDNA probes according to the method of Wang and Iynedijian (Wang and Iynedjian, 1997). To ensure equal RNA loading and even transfer, all membranes were stripped and re-hybridized with a `house-keeping gene' probe, cyclophilin. cDNA fragments used as probes for SREBP-1c, ChREBP, glucokinase, GLUT2, L-pyruvate kinase, insulin, BIP, CHOP10 and PDX1 mRNA detection were digested from the corresponding plasmids. cDNA probes for rat mitochondrial uncoupling protein 2 (UCP2), aldolase B, fatty acid synthase, acetyl-CoA carboxylase, glycerol-phosphate acyltransferase, HMG-CoA reductase, P21WAF1/CIP1, BAD, APO1, BclXL, IRS2 and low density lipoprotein receptor (LDLR), were prepared by RT-PCR and confirmed by sequencing. Cell proliferation/viability and apoptosis Quantification of cell proliferation/viability was measured using a Quick Cell Proliferation Assay Kit (LabForce/MBL, Nunningen, Switzerland) according to manufacturer's protocol. This assay is based on the cleavage of a tetrazolium salt WST-1 to formazan by mitochondrial dehydrogenases. Expansion in the number of viable cells results in an increase in the overall activity of the mitochondrial dehydrogenases and subsequently an augmentation in the amount of formazan dye formed. The formazan dye produced by viable cells was quantified with a multiwell spectrophotometer by measuring the absorbance at 440 nm. Experiments for DNA fragmentation were performed using a Quick Apoptosis DNA Ladder Detection Kit (LabForce/MBL, Nunningen, Switzerland) following the manufacturer's protocol. Statistics Results are expressed as mean  s.e.m. and statistical analyses were performed using Student's t-test.  Results Top Summary Introduction Materials and Methods Results Discussion References  Effects of chronic high-glucose treatment on insulin secretion and -cell gene expression in INS-1E cells As shown in Fig. 1A, 30 mM glucose treatment of INS-1E cells for 48 hours resulted in reduced glucose- and leucine-stimulated insulin secretion. In contrast, KCl-depolarization-elicited insulin release was unaffected, suggesting that Ca2+-stimulated exocytosis was unaffected. We could also confirm, as previously reported (Roche et al., 1998), that chronic high glucose treatment led to lipid accumulation and INS-1 cell apoptosis (see below). To explore the underlying mechanism, quantitative northern blotting was performed to investigate the gene expression patterns in INS-1E cells treated for 48 hours with 30 mM glucose. The mRNA levels of essential -cell genes such as insulin, Pdx1, Glut2, glucokinase and IRS2 were drastically suppressed by high-glucose treatment (Fig. 1B). In addition, pro-apoptotic genes, P21, Bad and APO-1 were upregulated, whereas the anti-apoptotic gene Bclxl was downregulated (Fig. 1B). Furthermore, lipogenic genes, fatty acid synthase, acetyl-CoA carboxylase, glycerol-phosphate acyltransferase, HMG-CoA reductase and LDL receptor were all markedly induced by high glucose treatment (Fig. 1C). Similar alterations in all genes mentioned above have been reported in an INS-1 stable cell line expressing naSREBP-1c (Wang et al., 2003). This strikingly similar gene expression profile suggested that chronic high glucose could cause -cell glucolipotoxicity through activation of SREBP-1c. View larger version (60K): [in this window] [in a new window]  Fig. 1. Effects of chronic high glucose treatment on insulin secretion and gene expression in INS-1E cell. (A) INS-1E cells in 24-well dishes were cultured in either standard (11.2 mM) or 30 mM glucose medium for 48 hours. After 5 hours equilibration in 2.5 mM glucose medium, cells were washed twice with KRBH. Insulin release from INS-1E cells stimulated with 20 mM glucose, 20 mM leucine and 20 mM KCl in KRBH buffer containing 2.5 mM (referred to Basal) was determined by radio-immunoassay and expressed as a percentage of cellular insulin content. The equilibration period is necessary to see the glucose-responsiveness of insulin release in INS-1 cells. Cellular insulin content was decreased by 32.46.7% after 48 hours treatment with 30 mM glucose. Data represent mean  s.e.m. of six independent experiments. **P<0.001. (B,C) The gene expression patterns in INS-1E cells cultured in either standard (11.2 mM) or 30 mM glucose medium for 48 hours were quantified by northern blotting. Total RNA samples (20 g/lane) were analysed by hybridizing with the indicated cDNA probes. Four independent experiments are shown side by side to demonstrate the consistency of the results.  However, we have also reported that the transcription, nuclear translocation and DNA-binding activity of ChREBP are regulated by glucose in INS-1 cells (Wang and Wollheim, 2002). As demonstrated in Fig. 1C, mRNA levels of ChREBP, L-PK and aldolase B were markedly increased by high glucose. ChREBP is known to regulate lipogenic gene expression in the liver (Dentin et al., 2004; Iizuka et al., 2004; Ishii et al., 2004), we therefore examined whether it is also involved in -cell glucolipotoxicity. SREBP-1c rather than ChREBP is implicated in glucolipotoxicity in INS-1 cells Differential gene expression patterns in INS-1 cells induced by ChREBP and naSREBP-1c are illustrated in Fig. 2A,B. Quantitative northern blotting was performed in two stable INS-1 cell lines previously established to express, respectively, ChREBP (Wang and Wollheim, 2002) and naSREBP-1c (Wang et al., 2003) in a doxycycline-dependent manner. The results displayed in Fig. 2A indicate that ChREBP predominantly targeted L-PK and aldolase B, although induction of ChREBP also slightly enhanced the expression of fatty acid synthase and acetyl-CoA carboxylase. In contrast, induction of SREBP-1c drastically increased the lipogenic gene expression for proteins such as, fatty acid synthase, acetyl-CoA carboxylase, HMG-CoA reductase and LDL receptor, whereas it did not affect the mRNA levels of L-PK and aldolase B (Fig. 2B). It is noteworthy that the function of SREBP-1c may also overlap with the function of SREBP-2 on target gene expression in INS-1 cells since HMG-CoA reductase is regulated by naSREBP-1c. In addition, the expression of IRS2 was suppressed by naSREBP-1c but unaffected by ChREBP. It has been reported recently that SREBP-1c binds to the human IRS2 promoter and suppresses its activity in rat and mouse hepatocytes (Ide et al., 2004). View larger version (51K): [in this window] [in a new window]  Fig. 2. Comparison of gene expression patterns in INS-1 cells allowing inducible expression, respectively, of ChREBP and the nuclear active form (na) of SREBP-1c. (A) ChREBP*16 cells were cultured in standard medium (11.2 mM glucose) with 0, 75, 150 or 500 ng/ml doxycycline for 24 hours. The culture was continued in 2.5 mmol/l glucose medium with the indicated concentrations of doxycycline for 16 hours, followed by an additional 8 hours in culture medium with 2.5, 6, 12 and 24 mM glucose and with or without doxycycline. The equilibration period is necessary to see the glucose-responsiveness of gene expression. (B) SREBP-1c*233 cells were cultured in 2.5 mM glucose medium with the indicated concentrations of doxycycline for 16 hours, followed by an additional 8 hours in culture medium with 2.5, 6, 12 and 24 mM glucose and with or without doxycycline. SREBP-1c was induced for a total of 24 hours to avoid its apoptotic effects. Gene expression patterns in these cells were evaluated by quantitative northern blotting. 20 g total RNA samples were analysed by hybridising with indicated cDNA probes. WT, the endogenous wild-type SREBP-1c; NA, the induced nuclear active form of SRENP-1c. The experiments were repeated two times with similar results.  Induction of ChREBP in INS-1 cells did not affect glucose-stimulated insulin secretion or cell growth. In contrast to the effect of naSREBP-1c, induction of ChREBP with 500 ng/ml doxycycline for 48 hours did not alter glucose-stimulated insulin secretion or cellular insulin content. To assess the impact of ChREBP on INS-1 cell growth and viability, we performed the WST-1 assay (Fig. 3B). This assay is based on the cleavage of a tetrazolium salt WST-1 to formazan by mitochondrial dehydrogenases. Expansion in the number of viable cells results in an increase in the overall activity of the mitochondrial dehydrogenases and subsequently an augmentation in the amount of formazan dye formed. Unlike overexpression of naSREBP-1c (Wang et al., 2003), maximum induction of ChREBP for 48 hours did not cause INS-1 cell growth arrest (Fig. 3B) or apoptosis as assessed by DNA fragmentation experiments (data not shown). We have previously shown that similar induction of SREBP-1c caused apoptosis in INS-1 cells (Wang et al., 2003). View larger version (14K): [in this window] [in a new window]  Fig. 3. Overexpression of ChREBP did not affect glucose-stimulated insulin secretion or cell growth. (A) ChREBP*16 cells were cultured with (+Dox) or without (-Dox) 500 ng/ml doxycycline in standard medium (11.2 mM glucose) for 24 hours and then equilibrated in 2.5 mM glucose medium for a further 24 hours. Insulin release from ChREBP*16 cells in KRBH buffer containing the indicated concentrations of glucose was determined by radio-immunoassay and expressed as a percentage of cellular insulin content. Data represent six independent experiments. (B) A WST-1 assay, presented as optical density at 440 nm, showed that ChREBP*16 cell growth/survival was not affected by 48 hours treatment with 500 ng/ml doxycycline.  Establishment of INS-1 stable cell line permitting inducible expression of DN-SREBP-1c To further substantiate the implication of SREBP-1c in chronic high-glucose-induced glucolipotoxicity, we generated an INS-1 stable cell line expressing DN-SREBP-1c, called DN-SREBP-1c*23 cells. This mutant protein contains an intact dimerization domain but lacks DNA-binding activity (Kim and Spiegelman, 1996). DN-SREBP-1c therefore exerts its dominant-negative function by forming non-functional heterodimers with endogenous SREBPs (Kim and Spiegelman, 1996). Immunofluorescence staining with an antibody against the N terminus of SREBP-1c demonstrated that DN-SREBP-1c protein was induced by doxycycline in an all-or-none manner (Fig. 4A). View larger version (63K): [in this window] [in a new window]  Fig. 4. Characteristics of the INS-1 stable cell line expressing DN-SREBP-1c. (A) Phase-contrast images (top) and immunofluorescence staining (bottom) with a rabbit polyclonal antibody against SREBP-1 showed that DN-SREBP-1c protein was induced by doxycycline in an all-or-none manner. DN-SREBP-1c*23 cells were cultured with (+Dox) or without (-Dox) 500 ng/ml doxycycline for 48 hours. (B) Gel-shift assay of nuclear extracts from DN-SREBP-1c*23 cells using the SRE sequence of the IRS2 promoter. DN-SREBP-1c*23 cells were cultured in either standard (11.2 mM) or 30 mM glucose medium for 48 hours, in the presence (+Dox) or absence (-Dox) of 500 ng/ml doxycycline. Monoclonal SREBP-1-specific antibody was used for the supershift experiment. Experiments were repeated two to three times with similar results. (C) EMSA of nuclear extracts from non-induced DN-SREBP-1c*23 cells using the SRE sequence of the IRS2 promoter. DN-SREBP-1c*23 cells were cultured in either standard (11.2 mM) or 30 mM glucose medium for 48 hours. Monoclonal SREBP-2-specific antibody was used for the supershift experiment. Experiments were repeated twice with similar results.  Effects of DN-SREBP-1c on chronic high-glucose-induced glucolipotoxicity in INS-1 cells Induction of DN-SREBP-1c abolished chronic high-glucose-induced SREBP-1 binding to the IRS2 promoter. DN-SREBP-1c*23 cells were cultured in either standard (11.2 mM) or 30 mM glucose medium for 48 hours, in the presence (+Dox) or absence (-Dox) of 500 ng/ml doxycycline. EMSA with the SRE element of the human IRS2 promoter (Ide et al., 2004) showed that SREBP protein binding was increased 10-fold by 48 hours treatment with 30 mM glucose, which was diminished by 80% after induction of DN-SREBP-1c (Fig. 4B). The specificity of SREBP-1 binding complexes was confirmed by the observed supershift with a monoclonal anti-SREBP-1 antibody (Fig. 4B). However, we could not exclude binding activity of SREBP-2 to the IRS2-SRE-element, since it would also be inhibited by DN-SREBP-1c (Rishi et al., 2004). Indeed, monoclonal anti-SREBP-2 antibody also caused a supershift of the retarded complex but to a much lesser extent than the SREBP-1-specific antibody (Fig. 4C). These results suggest that SREBP-1 accounts for the majority of the glucose-induced binding activity to the IRS2 promoter. Induction of DN-SREBP-1c diminished chronic high-glucose-induced lipid accumulation, apoptosis and impaired insulin secretion in INS-1 cells. As shown by Oil-Red-O staining (Fig. 5A), 30 mM glucose treatment of DN-SREBP-1c*23 cells for 48 hours resulted in massive lipid accumulation, which was largely prevented by induction of DN-SREBP-1c. Similarly, treatment of DN-SREBP-1c*23 cells for 48 and 72 hours with 30 mM glucose caused typical DNA fragmentation (Fig. 5B), a characteristic hallmark of cells undergoing apoptosis. DN-SREBP-1c largely protected INS-1 cells from apoptosis (Fig. 5B). View larger version (48K): [in this window] [in a new window]  Fig. 5. Induction of DN-SREBP-1c largely prevented chronic high-glucose-induced glucolipotoxicity in INS-1 cells. (A) DN-SREBP-1c diminished lipid droplets accumulation, as seen by staining with Oil Red-O. DN-SREBP-1c*23 cells were cultured in either standard (11.2 mM; Control) or 30 mM glucose (High glucose) medium for 48 hours, in the presence (+Dox) or absence (-Dox) of 500 ng/ml doxycycline. (B) DN-SREBP-1c prevented apoptosis. DNA fragmentation was assessed in DN-SREBP-1c*23 cells cultured in 30 mM glucose medium for 0, 24, 48, and 72 hours, in the presence (+Dox) or absence (-Dox) of 500 ng/ml doxycycline. (C) DN-SREBP-1c partially restored glucose-stimulated insulin secretion. DN-SREBP-1c*23 cells in 24-well dishes were cultured in either standard (11.2 mM; Control) or 30 mM glucose (High Glucose) medium for 48 hours. After 5 hours equilibration in 2.5 mM glucose medium, cells were washed twice with KRBH. Insulin release from DN-SREBP-1c*23 cells stimulated with either 2.5 (Basal) or 20 mM glucose was determined by radio-immunoassay and expressed as a percentage of cellular insulin content. Data represent mean  s.e.m. of six independent experiments. *P<0.01; **P<0.001.  In agreement with the results obtained in INS-1E (Fig. 1A), treatment of DN-SREBP-1c*23 cells with 30 mM glucose for 48 hours also led to reduced glucose-stimulated insulin secretion (Fig. 5C). The glucose-stimulated insulin secretion was partially restored by expression of DN-SREBP-1c (Fig. 5C). Unexpectedly, induction of DN-SREBP-1c slightly increased basal (2.5 mM) insulin release in control cells (Fig. 5C). DN-SREBP-1c corrected defective gene expression in INS-1 cells treated with chronic high glucose As demonstrated in Fig. 6, treatment of DN-SREBP-1c*23 cells with 30 mM glucose for 48 hours increased the mRNA levels of L-PK, aldolase B and ChREBP, which were not affected by induction of DN-SREBP-1c. These results suggest that high glucose may promote the expression of L-PK and aldolase B through a SREBP-1c-independent but ChREBP-dependent pathway. In contrast, the protective effects of DNSREBP-1c in high-glucose-treated DN-SREBP-1c*23 cells revealed the SREBP-1c-dependent gene expression patterns, including upregulation of fatty acid synthase, HMG-CoA reductase, LDLR and P21, as well as downregulation of GLUT2, glucokinase, PDX1, IRS2 and BCLXL (Fig. 6). These data further substantiate the notion that SREBP-1c-target genes are implicated in chronic high-glucose-mediated -cell glucolipotoxicity. Ucp2 is also a downstream target gene of SREBP-1c in INS-1 cells (Wang et al., 2003; Yamashita et al., 2004). Interestingly, induction of DN-SREBP-1c suppressed UCP2, which may account for the increased basal insulin secretion observed (Fig. 5C). View larger version (66K): [in this window] [in a new window]  Fig. 6. Effects of DN-SREBP-1c on gene expression patterns induced by chronic high-glucose in INS-1 cells. DN-SREBP-1c*23 cells were cultured in either standard (11.2 mM; -) or 30 mM (+) glucose medium for 48 hours, in the presence (+Dox) or absence (-Dox) of 500 ng/ml doxycycline. The gene expression pattern in these cells was quantitatively evaluated by northern blotting. 20 g total RNA samples were analysed by hybridising with the indicated cDNA probes. The experiments were repeated twice with similar results.  ER-stress and SREBP-1 activation could be the molecular mechanisms underlying -cell glucolipotoxicity Increased expression of GADD153/CHOP10 and BIP are characteristics of ER stress response in many cell types. We found that treatment of INS-1E cells for 48 hours with 30 mM glucose markedly induced these ER stress marker genes (Fig. 7A). Therefore, chronic high-glucose-induced ER stress could be the underlying mechanism involved in SREBP-1 activation and subsequently INS-1 cell glucolipotoxicity, since it has been well documented that ER stress causes SREBP processing through S1P and S2P (Werstuck et al., 2001; Ye et al., 2000). View larger version (27K): [in this window] [in a new window]  Fig. 7. ER stress and SREBP-1 activation are implicated in -cell glucolipotoxicity. (A) The gene expression patterns in INS-1E cells cultured in either standard (11.2 mM; -) or 30 mM (+) glucose medium for 48 hours were quantified by northern blotting. Total RNA samples (20 g/lane) were analysed by hybridizing with the indicated cDNA probes. Four independent experiments are shown side by side to demonstrate the consistency of the results. (B) Gel-shift assay of nuclear extracts from isolated rat islets using the SRE sequence of the IRS2 promoter. SREBP-1 protein binding activity was assessed in rat islets treated with 30 mM glucose for 0 (freshly isolated), 1, 2, 3, 4, and 5 days or alternatively with two ER stress inducers, thapsigargin (1 M) and tunicamycin (10 g/ml) for 1 day. The mouse monoconal antibody against SREBP-1 was used for supershift experiments.  A similar mechanism may also apply to islet  cells. The EMSA shown in Fig. 7B indicates that treatment of isolated rat islets with either chronic high glucose or two ER stress inducers, thapsigargin and tunicamycin, drastically enhanced SREBP-1 binding to the SRE sequence of the IRS2 promoter. The specificity of retarded SREBP-1 complexes was confirmed by the supershift in the presence of the monoclonal antibody against SREBP-1 (Fig. 7B).  Discussion Top Summary Introduction Materials and Methods Results Discussion References  It is well known that chronic high-glucose treatment in vitro causes -cell glucolipotoxicity, including lipid accumulation, impaired glucose-stimulated insulin secretion and apoptosis (Efanova et al., 1998; Roche et al., 1998). These characteristics resemble the description of -cell lipotoxicity in ob/ob mice and Zucker Diabetic Fatty (ZDF) rats (Unger, 2002; Unger and Zhou, 2001). Overexpression or overactivation of SREBP-1c in the islets of these animals has been proposed as the causal factor (Unger, 2002; Unger and Zhou, 2001). Consistently, overexpression of a nuclear active form of SREBP-1c in insulinoma cells (INS-1 and MIN6) and isolated rat islets results in typical characteristics of -cell glucolipotoxicity (Andreolas et al., 2002; Diraison et al., 2004; Wang et al., 2003; Yamashita et al., 2004). Some investigators refer to lipotoxicity as the consequence of increased circulating free fatty acids and cellular lipid accumulation (Unger, 2002; Unger and Zhou, 2001; Unger et al., 1999), whereas others suggest that glucotoxicity is the prerequisite for lipotoxicity, at least in  cells (Bonner-Weir et al., 1983; Harmon et al., 2001; Poitout and Robertson, 2002; Roche et al., 1998; Weir, 1982; Weir et al., 2001). Therefore, glucolipotoxicity is a more proper term to describe  cell dysfunction in type 2 diabetes. To elucidate the molecular mechanisms underlying -cell glucolipotoxicity, we first investigated the quantitative gene expression patterns in INS-1 cells treated chronically with high-glucose. The drastically reduced expression of essential -cell genes such as IRS2, insulin, Pdx1, Glut2, glucokinase and Bclxl, and markedly increased mRNA levels of lipogenic and proapoptotic genes should contribute to the glucolipotoxicity. Interestingly, this gene expression profile is strikingly similar to what we have reported in the INS-1 cell line expressing naSREBP-1c (Wang et al., 2003). In contrast, the characteristics of these gene expression patterns as well as typical glucolipotoxicity were not observed in the INS-1 cell line overexpressing another lipogenic transcription factor ChREBP. Similar negative results were obtained in INS-1 cells expressing, PPAR or C/EBP (H.W. and C.B.W., unpublished data), suggesting that SREBP-1c is the predominant transcription factor responsible for -cell glucolipotoxicity. To further substantiate this hypothesis, we established an INS-1 stable cell line with inducible expression of DN-SREBP-1c. Induction of DN-SREBP-1c diminished the chronic high-glucose-induced SREBP-1 binding to the SRE fragment of the IRS2 promoter. Consequently, the inhibitory effects of chronic high glucose on IRS2 expression were largely attenuated by DN-SREBP-1c. It has been reported that SREBP-1c binds to the IRS2 promoter and suppresses IRS2 expression in rodent hepatocytes (Ide et al., 2004). Our results suggest a similar mechanism in pancreatic  cells. Deletion of IRS2 in mouse hypothalamus and  cells has recently been shown to cause a type 2 diabetes-like syndrome (Kubota et al., 2004; Lin et al., 2004). IRS2 is also known to promote  cell growth/survival (Withers et al., 1998). We therefore propose that suppression of IRS2 expression by SREBP-1c should contribute, at least in part, to -cell glucolipotoxicity. We also demonstrated that dominant-negative suppression of SREBP-1c activation largely prevented glucolipotoxicity in INS-1 cells, including lipid accumulation, impaired glucose-stimulated insulin secretion and apoptosis. The protective effects of DN-SREBP-1c could be explained by nomalized expression of fatty acid synthase, HMG-CoA reductase, LDLR, P21, GLUT2, glucokinase, PDX1, IRS2 and BCLXL. In addition, DN-SREBP-1c also suppressed the expression of UCP2. In contrast, DN-SREBP-1c did not affect the expression of L-PK and aldolase B, which were targeted by ChREBP. Glucokinase is the rate-limiting enzyme for glycolysis and serves as the -cell glucose sensor (Wang and Iynedjian, 1997). PDX1 is required for maintaining -cell-specific gene expression and the -cell phenotype (Ahlgren et al., 1998; Wang et al., 2001). Mouse islets deficient in LDLR have been shown to be resistant to LDL-induced apoptosis (Roehrich et al., 2003). Deletion of Ucp2 restores -cell function in ob/ob mice and in animals fed a high-fat diet (Chan et al., 2004; Joseph et al., 2002; Zhang et al., 2001). In addition, mouse islets deficient in UCP2 are protected from fatty acid-induced lipotoxicity (Joseph et al., 2004), whereas its overexpression leads to impaired glucose-stimulated insulin secretion (Lameloise et al., 2001; Yamashita et al., 2004). Therefore, chronic high glucose may act through SREBP-1 to target multiple genes, causing -cell glucolipotoxicity. Most intriguingly, we found that chronic high glucose treatment caused ER stress response in INS-1 cells, evidenced by elevated expression of two characteristic genes, CHOP and BIP. It has been reported that glucose stimulates protein synthesis in pancreatic  cells"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   806   C0597295:Protein Synthesis [Molecular Function]
   762 E C0597552:synthetic protein [Amino Acid, Peptide, or Protein]
   762   C2936320:Synthetic Cells [Manufactured Object]
   760   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   760   C0220781:synthesis [Biologic Function]
   760   C1883254:Synthesis [Activity]

Phrase: "through dephosphorylation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1158884:Dephosphorylation [Molecular Function]
  1000   C3160734:Dephosphorylation [Molecular Function]

Phrase: "of the eukaryotic elongation factor (eEF2)"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0086206:Elongation Factor [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   827   C1521761:Factor [Functional Concept]
   827   C2827422:Factor [Conceptual Entity]

Phrase: "(Lameloise et al., 2001; Yamashita et al., 2004). Therefore, chronic high glucose may act through SREBP-1 to target multiple genes, causing -cell glucolipotoxicity. Most intriguingly, we found that chronic high glucose treatment caused ER stress response in INS-1 cells, evidenced by elevated expression of two characteristic genes, CHOP and BIP. It has been reported that glucose stimulates protein synthesis in pancreatic  cells through dephosphorylation of the eukaryotic elongation factor (eEF2) (Yan et al.,"

Phrase: "2003"

Phrase: ")"

Phrase: "and"

Phrase: "initiation factor"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0030943:Initiation Factor [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C0589507:Initiation [Mental Process]
   861   C1158830:Initiation [Genetic Function]
   861   C1521761:Factor [Functional Concept]
   861   C1704686:Initiation [Functional Concept]
   861   C2827422:Factor [Conceptual Entity]

Phrase: "(Yan et al., 2003) and initiation factor (eIF2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0013729:EIF-2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
  1000   C1166851:eIF-2 [Cell Component]
  1000   C3539639:EIF2 [Gene or Genome]

Phrase: ")"

Phrase: "(eIF2) (Gomez et al.,"

Phrase: "2004"

Phrase: ")"

Phrase: "and"

Phrase: "activation of the guanine nucleotide exchange factor eIF2B"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C1879547:Activation [Activity]

Phrase: "(Gomez et al., 2004) and activation of the guanine nucleotide exchange factor eIF2B (Gilligan et al.,"

Phrase: "1996"

Phrase: ") and activation of the guanine nucleotide exchange factor eIF2B (Gilligan et al., 1996)."
Processing 00000000.tx.235: We, therefore, postulate that chronic high glucose could induce ER stress through overloading protein synthesis. 

Phrase: "We,"

Phrase: "therefore,"

Phrase: "postulate"

Phrase: "that chronic high glucose"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C0860803:high glucose [Finding]
   827   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "could"

Phrase: "induce"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induce [Functional Concept]

Phrase: "ER stress through overloading protein synthesis."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   814   C3178870:Endoplasmic Reticulum Stress [Cell or Molecular Dysfunction]
   778   C0014239:Endoplasmic Reticulum [Cell Component]
   774   C0018850:stress protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   757   C1827667:Stress overload [Finding]
   748   C0035295:Reticulum [Body Part, Organ, or Organ Component]
   748   C0038435:Stress [Finding]
Processing 00000000.tx.236: Our data suggest that chronic high-glucose-induced ER stress could be the underlying mechanism in SREBP-1 processing/activation. 

Phrase: "Our data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "suggest"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that chronic high-glucose-induced ER stress"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   845   C3178870:Endoplasmic Reticulum Stress [Cell or Molecular Dysfunction]
   818   C0014239:Endoplasmic Reticulum [Cell Component]
   795   C0035295:Reticulum [Body Part, Organ, or Organ Component]
   795   C0038435:Stress [Finding]
   724 E C0231297:Stressful [Functional Concept]
   724   C0598268:Endoplasm [Cell Component]

Phrase: "could"

Phrase: "be"

Phrase: "the underlying mechanism in SREBP-1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   739   C0441712:Mechanism [Functional Concept]
   739   C1706376:Mechanism [Manufactured Object]

Phrase: "processing"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C1709694:Processing [Activity]
   966 E C1184743:Process [Body Part, Organ, or Organ Component]
   966 E C1522240:Process [Phenomenon or Process]

Phrase: "/activation."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1879547:Activation [Activity]
Processing 00000000.tx.237: Indeed, we found that treatment of isolated rat islets with chronic high glucose and two ER stress inducers, thapsigargin and tunicamycin, markedly increased the SREBP-1 binding activity to the IRS2 promoter. 

Phrase: "Indeed,"

Phrase: "we"

Phrase: "found"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0150312:Found [Quantitative Concept]
   966 E C0243095:Find [Finding]

Phrase: "that treatment of isolated rat islets"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   753   C0039798:treatment [Functional Concept]
   753   C0087111:Treatment [Therapeutic or Preventive Procedure]
   753   C1522326:Treatment [Functional Concept]
   753   C1533734:Treatment [Therapeutic or Preventive Procedure]
   753   C1705169:Treatment [Conceptual Entity]
   753   C3538994:TREATMENT [Research Activity]

Phrase: "with chronic high glucose"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C0860803:high glucose [Finding]
   827   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "and"

Phrase: "two ER stress inducers,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   717   C3178870:Endoplasmic Reticulum Stress [Cell or Molecular Dysfunction]

Phrase: "thapsigargin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0076374:Thapsigargin [Hazardous or Poisonous Substance,Organic Chemical]

Phrase: "and"

Phrase: "tunicamycin,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0041385:Tunicamycin [Antibiotic,Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "markedly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0522501:Markedly [Qualitative Concept]

Phrase: "increased"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
  1000   C0205217:Increased [Quantitative Concept]
  1000   C0442805:Increased [Functional Concept]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C1301820:Obtain [Functional Concept]
   907 E C1706701:Acquire [Activity]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "the SREBP-1 binding activity"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   850   C2266866:Binding Activity [Molecular Function]
   836   C1537044:protein activity [Molecular Function]
   793   C0205177:Activity [Functional Concept]
   793   C0439167:% activity [Quantitative Concept]
   793   C0441655:Activity [Activity]
   793   C1561536:*Activity [Idea or Concept]
   756   C0217529:Sterol Regulatory Element Binding Protein 1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   756   C1420398:STEROL REGULATORY ELEMENT-BINDING PROTEIN 1 [Gene or Genome]

Phrase: "to the IRS2 promoter."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0086860:Promoter [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   771   C0381451:Insulin Receptor Substrate-2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   771   C1334141:INSULIN RECEPTOR SUBSTRATE 2 [Gene or Genome]
   771   C1334191:Insulin Receptor Substrate 2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
Processing 00000000.tx.238: It has been well established that ER stress causes SREBP processing through S1P and S2P (Werstuck et al., 2001; Ye et al., 2000). 

Phrase: "It"

Phrase: "has"

Phrase: "been"

Phrase: "well established"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0205170:Well [Qualitative Concept]
   861   C0443211:Established [Qualitative Concept]
   861   C1272684:Established [Qualitative Concept]
   861   C3146287:Well [Manufactured Object]

Phrase: "that ER stress"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C3178870:Endoplasmic Reticulum Stress [Cell or Molecular Dysfunction]
   901   C0014239:Endoplasmic Reticulum [Cell Component]
   827   C0035295:Reticulum [Body Part, Organ, or Organ Component]
   827   C0038435:Stress [Finding]
   755 E C0231297:Stressful [Functional Concept]
   755   C0598268:Endoplasm [Cell Component]

Phrase: "causes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0015127:cause [Functional Concept]
  1000   C1314792:Causes [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]

Phrase: "SREBP processing through S1P"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0033666:protein processing [Molecular Function]
   757   C2985687:Processing Site [Spatial Concept]
   739   C1709694:Processing [Activity]

Phrase: "and"

Phrase: "S2P"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1423501:SITE-2 PROTEASE [Gene or Genome]
   827   C0030946:Protease [Amino Acid, Peptide, or Protein,Enzyme,Pharmacologic Substance]
   827   C1947941:Protease [Enzyme]

Phrase: "(Gilligan et al., 1996). We, therefore, postulate that chronic high glucose could induce ER stress through overloading protein synthesis. Our data suggest that chronic high-glucose-induced ER stress could be the underlying mechanism in SREBP-1 processing/activation. Indeed, we found that treatment of isolated rat islets with chronic high glucose and two ER stress inducers, thapsigargin and tunicamycin, markedly increased the SREBP-1 binding activity to the IRS2 promoter. It has been well established that ER stress causes SREBP processing through S1P and S2P (Werstuck et al.,"

Phrase: "2001"

Phrase: "; Ye et al.,"

Phrase: "2000"

Phrase: "). We, therefore, postulate that chronic high glucose could induce ER stress through overloading protein synthesis. Our data suggest that chronic high-glucose-induced ER stress could be the underlying mechanism in SREBP-1 processing/activation. Indeed, we found that treatment of isolated rat islets with chronic high glucose and two ER stress inducers, thapsigargin and tunicamycin, markedly increased the SREBP-1 binding activity to the IRS2 promoter. It has been well established that ER stress causes SREBP processing through S1P and S2P (Werstuck et al., 2001; Ye et al., 2000)."
Processing 00000000.tx.239: SREBP-1c activation induced by ER stress has also been implicated in hyperhomocysteinemia-induced liver steatosis (Werstuck et al., 2001). 

Phrase: "SREBP-1c activation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   829   C0599177:protein activation [Genetic Function]
   795   C1879547:Activation [Activity]
   787   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "induced by ER stress"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   862   C3178870:Endoplasmic Reticulum Stress [Cell or Molecular Dysfunction]
   806   C0014239:Endoplasmic Reticulum [Cell Component]
   760   C0035295:Reticulum [Body Part, Organ, or Organ Component]
   760   C0038435:Stress [Finding]
   760   C0205263:Induced [Functional Concept]

Phrase: "has"

Phrase: "also"

Phrase: "been"

Phrase: "implicated in hyperhomocysteinemia-induced liver steatosis"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   790   C0015695:liver steatosis [Disease or Syndrome]
   790   C2711227:Liver Steatosis [Disease or Syndrome]
   753   C0023884:Liver [Body Part, Organ, or Organ Component]
   753   C0152254:Steatosis [Pathologic Function]
   753   C0205263:Induced [Functional Concept]
   753   C0598608:Hyperhomocysteinemia [Disease or Syndrome]
   753   C0736268:LIVER [Body Part, Organ, or Organ Component]
   753   C1278929:Liver [Body Part, Organ, or Organ Component]
   753   C2346688:LIVER [Food]
   753   C3495426:HYPERHOMOCYSTEINEMIA [Disease or Syndrome]

Phrase: "(Werstuck et al., 2001; Ye et al., 2000). SREBP-1c activation induced by ER stress has also been implicated in hyperhomocysteinemia-induced liver steatosis (Werstuck et al.,"

Phrase: "2001"

Phrase: "). SREBP-1c activation induced by ER stress has also been implicated in hyperhomocysteinemia-induced liver steatosis (Werstuck et al., 2001)."
Processing 00000000.tx.240: Increased ER stress has been incriminated in ob/ob mice and in mice fed on a high-fat diet and proposed as the cause of insulin resistance (Ozcan et al., 2004). 

Phrase: "Increased ER stress"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   923   C3178870:Endoplasmic Reticulum Stress [Cell or Molecular Dysfunction]
   902   C0231298:Increased stress [Functional Concept]
   861   C0014239:Endoplasmic Reticulum [Cell Component]
   812   C0035295:Reticulum [Body Part, Organ, or Organ Component]
   812   C0038435:Stress [Finding]
   741 E C0231297:Stressful [Functional Concept]
   741   C0598268:Endoplasm [Cell Component]

Phrase: "has"

Phrase: "been"

Phrase: "incriminated in ob/ob mice"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0025914:Mice [Mammal]
   760   C0025929:mice [Mammal]
   760   C0026809:Mice [Mammal]

Phrase: "and in mice"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0025914:Mice [Mammal]
   790   C0025929:mice [Mammal]
   790   C0026809:Mice [Mammal]
   790   C1515981:And [Idea or Concept]

Phrase: "fed on a high-fat diet"
Meta Candidates (Total=15; Excluded=4; Pruned=0; Remaining=11)
   833   C0521974:Diet, High-Fat [Therapeutic or Preventive Procedure]
   790   C0301585:Fat diet [Therapeutic or Preventive Procedure]
   753   C0012155:Diet [Food]
   753   C0205250:High [Qualitative Concept]
   753   C0342895:FED [Disease or Syndrome]
   753   C0424612:FAT [Organism Attribute]
   753   C1299351:High [Qualitative Concept]
   753   C1442959:Diet [Organism Function]
   753   C1519433:DIET [Therapeutic or Preventive Procedure]
   753   C2700149:HIGH [Intellectual Product]
   753   C2983588:DIET [Food]
   748 E C0012171:Dietary Fat [Food]
   748 E C1527016:Dietary Fat [Research Activity]
   719 E C0204695:Feed [Health Care Activity]
   719 E C2987508:Feed [Activity]

Phrase: "and"

Phrase: "proposed as the cause of insulin resistance"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   778   C0021655:Insulin Resistance [Pathologic Function]
   778   C2700570:INSULIN RESISTANCE [Gene or Genome]
   748   C0015127:cause [Functional Concept]
   748   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   748   C0237834:Resistance [Mental Process]
   748   C1441414:PROPOSED [Idea or Concept]
   748   C1514892:Resistance [Physiologic Function]
   748   C1524003:Cause [Conceptual Entity]
   748   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   748   C1553874:Proposed [Qualitative Concept]
   748   C1578820:Proposed [Idea or Concept]
   748   C1579433:Insulin [Pharmacologic Substance]

Phrase: "(Werstuck et al., 2001). Increased ER stress has been incriminated in ob/ob mice and in mice fed on a high-fat diet and proposed as the cause of insulin resistance (Ozcan et al.,"

Phrase: "2004"

Phrase: "). Increased ER stress has been incriminated in ob/ob mice and in mice fed on a high-fat diet and proposed as the cause of insulin resistance (Ozcan et al., 2004)."
Processing 00000000.tx.241: Likewise, response to ER stress has been reported in rat  cells treated with fatty acids (Kharroubi et al., 2004). 

Phrase: "Likewise,"

Phrase: "response to ER stress"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C2613145:response to endoplasmic reticulum stress [Cell Function]
   844   C0149784:response to stress [Physiologic Function]
           response stress
   760   C0871261:Response [Organism Attribute]
   760   C1704632:Response [Finding]
   760   C1706817:Response [Intellectual Product]
   760   C2911692:Response [Mental Process]

Phrase: "has"

Phrase: "been"

Phrase: "reported in rat  cells"
Meta Candidates (Total=11; Excluded=4; Pruned=0; Remaining=7)
   770   C0007634:Cells [Cell]
   770   C0034693:Rat, NOS [Mammal]
   770   C0034721:Rat [Mammal]
   770   C0684224:Reported [Intellectual Product]
   770   C0700287:Reported [Health Care Activity]
   770   C3282337:Cells [Cell]
   770   C3496591:Reported [Clinical Attribute]
   737 E C1269647:Cell [Cell]
   737 E C1704653:Cell [Medical Device]
   737 E C1948049:Cell [Spatial Concept]
   737 E C3273238:Report [Intellectual Product]

Phrase: "treated with fatty acids"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   833   C0015684:Fatty Acids [Lipid]
   833   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   770   C0001128:Acids [Chemical]
   770   C1522326:Treated [Functional Concept]
   737 E C0202406:Acid [Laboratory Procedure]
   737 E C1292734:TREAT [Functional Concept]

Phrase: "(Ozcan et al., 2004). Likewise, response to ER stress has been reported in rat  cells treated with fatty acids (Kharroubi et al.,"

Phrase: "2004"

Phrase: "). Likewise, response to ER stress has been reported in rat  cells treated with fatty acids (Kharroubi et al., 2004)."
Processing 00000000.tx.242: Therefore, prolonged ER stress and SREBP-1c activation could be a common mechanism underlying both -cell dysfunction and insulin resistance in type 2 diabetes. 

Phrase: "Therefore,"

Phrase: "prolonged"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439590:Prolonged [Temporal Concept]

Phrase: "ER stress"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C3178870:Endoplasmic Reticulum Stress [Cell or Molecular Dysfunction]
   901   C0014239:Endoplasmic Reticulum [Cell Component]
   827   C0035295:Reticulum [Body Part, Organ, or Organ Component]
   827   C0038435:Stress [Finding]
   755 E C0231297:Stressful [Functional Concept]
   755   C0598268:Endoplasm [Cell Component]

Phrase: "and"

Phrase: "SREBP-1c activation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   829   C0599177:protein activation [Genetic Function]
   795   C1879547:Activation [Activity]
   787   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "could"

Phrase: "be"

Phrase: "a common mechanism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0441712:Mechanism [Functional Concept]
   861   C1706376:Mechanism [Manufactured Object]

Phrase: "underlying"

Phrase: "both -cell dysfunction"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0031847:dysfunction [Functional Concept]
   861   C0277785:Dysfunction, NOS [Qualitative Concept]
   805 E C0231174:Malfunction [Functional Concept]
   805 E C1881681:MALFUNCTION [Phenomenon or Process]

Phrase: "and"

Phrase: "insulin resistance in type 2 diabetes."
Meta Candidates (Total=11; Excluded=1; Pruned=0; Remaining=10)
   864   C0342335:Insulin resistance in diabetes [Disease or Syndrome]
           diabetes insulin resistance
   797 E C0854110:Insulin resistant diabetes [Disease or Syndrome]
   790   C0021655:Insulin Resistance [Pathologic Function]
   790   C2700570:INSULIN RESISTANCE [Gene or Genome]
   783   C0457592:Insulin type [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   753   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   753   C0237834:Resistance [Mental Process]
   753   C1514892:Resistance [Physiologic Function]
   753   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   753   C1579433:Insulin [Pharmacologic Substance]
Processing 00000000.tx.243: It is noteworthy that the genetic studies have associated SREBP-1c polymorphisms with obesity, insulin resistance and type 2 diabetes (Eberle et al., 2004; Laudes et al., 2004). 

Phrase: "It"

Phrase: "is"

Phrase: "noteworthy"

Phrase: "that"

Phrase: "the genetic studies"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   983   C2827447:Genetic Study [Research Activity]
   861   C0947630:studies [Laboratory Procedure]
   827 E C0557651:Study [Manufactured Object]
   827 E C2603343:Study [Research Activity]

Phrase: "have"

Phrase: "associated SREBP-1c polymorphisms with obesity,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   739   C0032529:polymorphisms [Genetic Function]
   706 E C1882417:Polymorphism [Qualitative Concept]

Phrase: "insulin resistance"
Meta Candidates (Total=12; Excluded=5; Pruned=0; Remaining=7)
  1000   C0021655:Insulin Resistance [Pathologic Function]
  1000   C2700570:INSULIN RESISTANCE [Gene or Genome]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0237834:Resistance [Mental Process]
   861   C1514892:Resistance [Physiologic Function]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332325:Resistant [Functional Concept]
   789 E C1550464:resistent [Idea or Concept]
   789 E C2827757:RESISTANT [Laboratory or Test Result]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "type 2 diabetes"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]

Phrase: "(Kharroubi et al., 2004). Therefore, prolonged ER stress and SREBP-1c activation could be a common mechanism underlying both -cell dysfunction and insulin resistance in type 2 diabetes. It is noteworthy that the genetic studies have associated SREBP-1c polymorphisms with obesity, insulin resistance and type 2 diabetes (Eberle et al.,"

Phrase: "2004"

Phrase: "; Laudes et al.,"

Phrase: "2004"

Phrase: "). Therefore, prolonged ER stress and SREBP-1c activation could be a common mechanism underlying both -cell dysfunction and insulin resistance in type 2 diabetes. It is noteworthy that the genetic studies have associated SREBP-1c polymorphisms with obesity, insulin resistance and type 2 diabetes (Eberle et al., 2004; Laudes et al., 2004)."
Processing 00000000.tx.244: SREBP-1c is the upstream suppressor of IRS2 (Ide et al., 2004), and the transactivator of Ucp2, Ldlr, stearoyl-CoA desaturase 1 and many lipogenic genes (Bene et al., 2001; Horton et al., 2003; Medvedev et al., 2002; Wang et al., 2003; Yahagi et al., 1999). 

Phrase: "SREBP-1c"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
  1000   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C2246292:sterol binding [Molecular Function]
   827   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0013879:Element [Element, Ion, or Isotope]
   799   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0038323:Sterol [Steroid]
   799   C0220905:regulatory [Regulation or Law]
   799   C0243122:binding [Functional Concept]
   799   C1145667:Binding [Activity]
   799   C1167622:Binding [Molecular Function]
   799   C1704735:Regulatory [Conceptual Entity]
   799   C1705248:Element [Conceptual Entity]

Phrase: "is"

Phrase: "the upstream suppressor of IRS2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C1710252:Suppressor [Manufactured Object]
   744   C2954564:Suppressor [Pharmacologic Substance]

Phrase: "(Eberle et al., 2004; Laudes et al., 2004). SREBP-1c is the upstream suppressor of IRS2 (Ide et al.,"

Phrase: "2004"

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "the transactivator of Ucp2,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0040627:Trans-Activator [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "Ldlr,"

Phrase: "stearoyl-CoA desaturase 1"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   923   C0038233:Stearoyl-CoA Desaturase [Amino Acid, Peptide, or Protein,Enzyme]
   923   C1419846:STEAROYL-CoA DESATURASE [Gene or Genome]
   861   C0075202:stearoyl-CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
   812   C0599871:desaturase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "and"

Phrase: "many lipogenic genes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0017337:Genes [Gene or Genome]

Phrase: "(Ide et al., 2004), and the transactivator of Ucp2, Ldlr, stearoyl-CoA desaturase 1 and many lipogenic genes (Bene et al.,"

Phrase: "2001"

Phrase: "; Horton et al.,"

Phrase: "2003"

Phrase: "; Medvedev et al.,"

Phrase: "2002"

Phrase: "; Wang et al.,"

Phrase: "2003"

Phrase: "; Yahagi et al.,"

Phrase: "1999"

Phrase: "), and the transactivator of Ucp2, Ldlr, stearoyl-CoA desaturase 1 and many lipogenic genes (Bene et al., 2001; Horton et al., 2003; Medvedev et al., 2002; Wang et al., 2003; Yahagi et al., 1999)."
Processing 00000000.tx.245: In addition to the aforementioned genes (IRS2, Ucp2 and Ldlr), stearoyl-CoA desaturase 1 (SCD1) deficiency has been shown to increase insulin sensitivity, fatty acid oxidation and energy expenditure, as well as promoting resistance to diet-induced obesity (Dobrzyn et al., 2004). 

Phrase: "In addition to the aforementioned genes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0017337:Genes [Gene or Genome]

Phrase: "(Bene et al., 2001; Horton et al., 2003; Medvedev et al., 2002; Wang et al., 2003; Yahagi et al., 1999). In addition to the aforementioned genes (IRS2,"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
  1000   C0381451:Insulin Receptor Substrate-2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
  1000   C1334141:INSULIN RECEPTOR SUBSTRATE 2 [Gene or Genome]
  1000   C1334191:Insulin Receptor Substrate 2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C0034818:Insulin Receptor [Amino Acid, Peptide, or Protein,Enzyme,Receptor]
   861   C1334133:INSULIN RECEPTOR [Gene or Genome]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   812   C1710236:Substrate [Manufactured Object]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "Ucp2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1421314:UCP2 [Gene or Genome]

Phrase: "and"

Phrase: "Ldlr"

Phrase: ")"

Phrase: ","

Phrase: "stearoyl-CoA desaturase 1 (SCD1) deficiency"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   804   C0011155:Deficiency [Functional Concept]
   804   C0162429:Deficiency [Disease or Syndrome]
   804   C1623416:deficiency [Qualitative Concept]
   733 E C1636779:% deficient [Quantitative Concept]
   717   C0038233:Stearoyl-CoA Desaturase [Amino Acid, Peptide, or Protein,Enzyme]
   717   C1419846:STEAROYL-CoA DESATURASE [Gene or Genome]

Phrase: "has"

Phrase: "been"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "increase"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "insulin sensitivity,"
Meta Candidates (Total=15; Excluded=4; Pruned=0; Remaining=11)
  1000   C0920563:Insulin Sensitivity [Pathologic Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036667:Sensitivity [Quantitative Concept]
   861   C0312418:Sensitivity [Mental Process]
   861   C0427965:Sensitivity [Finding]
   861   C1511883:Sensitivity [Quantitative Concept]
   861   C1522640:Sensitivity [Qualitative Concept]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   861   C2346484:SENSITIVITY [Phenomenon or Process]
   861   C2349185:Sensitivity [Qualitative Concept]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332324:Sensitive [Functional Concept]
   789 E C1550474:sensitive [Idea or Concept]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "fatty acid oxidation"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C1158366:fatty acid oxidation [Molecular Function]
   901   C0015684:Fatty acid [Lipid]
   827   C0001128:Acid [Chemical]
   827   C0030011:Oxidation [Molecular Function]
   827   C0202406:Acid [Laboratory Procedure]

Phrase: "and"

Phrase: "energy expenditure,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0014272:Energy Expenditure [Physiologic Function]
   861   C0015316:expenditure [Quantitative Concept]
   861   C0424589:Energy [Finding]
   861   C0542479:Energy [Natural Phenomenon or Process]
   861   C1442080:Energy [Quantitative Concept]

Phrase: "as well as"

Phrase: "promoting resistance to diet-induced obesity"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   754   C0332325:Resistant to [Functional Concept]
   753   C0237834:Resistance [Mental Process]
   753   C1514892:Resistance [Physiologic Function]

Phrase: "(IRS2, Ucp2 and Ldlr), stearoyl-CoA desaturase 1 (SCD1) deficiency has been shown to increase insulin sensitivity, fatty acid oxidation and energy expenditure, as well as promoting resistance to diet-induced obesity (Dobrzyn et al.,"

Phrase: "2004"

Phrase: "), stearoyl-CoA desaturase 1 (SCD1) deficiency has been shown to increase insulin sensitivity, fatty acid oxidation and energy expenditure, as well as promoting resistance to diet-induced obesity (Dobrzyn et al., 2004)."
Processing 00000000.tx.246: We, therefore, propose that SREBP-1c is one of the causative genes for development of both -cell dysfunction and insulin resistance in type 2 diabetes. 

Phrase: "We,"

Phrase: "therefore,"

Phrase: "propose"

Phrase: "that SREBP-1c"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
  1000   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C2246292:sterol binding [Molecular Function]
   827   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0013879:Element [Element, Ion, or Isotope]
   799   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0038323:Sterol [Steroid]
   799   C0220905:regulatory [Regulation or Law]
   799   C0243122:binding [Functional Concept]
   799   C1145667:Binding [Activity]
   799   C1167622:Binding [Molecular Function]
   799   C1704735:Regulatory [Conceptual Entity]
   799   C1705248:Element [Conceptual Entity]

Phrase: "is"

Phrase: "one of the causative genes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0205447:One [Quantitative Concept]

Phrase: "for development"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0243107:development [Physiologic Function]
  1000   C0678723:Development [Organism Function]
  1000   C1527148:Development [Functional Concept]
   928 E C0458003:Developmental [Qualitative Concept]

Phrase: "of both -cell dysfunction"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0031847:dysfunction [Functional Concept]
   861   C0277785:Dysfunction, NOS [Qualitative Concept]
   805 E C0231174:Malfunction [Functional Concept]
   805 E C1881681:MALFUNCTION [Phenomenon or Process]

Phrase: "and"

Phrase: "insulin resistance in type 2 diabetes."
Meta Candidates (Total=11; Excluded=1; Pruned=0; Remaining=10)
   864   C0342335:Insulin resistance in diabetes [Disease or Syndrome]
           diabetes insulin resistance
   797 E C0854110:Insulin resistant diabetes [Disease or Syndrome]
   790   C0021655:Insulin Resistance [Pathologic Function]
   790   C2700570:INSULIN RESISTANCE [Gene or Genome]
   783   C0457592:Insulin type [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   753   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   753   C0237834:Resistance [Mental Process]
   753   C1514892:Resistance [Physiologic Function]
   753   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   753   C1579433:Insulin [Pharmacologic Substance]
Processing 00000000.tx.247: In fact, SREBP-1c over-activation has been associated with liver steatosis, lipodystrophy, diabetic renal disease and/or -cell lipotoxicity in many animal models of type 2 diabetes, such as ob/ob, db/db, IRS2-/- and ap2-nSREBP-1c mice, streptozotocin-induced diabetic rats, Zucker diabetic fatty rats, and mice with liver overexpression of Socs-1/-3 (Kakuma et al., 2000; Lin et al., 2000; Matsuzaka et al., 2004; Riddle et al., 2001; Shimomura et al., 1999a; Shimomura et al., 1999b; Shimomura et al., 1999c; Shimomura et al., 2000; Sun et al., 2002; Takaishi et al., 2004; Tobe et al., 2001; Ueki et al., 2004; Unger and Zhou, 2001; Unger et al., 1999; Werstuck et al., 2001; Xu et al., 2004; Yahagi et al., 2002; You et al., 2002), as well as in patients with severe lipodystrophy (Bastard et al., 2002; Petersen et al., 2002). 

Phrase: "In fact,"

Phrase: "SREBP-1c over-activation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   836   C0599177:protein activation [Genetic Function]
   793   C1879547:Activation [Activity]
   756   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "has"

Phrase: "been"

Phrase: "associated with liver steatosis,"
Meta Candidates (Total=12; Excluded=3; Pruned=0; Remaining=9)
   833   C0015695:liver steatosis [Disease or Syndrome]
   833   C0332281:Associated with [Qualitative Concept]
           Associated
   833   C2711227:Liver Steatosis [Disease or Syndrome]
   770   C0023884:Liver [Body Part, Organ, or Organ Component]
   770   C0152254:Steatosis [Pathologic Function]
   770   C0736268:LIVER [Body Part, Organ, or Organ Component]
   770   C1278929:Liver [Body Part, Organ, or Organ Component]
   770   C2346688:LIVER [Food]
   737 E C0750490:Associate [Idea or Concept]
   737 E C1706221:Associate [Professional or Occupational Group]
   715 E C0205054:Hepatic [Body Location or Region]

Phrase: "lipodystrophy,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0023787:Lipodystrophy [Disease or Syndrome]

Phrase: "diabetic renal disease"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
  1000   C0011881:Diabetic renal disease [Disease or Syndrome]
   901   C0022658:Renal disease [Disease or Syndrome]
   827   C0012634:Disease [Disease or Syndrome]
   827   C0022646:Renal [Body Part, Organ, or Organ Component]
   771 E C1836721:MALS [Finding]
   771 E C3538764:MALS [Gene or Genome]
   771 E C3540595:MAL [Gene or Genome]

Phrase: "and/or -"

Phrase: "cell lipotoxicity in many animal models of type 2 diabetes,"

Phrase: "such as ob/ob,"

Phrase: "db/db,"

Phrase: "IRS2-/-"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
  1000   C0381451:Insulin Receptor Substrate-2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
  1000   C1334141:INSULIN RECEPTOR SUBSTRATE 2 [Gene or Genome]
  1000   C1334191:Insulin Receptor Substrate 2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C0034818:Insulin Receptor [Amino Acid, Peptide, or Protein,Enzyme,Receptor]
   861   C1334133:INSULIN RECEPTOR [Gene or Genome]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   812   C1710236:Substrate [Manufactured Object]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "ap2-nSREBP-1c mice,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0025914:Mice [Mammal]
   812   C0025929:mice [Mammal]
   812   C0026809:Mice [Mammal]

Phrase: "streptozotocin-induced diabetic rats,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0034693:rats [Mammal]
   812   C0034721:Rats [Mammal]
   812   C0241863:DIABETIC [Finding]

Phrase: "Zucker diabetic fatty rats,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   902   C0034719:Rats, Zucker [Mammal]
   812   C0034693:rats [Mammal]
   812   C0034721:Rats [Mammal]

Phrase: "and"

Phrase: "mice with liver overexpression of Socs-1/-3"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   750   C1517914:Mouse Liver [Tissue]
   744   C0025914:Mice [Mammal]
   744   C0025929:mice [Mammal]
   744   C0026809:Mice [Mammal]

Phrase: "(Dobrzyn et al., 2004). We, therefore, propose that SREBP-1c is one of the causative genes for development of both -cell dysfunction and insulin resistance in type 2 diabetes. In fact, SREBP-1c over-activation has been associated with liver steatosis, lipodystrophy, diabetic renal disease and/or -cell lipotoxicity in many animal models of type 2 diabetes, such as ob/ob, db/db, IRS2-/- and ap2-nSREBP-1c mice, streptozotocin-induced diabetic rats, Zucker diabetic fatty rats, and mice with liver overexpression of Socs-1/-3 (Kakuma et al.,"

Phrase: "2000"

Phrase: "; Lin et al.,"

Phrase: "2000"

Phrase: "; Matsuzaka et al.,"

Phrase: "2004"

Phrase: "; Riddle et al.,"

Phrase: "2001"

Phrase: "; Shimomura et al.,"

Phrase: "1999a"

Phrase: "; Shimomura et al.,"

Phrase: "1999b"

Phrase: "; Shimomura et al.,"

Phrase: "1999c"

Phrase: "; Shimomura et al.,"

Phrase: "2000"

Phrase: "; Sun et al.,"

Phrase: "2002"

Phrase: "; Takaishi et al.,"

Phrase: "2004"

Phrase: "; Tobe et al.,"

Phrase: "2001"

Phrase: "; Ueki et al.,"

Phrase: "2004"

Phrase: "; Unger"

Phrase: "and"

Phrase: "Zhou,"

Phrase: "2001"

Phrase: "; Unger et al.,"

Phrase: "1999"

Phrase: "; Werstuck et al.,"

Phrase: "2001"

Phrase: "; Xu et al.,"

Phrase: "2004"

Phrase: "; Yahagi et al.,"

Phrase: "2002"

Phrase: ";"

Phrase: "You et al.,"

Phrase: "2002"

Phrase: ")"

Phrase: ","

Phrase: "as well as in patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0030705:Patients [Patient or Disabled Group]
   760   C0205170:Well [Qualitative Concept]
   760   C3146287:Well [Manufactured Object]

Phrase: "with severe lipodystrophy"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0023787:Lipodystrophy [Disease or Syndrome]

Phrase: "(Kakuma et al., 2000; Lin et al., 2000; Matsuzaka et al., 2004; Riddle et al., 2001; Shimomura et al., 1999a; Shimomura et al., 1999b; Shimomura et al., 1999c; Shimomura et al., 2000; Sun et al., 2002; Takaishi et al., 2004; Tobe et al., 2001; Ueki et al., 2004; Unger and Zhou, 2001; Unger et al., 1999; Werstuck et al., 2001; Xu et al., 2004; Yahagi et al., 2002; You et al., 2002), as well as in patients with severe lipodystrophy (Bastard et al.,"

Phrase: "2002"

Phrase: "; Petersen et al.,"

Phrase: "2002"

Phrase: "), as well as in patients with severe lipodystrophy (Bastard et al., 2002; Petersen et al., 2002)."
Processing 00000000.tx.248: Treatment with some antidiabetic drugs or hormones including metformin, troglitazone, leptin and adiponectin could prevent the diabetes-associated lipotoxicity in these animals and patients through inhibition of SREBP-1c activation (Lin et al., 2000; Petersen et al., 2002; Shimomura et al., 1999c; Xu et al., 2004). 

Phrase: "Treatment with some antidiabetic drugs"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   760   C0039798:treatment [Functional Concept]
   760   C0087111:Treatment [Therapeutic or Preventive Procedure]
   760   C1522326:Treatment [Functional Concept]
   760   C1533734:Treatment [Therapeutic or Preventive Procedure]
   760   C1705169:Treatment [Conceptual Entity]
   760   C3538994:TREATMENT [Research Activity]

Phrase: "or"

Phrase: "hormones"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0019932:Hormones [Hormone]
   916 E C0458083:Hormonal [Qualitative Concept]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "metformin,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025598:Metformin [Organic Chemical,Pharmacologic Substance]

Phrase: "troglitazone,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0245514:troglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: "leptin"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0299583:Leptin [Amino Acid, Peptide, or Protein,Hormone]
  1000   C1416825:LEPTIN [Gene or Genome]

Phrase: "and"

Phrase: "adiponectin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0389071:Adiponectin [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "could"

Phrase: "prevent"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0309872:PREVENT [Pharmacologic Substance]

Phrase: "the diabetes-associated lipotoxicity in these animals"

Phrase: "and"

Phrase: "patients through inhibition of SREBP-1c activation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   738   C0030705:Patients [Patient or Disabled Group]

Phrase: "(Bastard et al., 2002; Petersen et al., 2002). Treatment with some antidiabetic drugs or hormones including metformin, troglitazone, leptin and adiponectin could prevent the diabetes-associated lipotoxicity in these animals and patients through inhibition of SREBP-1c activation (Lin et al.,"

Phrase: "2000"

Phrase: "; Petersen et al.,"

Phrase: "2002"

Phrase: "; Shimomura et al.,"

Phrase: "1999c"

Phrase: "; Xu et al.,"

Phrase: "2004"

Phrase: "). Treatment with some antidiabetic drugs or hormones including metformin, troglitazone, leptin and adiponectin could prevent the diabetes-associated lipotoxicity in these animals and patients through inhibition of SREBP-1c activation (Lin et al., 2000; Petersen et al., 2002; Shimomura et al., 1999c; Xu et al., 2004)."
Processing 00000000.tx.249: Genetic manipulations to suppress SREBP-1c function are shown to be equally effective (Engelking et al., 2004; Takaishi et al., 2004; Ueki et al., 2004). 

Phrase: "Genetic manipulations to"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   884   C0178659:genetic manipulation [Molecular Biology Research Technique]
   827   C0185111:MANIPULATIONS [Therapeutic or Preventive Procedure]
   827   C0947647:Manipulations NOS [Therapeutic or Preventive Procedure]

Phrase: "suppress"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1260953:suppress [Functional Concept]

Phrase: "SREBP-1c function"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   829   C0815043:protein function [Amino Acid, Peptide, or Protein]
   829   C1527118:Protein Function [Molecular Function]
   795   C0031843:function [Physiologic Function]
   795   C0542341:Function [Functional Concept]
   795   C0700205:FUNCTION [Classification]
   795   C1705273:Function [Intellectual Product]
   787   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   724 E C0205245:Functional [Functional Concept]
   724 E C2700217:Functional [Conceptual Entity]

Phrase: "are"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "equally effective"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1280519:effective [Qualitative Concept]
   861   C1704419:Effective [Qualitative Concept]

Phrase: "(Lin et al., 2000; Petersen et al., 2002; Shimomura et al., 1999c; Xu et al., 2004). Genetic manipulations to suppress SREBP-1c function are shown to be equally effective (Engelking et al.,"

Phrase: "2004"

Phrase: "; Takaishi et al.,"

Phrase: "2004"

Phrase: "; Ueki et al.,"

Phrase: "2004"

Phrase: "). Genetic manipulations to suppress SREBP-1c function are shown to be equally effective (Engelking et al., 2004; Takaishi et al., 2004; Ueki et al., 2004)."
Processing 00000000.tx.250: In summary, we found that chronic high glucose treatment alone could cause typical glucolipotoxicity and a gene expression profile resembling that caused by naSREBP-1c expression in INS-1 cells (Wang et al., 2003). 

Phrase: "In summary,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1552616:summary [Intellectual Product]
  1000   C1706244:Summary [Intellectual Product]

Phrase: "we"

Phrase: "found"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0150312:Found [Quantitative Concept]
   966 E C0243095:Find [Finding]

Phrase: "that chronic high glucose treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   812   C0039798:treatment [Functional Concept]
   812   C0087111:Treatment [Therapeutic or Preventive Procedure]
   812   C1522326:Treatment [Functional Concept]
   812   C1533734:Treatment [Therapeutic or Preventive Procedure]
   812   C1705169:Treatment [Conceptual Entity]
   812   C3538994:TREATMENT [Research Activity]

Phrase: "alone"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205171:Alone [Quantitative Concept]
  1000   C0439044:alone [Finding]
  1000   C0679994:alone [Group Attribute]

Phrase: "could"

Phrase: "cause"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0015127:cause [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]

Phrase: "typical glucolipotoxicity"

Phrase: "and"

Phrase: "a gene expression profile"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C1449575:gene expression profile [Laboratory Procedure]
  1000   C1956267:Profile, Gene Expression [Quantitative Concept]
   827   C1979963:Profile [Laboratory Procedure]
   827   C2003903:Profile [Functional Concept]
   734   C0017262:Gene Expression [Genetic Function]

Phrase: "resembling"

Phrase: "that"

Phrase: "caused by naSREBP-1c expression"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0185117:Expression [Therapeutic or Preventive Procedure]
   726   C0015127:cause [Functional Concept]
   726   C1524003:Cause [Conceptual Entity]

Phrase: "in"

Phrase: "INS-1 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "(Engelking et al., 2004; Takaishi et al., 2004; Ueki et al., 2004). In summary, we found that chronic high glucose treatment alone could cause typical glucolipotoxicity and a gene expression profile resembling that caused by naSREBP-1c expression in INS-1 cells (Wang et al.,"

Phrase: "2003"

Phrase: "). In summary, we found that chronic high glucose treatment alone could cause typical glucolipotoxicity and a gene expression profile resembling that caused by naSREBP-1c expression in INS-1 cells (Wang et al., 2003)."
Processing 00000000.tx.251: This gene expression profile (Wang et al., 2003) has also been most recently confirmed in mice with -cell-specific overexpression of SREBP-1c (Takahashi et al., 2005), suggesting that the results in our INS-1 cell model correlate well with native  cells in vivo. 

Phrase: "This gene expression profile"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C1449575:gene expression profile [Laboratory Procedure]
  1000   C1956267:Profile, Gene Expression [Quantitative Concept]
   827   C1979963:Profile [Laboratory Procedure]
   827   C2003903:Profile [Functional Concept]
   734   C0017262:Gene Expression [Genetic Function]

Phrase: "(Wang et al., 2003). This gene expression profile (Wang et al.,"

Phrase: "2003"

Phrase: ")"

Phrase: "has"

Phrase: "also"

Phrase: "been"

Phrase: "most recently"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0205393:Most [Quantitative Concept]
   861   C0332185:Recently [Temporal Concept]

Phrase: "confirmed in mice"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   790   C0025914:Mice [Mammal]
   790   C0025929:mice [Mammal]
   790   C0026809:Mice [Mammal]
   790   C0521093:confirmed [Qualitative Concept]
   790   C0750484:Confirmed [Idea or Concept]
   756 E C1456348:Confirm [Qualitative Concept]

Phrase: "with -cell-specific overexpression"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1514559:Overexpression [Genetic Function]

Phrase: "of SREBP-1c"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
  1000   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C2246292:sterol binding [Molecular Function]
   827   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0013879:Element [Element, Ion, or Isotope]
   799   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0038323:Sterol [Steroid]
   799   C0220905:regulatory [Regulation or Law]
   799   C0243122:binding [Functional Concept]
   799   C1145667:Binding [Activity]
   799   C1167622:Binding [Molecular Function]
   799   C1704735:Regulatory [Conceptual Entity]
   799   C1705248:Element [Conceptual Entity]

Phrase: "(Wang et al., 2003) has also been most recently confirmed in mice with -cell-specific overexpression of SREBP-1c (Takahashi et al.,"

Phrase: "2005"

Phrase: ")"

Phrase: ","

Phrase: "suggesting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "that"

Phrase: "the results in our"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   737   C1274040:Result [Functional Concept]
   737   C1546471:Result [Idea or Concept]
   737   C2825142:Result [Finding]

Phrase: "INS-1 cell model"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C3161035:Model [Intellectual Product]

Phrase: "correlate"

Phrase: "well with native  cells"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   819   C2347578:Cells/well [Quantitative Concept]
   770   C0007634:Cells [Cell]
   770   C0205170:Well [Qualitative Concept]
   770   C0302891:Native [Functional Concept]
   770   C3146287:Well [Manufactured Object]
   770   C3282337:Cells [Cell]
   737 E C1269647:Cell [Cell]
   737 E C1704653:Cell [Medical Device]
   737 E C1948049:Cell [Spatial Concept]

Phrase: "in vivo."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1515655:In Vivo [Spatial Concept]
           vivo
Processing 00000000.tx.252: However, it remains to be determined whether naSREBP-1c-induced apoptosis and impaired glucose-stimulated insulin secretion occurs via lipid accumulation or through an independent mechanism. 

Phrase: "However,"

Phrase: "it"

Phrase: "remains"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "determined"

Phrase: "whether"

Phrase: "naSREBP-1c-induced apoptosis"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   812   C0162638:Apoptosis [Cell Function]
   741 E C1516044:Apoptotic [Qualitative Concept]

Phrase: "and"

Phrase: "impaired glucose-stimulated insulin secretion"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   853   C1719133:Glucose/Insulin [Quantitative Concept]
   840   C1256369:insulin secretion [Cell Function]
   804   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   804   C0036536:secretion [Biologic Function]
   804   C0036537:Secretion [Body Substance]
   804   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   804   C1579433:Insulin [Pharmacologic Substance]
   748 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   721 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "occurs via lipid accumulation"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   833   C0333574:Lipid accumulation [Finding]
   770   C0023779:Lipid [Lipid]
   770   C1709305:Occur [Activity]
   770   C2745955:OCCUR [Temporal Concept]

Phrase: "or through an independent mechanism."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0085862:Independent [Idea or Concept]
   760   C0441712:Mechanism [Functional Concept]
   760   C1299583:Independent [Finding]
   760   C1706376:Mechanism [Manufactured Object]
Processing 00000000.tx.253: Most importantly, we found that dominant-negative suppression of SREBP-1c function could prevent glucolipotoxicity in INS-1 cells. 

Phrase: "Most importantly,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0205393:Most [Quantitative Concept]

Phrase: "we"

Phrase: "found"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0150312:Found [Quantitative Concept]
   966 E C0243095:Find [Finding]

Phrase: "that dominant-negative suppression"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   827   C0221103:Suppression [Pathologic Function]
   827   C0301625:Suppression [Organism Function]
   827   C0439181:% suppression [Quantitative Concept]
   827   C0728721:suppression [Mental Process]
   734   C1512032:Dominant Negative [Cell or Molecular Dysfunction]

Phrase: "of SREBP-1c function"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   829   C0815043:protein function [Amino Acid, Peptide, or Protein]
   829   C1527118:Protein Function [Molecular Function]
   795   C0031843:function [Physiologic Function]
   795   C0542341:Function [Functional Concept]
   795   C0700205:FUNCTION [Classification]
   795   C1705273:Function [Intellectual Product]
   787   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   724 E C0205245:Functional [Functional Concept]
   724 E C2700217:Functional [Conceptual Entity]

Phrase: "could"

Phrase: "prevent"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0309872:PREVENT [Pharmacologic Substance]

Phrase: "glucolipotoxicity in"

Phrase: "INS-1 cells."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.254: We have further implicated ERnstress in the activation of SREBP-1c, leading to -cell glucolipotoxicity. 

Phrase: "We"

Phrase: "have"

Phrase: "further implicated ERnstress in the activation"

Phrase: "of SREBP-1c,"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
  1000   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C2246292:sterol binding [Molecular Function]
   827   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0013879:Element [Element, Ion, or Isotope]
   799   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0038323:Sterol [Steroid]
   799   C0220905:regulatory [Regulation or Law]
   799   C0243122:binding [Functional Concept]
   799   C1145667:Binding [Activity]
   799   C1167622:Binding [Molecular Function]
   799   C1704735:Regulatory [Conceptual Entity]
   799   C1705248:Element [Conceptual Entity]

Phrase: "leading"
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
  1000   C0332152:Leading [Temporal Concept]
  1000   C1522538:Leading [Functional Concept]
   966 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   966 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   966 E C2348269:Lead [Element, Ion, or Isotope]
   966 E C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "to -cell glucolipotoxicity."
Processing 00000000.tx.255: Therefore, the present study should help to clarify the molecular mechanisms underlying development of -cell glucolipotoxicity, a process thought to cause the loss of both -cell mass and insulin secretory response to glucose in type 2 diabetes. 

Phrase: "Therefore,"

Phrase: "the present study"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0150312:Present [Quantitative Concept]
   861   C0449450:Present [Idea or Concept]
   861   C0557651:Study [Manufactured Object]
   861   C2603343:Study [Research Activity]

Phrase: "should"

Phrase: "help"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0018896:Help [Social Behavior]
  1000   C1552861:help [Idea or Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "clarify"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2986669:Clarify [Activity]

Phrase: "the molecular mechanisms"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0441712:Mechanisms [Functional Concept]
   827 E C1706376:Mechanism [Manufactured Object]

Phrase: "underlying"

Phrase: "development of -cell glucolipotoxicity,"

Phrase: "a process"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1184743:Process [Body Part, Organ, or Organ Component]
  1000   C1522240:Process [Phenomenon or Process]

Phrase: "thought"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0039869:Thought [Mental Process]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "cause"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0015127:cause [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]

Phrase: "the loss of both -cell mass"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1517945:Loss [Quantitative Concept]

Phrase: "and"

Phrase: "insulin secretory response to glucose"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0871261:Response [Organism Attribute]
   760   C1704632:Response [Finding]
   760   C1706817:Response [Intellectual Product]
   760   C2911692:Response [Mental Process]

Phrase: "in type 2 diabetes."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]
Processing 00000000.tx.256: Prevention of excessive ER stress and SREBP-1c action should be considered for therapy aimed at protection of -cell function in type 2 diabetes.  

Phrase: "Prevention of excessive ER stress"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0199176:Prevention [Therapeutic or Preventive Procedure]
   753   C1706420:PREVENTION [Research Activity]
   753   C2700409:prevention [Qualitative Concept]

Phrase: "and"

Phrase: "SREBP-1c action"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   845   C1145667:Binding action [Activity]
   795   C0441472:Action [Functional Concept]
   795   C3266814:Action [Activity]
   787   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "should"

Phrase: "be"

Phrase: "considered for therapy"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0039798:therapy [Functional Concept]
   790   C0087111:Therapy [Therapeutic or Preventive Procedure]
   790   C0750591:considered [Idea or Concept]
   790   C1363945:Therapy [Finding]

Phrase: "aimed at protection of -cell function"
Meta Candidates (Total=15; Excluded=0; Pruned=0; Remaining=15)
   790   C0007613:Cell Function [Cell Function]
   783   C0524828:Cell Protection [Physiologic Function]
   753   C0007634:Cell [Cell]
   753   C0031843:function [Physiologic Function]
   753   C0542341:Function [Functional Concept]
   753   C0700205:FUNCTION [Classification]
   753   C1269647:Cell [Cell]
   753   C1545588:Protection [Finding]
   753   C1704653:Cell [Medical Device]
   753   C1705273:Function [Intellectual Product]
   753   C1948049:Cell [Spatial Concept]
   719   C1947946:Aim [Idea or Concept]
   719   C2948600:Aim [Pharmacologic Substance]
   719   C3540471:AIM [Gene or Genome]
   719   C3540472:AIM [Functional Concept]

Phrase: "in type 2 diabetes."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]
Processing 00000000.tx.257: Acknowledgments  We are grateful to D. 

Phrase: "Acknowledgments"

Phrase: "We"

Phrase: "are"

Phrase: "grateful to D."
Processing 00000000.tx.258: Cornut-Harry, D. 

Phrase: "Cornut-Harry,"

Phrase: "D."
Processing 00000000.tx.259: Nappey, Y. 

Phrase: "Nappey,"

Phrase: "Y."
Processing 00000000.tx.260: Dupr and V. 

Phrase: "Dupr"

Phrase: "and"

Phrase: "V."
Processing 00000000.tx.261: Calvo for expert technical assistance. 

Phrase: "Calvo for expert technical assistance."
Processing 00000000.tx.262: We are indebted to B. 

Phrase: "We"

Phrase: "are"

Phrase: "indebted to B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   718   C0581901:indebtedness [Finding]
Processing 00000000.tx.263: M. 

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.264: Spiegelman (for the naSREBP-1c and DN-SREBP-1c cDNAs), D. 

Phrase: "Spiegelman"

Phrase: "("

Phrase: "for the naSREBP-1c"

Phrase: "and"

Phrase: "DN-SREBP-1c cDNAs"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   814   C1512032:Dominant-Negative Mutant [Cell or Molecular Dysfunction]
   748   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: ")"

Phrase: ","

Phrase: "D."
Processing 00000000.tx.265: Ron (for the CHOP cDNA), R. 

Phrase: "Ron (for the CHOP cDNA"

Phrase: ")"

Phrase: ","

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.266: Prywes (for the BIP cDNA), H. 

Phrase: "Prywes"

Phrase: "("

Phrase: "for the BIP cDNA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0006556:cDNA [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: ")"

Phrase: ","

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.267: Bujard (for the PUHD 10-3 vector), and N. 

Phrase: "Bujard"

Phrase: "("

Phrase: "for the PUHD 10-3 vector"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0086022:Vector [Nucleic Acid, Nucleoside, or Nucleotide]
   812   C0442335:Vector [Spatial Concept]
   812   C1705099:Vector [Idea or Concept]

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "N."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]
Processing 00000000.tx.268: Quintrell (for the pTKhygro plasmid). 

Phrase: "Quintrell"

Phrase: "("

Phrase: "for the pTKhygro plasmid"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0032136:Plasmid [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "), and N. Quintrell (for the pTKhygro plasmid)."
Processing 00000000.tx.269: This work was supported by the Swiss National Science Foundation (grant no. 32-66907.01 to C.B.W.) and Olga Mayenfisch Stiftung. 

Phrase: "This work"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0043227:Work [Occupational Activity]

Phrase: "was"

Phrase: "supported by the Swiss National Science Foundation"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   748   C0016617:Foundation [Organization]
   748   C0036397:Science [Occupation or Discipline]
   748   C0241315:Swiss [Population Group]
   748   C1521721:Supported [Conceptual Entity]
   748   C3245503:national [Intellectual Product]
   714 E C0183683:Support [Medical Device]

Phrase: "(for the pTKhygro plasmid). This work was supported by the Swiss National Science Foundation (grant"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0018173:Grant [Quantitative Concept]
  1000   C1548284:Grant [Idea or Concept]

Phrase: "no. 32-66907.01 to C.B."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C1298908:no [Idea or Concept]
   748   C1549444:No [Idea or Concept]

Phrase: "W.)"

Phrase: "and"

Phrase: "Olga Mayenfisch Stiftung."
Processing 00000000.tx.270: The authors declare no conflict of interest.  

Phrase: "The authors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0221193:Authors [Professional or Occupational Group]

Phrase: "declare"

Phrase: "no conflict of interest."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0079152:Conflict of Interest [Idea or Concept]
   827   C0009671:Conflict [Individual Behavior]
   827   C0543488:Interest [Mental Process]
   827   C1705242:Conflict [Qualitative Concept]
Processing 00000000.tx.271: References Top Summary Introduction Materials and Methods Results Discussion References  Ahlgren, U., Johnson, J., Johnson, L., Simu, K. and Edlund, H. 

Phrase: "References"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Top Summary Introduction Materials"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0520510:Materials [Substance]

Phrase: "and"

Phrase: "Methods Results Discussion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "References"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Ahlgren,"

Phrase: "U.,"

Phrase: "Johnson,"

Phrase: "J.,"

Phrase: "Johnson,"

Phrase: "L.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]

Phrase: "Simu,"

Phrase: "K."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "and"

Phrase: "Edlund,"

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.272: (1998). 

Phrase: "(grant no. 32-66907.01 to C.B.W.) and Olga Mayenfisch Stiftung. The authors declare no conflict of interest.  References Top Summary Introduction Materials and Methods Results Discussion References  Ahlgren, U., Johnson, J., Johnson, L., Simu, K. and Edlund, H. (1998"

Phrase: "). This work was supported by the Swiss National Science Foundation (grant no. 32-66907.01 to C.B.W.) and Olga Mayenfisch Stiftung. The authors declare no conflict of interest.  References Top Summary Introduction Materials and Methods Results Discussion References  Ahlgren, U., Johnson, J., Johnson, L., Simu, K. and Edlund, H. (1998)."
Processing 00000000.tx.273: Beta-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes. 

Phrase: "Beta-cell-specific inactivation of the mouse Ipf1/Pdx1 gene"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   757   C0598496:Gene Inactivation [Genetic Function]
   739   C0544461:Inactivation [Cell or Molecular Dysfunction]

Phrase: "results in loss of the beta-cell phenotype"
Meta Candidates (Total=17; Excluded=0; Pruned=0; Remaining=17)
   793   C1318445:Cell phenotype result [Laboratory or Test Result]
   770   C0030281:Beta cell [Cell]
   770   C0427385:Cell phenotype [Laboratory Procedure]
   770   C1318444:Cell phenotype [Organism Attribute]
   744   C0007634:Cell [Cell]
   744   C0031437:Phenotype [Organism Attribute]
   744   C0330390:Beta [Plant]
   744   C0439096:Beta [Intellectual Product]
   744   C1269647:Cell [Cell]
   744   C1274040:Result [Functional Concept]
   744   C1285572:Phenotype [Laboratory Procedure]
   744   C1517945:Loss [Quantitative Concept]
   744   C1546471:Result [Idea or Concept]
   744   C1704653:Cell [Medical Device]
   744   C1948049:Cell [Spatial Concept]
   744   C2004068:Beta [Qualitative Concept]
   744   C2825142:Result [Finding]

Phrase: "and"

Phrase: "maturity onset diabetes."
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
  1000   C0011860:Maturity-Onset Diabetes [Disease or Syndrome]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332162:Onset [Qualitative Concept]
   827   C0449989:Maturity [Qualitative Concept]
   827   C0700597:Maturity [Temporal Concept]
   755 E C0205286:Mature [Temporal Concept]
Processing 00000000.tx.274: Genes Dev. 

Phrase: "Genes Dev."
Processing 00000000.tx.275: 12, 1763-1768.[Abstract/Free FullText] Andreolas, C., da Silva Xavier, G., Diraison, F., Zhao, C., Varadi, A., Lopez-Casillas, F., Ferre, P., Foufelle, F. and Rutter, G. 

Phrase: "12,"

Phrase: "1763-1768."

Phrase: "[Abstract/Free FullText"

Phrase: "] Andreolas,"

Phrase: "C.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "da Silva Xavier,"

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "Diraison,"

Phrase: "F.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "Zhao,"

Phrase: "C.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "Varadi,"

Phrase: "A.,"

Phrase: "Lopez-Casillas,"

Phrase: "F.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "Ferre,"

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Foufelle,"

Phrase: "F."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "and"

Phrase: "Rutter,"

Phrase: "G."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]
Processing 00000000.tx.276: A. 

Phrase: "A."
Processing 00000000.tx.277: (2002). 

Phrase: "(1998). Beta-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes. Genes Dev. 12, 1763-1768.[Abstract/Free FullText] Andreolas, C., da Silva Xavier, G., Diraison, F., Zhao, C., Varadi, A., Lopez-Casillas, F., Ferre, P., Foufelle, F. and Rutter, G. A. (2002"

Phrase: "). Beta-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes. Genes Dev. 12, 1763-1768.[Abstract/Free FullText] Andreolas, C., da Silva Xavier, G., Diraison, F., Zhao, C., Varadi, A., Lopez-Casillas, F., Ferre, P., Foufelle, F. and Rutter, G. A. (2002)."
Processing 00000000.tx.278: Stimulation of acetyl-CoA carboxylase gene expression by glucose requires insulin release and sterol regulatory element binding protein 1c in pancreatic MIN6 beta-cells. 

Phrase: "Stimulation of acetyl-CoA carboxylase gene expression"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C1292856:Stimulation [Therapeutic or Preventive Procedure]
   748   C1948023:Stimulation [Natural Phenomenon or Process]

Phrase: "by glucose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "requires"

Phrase: "insulin release"
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0030685:Release [Health Care Activity]
   861   C0391871:Release [Functional Concept]
   861   C0439180:% release [Quantitative Concept]
   861   C0680255:release [Health Care Activity]
   861   C1283071:Release [Functional Concept]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   861   C1963578:Release [Therapeutic or Preventive Procedure]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "sterol regulatory element binding protein 1c in pancreatic MIN6 beta-cells."
Meta Candidates (Total=17; Excluded=1; Pruned=0; Remaining=16)
   846   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   756   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   756   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   754 E C0033618:Protein Binding [Molecular Function]
   754   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   754   C1750295:beta protein [Genetic Function]
   754   C2246292:sterol binding [Molecular Function]
   754   C2362547:Beta protein [Amino Acid, Peptide, or Protein]
   738   C0013879:Element [Element, Ion, or Isotope]
   738   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   738   C0038323:Sterol [Steroid]
   738   C0220905:regulatory [Regulation or Law]
   738   C0243122:binding [Functional Concept]
   738   C1145667:Binding [Activity]
   738   C1167622:Binding [Molecular Function]
   738   C1704735:Regulatory [Conceptual Entity]
   738   C1705248:Element [Conceptual Entity]
Processing 00000000.tx.279: Diabetes 51, 2536-2545.[Abstract/Free FullText] Asfari, M., Janjic, D., Meda, P., Li, G., Halban, P. 

Phrase: "Diabetes 51,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: "2536-2545."

Phrase: "[Abstract/Free FullText"

Phrase: "] Asfari,"

Phrase: "M."

Phrase: ","

Phrase: "Janjic,"

Phrase: "D."

Phrase: ","

Phrase: "Meda,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1084907:Meda [Fish]

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Li,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3495095:Li+ [Element, Ion, or Isotope]

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "Halban,"

Phrase: "P."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]
Processing 00000000.tx.280: A. and Wollheim, C. 

Phrase: "A."

Phrase: "and"

Phrase: "Wollheim,"

Phrase: "C."
Processing 00000000.tx.281: B. 

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.282: (1992). 

Phrase: "(2002). Stimulation of acetyl-CoA carboxylase gene expression by glucose requires insulin release and sterol regulatory element binding protein 1c in pancreatic MIN6 beta-cells. Diabetes 51, 2536-2545.[Abstract/Free FullText] Asfari, M., Janjic, D., Meda, P., Li, G., Halban, P. A. and Wollheim, C. B. (1992"

Phrase: "). Stimulation of acetyl-CoA carboxylase gene expression by glucose requires insulin release and sterol regulatory element binding protein 1c in pancreatic MIN6 beta-cells. Diabetes 51, 2536-2545.[Abstract/Free FullText] Asfari, M., Janjic, D., Meda, P., Li, G., Halban, P. A. and Wollheim, C. B. (1992)."
Processing 00000000.tx.283: Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines. 

Phrase: "Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines."
Processing 00000000.tx.284: Endocrinology 130, 167-178.[Abstract] Bastard, J. 

Phrase: "Endocrinology 130,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0014137:Endocrinology [Biomedical Occupation or Discipline]
   789 E C0694557:endocrinologic [Functional Concept]

Phrase: "167-178."

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Bastard,"

Phrase: "J."
Processing 00000000.tx.285: P., Caron, M., Vidal, H., Jan, V., Auclair, M., Vigouroux, C., Luboinski, J., Laville, M., Maachi, M., Girard, P. 

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Caron,"

Phrase: "M."

Phrase: ","

Phrase: "Vidal,"

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Jan,"

Phrase: "V.,"

Phrase: "Auclair,"

Phrase: "M."

Phrase: ","

Phrase: "Vigouroux,"

Phrase: "C.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "Luboinski,"

Phrase: "J.,"

Phrase: "Laville,"

Phrase: "M."

Phrase: ","

Phrase: "Maachi,"

Phrase: "M."

Phrase: ","

Phrase: "Girard,"

Phrase: "P."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]
Processing 00000000.tx.286: M. et al. 

Phrase: "M. et al."
Processing 00000000.tx.287: (2002). 

Phrase: "(1992). Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines. Endocrinology 130, 167-178.[Abstract] Bastard, J. P., Caron, M., Vidal, H., Jan, V., Auclair, M., Vigouroux, C., Luboinski, J., Laville, M., Maachi, M., Girard, P. M. et al. (2002"

Phrase: "). Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines. Endocrinology 130, 167-178.[Abstract] Bastard, J. P., Caron, M., Vidal, H., Jan, V., Auclair, M., Vigouroux, C., Luboinski, J., Laville, M., Maachi, M., Girard, P. M. et al. (2002)."
Processing 00000000.tx.288: Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. 

Phrase: "Association between altered expression of adipogenic factor SREBP1"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   744   C0004083:Association [Mental Process]
   744   C0439849:Association [Qualitative Concept]
   744   C0596306:Association [Phenomenon or Process]
   744   C0699792:association [Social Behavior]

Phrase: "in lipoatrophic adipose tissue"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C0001527:Adipose tissue [Tissue]
   827   C0040300:Tissue [Tissue]
   827   C1547928:Tissue [Intellectual Product]
   755   C0028754:Adiposity [Disease or Syndrome]
   755   C1563743:adiposity [Organism Attribute]

Phrase: "from HIV-1-infected patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   886   C1549592:HIV(+) patient [Intellectual Product]
   812   C0030705:Patients [Patient or Disabled Group]

Phrase: "and"

Phrase: "abnormal adipocyte differentiation"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   901   C1159884:adipocyte differentiation [Cell Function]
   827   C0007589:Differentiation [Cell Function]
   827   C1511938:Differentiation [Clinical Attribute]
   827   C2945687:Differentiation [Functional Concept]
   755 E C0205615:Differentiated [Qualitative Concept]

Phrase: "and"

Phrase: "insulin resistance."
Meta Candidates (Total=12; Excluded=5; Pruned=0; Remaining=7)
  1000   C0021655:Insulin Resistance [Pathologic Function]
  1000   C2700570:INSULIN RESISTANCE [Gene or Genome]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0237834:Resistance [Mental Process]
   861   C1514892:Resistance [Physiologic Function]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332325:Resistant [Functional Concept]
   789 E C1550464:resistent [Idea or Concept]
   789 E C2827757:RESISTANT [Laboratory or Test Result]
   777 E C3537244:Insulins [Pharmacologic Substance]
Processing 00000000.tx.289: Lancet 359, 1026-1031.[CrossRef][Medline] Bene, H., Lasky, D. and Ntambi, J. 

Phrase: "Lancet 359,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0777169:Lancet [Medical Device]

Phrase: "1026-1031."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Bene,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1416990:BENE [Gene or Genome]

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Lasky,"

Phrase: "D."

Phrase: "and"

Phrase: "Ntambi,"

Phrase: "J."
Processing 00000000.tx.290: M. 

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.291: (2001). 

Phrase: "(2002). Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 359, 1026-1031.[CrossRef][Medline] Bene, H., Lasky, D. and Ntambi, J. M. (2001"

Phrase: "). Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 359, 1026-1031.[CrossRef][Medline] Bene, H., Lasky, D. and Ntambi, J. M. (2001)."
Processing 00000000.tx.292: Cloning and characterization of the human stearoyl-CoA desaturase gene promoter: transcriptional activation by sterol regulatory element binding protein and repression by polyunsaturated fatty acids and cholesterol. 

Phrase: "Cloning"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0009015:Cloning [Research Activity]

Phrase: "and"

Phrase: "characterization of the human stearoyl-CoA desaturase gene promoter"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C1880022:Characterization [Activity]

Phrase: ":"

Phrase: "transcriptional activation by sterol regulatory element binding protein"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0162493:Transcriptional Activation [Genetic Function]
   767   C0599177:protein activation [Genetic Function]
   744   C1879547:Activation [Activity]

Phrase: "and"

Phrase: "repression by polyunsaturated fatty acids"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0035143:Repression [Mental Process]

Phrase: "and"

Phrase: "cholesterol."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0008377:Cholesterol [Biologically Active Substance,Steroid]
Processing 00000000.tx.293: Biochem. 

Phrase: "Biochem."
Processing 00000000.tx.294: Biophys. 

Phrase: "Biophys."
Processing 00000000.tx.295: Res. 

Phrase: "Res."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347379:RES [Finding]
Processing 00000000.tx.296: Commun. 

Phrase: "Commun."
Processing 00000000.tx.297: 284, 1194-1198.[CrossRef][Medline] Bonner-Weir, S., Trent, D. 

Phrase: "284,"

Phrase: "1194-1198."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Bonner-Weir,"

Phrase: "S."

Phrase: ","

Phrase: "Trent,"

Phrase: "D."
Processing 00000000.tx.298: F. and Weir, G. 

Phrase: "F."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "and"

Phrase: "Weir,"

Phrase: "G."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]
Processing 00000000.tx.299: C. 

Phrase: "C."
Processing 00000000.tx.300: (1983). 

Phrase: "(2001). Cloning and characterization of the human stearoyl-CoA desaturase gene promoter: transcriptional activation by sterol regulatory element binding protein and repression by polyunsaturated fatty acids and cholesterol. Biochem. Biophys. Res. Commun. 284, 1194-1198.[CrossRef][Medline] Bonner-Weir, S., Trent, D. F. and Weir, G. C. (1983"

Phrase: "). Cloning and characterization of the human stearoyl-CoA desaturase gene promoter: transcriptional activation by sterol regulatory element binding protein and repression by polyunsaturated fatty acids and cholesterol. Biochem. Biophys. Res. Commun. 284, 1194-1198.[CrossRef][Medline] Bonner-Weir, S., Trent, D. F. and Weir, G. C. (1983)."
Processing 00000000.tx.301: Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release. 

Phrase: "Partial pancreatectomy in the rat"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   806   C0161912:Partial pancreatectomy [Therapeutic or Preventive Procedure]
   760   C0030279:Pancreatectomy [Therapeutic or Preventive Procedure]

Phrase: "and"

Phrase: "subsequent defect in glucose-induced insulin release."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C1457869:Defect [Functional Concept]
   748   C1861101:DEFECT [Disease or Syndrome]
Processing 00000000.tx.302: J. 

Phrase: "J."
Processing 00000000.tx.303: Clin. 

Phrase: "Clin."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1315013:CLIN [Intellectual Product]
Processing 00000000.tx.304: Invest. 

Phrase: "Invest."
Processing 00000000.tx.305: 71, 1544-1553.[Medline] Brown, M. 

Phrase: "71,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450389:71 [Intellectual Product]

Phrase: "1544-1553."

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Brown,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0678579:Brown [Natural Phenomenon or Process]

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.306: S. and Goldstein, J. 

Phrase: "S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]

Phrase: "and"

Phrase: "Goldstein,"

Phrase: "J."
Processing 00000000.tx.307: L. 

Phrase: "L."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]
Processing 00000000.tx.308: (1997). 

Phrase: "(1983). Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release. J. Clin. Invest. 71, 1544-1553.[Medline] Brown, M. S. and Goldstein, J. L. (1997"

Phrase: "). Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release. J. Clin. Invest. 71, 1544-1553.[Medline] Brown, M. S. and Goldstein, J. L. (1997)."
Processing 00000000.tx.309: The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. 

Phrase: "The SREBP pathway"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   876   C1514829:Regulatory Pathway [Functional Concept]
   799   C1704259:Pathway [Molecular Function]
   799   C1705987:Pathway [Conceptual Entity]

Phrase: ":"

Phrase: "regulation of cholesterol metabolism"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   881   C1159402:regulation of metabolism [Organism Function]
           metabolism regulation
   770   C0851285:Regulation [Governmental or Regulatory Activity]
   770   C1327622:Regulation [Biologic Function]

Phrase: "by proteolysis"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0597304:Proteolysis [Molecular Function]
   928 E C1947941:proteolytic [Enzyme]

Phrase: "of a membrane-bound transcription factor."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0040648:TRANSCRIPTION FACTOR [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   812   C0040649:Transcription [Genetic Function]
   812   C1521761:Factor [Functional Concept]
   812   C2827422:Factor [Conceptual Entity]
Processing 00000000.tx.310: Cell 89, 331-340.[CrossRef][Medline] Butler, A. 

Phrase: "Cell 89,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0007634:Cell [Cell]
   861   C1269647:Cell [Cell]
   861   C1704653:Cell [Medical Device]
   861   C1948049:Cell [Spatial Concept]

Phrase: "331-340."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Butler,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0402644:Butler [Professional or Occupational Group]

Phrase: "A."
Processing 00000000.tx.311: E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. 

Phrase: "E.,"

Phrase: "Janson,"

Phrase: "J.,"

Phrase: "Bonner-Weir,"

Phrase: "S."

Phrase: ","

Phrase: "Ritzel,"

Phrase: "R.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]

Phrase: "Rizza,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.312: A. and Butler, P. 

Phrase: "A."

Phrase: "and"

Phrase: "Butler,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0402644:Butler [Professional or Occupational Group]

Phrase: "P."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]
Processing 00000000.tx.313: C. 

Phrase: "C."
Processing 00000000.tx.314: (2003). 

Phrase: "(1997). The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89, 331-340.[CrossRef][Medline] Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A. and Butler, P. C. (2003"

Phrase: "). The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89, 331-340.[CrossRef][Medline] Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A. and Butler, P. C. (2003)."
Processing 00000000.tx.315: Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. 

Phrase: "Beta-cell deficit"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0162429:Deficit, NOS [Disease or Syndrome]
   827   C2987487:Deficit [Qualitative Concept]
   734   C0030281:Beta cell [Cell]

Phrase: "and"

Phrase: "increased beta-cell apoptosis in humans"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0162638:Apoptosis [Cell Function]

Phrase: "with type 2 diabetes."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]
Processing 00000000.tx.316: Diabetes 52, 102-110.[Abstract/Free FullText] Chan, C. 

Phrase: "Diabetes 52,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: "102-110."

Phrase: "[Abstract/Free FullText"

Phrase: "] Chan,"

Phrase: "C."
Processing 00000000.tx.317: B., Saleh, M. 

Phrase: "B.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "Saleh,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.318: C., Koshkin, V. and Wheeler, M. 

Phrase: "C., Koshkin,"

Phrase: "V."

Phrase: "and"

Phrase: "Wheeler,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.319: B. 

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.320: (2004). 

Phrase: "(2003). Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52, 102-110.[Abstract/Free FullText] Chan, C. B., Saleh, M. C., Koshkin, V. and Wheeler, M. B. (2004"

Phrase: "). Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52, 102-110.[Abstract/Free FullText] Chan, C. B., Saleh, M. C., Koshkin, V. and Wheeler, M. B. (2004)."
Processing 00000000.tx.321: Uncoupling protein 2 and islet function. 

Phrase: "Uncoupling protein 2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0536847:uncoupling protein-2 [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
  1000   C1421314:UNCOUPLING PROTEIN 2 [Gene or Genome]
   827   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "and"

Phrase: "islet function."
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   861   C0031843:function [Physiologic Function]
   861   C0542341:Function [Functional Concept]
   861   C0700205:FUNCTION [Classification]
   861   C1705273:Function [Intellectual Product]
   789 E C0205245:Functional [Functional Concept]
   789 E C2700217:Functional [Conceptual Entity]
Processing 00000000.tx.322: Diabetes 53, S136-S142.[Abstract/Free FullText] Dentin, R., Pegorier, J. 

Phrase: "Diabetes 53,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: "S136-S142."

Phrase: "[Abstract/Free FullText"

Phrase: "] Dentin,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0011429:Dentin [Body Part, Organ, or Organ Component]

Phrase: "R.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]

Phrase: "Pegorier,"

Phrase: "J."
Processing 00000000.tx.323: P., Benhamed, F., Foufelle, F., Ferre, P., Fauveau, V., Magnuson, M. 

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Benhamed,"

Phrase: "F.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "Foufelle,"

Phrase: "F.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "Ferre,"

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Fauveau,"

Phrase: "V.,"

Phrase: "Magnuson,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.324: A., Girard, J. and Postic, C. 

Phrase: "A.,"

Phrase: "Girard,"

Phrase: "J."

Phrase: "and"

Phrase: "Postic, C."
Processing 00000000.tx.325: (2004). 

Phrase: "(2004). Uncoupling protein 2 and islet function. Diabetes 53, S136-S142.[Abstract/Free FullText] Dentin, R., Pegorier, J. P., Benhamed, F., Foufelle, F., Ferre, P., Fauveau, V., Magnuson, M. A., Girard, J. and Postic, C. (2004"

Phrase: "). Uncoupling protein 2 and islet function. Diabetes 53, S136-S142.[Abstract/Free FullText] Dentin, R., Pegorier, J. P., Benhamed, F., Foufelle, F., Ferre, P., Fauveau, V., Magnuson, M. A., Girard, J. and Postic, C. (2004)."
Processing 00000000.tx.326: Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression. 

Phrase: "Hepatic glucokinase"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0017713:Glucokinase [Amino Acid, Peptide, or Protein,Enzyme]
   861   C1415014:GLUCOKINASE [Gene or Genome]

Phrase: "is"

Phrase: "required for the synergistic action of ChREBP"
Meta Candidates (Total=24; Excluded=1; Pruned=0; Remaining=23)
   820   C1826259:carbohydrate response element binding protein [Gene or Genome]
   797   C3158709:carbohydrate response element binding [Genetic Function]
   772   C0108401:carbohydrate-binding protein [Amino Acid, Peptide, or Protein,Receptor]
   756   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   756   C0600508:Response Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   754 E C0033618:Protein Binding [Molecular Function]
   754   C1145667:Binding action [Activity]
           Binding
   754   C1148582:carbohydrate binding [Molecular Function]
   754   C2985857:Required Response [Idea or Concept]
   738   C0007004:Carbohydrate [Carbohydrate]
   738   C0013879:Element [Element, Ion, or Isotope]
   738   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   738   C0243122:binding [Functional Concept]
   738   C0441472:Action [Functional Concept]
   738   C0871261:Response [Organism Attribute]
   738   C1167622:Binding [Molecular Function]
   738   C1514873:Required [Functional Concept]
   738   C1704632:Response [Finding]
   738   C1705248:Element [Conceptual Entity]
   738   C1706817:Response [Intellectual Product]
   738   C2911692:Response [Mental Process]
   738   C2986495:Synergistic [Qualitative Concept]
   738   C3266814:Action [Activity]

Phrase: "and"

Phrase: "SREBP-1c on glycolytic"
Meta Candidates (Total=15; Excluded=1; Pruned=0; Remaining=14)
   909   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   770   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   770   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   767 E C0033618:Protein Binding [Molecular Function]
   767   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   767   C2246292:sterol binding [Molecular Function]
   744   C0013879:Element [Element, Ion, or Isotope]
   744   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   744   C0038323:Sterol [Steroid]
   744   C0220905:regulatory [Regulation or Law]
   744   C0243122:binding [Functional Concept]
   744   C1145667:Binding [Activity]
   744   C1167622:Binding [Molecular Function]
   744   C1704735:Regulatory [Conceptual Entity]
   744   C1705248:Element [Conceptual Entity]

Phrase: "and"

Phrase: "lipogenic gene expression."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0017262:Gene Expression [Genetic Function]
   827   C0017337:Gene [Gene or Genome]
   827   C0185117:Expression [Therapeutic or Preventive Procedure]
Processing 00000000.tx.327: J. 

Phrase: "J."
Processing 00000000.tx.328: Biol. 

Phrase: "Biol."
Processing 00000000.tx.329: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.330: 279, 20314-20326.[Abstract/Free FullText] Diraison, F., Parton, L., Ferre, P., Foufelle, F., Briscoe, C. 

Phrase: "279,"

Phrase: "20314-20326."

Phrase: "[Abstract/Free FullText"

Phrase: "] Diraison,"

Phrase: "F.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "Parton,"

Phrase: "L.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]

Phrase: "Ferre,"

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Foufelle,"

Phrase: "F.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "Briscoe,"

Phrase: "C."
Processing 00000000.tx.331: P., Leclerc, I. and Rutter, G. 

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Leclerc,"

Phrase: "I."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "and"

Phrase: "Rutter,"

Phrase: "G."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]
Processing 00000000.tx.332: A. 

Phrase: "A."
Processing 00000000.tx.333: (2004). 

Phrase: "(2004). Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression. J. Biol. Chem. 279, 20314-20326.[Abstract/Free FullText] Diraison, F., Parton, L., Ferre, P., Foufelle, F., Briscoe, C. P., Leclerc, I. and Rutter, G. A. (2004"

Phrase: "). Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression. J. Biol. Chem. 279, 20314-20326.[Abstract/Free FullText] Diraison, F., Parton, L., Ferre, P., Foufelle, F., Briscoe, C. P., Leclerc, I. and Rutter, G. A. (2004)."
Processing 00000000.tx.334: Over-expression of sterol-regulatory-element-binding protein-1c (SREBP1c) in rat pancreatic islets induces lipogenesis and decreases glucose-stimulated insulin release: modulation by 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR). 

Phrase: "Over-expression of sterol-regulatory-element-binding protein-1c (SREBP1c)"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   762   C1171362:expression protein [Genetic Function]
   742   C0185117:Expression [Therapeutic or Preventive Procedure]
   742   C0205136:Over [Spatial Concept]
   716   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "in rat pancreatic islets"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C0022131:Pancreatic Islets [Body Part, Organ, or Organ Component]
   827   C0030274:Pancreatic [Body Part, Organ, or Organ Component]

Phrase: "induces"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induce [Functional Concept]

Phrase: "lipogenesis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0596843:lipogenesis [Molecular Function]
  1000   C1563744:Lipogenesis [Organism Function]

Phrase: "and"

Phrase: "decreases"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0392756:Decrease [Qualitative Concept]
  1000   C0547047:Decrease [Quantitative Concept]

Phrase: "glucose-stimulated insulin release"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
   875   C1719133:Glucose/Insulin [Quantitative Concept]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0030685:Release [Health Care Activity]
   812   C0391871:Release [Functional Concept]
   812   C0439180:% release [Quantitative Concept]
   812   C0680255:release [Health Care Activity]
   812   C1283071:Release [Functional Concept]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   812   C1963578:Release [Therapeutic or Preventive Procedure]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: ":"

Phrase: "modulation by 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR)."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0443264:Modulation [Spatial Concept]
Processing 00000000.tx.335: Biochem. 

Phrase: "Biochem."
Processing 00000000.tx.336: J. 

Phrase: "J."
Processing 00000000.tx.337: 378, 769-778.[CrossRef][Medline] Dobrzyn, P., Dobrzyn, A., Miyazaki, M., Cohen, P., Asilmaz, E., Hardie, D. 

Phrase: "378,"

Phrase: "769-778."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Dobrzyn,"

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Dobrzyn,"

Phrase: "A.,"

Phrase: "Miyazaki,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0315755:Miyazaki [Bacterium]

Phrase: "M."

Phrase: ","

Phrase: "Cohen,"

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Asilmaz,"

Phrase: "E.,"

Phrase: "Hardie,"

Phrase: "D."
Processing 00000000.tx.338: G., Friedman, J. 

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "Friedman,"

Phrase: "J."
Processing 00000000.tx.339: M. and Ntambi, J. 

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]

Phrase: "and"

Phrase: "Ntambi,"

Phrase: "J."
Processing 00000000.tx.340: M. 

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.341: (2004). 

Phrase: "(2004). Over-expression of sterol-regulatory-element-binding protein-1c (SREBP1c) in rat pancreatic islets induces lipogenesis and decreases glucose-stimulated insulin release: modulation by 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR). Biochem. J. 378, 769-778.[CrossRef][Medline] Dobrzyn, P., Dobrzyn, A., Miyazaki, M., Cohen, P., Asilmaz, E., Hardie, D. G., Friedman, J. M. and Ntambi, J. M. (2004"

Phrase: "). Over-expression of sterol-regulatory-element-binding protein-1c (SREBP1c) in rat pancreatic islets induces lipogenesis and decreases glucose-stimulated insulin release: modulation by 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR). Biochem. J. 378, 769-778.[CrossRef][Medline] Dobrzyn, P., Dobrzyn, A., Miyazaki, M., Cohen, P., Asilmaz, E., Hardie, D. G., Friedman, J. M. and Ntambi, J. M. (2004)."
Processing 00000000.tx.342: Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver. 

Phrase: "Stearoyl-CoA desaturase 1 deficiency"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   804   C0011155:Deficiency [Functional Concept]
   804   C0162429:Deficiency [Disease or Syndrome]
   804   C1623416:deficiency [Qualitative Concept]
   733 E C1636779:% deficient [Quantitative Concept]
   717   C0038233:Stearoyl-CoA Desaturase [Amino Acid, Peptide, or Protein,Enzyme]
   717   C1419846:STEAROYL-CoA DESATURASE [Gene or Genome]

Phrase: "increases"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "fatty acid oxidation by activating AMP-activated protein kinase"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C1158366:fatty acid oxidation [Molecular Function]
   764   C0015684:Fatty acid [Lipid]
   762   C1159301:protein oxidation [Molecular Function]
   742   C0001128:Acid [Chemical]
   742   C0030011:Oxidation [Molecular Function]
   742   C0202406:Acid [Laboratory Procedure]

Phrase: "in liver."
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0023884:Liver [Body Part, Organ, or Organ Component]
  1000   C0736268:LIVER [Body Part, Organ, or Organ Component]
  1000   C1278929:Liver [Body Part, Organ, or Organ Component]
  1000   C2346688:LIVER [Food]
   944 E C0205054:Hepatic [Body Location or Region]
Processing 00000000.tx.343: Proc. 

Phrase: "Proc."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1418943:PROC [Gene or Genome]
Processing 00000000.tx.344: Natl. 

Phrase: "Natl."
Processing 00000000.tx.345: Acad. 

Phrase: "Acad."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0268596:ACAD [Disease or Syndrome]
  1000   C2700624:ACAD [Cell Function]
Processing 00000000.tx.346: Sci. 

Phrase: "Sci."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3642273:SCI [Professional or Occupational Group]
Processing 00000000.tx.347: USA 101, 6409-6414.[Abstract/Free FullText] Eberle, D., Clement, K., Meyre, D., Sahbatou, M., Vaxillaire, M., Le Gall, A., Ferre, P., Basdevant, A., Froguel, P. and Foufelle, F. 

Phrase: "USA 101,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0041703:USA [Geographic Area]

Phrase: "6409-6414."

Phrase: "[Abstract/Free FullText"

Phrase: "] Eberle,"

Phrase: "D."

Phrase: ","

Phrase: "Clement,"

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Meyre,"

Phrase: "D."

Phrase: ","

Phrase: "Sahbatou,"

Phrase: "M."

Phrase: ","

Phrase: "Vaxillaire,"

Phrase: "M."

Phrase: ","

Phrase: "Le Gall,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2700230:Gall [Plant]

Phrase: "A.,"

Phrase: "Ferre,"

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Basdevant,"

Phrase: "A.,"

Phrase: "Froguel,"

Phrase: "P."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "and"

Phrase: "Foufelle,"

Phrase: "F."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]
Processing 00000000.tx.348: (2004). 

Phrase: "(2004). Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver. Proc. Natl. Acad. Sci. USA 101, 6409-6414.[Abstract/Free FullText] Eberle, D., Clement, K., Meyre, D., Sahbatou, M., Vaxillaire, M., Le Gall, A., Ferre, P., Basdevant, A., Froguel, P. and Foufelle, F. (2004"

Phrase: "). Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver. Proc. Natl. Acad. Sci. USA 101, 6409-6414.[Abstract/Free FullText] Eberle, D., Clement, K., Meyre, D., Sahbatou, M., Vaxillaire, M., Le Gall, A., Ferre, P., Basdevant, A., Froguel, P. and Foufelle, F. (2004)."
Processing 00000000.tx.349: SREBF-1 gene polymorphisms are associated with obesity and type 2 diabetes in French obese and diabetic cohorts. 

Phrase: "SREBF-1 gene polymorphisms"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0678951:gene polymorphisms [Genetic Function]
   812   C0032529:polymorphisms [Genetic Function]
   779 E C1882417:Polymorphism [Qualitative Concept]

Phrase: "are"

Phrase: "associated with obesity"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   882   C0332281:Associated with [Qualitative Concept]
           Associated
   790   C0028754:Obesity [Disease or Syndrome]
   790   C1963185:Obesity [Finding]
   756 E C0750490:Associate [Idea or Concept]
   756 E C1706221:Associate [Professional or Occupational Group]

Phrase: "and"

Phrase: "type 2 diabetes in French obese"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   833   C0011860:Type 2 Diabetes [Disease or Syndrome]
   790   C0441730:Type 2 [Classification]
   783   C1320657:Diabetes type [Finding]
   753   C0011847:Diabetes [Disease or Syndrome]
   753   C0011849:Diabetes [Disease or Syndrome]
   753   C0332307:Type [Qualitative Concept]
   753   C1547052:*Type [Quantitative Concept]

Phrase: "and"

Phrase: "diabetic cohorts."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0599755:cohorts [Population Group]
Processing 00000000.tx.350: Diabetes 53, 2153-2157.[Abstract/Free FullText] Efanova, I. 

Phrase: "Diabetes 53,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: "2153-2157."

Phrase: "[Abstract/Free FullText"

Phrase: "] Efanova,"

Phrase: "I."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
Processing 00000000.tx.351: B., Zaitsev, S. 

Phrase: "B.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "Zaitsev,"

Phrase: "S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]
Processing 00000000.tx.352: V., Zhivotovsky, B., Kohler, M., Efendic, S., Orrenius, S. and Berggren, P. 

Phrase: "V., Zhivotovsky,"

Phrase: "B.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "Kohler,"

Phrase: "M."

Phrase: ","

Phrase: "Efendic,"

Phrase: "S."

Phrase: ","

Phrase: "Orrenius,"

Phrase: "S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]

Phrase: "and"

Phrase: "Berggren,"

Phrase: "P."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]
Processing 00000000.tx.353: O. 

Phrase: "O."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439114:O NOS [Intellectual Product]
Processing 00000000.tx.354: (1998). 

Phrase: "(2004). SREBF-1 gene polymorphisms are associated with obesity and type 2 diabetes in French obese and diabetic cohorts. Diabetes 53, 2153-2157.[Abstract/Free FullText] Efanova, I. B., Zaitsev, S. V., Zhivotovsky, B., Kohler, M., Efendic, S., Orrenius, S. and Berggren, P. O. (1998"

Phrase: "). SREBF-1 gene polymorphisms are associated with obesity and type 2 diabetes in French obese and diabetic cohorts. Diabetes 53, 2153-2157.[Abstract/Free FullText] Efanova, I. B., Zaitsev, S. V., Zhivotovsky, B., Kohler, M., Efendic, S., Orrenius, S. and Berggren, P. O. (1998)."
Processing 00000000.tx.355: Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. 

Phrase: "Glucose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "and"

Phrase: "tolbutamide"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0040374:Tolbutamide [Organic Chemical,Pharmacologic Substance]
   944 E C0701229:Orinase [Organic Chemical,Pharmacologic Substance]

Phrase: "induce"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induce [Functional Concept]

Phrase: "apoptosis in pancreatic beta-cells."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   883   C3157088:pancreatic beta cell apoptosis [Cell Function]
   760   C0162638:Apoptosis [Cell Function]
Processing 00000000.tx.356: A process dependent on intracellular Ca2+ concentration. 

Phrase: "A process"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1184743:Process [Body Part, Organ, or Organ Component]
  1000   C1522240:Process [Phenomenon or Process]

Phrase: "dependent on intracellular Ca2+ concentration."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0851827:Dependent [Qualitative Concept]
   760   C1701901:Dependent [Qualitative Concept]
   760   C3244310:dependent [Functional Concept]
Processing 00000000.tx.357: J. 

Phrase: "J."
Processing 00000000.tx.358: Biol. 

Phrase: "Biol."
Processing 00000000.tx.359: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.360: 273, 33501-33507.[Abstract/Free FullText] Engelking, L. 

Phrase: "273,"

Phrase: "33501-33507."

Phrase: "[Abstract/Free FullText"

Phrase: "] Engelking,"

Phrase: "L."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]
Processing 00000000.tx.361: J., Kuriyama, H., Hammer, R. 

Phrase: "J.,"

Phrase: "Kuriyama,"

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Hammer,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0181107:Hammer [Manufactured Object]

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.362: E., Horton, J. 

Phrase: "E.,"

Phrase: "Horton,"

Phrase: "J."
Processing 00000000.tx.363: D., Brown, M. 

Phrase: "D."

Phrase: ","

Phrase: "Brown,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0678579:Brown [Natural Phenomenon or Process]

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.364: S., Goldstein, J. 

Phrase: "S."

Phrase: ","

Phrase: "Goldstein,"

Phrase: "J."
Processing 00000000.tx.365: L. and Liang, G. 

Phrase: "L."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]

Phrase: "and"

Phrase: "Liang,"

Phrase: "G."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]
Processing 00000000.tx.366: (2004). 

Phrase: "(1998). Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration. J. Biol. Chem. 273, 33501-33507.[Abstract/Free FullText] Engelking, L. J., Kuriyama, H., Hammer, R. E., Horton, J. D., Brown, M. S., Goldstein, J. L. and Liang, G. (2004"

Phrase: "). Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration. J. Biol. Chem. 273, 33501-33507.[Abstract/Free FullText] Engelking, L. J., Kuriyama, H., Hammer, R. E., Horton, J. D., Brown, M. S., Goldstein, J. L. and Liang, G. (2004)."
Processing 00000000.tx.367: Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis. 

Phrase: "Overexpression of Insig-1"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1514559:Overexpression [Genetic Function]

Phrase: "in the livers"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
  1000   C0023884:Livers [Body Part, Organ, or Organ Component]
   966 E C0736268:LIVER [Body Part, Organ, or Organ Component]
   966 E C1278929:Liver [Body Part, Organ, or Organ Component]
   966 E C2346688:LIVER [Food]
   928 E C0205054:Hepatic [Body Location or Region]

Phrase: "of transgenic mice"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0025936:Mice, Transgenic [Mammal]
   861   C0003069:Transgenic [Animal]
   861   C0025914:Mice [Mammal]
   861   C0025929:mice [Mammal]
   861   C0026809:Mice [Mammal]

Phrase: "inhibits"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   944   C0018790:arrested [Disease or Syndrome]
   944   C0237477:Arrest [Temporal Concept]
   944   C0392351:arrest [Governmental or Regulatory Activity]
   944   C0521111:Retarded [Qualitative Concept]
   916 E C0311403:Inhibited [Qualitative Concept]
   916 E C3463820:Inhibiting [Activity]

Phrase: "SREBP processing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0033666:protein processing [Molecular Function]
   799   C1709694:Processing [Activity]

Phrase: "and"

Phrase: "reduces"

Phrase: "insulin-stimulated lipogenesis."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0596843:lipogenesis [Molecular Function]
   827   C1563744:Lipogenesis [Organism Function]
Processing 00000000.tx.368: J. 

Phrase: "J."
Processing 00000000.tx.369: Clin. 

Phrase: "Clin."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1315013:CLIN [Intellectual Product]
Processing 00000000.tx.370: Invest. 

Phrase: "Invest."
Processing 00000000.tx.371: 113, 1168-1175.[Abstract/Free FullText] Flamez, D., Berger, V., Kruhoffer, M., Orntoft, T., Pipeleers, D. and Schuit, F. 

Phrase: "113,"

Phrase: "1168-1175."

Phrase: "[Abstract/Free FullText"

Phrase: "] Flamez,"

Phrase: "D."

Phrase: ","

Phrase: "Berger,"

Phrase: "V.,"

Phrase: "Kruhoffer,"

Phrase: "M."

Phrase: ","

Phrase: "Orntoft,"

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Pipeleers,"

Phrase: "D."

Phrase: "and"

Phrase: "Schuit,"

Phrase: "F."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]
Processing 00000000.tx.372: C. 

Phrase: "C."
Processing 00000000.tx.373: (2002). 

Phrase: "(2004). Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis. J. Clin. Invest. 113, 1168-1175.[Abstract/Free FullText] Flamez, D., Berger, V., Kruhoffer, M., Orntoft, T., Pipeleers, D. and Schuit, F. C. (2002"

Phrase: "). Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis. J. Clin. Invest. 113, 1168-1175.[Abstract/Free FullText] Flamez, D., Berger, V., Kruhoffer, M., Orntoft, T., Pipeleers, D. and Schuit, F. C. (2002)."
Processing 00000000.tx.374: Critical role for cataplerosis via citrate in glucose-regulated insulin release. 

Phrase: "Critical role for cataplerosis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0035820:Role [Social Behavior]
   770   C1705810:Role [Conceptual Entity]

Phrase: "via citrate"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0008857:Citrate [Organic Chemical]
  1000   C0376259:Citrate [Organic Chemical,Pharmacologic Substance]

Phrase: "in glucose-regulated insulin release."
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
   875   C1719133:Glucose/Insulin [Quantitative Concept]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0030685:Release [Health Care Activity]
   812   C0391871:Release [Functional Concept]
   812   C0439180:% release [Quantitative Concept]
   812   C0680255:release [Health Care Activity]
   812   C1283071:Release [Functional Concept]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   812   C1963578:Release [Therapeutic or Preventive Procedure]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]
Processing 00000000.tx.375: Diabetes 51, 2018-2024.[Abstract/Free FullText] Gilligan, M., Welsh, G. 

Phrase: "Diabetes 51,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: "2018-2024."

Phrase: "[Abstract/Free FullText"

Phrase: "] Gilligan,"

Phrase: "M."

Phrase: ","

Phrase: "Welsh,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0043114:Welsh [Population Group]

Phrase: "G."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]
Processing 00000000.tx.376: I., Flynn, A., Bujalska, I., Diggle, T. 

Phrase: "I.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Flynn,"

Phrase: "A.,"

Phrase: "Bujalska,"

Phrase: "I.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Diggle,"

Phrase: "T."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]
Processing 00000000.tx.377: A., Denton, R. 

Phrase: "A.,"

Phrase: "Denton,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.378: M., Proud, C. 

Phrase: "M."

Phrase: ","

Phrase: "Proud,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   928   C0683296:pride [Mental Process]

Phrase: "C."
Processing 00000000.tx.379: G. and Docherty, K. 

Phrase: "G."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "and"

Phrase: "Docherty,"

Phrase: "K."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]
Processing 00000000.tx.380: (1996). 

Phrase: "(2002). Critical role for cataplerosis via citrate in glucose-regulated insulin release. Diabetes 51, 2018-2024.[Abstract/Free FullText] Gilligan, M., Welsh, G. I., Flynn, A., Bujalska, I., Diggle, T. A., Denton, R. M., Proud, C. G. and Docherty, K. (1996"

Phrase: "). Critical role for cataplerosis via citrate in glucose-regulated insulin release. Diabetes 51, 2018-2024.[Abstract/Free FullText] Gilligan, M., Welsh, G. I., Flynn, A., Bujalska, I., Diggle, T. A., Denton, R. M., Proud, C. G. and Docherty, K. (1996)."
Processing 00000000.tx.381: Glucose stimulates the activity of the guanine nucleotide-exchange factor eIF-2B in isolated rat islets of Langerhans. 

Phrase: "Glucose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "stimulates"

Phrase: "the activity of the guanine nucleotide-exchange factor eIF-2B"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   739   C0205177:Activity [Functional Concept]
   739   C0439167:% activity [Quantitative Concept]
   739   C0441655:Activity [Activity]
   739   C1561536:*Activity [Idea or Concept]

Phrase: "in isolated rat islets"

Phrase: "of Langerhans."
Processing 00000000.tx.382: J. 

Phrase: "J."
Processing 00000000.tx.383: Biol. 

Phrase: "Biol."
Processing 00000000.tx.384: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.385: 271, 2121-2125.[Abstract/Free FullText] Gomez, E., Powell, M. 

Phrase: "271,"

Phrase: "2121-2125."

Phrase: "[Abstract/Free FullText"

Phrase: "] Gomez,"

Phrase: "E.,"

Phrase: "Powell,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.386: L., Greenman, I. 

Phrase: "L., Greenman,"

Phrase: "I."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
Processing 00000000.tx.387: C. and Herbert, T. 

Phrase: "C."

Phrase: "and"

Phrase: "Herbert,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0331828:Herbert [Health Care Related Organization]

Phrase: "T."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]
Processing 00000000.tx.388: P. 

Phrase: "P."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]
Processing 00000000.tx.389: (2004). 

Phrase: "(1996). Glucose stimulates the activity of the guanine nucleotide-exchange factor eIF-2B in isolated rat islets of Langerhans. J. Biol. Chem. 271, 2121-2125.[Abstract/Free FullText] Gomez, E., Powell, M. L., Greenman, I. C. and Herbert, T. P. (2004"

Phrase: "). Glucose stimulates the activity of the guanine nucleotide-exchange factor eIF-2B in isolated rat islets of Langerhans. J. Biol. Chem. 271, 2121-2125.[Abstract/Free FullText] Gomez, E., Powell, M. L., Greenman, I. C. and Herbert, T. P. (2004)."
Processing 00000000.tx.390: Glucose-stimulated protein synthesis in pancreatic beta-cells parallels an increase in the availability of the translational ternary complex (eIF2-GTP.Met-tRNAi) and the dephosphorylation of eIF2 alpha. 

Phrase: "Glucose-stimulated protein synthesis in pancreatic beta-cells"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   770   C0597295:Protein Synthesis [Molecular Function]
   767   C1750295:beta protein [Genetic Function]
   767   C2362547:Beta protein [Amino Acid, Peptide, or Protein]
   767   C2599779:Glucose & Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance,Carbohydrate]
   744   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   744   C0220781:synthesis [Biologic Function]
   744   C1883254:Synthesis [Activity]
   744   C1948023:Stimulated [Natural Phenomenon or Process]
   731 E C0597552:synthetic protein [Amino Acid, Peptide, or Protein]
   731   C2936320:Synthetic Cells [Manufactured Object]

Phrase: "parallels"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2348042:Parallel [Qualitative Concept]
  1000   C2826345:PARALLEL [Research Activity]

Phrase: "an increase in the availability of the translational ternary complex"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   739   C0442805:Increase [Functional Concept]

Phrase: "(2004). Glucose-stimulated protein synthesis in pancreatic beta-cells parallels an increase in the availability of the translational ternary complex (eIF2-GTP.Met-tRNAi"

Phrase: ")"

Phrase: "and"

Phrase: "the dephosphorylation of eIF2 alpha."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1158884:Dephosphorylation [Molecular Function]
   760   C3160734:Dephosphorylation [Molecular Function]
Processing 00000000.tx.391: J. 

Phrase: "J."
Processing 00000000.tx.392: Biol. 

Phrase: "Biol."
Processing 00000000.tx.393: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.394: 279, 53937-53946.[Abstract/Free FullText] Gossen, M., Freundlieb, S., Bender, G., Muller, G., Hillen, W. and Bujard, H. 

Phrase: "279,"

Phrase: "53937-53946."

Phrase: "[Abstract/Free FullText"

Phrase: "] Gossen,"

Phrase: "M."

Phrase: ","

Phrase: "Freundlieb,"

Phrase: "S."

Phrase: ","

Phrase: "Bender,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0491941:BENDER [Medical Device]

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "Muller,"

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "Hillen,"

Phrase: "W."

Phrase: "and"

Phrase: "Bujard,"

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.395: (1995). 

Phrase: "(eIF2-GTP.Met-tRNAi) and the dephosphorylation of eIF2 alpha. J. Biol. Chem. 279, 53937-53946.[Abstract/Free FullText] Gossen, M., Freundlieb, S., Bender, G., Muller, G., Hillen, W. and Bujard, H. (1995"

Phrase: ") and the dephosphorylation of eIF2 alpha. J. Biol. Chem. 279, 53937-53946.[Abstract/Free FullText] Gossen, M., Freundlieb, S., Bender, G., Muller, G., Hillen, W. and Bujard, H. (1995)."
Processing 00000000.tx.396: Transcriptional activation by tetracyclines in mammalian cells. 

Phrase: "Transcriptional activation by tetracyclines"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C0162493:Transcriptional Activation [Genetic Function]
   770   C1879547:Activation [Activity]

Phrase: "in mammalian cells."
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   983   C1512977:Mammalian Cell [Cell]
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.397: Science 268, 1766-1769.[Medline] Harmon, J. 

Phrase: "Science 268,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0036397:Science [Occupation or Discipline]

Phrase: "1766-1769."

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Harmon,"

Phrase: "J."
Processing 00000000.tx.398: S., Gleason, C. 

Phrase: "S."

Phrase: ","

Phrase: "Gleason,"

Phrase: "C."
Processing 00000000.tx.399: E., Tanaka, Y., Poitout, V. and Robertson, R. 

Phrase: "E.,"

Phrase: "Tanaka,"

Phrase: "Y.,"

Phrase: "Poitout,"

Phrase: "V."

Phrase: "and"

Phrase: "Robertson,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.400: P. 

Phrase: "P."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]
Processing 00000000.tx.401: (2001). 

Phrase: "(1995). Transcriptional activation by tetracyclines in mammalian cells. Science 268, 1766-1769.[Medline] Harmon, J. S., Gleason, C. E., Tanaka, Y., Poitout, V. and Robertson, R. P. (2001"

Phrase: "). Transcriptional activation by tetracyclines in mammalian cells. Science 268, 1766-1769.[Medline] Harmon, J. S., Gleason, C. E., Tanaka, Y., Poitout, V. and Robertson, R. P. (2001)."
Processing 00000000.tx.402: Antecedent hyperglycemia, not hyperlipidemia, is associated with increased islet triacylglycerol content and decreased insulin gene mRNA level in Zucker diabetic fatty rats. 

Phrase: "Antecedent hyperglycemia,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0020456:Hyperglycaemia [Disease or Syndrome]

Phrase: "not hyperlipidemia,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0020473:Hyperlipidaemia [Disease or Syndrome]

Phrase: "is"

Phrase: "associated with increased islet triacylglycerol content"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   790   C0332281:Associated with [Qualitative Concept]
           Associated
   753   C0041004:Triacylglycerol [Biologically Active Substance,Lipid]
   753   C0205217:Increased [Quantitative Concept]
   753   C0423896:Content [Mental Process]
   753   C0442805:Increased [Functional Concept]
   753   C0456205:Content [Conceptual Entity]
   719 E C0750490:Associate [Idea or Concept]
   719 E C1706221:Associate [Professional or Occupational Group]

Phrase: "and"

Phrase: "decreased insulin gene mRNA level in Zucker diabetic fatty rats."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   777   C1295676:Decreased insulin level [Finding]
   757   C0202098:Insulin level [Laboratory Procedure]
   757   C0428405:insulin level [Laboratory or Test Result]
   739   C0035696:mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   739   C0441889:Level [Qualitative Concept]
   739   C0456079:Level [Classification]
   739   C1547707:Level [Geographic Area]
   739   C2946261:Level [Pharmacologic Substance]
Processing 00000000.tx.403: Diabetes 50, 2481-2486.[Abstract/Free FullText] Horton, J. 

Phrase: "Diabetes 50,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: "2481-2486."

Phrase: "[Abstract/Free FullText"

Phrase: "] Horton,"

Phrase: "J."
Processing 00000000.tx.404: D., Goldstein, J. 

Phrase: "D."

Phrase: ","

Phrase: "Goldstein,"

Phrase: "J."
Processing 00000000.tx.405: L. and Brown, M. 

Phrase: "L."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]

Phrase: "and"

Phrase: "Brown,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0678579:Brown [Natural Phenomenon or Process]

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.406: S. 

Phrase: "S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]
Processing 00000000.tx.407: (2002). 

Phrase: "(2001). Antecedent hyperglycemia, not hyperlipidemia, is associated with increased islet triacylglycerol content and decreased insulin gene mRNA level in Zucker diabetic fatty rats. Diabetes 50, 2481-2486.[Abstract/Free FullText] Horton, J. D., Goldstein, J. L. and Brown, M. S. (2002"

Phrase: "). Antecedent hyperglycemia, not hyperlipidemia, is associated with increased islet triacylglycerol content and decreased insulin gene mRNA level in Zucker diabetic fatty rats. Diabetes 50, 2481-2486.[Abstract/Free FullText] Horton, J. D., Goldstein, J. L. and Brown, M. S. (2002)."
Processing 00000000.tx.408: SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. 

Phrase: "SREBPs"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
  1000   C1566548:Sterol Regulatory Element Binding Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   875   C0815047:regulatory proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   875   C2246292:sterol binding [Molecular Function]
   840   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   840   C0242210:Binding Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0013879:Element [Element, Ion, or Isotope]
   804   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0038323:Sterol [Steroid]
   804   C0220905:regulatory [Regulation or Law]
   804   C0243122:binding [Functional Concept]
   804   C1145667:Binding [Activity]
   804   C1167622:Binding [Molecular Function]
   804   C1704735:Regulatory [Conceptual Entity]
   804   C1705248:Element [Conceptual Entity]

Phrase: ":"

Phrase: "activators of the complete program of cholesterol"

Phrase: "and"

Phrase: "fatty acid synthesis in the liver."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   833   C0596562:fatty acid synthesis [Molecular Function]
   753   C0220781:synthesis [Biologic Function]
   753   C1883254:Synthesis [Activity]
Processing 00000000.tx.409: J. 

Phrase: "J."
Processing 00000000.tx.410: Clin. 

Phrase: "Clin."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1315013:CLIN [Intellectual Product]
Processing 00000000.tx.411: Invest. 

Phrase: "Invest."
Processing 00000000.tx.412: 109, 1125-1131.[Free FullText] Horton, J. 

Phrase: "109,"

Phrase: "1125-1131."

Phrase: "[Free FullText"

Phrase: "] Horton,"

Phrase: "J."
Processing 00000000.tx.413: D., Shah, N. 

Phrase: "D."

Phrase: ","

Phrase: "Shah,"

Phrase: "N."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]
Processing 00000000.tx.414: A., Warrington, J. 

Phrase: "A.,"

Phrase: "Warrington,"

Phrase: "J."
Processing 00000000.tx.415: A., Anderson, N. 

Phrase: "A.,"

Phrase: "Anderson,"

Phrase: "N."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]
Processing 00000000.tx.416: N., Park, S. 

Phrase: "N., Park,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0562547:Park [Manufactured Object]
   861   C3160718:PARK [Disease or Syndrome]

Phrase: "S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]
Processing 00000000.tx.417: W., Brown, M. 

Phrase: "W., Brown,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0678579:Brown [Natural Phenomenon or Process]

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.418: S. and Goldstein, J. 

Phrase: "S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]

Phrase: "and"

Phrase: "Goldstein,"

Phrase: "J."
Processing 00000000.tx.419: L. 

Phrase: "L."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]
Processing 00000000.tx.420: (2003). 

Phrase: "(2002). SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109, 1125-1131.[Free FullText] Horton, J. D., Shah, N. A., Warrington, J. A., Anderson, N. N., Park, S. W., Brown, M. S. and Goldstein, J. L. (2003"

Phrase: "). SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109, 1125-1131.[Free FullText] Horton, J. D., Shah, N. A., Warrington, J. A., Anderson, N. N., Park, S. W., Brown, M. S. and Goldstein, J. L. (2003)."
Processing 00000000.tx.421: Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. 

Phrase: "Combined analysis of oligonucleotide microarray data"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   783   C0010992:Data Analysis [Occupational Activity]
   783   C1449575:Microarray Analysis [Laboratory Procedure]
   753   C0002778:Analysis [Laboratory Procedure]
   753   C0936012:Analysis [Research Activity]
   753   C1524024:analysis [Functional Concept]

Phrase: "from transgenic"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0003069:Transgenic [Animal]

Phrase: "and"

Phrase: "knockout mice"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0206745:Knock-out Mice [Mammal]
   861   C0025914:Mice [Mammal]
   861   C0025929:mice [Mammal]
   861   C0026809:Mice [Mammal]

Phrase: "identifies"

Phrase: "direct SREBP target genes."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   864   C0017362:Regulatory Genes [Gene or Genome]
   806   C0751455:protein gene [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   795   C1332838:Target Gene [Gene or Genome]
   793   C0017337:Genes [Gene or Genome]
   711   C1550500:direct target [Idea or Concept]
Processing 00000000.tx.422: Proc. 

Phrase: "Proc."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1418943:PROC [Gene or Genome]
Processing 00000000.tx.423: Natl. 

Phrase: "Natl."
Processing 00000000.tx.424: Acad. 

Phrase: "Acad."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0268596:ACAD [Disease or Syndrome]
  1000   C2700624:ACAD [Cell Function]
Processing 00000000.tx.425: Sci. 

Phrase: "Sci."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3642273:SCI [Professional or Occupational Group]
Processing 00000000.tx.426: USA 100, 12027-12032.[Abstract/Free FullText] Ide, T., Shimano, H., Yahagi, N., Matsuzaka, T., Nakakuki, M., Yamamoto, T., Nakagawa, Y., Takahashi, A., Suzuki, H., Sone, H. et al. 

Phrase: "USA 100,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0041703:USA [Geographic Area]

Phrase: "12027-12032."

Phrase: "[Abstract/Free FullText"

Phrase: "] Ide,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0328104:Ide [Fish]
  1000   C1415875:IDE [Gene or Genome]
  1000   C2826366:IDE [Idea or Concept]

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Shimano,"

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Yahagi,"

Phrase: "N.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]

Phrase: "Matsuzaka,"

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Nakakuki,"

Phrase: "M."

Phrase: ","

Phrase: "Yamamoto,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450955:Yamamoto [Body Location or Region]

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Nakagawa,"

Phrase: "Y.,"

Phrase: "Takahashi,"

Phrase: "A.,"

Phrase: "Suzuki,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0998924:suzuki [Fish]

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Sone,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1564199:Sone [Pharmacologic Substance,Steroid]
  1000   C1825500:SONE [Gene or Genome]

Phrase: "H. et al."
Processing 00000000.tx.427: (2004). 

Phrase: "(2003). Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl. Acad. Sci. USA 100, 12027-12032.[Abstract/Free FullText] Ide, T., Shimano, H., Yahagi, N., Matsuzaka, T., Nakakuki, M., Yamamoto, T., Nakagawa, Y., Takahashi, A., Suzuki, H., Sone, H. et al. (2004"

Phrase: "). Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl. Acad. Sci. USA 100, 12027-12032.[Abstract/Free FullText] Ide, T., Shimano, H., Yahagi, N., Matsuzaka, T., Nakakuki, M., Yamamoto, T., Nakagawa, Y., Takahashi, A., Suzuki, H., Sone, H. et al. (2004)."
Processing 00000000.tx.428: SREBPs suppress IRS-2-mediated insulin signalling in the liver. 

Phrase: "SREBPs"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
  1000   C1566548:Sterol Regulatory Element Binding Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   875   C0815047:regulatory proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   875   C2246292:sterol binding [Molecular Function]
   840   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   840   C0242210:Binding Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0013879:Element [Element, Ion, or Isotope]
   804   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0038323:Sterol [Steroid]
   804   C0220905:regulatory [Regulation or Law]
   804   C0243122:binding [Functional Concept]
   804   C1145667:Binding [Activity]
   804   C1167622:Binding [Molecular Function]
   804   C1704735:Regulatory [Conceptual Entity]
   804   C1705248:Element [Conceptual Entity]

Phrase: "suppress"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1260953:suppress [Functional Concept]

Phrase: "IRS-2-mediated insulin signalling in the liver."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   744   C3537152:signalling [Biologic Function]
   711 E C1710082:Signal [Phenomenon or Process]
Processing 00000000.tx.429: Nat. 

Phrase: "Nat."
Processing 00000000.tx.430: Cell Biol. 

Phrase: "Cell Biol."
Processing 00000000.tx.431: 6, 351-357.[CrossRef][Medline] Iizuka, K., Bruick, R. 

Phrase: "6,"

Phrase: "351-357."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Iizuka,"

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Bruick,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.432: K., Liang, G., Horton, J. 

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Liang,"

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "Horton,"

Phrase: "J."
Processing 00000000.tx.433: D. and Uyeda, K. 

Phrase: "D."

Phrase: "and"

Phrase: "Uyeda,"

Phrase: "K."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]
Processing 00000000.tx.434: (2004). 

Phrase: "(2004). SREBPs suppress IRS-2-mediated insulin signalling in the liver. Nat. Cell Biol. 6, 351-357.[CrossRef][Medline] Iizuka, K., Bruick, R. K., Liang, G., Horton, J. D. and Uyeda, K. (2004"

Phrase: "). SREBPs suppress IRS-2-mediated insulin signalling in the liver. Nat. Cell Biol. 6, 351-357.[CrossRef][Medline] Iizuka, K., Bruick, R. K., Liang, G., Horton, J. D. and Uyeda, K. (2004)."
Processing 00000000.tx.435: Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. 

Phrase: "Deficiency of carbohydrate response element-binding protein"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   774   C0033626:Protein Deficiency [Disease or Syndrome]
   748   C0011155:Deficiency [Functional Concept]
   748   C0162429:Deficiency [Disease or Syndrome]
   748   C1623416:deficiency [Qualitative Concept]
   731   C1826259:carbohydrate response element binding protein [Gene or Genome]

Phrase: "(2004). Deficiency of carbohydrate response element-binding protein (ChREBP"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C1826259:carbohydrate response element binding protein [Gene or Genome]
   937   C3158709:carbohydrate response element binding [Genetic Function]
   911   C0108401:carbohydrate-binding protein [Amino Acid, Peptide, or Protein,Receptor]
   875   C1148582:carbohydrate binding [Molecular Function]
   840   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0243122:binding [Functional Concept]
   804   C1145667:Binding [Activity]
   804   C1167622:Binding [Molecular Function]

Phrase: ")"

Phrase: "reduces"

Phrase: "lipogenesis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0596843:lipogenesis [Molecular Function]
  1000   C1563744:Lipogenesis [Organism Function]

Phrase: "as well as"

Phrase: "glycolysis."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017952:Glycolysis [Molecular Function]
Processing 00000000.tx.436: Proc. 

Phrase: "Proc."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1418943:PROC [Gene or Genome]
Processing 00000000.tx.437: Natl. 

Phrase: "Natl."
Processing 00000000.tx.438: Acad. 

Phrase: "Acad."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0268596:ACAD [Disease or Syndrome]
  1000   C2700624:ACAD [Cell Function]
Processing 00000000.tx.439: Sci. 

Phrase: "Sci."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3642273:SCI [Professional or Occupational Group]
Processing 00000000.tx.440: USA 101, 7281-7286.[Abstract/Free FullText] Ishii, S., Iizuka, K., Miller, B. 

Phrase: "USA 101,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0041703:USA [Geographic Area]

Phrase: "7281-7286."

Phrase: "[Abstract/Free FullText"

Phrase: "] Ishii,"

Phrase: "S."

Phrase: ","

Phrase: "Iizuka,"

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Miller,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0402830:Miller [Professional or Occupational Group]

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.441: C. and Uyeda, K. 

Phrase: "C."

Phrase: "and"

Phrase: "Uyeda,"

Phrase: "K."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]
Processing 00000000.tx.442: (2004). 

Phrase: "(ChREBP) reduces lipogenesis as well as glycolysis. Proc. Natl. Acad. Sci. USA 101, 7281-7286.[Abstract/Free FullText] Ishii, S., Iizuka, K., Miller, B. C. and Uyeda, K. (2004"

Phrase: ") reduces lipogenesis as well as glycolysis. Proc. Natl. Acad. Sci. USA 101, 7281-7286.[Abstract/Free FullText] Ishii, S., Iizuka, K., Miller, B. C. and Uyeda, K. (2004)."
Processing 00000000.tx.443: Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription. 

Phrase: "Carbohydrate response element binding protein directly"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   947   C1826259:carbohydrate response element binding protein [Gene or Genome]
   901   C3158709:carbohydrate response element binding [Genetic Function]
   885   C0108401:carbohydrate-binding protein [Amino Acid, Peptide, or Protein,Receptor]
   858   C1148582:carbohydrate binding [Molecular Function]
   827   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0243122:binding [Functional Concept]
   799   C1145667:Binding [Activity]
   799   C1167622:Binding [Molecular Function]

Phrase: "promotes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033414:Promote [Activity]

Phrase: "lipogenic enzyme gene transcription."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0040649:Gene Transcription [Genetic Function]
           Transcription
Processing 00000000.tx.444: Proc. 

Phrase: "Proc."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1418943:PROC [Gene or Genome]
Processing 00000000.tx.445: Natl. 

Phrase: "Natl."
Processing 00000000.tx.446: Acad. 

Phrase: "Acad."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0268596:ACAD [Disease or Syndrome]
  1000   C2700624:ACAD [Cell Function]
Processing 00000000.tx.447: Sci. 

Phrase: "Sci."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3642273:SCI [Professional or Occupational Group]
Processing 00000000.tx.448: USA 101, 15597-15602.[Abstract/Free FullText] Joseph, J. 

Phrase: "USA 101,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0041703:USA [Geographic Area]

Phrase: "15597-15602."

Phrase: "[Abstract/Free FullText"

Phrase: "] Joseph,"

Phrase: "J."
Processing 00000000.tx.449: W., Koshkin, V., Zhang, C. 

Phrase: "W., Koshkin,"

Phrase: "V.,"

Phrase: "Zhang,"

Phrase: "C."
Processing 00000000.tx.450: Y., Wang, J., Lowell, B. 

Phrase: "Y.,"

Phrase: "Wang,"

Phrase: "J.,"

Phrase: "Lowell,"

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.451: B., Chan, C. 

Phrase: "B.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "Chan,"

Phrase: "C."
Processing 00000000.tx.452: B. and Wheeler, M. 

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "and"

Phrase: "Wheeler,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.453: B. 

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.454: (2002). 

Phrase: "(2004). Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription. Proc. Natl. Acad. Sci. USA 101, 15597-15602.[Abstract/Free FullText] Joseph, J. W., Koshkin, V., Zhang, C. Y., Wang, J., Lowell, B. B., Chan, C. B. and Wheeler, M. B. (2002"

Phrase: "). Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription. Proc. Natl. Acad. Sci. USA 101, 15597-15602.[Abstract/Free FullText] Joseph, J. W., Koshkin, V., Zhang, C. Y., Wang, J., Lowell, B. B., Chan, C. B. and Wheeler, M. B. (2002)."
Processing 00000000.tx.455: Uncoupling protein 2 knockout mice have enhanced insulin secretory capacity after a high-fat diet. 

Phrase: "Uncoupling protein 2 knockout mice"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   840   C0206745:Knock-out Mice [Mammal]
   804   C0025914:Mice [Mammal]
   804   C0025929:mice [Mammal]
   804   C0026809:Mice [Mammal]
   717   C0536847:uncoupling protein-2 [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   717   C1421314:UNCOUPLING PROTEIN 2 [Gene or Genome]

Phrase: "have"

Phrase: "enhanced insulin secretory capacity after a high-fat diet."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C1516240:Capacity [Quantitative Concept]
Processing 00000000.tx.456: Diabetes 51, 3211-3219.[Abstract/Free FullText] Joseph, J. 

Phrase: "Diabetes 51,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: "3211-3219."

Phrase: "[Abstract/Free FullText"

Phrase: "] Joseph,"

Phrase: "J."
Processing 00000000.tx.457: W., Koshkin, V., Saleh, M. 

Phrase: "W., Koshkin,"

Phrase: "V.,"

Phrase: "Saleh,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.458: C., Sivitz, W. 

Phrase: "C., Sivitz,"

Phrase: "W."
Processing 00000000.tx.459: I., Zhang, C. 

Phrase: "I.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Zhang,"

Phrase: "C."
Processing 00000000.tx.460: Y., Lowell, B. 

Phrase: "Y.,"

Phrase: "Lowell,"

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.461: B., Chan, C. 

Phrase: "B.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "Chan,"

Phrase: "C."
Processing 00000000.tx.462: B. and Wheeler, M. 

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "and"

Phrase: "Wheeler,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.463: B. 

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.464: (2004). 

Phrase: "(2002). Uncoupling protein 2 knockout mice have enhanced insulin secretory capacity after a high-fat diet. Diabetes 51, 3211-3219.[Abstract/Free FullText] Joseph, J. W., Koshkin, V., Saleh, M. C., Sivitz, W. I., Zhang, C. Y., Lowell, B. B., Chan, C. B. and Wheeler, M. B. (2004"

Phrase: "). Uncoupling protein 2 knockout mice have enhanced insulin secretory capacity after a high-fat diet. Diabetes 51, 3211-3219.[Abstract/Free FullText] Joseph, J. W., Koshkin, V., Saleh, M. C., Sivitz, W. I., Zhang, C. Y., Lowell, B. B., Chan, C. B. and Wheeler, M. B. (2004)."
Processing 00000000.tx.465: Free fatty acid-induced beta-cell defects are dependent on uncoupling protein 2 expression. 

Phrase: "Free fatty acid-induced beta-cell defects"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   795   C0243067:defects [Functional Concept]
   762 E C1457869:Defect [Functional Concept]
   762 E C1861101:DEFECT [Disease or Syndrome]
   710   C1183428:Free cell [Cell]

Phrase: "are"

Phrase: "dependent on uncoupling protein 2 expression."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0851827:Dependent [Qualitative Concept]
   753   C1701901:Dependent [Qualitative Concept]
   753   C3244310:dependent [Functional Concept]
Processing 00000000.tx.466: J. 

Phrase: "J."
Processing 00000000.tx.467: Biol. 

Phrase: "Biol."
Processing 00000000.tx.468: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.469: 279, 51049-51056.[Abstract/Free FullText] Kakuma, T., Lee, Y., Higa, M., Wang, Z., Pan, W., Shimomura, I. and Unger, R. 

Phrase: "279,"

Phrase: "51049-51056."

Phrase: "[Abstract/Free FullText"

Phrase: "] Kakuma,"

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Lee,"

Phrase: "Y.,"

Phrase: "Higa,"

Phrase: "M."

Phrase: ","

Phrase: "Wang,"

Phrase: "Z.,"

Phrase: "Pan,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0085999:Pan [Mammal]

Phrase: "W.,"

Phrase: "Shimomura,"

Phrase: "I."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "and"

Phrase: "Unger,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.470: H. 

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.471: (2000). 

Phrase: "(2004). Free fatty acid-induced beta-cell defects are dependent on uncoupling protein 2 expression. J. Biol. Chem. 279, 51049-51056.[Abstract/Free FullText] Kakuma, T., Lee, Y., Higa, M., Wang, Z., Pan, W., Shimomura, I. and Unger, R. H. (2000"

Phrase: "). Free fatty acid-induced beta-cell defects are dependent on uncoupling protein 2 expression. J. Biol. Chem. 279, 51049-51056.[Abstract/Free FullText] Kakuma, T., Lee, Y., Higa, M., Wang, Z., Pan, W., Shimomura, I. and Unger, R. H. (2000)."
Processing 00000000.tx.472: Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. 

Phrase: "Leptin,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0299583:Leptin [Amino Acid, Peptide, or Protein,Hormone]
  1000   C1416825:LEPTIN [Gene or Genome]

Phrase: "troglitazone,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0245514:troglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "the expression of sterol regulatory element binding proteins"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   750   C1171362:expression protein [Genetic Function]
   744   C0185117:Expression [Therapeutic or Preventive Procedure]
   703   C1566548:Sterol Regulatory Element Binding Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "in liver"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0023884:Liver [Body Part, Organ, or Organ Component]
  1000   C0736268:LIVER [Body Part, Organ, or Organ Component]
  1000   C1278929:Liver [Body Part, Organ, or Organ Component]
  1000   C2346688:LIVER [Food]
   944 E C0205054:Hepatic [Body Location or Region]

Phrase: "and"

Phrase: "pancreatic islets."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0022131:Pancreatic Islets [Body Part, Organ, or Organ Component]
   861   C0030274:Pancreatic [Body Part, Organ, or Organ Component]
Processing 00000000.tx.473: Proc. 

Phrase: "Proc."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1418943:PROC [Gene or Genome]
Processing 00000000.tx.474: Natl. 

Phrase: "Natl."
Processing 00000000.tx.475: Acad. 

Phrase: "Acad."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0268596:ACAD [Disease or Syndrome]
  1000   C2700624:ACAD [Cell Function]
Processing 00000000.tx.476: Sci. 

Phrase: "Sci."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3642273:SCI [Professional or Occupational Group]
Processing 00000000.tx.477: USA 97, 8536-8541.[Abstract/Free FullText] Kharroubi, I., Ladriere, L., Cardozo, A. 

Phrase: "USA 97,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0041703:USA [Geographic Area]
   861   C0439073:97 [Intellectual Product]
   861   C0439082:>97 [Quantitative Concept]

Phrase: "8536-8541."

Phrase: "[Abstract/Free FullText"

Phrase: "] Kharroubi,"

Phrase: "I.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Ladriere,"

Phrase: "L.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]

Phrase: "Cardozo,"

Phrase: "A."
Processing 00000000.tx.478: K., Dogusan, Z., Cnop, M. and Eizirik, D. 

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Dogusan,"

Phrase: "Z.,"

Phrase: "Cnop,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0280276:CNOP [Therapeutic or Preventive Procedure]

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]

Phrase: "and"

Phrase: "Eizirik,"

Phrase: "D."
Processing 00000000.tx.479: L. 

Phrase: "L."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]
Processing 00000000.tx.480: (2004). 

Phrase: "(2000). Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. Proc. Natl. Acad. Sci. USA 97, 8536-8541.[Abstract/Free FullText] Kharroubi, I., Ladriere, L., Cardozo, A. K., Dogusan, Z., Cnop, M. and Eizirik, D. L. (2004"

Phrase: "). Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. Proc. Natl. Acad. Sci. USA 97, 8536-8541.[Abstract/Free FullText] Kharroubi, I., Ladriere, L., Cardozo, A. K., Dogusan, Z., Cnop, M. and Eizirik, D. L. (2004)."
Processing 00000000.tx.481: Free fatty acids and cytokines induce pancreatic beta-cell apoptosis by different mechanisms: role of nuclear factor-kappaB and endoplasmic reticulum stress. 

Phrase: "Free fatty acids"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C0015688:Free Fatty Acids [Lipid]
   966 E C2698488:Free Fatty Acid [Laboratory Procedure]
   901   C0015684:Fatty Acids [Lipid]
   827   C0001128:Acids [Chemical]
   827   C0332296:free [Functional Concept]
   827   C1880497:Free [Qualitative Concept]
   827   C1996904:Free [Qualitative Concept]
   793 E C0202406:Acid [Laboratory Procedure]

Phrase: "and"

Phrase: "cytokines"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0079189:Cytokines [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C1524094:Cytokines [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "induce"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induce [Functional Concept]

Phrase: "pancreatic beta-cell apoptosis by different mechanisms"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   853   C3157088:pancreatic beta cell apoptosis [Cell Function]
   748   C0162638:Apoptosis [Cell Function]

Phrase: ":"

Phrase: "role of nuclear factor-kappaB"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0035820:Role [Social Behavior]
   760   C1705810:Role [Conceptual Entity]

Phrase: "and"

Phrase: "endoplasmic reticulum stress."
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C3178870:Endoplasmic Reticulum Stress [Cell or Molecular Dysfunction]
   901   C0014239:Endoplasmic Reticulum [Cell Component]
   827   C0035295:Reticulum [Body Part, Organ, or Organ Component]
   827   C0038435:Stress [Finding]
   755 E C0231297:Stressful [Functional Concept]
   755   C0598268:Endoplasm [Cell Component]
Processing 00000000.tx.482: Endocrinology 145, 5087-5096.[Abstract/Free FullText] Kim, J. 

Phrase: "Endocrinology 145,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0014137:Endocrinology [Biomedical Occupation or Discipline]
   789 E C0694557:endocrinologic [Functional Concept]

Phrase: "5087-5096."

Phrase: "[Abstract/Free FullText"

Phrase: "] Kim,"

Phrase: "J."
Processing 00000000.tx.483: B. and Spiegelman, B. 

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "and"

Phrase: "Spiegelman,"

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.484: M. 

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.485: (1996). 

Phrase: "(2004). Free fatty acids and cytokines induce pancreatic beta-cell apoptosis by different mechanisms: role of nuclear factor-kappaB and endoplasmic reticulum stress. Endocrinology 145, 5087-5096.[Abstract/Free FullText] Kim, J. B. and Spiegelman, B. M. (1996"

Phrase: "). Free fatty acids and cytokines induce pancreatic beta-cell apoptosis by different mechanisms: role of nuclear factor-kappaB and endoplasmic reticulum stress. Endocrinology 145, 5087-5096.[Abstract/Free FullText] Kim, J. B. and Spiegelman, B. M. (1996)."
Processing 00000000.tx.486: ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. 

Phrase: "ADD1/SREBP1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0217529:SREBP-1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C1420398:SREBP1 [Gene or Genome]
   861   C3538602:SREBP1 [Gene or Genome]

Phrase: "promotes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033414:Promote [Activity]

Phrase: "adipocyte differentiation"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C1159884:adipocyte differentiation [Cell Function]
   861   C0007589:Differentiation [Cell Function]
   861   C1511938:Differentiation [Clinical Attribute]
   861   C2945687:Differentiation [Functional Concept]
   789 E C0205615:Differentiated [Qualitative Concept]

Phrase: "and"

Phrase: "gene expression"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0017262:Gene Expression [Genetic Function]
   861   C0017337:Gene [Gene or Genome]
   861   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "linked to fatty acid metabolism."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   862   C0596563:Fatty Acid Metabolism [Molecular Function]
   806   C0015684:Fatty acid [Lipid]
   760   C0001128:Acid [Chemical]
   760   C0025519:Metabolism [Organism Function]
   760   C0025520:metabolism [Functional Concept]
   760   C0202406:Acid [Laboratory Procedure]
   726   C1517892:Link [Intellectual Product]
   726   C1704666:Link [Intellectual Product]
Processing 00000000.tx.487: Genes Dev. 

Phrase: "Genes Dev."
Processing 00000000.tx.488: 10, 1096-1107.[Abstract] Kubota, N., Terauchi, Y., Tobe, K., Yano, W., Suzuki, R., Ueki, K., Takamoto, I., Satoh, H., Maki, T., Kubota, T. et al. 

Phrase: "10,"

Phrase: "1096-1107."

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Kubota,"

Phrase: "N.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]

Phrase: "Terauchi,"

Phrase: "Y.,"

Phrase: "Tobe,"

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Yano,"

Phrase: "W.,"

Phrase: "Suzuki,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0998924:suzuki [Fish]

Phrase: "R.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]

Phrase: "Ueki,"

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Takamoto,"

Phrase: "I.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Satoh,"

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Maki,"

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Kubota,"

Phrase: "T. et al."
Processing 00000000.tx.489: (2004). 

Phrase: "(1996). ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev. 10, 1096-1107.[Abstract] Kubota, N., Terauchi, Y., Tobe, K., Yano, W., Suzuki, R., Ueki, K., Takamoto, I., Satoh, H., Maki, T., Kubota, T. et al. (2004"

Phrase: "). ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev. 10, 1096-1107.[Abstract] Kubota, N., Terauchi, Y., Tobe, K., Yano, W., Suzuki, R., Ueki, K., Takamoto, I., Satoh, H., Maki, T., Kubota, T. et al. (2004)."
Processing 00000000.tx.490: Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus. 

Phrase: "Insulin receptor substrate 2"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
  1000   C0381451:Insulin Receptor Substrate-2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
  1000   C1334141:INSULIN RECEPTOR SUBSTRATE 2 [Gene or Genome]
  1000   C1334191:Insulin Receptor Substrate 2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C0034818:Insulin Receptor [Amino Acid, Peptide, or Protein,Enzyme,Receptor]
   861   C1334133:INSULIN RECEPTOR [Gene or Genome]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   812   C1710236:Substrate [Manufactured Object]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "plays"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032214:Play [Daily or Recreational Activity]
  1000   C0600138:Plays [Finding]

Phrase: "a crucial role in beta cells"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0035820:Role [Social Behavior]
   753   C1705810:Role [Conceptual Entity]

Phrase: "and"

Phrase: "the hypothalamus."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0020663:Hypothalamus [Body Part, Organ, or Organ Component]
  1000   C1280712:Hypothalamus [Body Part, Organ, or Organ Component]
Processing 00000000.tx.491: J. 

Phrase: "J."
Processing 00000000.tx.492: Clin. 

Phrase: "Clin."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1315013:CLIN [Intellectual Product]
Processing 00000000.tx.493: Invest. 

Phrase: "Invest."
Processing 00000000.tx.494: 114, 917-927.[Abstract/Free FullText] Lameloise, N., Muzzin, P., Prentki, M. and Assimacopoulos-Jeannet, F. 

Phrase: "114,"

Phrase: "917-927."

Phrase: "[Abstract/Free FullText"

Phrase: "] Lameloise,"

Phrase: "N.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]

Phrase: "Muzzin,"

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Prentki,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]

Phrase: "and"

Phrase: "Assimacopoulos-Jeannet,"

Phrase: "F."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]
Processing 00000000.tx.495: (2001). 

Phrase: "(2004). Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus. J. Clin. Invest. 114, 917-927.[Abstract/Free FullText] Lameloise, N., Muzzin, P., Prentki, M. and Assimacopoulos-Jeannet, F. (2001"

Phrase: "). Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus. J. Clin. Invest. 114, 917-927.[Abstract/Free FullText] Lameloise, N., Muzzin, P., Prentki, M. and Assimacopoulos-Jeannet, F. (2001)."
Processing 00000000.tx.496: Uncoupling protein 2, a possible link between fatty acid excess and impaired glucose-induced insulin secretion? 

Phrase: "Uncoupling protein 2,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0536847:uncoupling protein-2 [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
  1000   C1421314:UNCOUPLING PROTEIN 2 [Gene or Genome]
   827   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "a possible link between fatty acid excess"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C1517892:Link [Intellectual Product]
   748   C1704666:Link [Intellectual Product]

Phrase: "and"

Phrase: "impaired glucose-induced insulin secretion?"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   853   C1719133:Glucose/Insulin [Quantitative Concept]
   840   C1256369:insulin secretion [Cell Function]
   804   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   804   C0036536:secretion [Biologic Function]
   804   C0036537:Secretion [Body Substance]
   804   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   804   C1579433:Insulin [Pharmacologic Substance]
   748 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   721 E C3537244:Insulins [Pharmacologic Substance]
Processing 00000000.tx.497: Diabetes 50, 803-809.[Abstract/Free FullText] Laudes, M., Barroso, I., Luan, J., Soos, M. 

Phrase: "Diabetes 50,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: "803-809."

Phrase: "[Abstract/Free FullText"

Phrase: "] Laudes,"

Phrase: "M."

Phrase: ","

Phrase: "Barroso,"

Phrase: "I.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Luan,"

Phrase: "J.,"

Phrase: "Soos,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.498: A., Yeo, G., Meirhaeghe, A., Logie, L., Vidal-Puig, A., Schafer, A. 

Phrase: "A.,"

Phrase: "Yeo,"

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "Meirhaeghe,"

Phrase: "A.,"

Phrase: "Logie,"

Phrase: "L.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]

Phrase: "Vidal-Puig,"

Phrase: "A.,"

Phrase: "Schafer,"

Phrase: "A."
Processing 00000000.tx.499: J., Wareham, N. 

Phrase: "J.,"

Phrase: "Wareham,"

Phrase: "N."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]
Processing 00000000.tx.500: J. et al. 

Phrase: "J. et al."
Processing 00000000.tx.501: (2004). 

Phrase: "(2001). Uncoupling protein 2, a possible link between fatty acid excess and impaired glucose-induced insulin secretion? Diabetes 50, 803-809.[Abstract/Free FullText] Laudes, M., Barroso, I., Luan, J., Soos, M. A., Yeo, G., Meirhaeghe, A., Logie, L., Vidal-Puig, A., Schafer, A. J., Wareham, N. J. et al. (2004"

Phrase: "). Uncoupling protein 2, a possible link between fatty acid excess and impaired glucose-induced insulin secretion? Diabetes 50, 803-809.[Abstract/Free FullText] Laudes, M., Barroso, I., Luan, J., Soos, M. A., Yeo, G., Meirhaeghe, A., Logie, L., Vidal-Puig, A., Schafer, A. J., Wareham, N. J. et al. (2004)."
Processing 00000000.tx.502: Genetic variants in human sterol regulatory element binding protein-1c in syndromes of severe insulin resistance and type 2 diabetes. 

Phrase: "Genetic variants in human sterol regulatory element binding protein-1c"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   739   C0205419:variants [Qualitative Concept]

Phrase: "in syndromes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0039082:Syndromes [Disease or Syndrome]
  1000   C1558916:SYNDROMES [Finding]

Phrase: "of severe insulin resistance"
Meta Candidates (Total=12; Excluded=5; Pruned=0; Remaining=7)
   901   C0021655:Insulin Resistance [Pathologic Function]
   901   C2700570:INSULIN RESISTANCE [Gene or Genome]
   827   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C0237834:Resistance [Mental Process]
   827   C1514892:Resistance [Physiologic Function]
   827   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C1579433:Insulin [Pharmacologic Substance]
   771 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   755 E C0332325:Resistant [Functional Concept]
   755 E C1550464:resistent [Idea or Concept]
   755 E C2827757:RESISTANT [Laboratory or Test Result]
   743 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "type 2 diabetes."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]
Processing 00000000.tx.503: Diabetes 53, 842-846.[Abstract/Free FullText] Lin, H. 

Phrase: "Diabetes 53,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: "842-846."

Phrase: "[Abstract/Free FullText"

Phrase: "] Lin,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0861352:LIN [Neoplastic Process]

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.504: Z., Yang, S. 

Phrase: "Z.,"

Phrase: "Yang,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2945617:yang [Idea or Concept]

Phrase: "S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]
Processing 00000000.tx.505: Q., Chuckaree, C., Kuhajda, F., Ronnet, G. and Diehl, A. 

Phrase: "Q., Chuckaree,"

Phrase: "C.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "Kuhajda,"

Phrase: "F.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "Ronnet,"

Phrase: "G."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "and"

Phrase: "Diehl,"

Phrase: "A."
Processing 00000000.tx.506: M. 

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.507: (2000). 

Phrase: "(2004). Genetic variants in human sterol regulatory element binding protein-1c in syndromes of severe insulin resistance and type 2 diabetes. Diabetes 53, 842-846.[Abstract/Free FullText] Lin, H. Z., Yang, S. Q., Chuckaree, C., Kuhajda, F., Ronnet, G. and Diehl, A. M. (2000"

Phrase: "). Genetic variants in human sterol regulatory element binding protein-1c in syndromes of severe insulin resistance and type 2 diabetes. Diabetes 53, 842-846.[Abstract/Free FullText] Lin, H. Z., Yang, S. Q., Chuckaree, C., Kuhajda, F., Ronnet, G. and Diehl, A. M. (2000)."
Processing 00000000.tx.508: Metformin reverses fatty liver disease in obese, leptin-deficient mice. 

Phrase: "Metformin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025598:Metformin [Organic Chemical,Pharmacologic Substance]

Phrase: "reverses"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1555029:Reverse [Idea or Concept]

Phrase: "fatty liver disease in obese, leptin-deficient mice."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0023895:Liver disease [Disease or Syndrome]
   744   C0012634:Disease [Disease or Syndrome]
Processing 00000000.tx.509: Nat. 

Phrase: "Nat."
Processing 00000000.tx.510: Med. 

Phrase: "Med."
Processing 00000000.tx.511: 6, 998-1003.[CrossRef][Medline] Lin, X., Taguchi, A., Park, S., Kushner, J. 

Phrase: "6,"

Phrase: "998-1003."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Lin,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0861352:LIN [Neoplastic Process]

Phrase: "X.,"

Phrase: "Taguchi,"

Phrase: "A.,"

Phrase: "Park,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0562547:Park [Manufactured Object]
  1000   C3160718:PARK [Disease or Syndrome]

Phrase: "S."

Phrase: ","

Phrase: "Kushner,"

Phrase: "J."
Processing 00000000.tx.512: A., Li, F., Li, Y. and White, M. 

Phrase: "A.,"

Phrase: "Li,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3495095:Li+ [Element, Ion, or Isotope]

Phrase: "F.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "Li,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3495095:Li+ [Element, Ion, or Isotope]

Phrase: "Y."

Phrase: "and"

Phrase: "White,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0007457:White [Population Group]
  1000   C0043157:White [Population Group]
  1000   C0220938:White [Qualitative Concept]

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.513: F. 

Phrase: "F."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]
Processing 00000000.tx.514: (2004). 

Phrase: "(2000). Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat. Med. 6, 998-1003.[CrossRef][Medline] Lin, X., Taguchi, A., Park, S., Kushner, J. A., Li, F., Li, Y. and White, M. F. (2004"

Phrase: "). Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat. Med. 6, 998-1003.[CrossRef][Medline] Lin, X., Taguchi, A., Park, S., Kushner, J. A., Li, F., Li, Y. and White, M. F. (2004)."
Processing 00000000.tx.515: Dysregulation of insulin receptor substrate 2 in beta cells and brain causes obesity and diabetes. 

Phrase: "Dysregulation of insulin receptor substrate 2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   716   C0381451:Insulin Receptor Substrate-2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   716   C1334141:INSULIN RECEPTOR SUBSTRATE 2 [Gene or Genome]
   716   C1334191:Insulin Receptor Substrate 2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "in beta cells"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   966   C0030281:Beta cell [Cell]
   861   C0007634:Cells [Cell]
   861   C0330390:Beta [Plant]
   861   C0439096:Beta [Intellectual Product]
   861   C2004068:Beta [Qualitative Concept]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "and"

Phrase: "brain"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0006104:Brain [Body Part, Organ, or Organ Component]
  1000   C1269537:Brain [Body Part, Organ, or Organ Component]

Phrase: "causes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0015127:cause [Functional Concept]
  1000   C1314792:Causes [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]

Phrase: "obesity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0028754:Obesity [Disease or Syndrome]
  1000   C1963185:Obesity [Finding]

Phrase: "and"

Phrase: "diabetes."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011847:Diabetes [Disease or Syndrome]
  1000   C0011849:Diabetes [Disease or Syndrome]
Processing 00000000.tx.516: J. 

Phrase: "J."
Processing 00000000.tx.517: Clin. 

Phrase: "Clin."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1315013:CLIN [Intellectual Product]
Processing 00000000.tx.518: Invest. 

Phrase: "Invest."
Processing 00000000.tx.519: 114, 908-916.[Abstract/Free FullText] Loftus, T. 

Phrase: "114,"

Phrase: "908-916."

Phrase: "[Abstract/Free FullText"

Phrase: "] Loftus,"

Phrase: "T."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]
Processing 00000000.tx.520: M. and Lane, M. 

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]

Phrase: "and"

Phrase: "Lane,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1708639:Lane [Spatial Concept]

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.521: D. 

Phrase: "D."
Processing 00000000.tx.522: (1997). 

Phrase: "(2004). Dysregulation of insulin receptor substrate 2 in beta cells and brain causes obesity and diabetes. J. Clin. Invest. 114, 908-916.[Abstract/Free FullText] Loftus, T. M. and Lane, M. D. (1997"

Phrase: "). Dysregulation of insulin receptor substrate 2 in beta cells and brain causes obesity and diabetes. J. Clin. Invest. 114, 908-916.[Abstract/Free FullText] Loftus, T. M. and Lane, M. D. (1997)."
Processing 00000000.tx.523: Modulating the transcriptional control of adipogenesis. 

Phrase: "Modulating"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443264:Modulating [Spatial Concept]

Phrase: "the transcriptional control of adipogenesis."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   806   C1158770:Transcriptional Control [Genetic Function]
   760   C0243148:control [Qualitative Concept]
   760   C1550141:Control [Substance]
   760   C1882979:Control [Conceptual Entity]
   760   C2587213:Control [Functional Concept]
   760   C3274648:Control [Qualitative Concept]
Processing 00000000.tx.524: Curr. 

Phrase: "Curr."
Processing 00000000.tx.525: Opin. 

Phrase: "Opin."
Processing 00000000.tx.526: Genet. 

Phrase: "Genet."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0325074:Genet [Mammal]
Processing 00000000.tx.527: Dev. 

Phrase: "Dev."
Processing 00000000.tx.528: 7, 603-608.[CrossRef][Medline] Matsuzaka, T., Shimano, H., Yahagi, N., Amemiya-Kudo, M., Okazaki, H., Tamura, Y., Iizuka, Y., Ohashi, K., Tomita, S., Sekiya, M. et al. 

Phrase: "7,"

Phrase: "603-608."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Matsuzaka,"

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Shimano,"

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Yahagi,"

Phrase: "N.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]

Phrase: "Amemiya-Kudo,"

Phrase: "M."

Phrase: ","

Phrase: "Okazaki,"

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Tamura,"

Phrase: "Y.,"

Phrase: "Iizuka,"

Phrase: "Y.,"

Phrase: "Ohashi,"

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Tomita,"

Phrase: "S."

Phrase: ","

Phrase: "Sekiya,"

Phrase: "M. et al."
Processing 00000000.tx.529: (2004). 

Phrase: "(1997). Modulating the transcriptional control of adipogenesis. Curr. Opin. Genet. Dev. 7, 603-608.[CrossRef][Medline] Matsuzaka, T., Shimano, H., Yahagi, N., Amemiya-Kudo, M., Okazaki, H., Tamura, Y., Iizuka, Y., Ohashi, K., Tomita, S., Sekiya, M. et al. (2004"

Phrase: "). Modulating the transcriptional control of adipogenesis. Curr. Opin. Genet. Dev. 7, 603-608.[CrossRef][Medline] Matsuzaka, T., Shimano, H., Yahagi, N., Amemiya-Kudo, M., Okazaki, H., Tamura, Y., Iizuka, Y., Ohashi, K., Tomita, S., Sekiya, M. et al. (2004)."
Processing 00000000.tx.530: Insulin-independent induction of sterol regulatory element-binding protein-1c expression in the livers of streptozotocin-treated mice. 

Phrase: "Insulin-independent induction of sterol regulatory element-binding protein-1c expression"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   738   C0205263:Induction [Functional Concept]
   738   C0857127:induction [Therapeutic or Preventive Procedure]

Phrase: "in the livers"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
  1000   C0023884:Livers [Body Part, Organ, or Organ Component]
   966 E C0736268:LIVER [Body Part, Organ, or Organ Component]
   966 E C1278929:Liver [Body Part, Organ, or Organ Component]
   966 E C2346688:LIVER [Food]
   928 E C0205054:Hepatic [Body Location or Region]

Phrase: "of streptozotocin-treated mice."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0025914:Mice [Mammal]
   827   C0025929:mice [Mammal]
   827   C0026809:Mice [Mammal]
Processing 00000000.tx.531: Diabetes 53, 560-569.[Abstract/Free FullText] Medvedev, A. 

Phrase: "Diabetes 53,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: "560-569."

Phrase: "[Abstract/Free FullText"

Phrase: "] Medvedev,"

Phrase: "A."
Processing 00000000.tx.532: V., Robidoux, J., Bai, X., Cao, W., Floering, L. 

Phrase: "V., Robidoux,"

Phrase: "J.,"

Phrase: "Bai,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0234880:bai [Individual Behavior]

Phrase: "X.,"

Phrase: "Cao,"

Phrase: "W.,"

Phrase: "Floering,"

Phrase: "L."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]
Processing 00000000.tx.533: M., Daniel, K. 

Phrase: "M."

Phrase: ","

Phrase: "Daniel,"

Phrase: "K."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]
Processing 00000000.tx.534: W. and Collins, S. 

Phrase: "W."

Phrase: "and"

Phrase: "Collins,"

Phrase: "S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]
Processing 00000000.tx.535: (2002). 

Phrase: "(2004). Insulin-independent induction of sterol regulatory element-binding protein-1c expression in the livers of streptozotocin-treated mice. Diabetes 53, 560-569.[Abstract/Free FullText] Medvedev, A. V., Robidoux, J., Bai, X., Cao, W., Floering, L. M., Daniel, K. W. and Collins, S. (2002"

Phrase: "). Insulin-independent induction of sterol regulatory element-binding protein-1c expression in the livers of streptozotocin-treated mice. Diabetes 53, 560-569.[Abstract/Free FullText] Medvedev, A. V., Robidoux, J., Bai, X., Cao, W., Floering, L. M., Daniel, K. W. and Collins, S. (2002)."
Processing 00000000.tx.536: Regulation of the uncoupling protein-2 gene in INS-1 beta-cells by oleic acid. 

Phrase: "Regulation of the uncoupling protein-2 gene"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   774   C0017263:Gene Regulation [Genetic Function]
   748   C0851285:Regulation [Governmental or Regulatory Activity]
   748   C1327622:Regulation [Biologic Function]

Phrase: "in"

Phrase: "INS-1 beta-cells"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   867   C0030281:Beta cell [Cell]
   827   C0007634:Cells [Cell]
   827   C0330390:Beta [Plant]
   827   C0439096:Beta [Intellectual Product]
   827   C2004068:Beta [Qualitative Concept]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]

Phrase: "by oleic acid."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0028928:Oleic Acid [Biologically Active Substance,Lipid,Pharmacologic Substance]
  1000   C0028929:Oleic Acid [Lipid]
   861   C0001128:Acid [Chemical]
   861   C0202406:Acid [Laboratory Procedure]
Processing 00000000.tx.537: J. 

Phrase: "J."
Processing 00000000.tx.538: Biol. 

Phrase: "Biol."
Processing 00000000.tx.539: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.540: 277, 42639-42644.[Abstract/Free FullText] Ozcan, U., Cao, Q., Yilmaz, E., Lee, A. 

Phrase: "277,"

Phrase: "42639-42644."

Phrase: "[Abstract/Free FullText"

Phrase: "] Ozcan,"

Phrase: "U.,"

Phrase: "Cao,"

Phrase: "Q.,"

Phrase: "Yilmaz,"

Phrase: "E.,"

Phrase: "Lee,"

Phrase: "A."
Processing 00000000.tx.541: H., Iwakoshi, N. 

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Iwakoshi,"

Phrase: "N."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]
Processing 00000000.tx.542: N., Ozdelen, E., Tuncman, G., Gorgun, C., Glimcher, L. 

Phrase: "N., Ozdelen,"

Phrase: "E.,"

Phrase: "Tuncman,"

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "Gorgun,"

Phrase: "C.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "Glimcher,"

Phrase: "L."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]
Processing 00000000.tx.543: H. and Hotamisligil, G. 

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "and"

Phrase: "Hotamisligil,"

Phrase: "G."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]
Processing 00000000.tx.544: S. 

Phrase: "S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]
Processing 00000000.tx.545: (2004). 

Phrase: "(2002). Regulation of the uncoupling protein-2 gene in INS-1 beta-cells by oleic acid. J. Biol. Chem. 277, 42639-42644.[Abstract/Free FullText] Ozcan, U., Cao, Q., Yilmaz, E., Lee, A. H., Iwakoshi, N. N., Ozdelen, E., Tuncman, G., Gorgun, C., Glimcher, L. H. and Hotamisligil, G. S. (2004"

Phrase: "). Regulation of the uncoupling protein-2 gene in INS-1 beta-cells by oleic acid. J. Biol. Chem. 277, 42639-42644.[Abstract/Free FullText] Ozcan, U., Cao, Q., Yilmaz, E., Lee, A. H., Iwakoshi, N. N., Ozdelen, E., Tuncman, G., Gorgun, C., Glimcher, L. H. and Hotamisligil, G. S. (2004)."
Processing 00000000.tx.546: Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. 

Phrase: "Endoplasmic reticulum stress"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C3178870:Endoplasmic Reticulum Stress [Cell or Molecular Dysfunction]
   901   C0014239:Endoplasmic Reticulum [Cell Component]
   827   C0035295:Reticulum [Body Part, Organ, or Organ Component]
   827   C0038435:Stress [Finding]
   755 E C0231297:Stressful [Functional Concept]
   755   C0598268:Endoplasm [Cell Component]

Phrase: "links"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1517892:Link [Intellectual Product]
  1000   C1704666:Link [Intellectual Product]

Phrase: "obesity,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0028754:Obesity [Disease or Syndrome]
  1000   C1963185:Obesity [Finding]

Phrase: "insulin action,"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0441472:Action [Functional Concept]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   861   C3266814:Action [Activity]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "type 2 diabetes."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]
Processing 00000000.tx.547: Science 306, 457-461.[Abstract/Free FullText] Petersen, K. 

Phrase: "Science 306,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0036397:Science [Occupation or Discipline]

Phrase: "457-461."

Phrase: "[Abstract/Free FullText"

Phrase: "] Petersen,"

Phrase: "K."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]
Processing 00000000.tx.548: F., Oral, E. 

Phrase: "F.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "Oral,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0442027:Oral [Spatial Concept]

Phrase: "E."
Processing 00000000.tx.549: A., Dufour, S., Befroy, D., Ariyan, C., Yu, C., Cline, G. 

Phrase: "A.,"

Phrase: "Dufour,"

Phrase: "S."

Phrase: ","

Phrase: "Befroy,"

Phrase: "D."

Phrase: ","

Phrase: "Ariyan,"

Phrase: "C.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "Yu,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1006780:yu [Plant]

Phrase: "C.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "Cline,"

Phrase: "G."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]
Processing 00000000.tx.550: W., DePaoli, A. 

Phrase: "W., DePaoli,"

Phrase: "A."
Processing 00000000.tx.551: M., Taylor, S. 

Phrase: "M."

Phrase: ","

Phrase: "Taylor,"

Phrase: "S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]
Processing 00000000.tx.552: I., Gorden, P. et al. 

Phrase: "I.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Gorden,"

Phrase: "P. et al."
Processing 00000000.tx.553: (2002). 

Phrase: "(2004). Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306, 457-461.[Abstract/Free FullText] Petersen, K. F., Oral, E. A., Dufour, S., Befroy, D., Ariyan, C., Yu, C., Cline, G. W., DePaoli, A. M., Taylor, S. I., Gorden, P. et al. (2002"

Phrase: "). Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306, 457-461.[Abstract/Free FullText] Petersen, K. F., Oral, E. A., Dufour, S., Befroy, D., Ariyan, C., Yu, C., Cline, G. W., DePaoli, A. M., Taylor, S. I., Gorden, P. et al. (2002)."
Processing 00000000.tx.554: Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. 

Phrase: "Leptin"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0299583:Leptin [Amino Acid, Peptide, or Protein,Hormone]
  1000   C1416825:LEPTIN [Gene or Genome]

Phrase: "reverses"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1555029:Reverse [Idea or Concept]

Phrase: "insulin resistance"
Meta Candidates (Total=12; Excluded=5; Pruned=0; Remaining=7)
  1000   C0021655:Insulin Resistance [Pathologic Function]
  1000   C2700570:INSULIN RESISTANCE [Gene or Genome]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0237834:Resistance [Mental Process]
   861   C1514892:Resistance [Physiologic Function]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332325:Resistant [Functional Concept]
   789 E C1550464:resistent [Idea or Concept]
   789 E C2827757:RESISTANT [Laboratory or Test Result]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "hepatic steatosis in patients"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   833   C0015695:hepatic steatosis [Disease or Syndrome]
   833   C2711227:Hepatic steatosis [Disease or Syndrome]
   770   C0152254:Steatosis [Pathologic Function]
   770   C0205054:Hepatic [Body Location or Region]

Phrase: "with severe lipodystrophy."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0023787:Lipodystrophy [Disease or Syndrome]
Processing 00000000.tx.555: J. 

Phrase: "J."
Processing 00000000.tx.556: Clin. 

Phrase: "Clin."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1315013:CLIN [Intellectual Product]
Processing 00000000.tx.557: Invest. 

Phrase: "Invest."
Processing 00000000.tx.558: 109, 1345-1350.[Abstract/Free FullText] Poitout, V. and Robertson, R. 

Phrase: "109,"

Phrase: "1345-1350."

Phrase: "[Abstract/Free FullText"

Phrase: "] Poitout,"

Phrase: "V."

Phrase: "and"

Phrase: "Robertson,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.559: P. 

Phrase: "P."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]
Processing 00000000.tx.560: (2002). 

Phrase: "(2002). Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J. Clin. Invest. 109, 1345-1350.[Abstract/Free FullText] Poitout, V. and Robertson, R. P. (2002"

Phrase: "). Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J. Clin. Invest. 109, 1345-1350.[Abstract/Free FullText] Poitout, V. and Robertson, R. P. (2002)."
Processing 00000000.tx.561: Minireview: Secondary beta-cell failure in type 2 diabetes - a convergence of glucotoxicity and lipotoxicity. 

Phrase: "Minireview"

Phrase: ":"

Phrase: "Secondary beta-cell failure in type 2 diabetes -"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0231174:Failure [Functional Concept]
   744   C0680095:failure [Individual Behavior]

Phrase: "a convergence of glucotoxicity"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0443193:Convergence [Spatial Concept]
   770   C1446614:Convergence [Finding]
   770   C2700387:Convergence [Activity]

Phrase: "and"

Phrase: "lipotoxicity."
Processing 00000000.tx.562: Endocrinology 143, 339-342.[Abstract/Free FullText] Riddle, T. 

Phrase: "Endocrinology 143,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0014137:Endocrinology [Biomedical Occupation or Discipline]
   789 E C0694557:endocrinologic [Functional Concept]

Phrase: "339-342."

Phrase: "[Abstract/Free FullText"

Phrase: "] Riddle,"

Phrase: "T."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]
Processing 00000000.tx.563: M., Kuhel, D. 

Phrase: "M."

Phrase: ","

Phrase: "Kuhel,"

Phrase: "D."
Processing 00000000.tx.564: G., Woollett, L. 

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "Woollett,"

Phrase: "L."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]
Processing 00000000.tx.565: A., Fichtenbaum, C. 

Phrase: "A.,"

Phrase: "Fichtenbaum,"

Phrase: "C."
Processing 00000000.tx.566: J. and Hui, D. 

Phrase: "J."

Phrase: "and"

Phrase: "Hui,"

Phrase: "D."
Processing 00000000.tx.567: Y. 

Phrase: "Y."
Processing 00000000.tx.568: (2001). 

Phrase: "(2002). Minireview: Secondary beta-cell failure in type 2 diabetes - a convergence of glucotoxicity and lipotoxicity. Endocrinology 143, 339-342.[Abstract/Free FullText] Riddle, T. M., Kuhel, D. G., Woollett, L. A., Fichtenbaum, C. J. and Hui, D. Y. (2001"

Phrase: "). Minireview: Secondary beta-cell failure in type 2 diabetes - a convergence of glucotoxicity and lipotoxicity. Endocrinology 143, 339-342.[Abstract/Free FullText] Riddle, T. M., Kuhel, D. G., Woollett, L. A., Fichtenbaum, C. J. and Hui, D. Y. (2001)."
Processing 00000000.tx.569: HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. 

Phrase: "HIV protease inhibitor"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
  1000   C0162714:HIV Protease Inhibitor [Pharmacologic Substance]
  1000   C3536890:HIV Protease Inhibitor [Pharmacologic Substance]
           Protease Inhibitor
  1000   C3536912:HIV Protease Inhibitor [Pharmacologic Substance]
   901   C0033607:Protease Inhibitor [Biologically Active Substance,Pharmacologic Substance]
   901   C0079522:HIV Protease [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0019682:HIV [Virus]
   827   C0019699:HIV+ [Finding]
   827   C0030946:Protease [Amino Acid, Peptide, or Protein,Enzyme,Pharmacologic Substance]
   827   C1947941:Protease [Enzyme]
   827   C1999216:Inhibitor [Qualitative Concept]

Phrase: "induces"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induce [Functional Concept]

Phrase: "fatty acid"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0015684:Fatty acid [Lipid]
   861   C0001128:Acid [Chemical]
   861   C0202406:Acid [Laboratory Procedure]

Phrase: "and"

Phrase: "sterol biosynthesis in liver"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   833   C1156542:Sterol Biosynthesis [Molecular Function]
   770   C0005572:biosynthesis [Functional Concept]
   770   C0220781:Biosynthesis [Biologic Function]

Phrase: "and"

Phrase: "adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   750   C0001527:Adipose tissues [Tissue]
   735   C0040300:Tissues [Tissue]
   702 E C1547928:Tissue [Intellectual Product]

Phrase: "in the nucleus."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0007610:Nucleus [Cell Component]
Processing 00000000.tx.570: J. 

Phrase: "J."
Processing 00000000.tx.571: Biol. 

Phrase: "Biol."
Processing 00000000.tx.572: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.573: 276, 37514-37519.[Abstract/Free FullText] Rishi, V., Gal, J., Krylov, D., Fridriksson, J., Boysen, M. 

Phrase: "276,"

Phrase: "37514-37519."

Phrase: "[Abstract/Free FullText"

Phrase: "] Rishi,"

Phrase: "V.,"

Phrase: "Gal,"

Phrase: "J.,"

Phrase: "Krylov,"

Phrase: "D."

Phrase: ","

Phrase: "Fridriksson,"

Phrase: "J.,"

Phrase: "Boysen,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.574: S., Mandrup, S. and Vinson, C. 

Phrase: "S."

Phrase: ","

Phrase: "Mandrup,"

Phrase: "S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]

Phrase: "and"

Phrase: "Vinson,"

Phrase: "C."
Processing 00000000.tx.575: (2004). 

Phrase: "(2001). HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J. Biol. Chem. 276, 37514-37519.[Abstract/Free FullText] Rishi, V., Gal, J., Krylov, D., Fridriksson, J., Boysen, M. S., Mandrup, S. and Vinson, C. (2004"

Phrase: "). HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J. Biol. Chem. 276, 37514-37519.[Abstract/Free FullText] Rishi, V., Gal, J., Krylov, D., Fridriksson, J., Boysen, M. S., Mandrup, S. and Vinson, C. (2004)."
Processing 00000000.tx.576: SREBP-1 dimerization specificity maps to both the helix-loop-helix and leucine zipper domains: use of a dominant negative. 

Phrase: "SREBP-1 dimerization specificity"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   793   C0037791:Specificity [Quantitative Concept]
   793   C1511884:Specificity [Quantitative Concept]
   756   C0217529:Sterol Regulatory Element Binding Protein 1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   756   C1420398:STEROL REGULATORY ELEMENT-BINDING PROTEIN 1 [Gene or Genome]
   721 E C0205369:Specific [Qualitative Concept]
   721 E C1552740:specific [Intellectual Product]

Phrase: "maps to both"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0024779:Map [Manufactured Object]
   790   C0026045:MAPs [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   790   C1706473:Map [Conceptual Entity]

Phrase: "the helix-loop-helix"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0282642:helix loop helix [Spatial Concept]

Phrase: "and"

Phrase: "leucine zipper domains"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   901   C0079686:Leucine Zipper [Amino Acid, Peptide, or Protein]
   827   C0023401:Leucine [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
   827   C0453984:Zipper [Manufactured Object]
   793   C1880389:Domain [Functional Concept]
   793   C1883221:Domain [Conceptual Entity]
   793   C3541951:Domain [Intellectual Product]

Phrase: ":"

Phrase: "use of a dominant negative."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   806   C1524063:Use of [Functional Concept]
   760   C0042153:use [Functional Concept]
   760   C0457083:Use [Functional Concept]
   760   C1947944:Use [Intellectual Product]
Processing 00000000.tx.577: J. 

Phrase: "J."
Processing 00000000.tx.578: Biol. 

Phrase: "Biol."
Processing 00000000.tx.579: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.580: 279, 11863-11874.[Abstract/Free FullText] Roche, E., Farfari, S., Witters, L. 

Phrase: "279,"

Phrase: "11863-11874."

Phrase: "[Abstract/Free FullText"

Phrase: "] Roche,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0331965:Roche [Health Care Related Organization]

Phrase: "E.,"

Phrase: "Farfari,"

Phrase: "S."

Phrase: ","

Phrase: "Witters,"

Phrase: "L."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]
Processing 00000000.tx.581: A., Assimacopoulos-Jeannet, F., Thumelin, S., Brun, T., Corkey, B. 

Phrase: "A.,"

Phrase: "Assimacopoulos-Jeannet,"

Phrase: "F.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "Thumelin,"

Phrase: "S."

Phrase: ","

Phrase: "Brun,"

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Corkey,"

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.582: E., Saha, A. 

Phrase: "E.,"

Phrase: "Saha,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0672708:SAHA [Organic Chemical,Pharmacologic Substance]

Phrase: "A."
Processing 00000000.tx.583: K. and Prentki, M. 

Phrase: "K."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "and"

Phrase: "Prentki,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.584: (1998). 

Phrase: "(2004). SREBP-1 dimerization specificity maps to both the helix-loop-helix and leucine zipper domains: use of a dominant negative. J. Biol. Chem. 279, 11863-11874.[Abstract/Free FullText] Roche, E., Farfari, S., Witters, L. A., Assimacopoulos-Jeannet, F., Thumelin, S., Brun, T., Corkey, B. E., Saha, A. K. and Prentki, M. (1998"

Phrase: "). SREBP-1 dimerization specificity maps to both the helix-loop-helix and leucine zipper domains: use of a dominant negative. J. Biol. Chem. 279, 11863-11874.[Abstract/Free FullText] Roche, E., Farfari, S., Witters, L. A., Assimacopoulos-Jeannet, F., Thumelin, S., Brun, T., Corkey, B. E., Saha, A. K. and Prentki, M. (1998)."
Processing 00000000.tx.585: Long-term exposure of beta-INS cells to high glucose concentrations increases anaplerosis, lipogenesis, and lipogenic gene expression. 

Phrase: "Long-term exposure of beta-"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0274281:Exposure, NOS [Injury or Poisoning]
   760   C0332157:Exposure [Clinical Attribute]

Phrase: "INS cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "to high glucose concentrations"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   884   C0427743:Glucose concentration [Laboratory Procedure]
   884   C1287281:Glucose concentration [Laboratory or Test Result]
   827   C0086045:Concentrations [Mental Process]
   793 E C1446561:Concentration [Quantitative Concept]
   743 E C1880165:Concentrated [Biomedical or Dental Material]
   734   C0860803:high glucose [Finding]

Phrase: "increases"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "anaplerosis,"

Phrase: "lipogenesis,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0596843:lipogenesis [Molecular Function]
  1000   C1563744:Lipogenesis [Organism Function]

Phrase: "and"

Phrase: "lipogenic gene expression."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0017262:Gene Expression [Genetic Function]
   827   C0017337:Gene [Gene or Genome]
   827   C0185117:Expression [Therapeutic or Preventive Procedure]
Processing 00000000.tx.586: Diabetes 47, 1086-1094.[Abstract] Roehrich, M. 

Phrase: "Diabetes 47,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: "1086-1094."

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Roehrich,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.587: E., Mooser, V., Lenain, V., Herz, J., Nimpf, J., Azhar, S., Bideau, M., Capponi, A., Nicod, P., Haefliger, J. 

Phrase: "E.,"

Phrase: "Mooser,"

Phrase: "V.,"

Phrase: "Lenain,"

Phrase: "V.,"

Phrase: "Herz,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439482:Herz [Quantitative Concept]

Phrase: "J.,"

Phrase: "Nimpf,"

Phrase: "J.,"

Phrase: "Azhar,"

Phrase: "S."

Phrase: ","

Phrase: "Bideau,"

Phrase: "M."

Phrase: ","

Phrase: "Capponi,"

Phrase: "A.,"

Phrase: "Nicod,"

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Haefliger,"

Phrase: "J."
Processing 00000000.tx.588: A. et al. 

Phrase: "A. et al."
Processing 00000000.tx.589: (2003). 

Phrase: "(1998). Long-term exposure of beta-INS cells to high glucose concentrations increases anaplerosis, lipogenesis, and lipogenic gene expression. Diabetes 47, 1086-1094.[Abstract] Roehrich, M. E., Mooser, V., Lenain, V., Herz, J., Nimpf, J., Azhar, S., Bideau, M., Capponi, A., Nicod, P., Haefliger, J. A. et al. (2003"

Phrase: "). Long-term exposure of beta-INS cells to high glucose concentrations increases anaplerosis, lipogenesis, and lipogenic gene expression. Diabetes 47, 1086-1094.[Abstract] Roehrich, M. E., Mooser, V., Lenain, V., Herz, J., Nimpf, J., Azhar, S., Bideau, M., Capponi, A., Nicod, P., Haefliger, J. A. et al. (2003)."
Processing 00000000.tx.590: Insulin-secreting beta-cell dysfunction induced by human lipoproteins. 

Phrase: "Insulin-secreting beta-cell dysfunction"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   884   C1969875:Beta-cell dysfunction [Finding]
   804   C0031847:dysfunction [Functional Concept]
   804   C0277785:Dysfunction, NOS [Qualitative Concept]
   748 E C0231174:Malfunction [Functional Concept]
   748 E C1881681:MALFUNCTION [Phenomenon or Process]
   722   C0030281:Insulin-secreting cell [Cell]
           Insulin Cell

Phrase: "induced by human lipoproteins."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0023820:Lipoproteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   770   C0086418:Human [Human]
   770   C0205263:Induced [Functional Concept]
Processing 00000000.tx.591: J. 

Phrase: "J."
Processing 00000000.tx.592: Biol. 

Phrase: "Biol."
Processing 00000000.tx.593: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.594: 278, 18368-18375.[Abstract/Free FullText] Rubi, B., Ishihara, H., Hegardt, F. 

Phrase: "278,"

Phrase: "18368-18375."

Phrase: "[Abstract/Free FullText"

Phrase: "] Rubi,"

Phrase: "B.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "Ishihara,"

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Hegardt,"

Phrase: "F."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]
Processing 00000000.tx.595: G., Wollheim, C. 

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "Wollheim,"

Phrase: "C."
Processing 00000000.tx.596: B. and Maechler, P. 

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "and"

Phrase: "Maechler,"

Phrase: "P."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]
Processing 00000000.tx.597: (2001). 

Phrase: "(2003). Insulin-secreting beta-cell dysfunction induced by human lipoproteins. J. Biol. Chem. 278, 18368-18375.[Abstract/Free FullText] Rubi, B., Ishihara, H., Hegardt, F. G., Wollheim, C. B. and Maechler, P. (2001"

Phrase: "). Insulin-secreting beta-cell dysfunction induced by human lipoproteins. J. Biol. Chem. 278, 18368-18375.[Abstract/Free FullText] Rubi, B., Ishihara, H., Hegardt, F. G., Wollheim, C. B. and Maechler, P. (2001)."
Processing 00000000.tx.598: GAD65-mediated glutamate decarboxylation reduces glucose-stimulated insulin secretion in pancreatic beta cells. 

Phrase: "GAD65-mediated glutamate decarboxylation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0011094:Decarboxylation [Natural Phenomenon or Process]

Phrase: "reduces"

Phrase: "glucose-stimulated insulin secretion in pancreatic beta cells."
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   770   C1256369:insulin secretion [Cell Function]
   767   C0030296:Pancreatic Secretion [Body Substance]
   767   C0232787:Pancreatic secretion [Organ or Tissue Function]
   767   C1719133:Glucose/Insulin [Quantitative Concept]
   750   C0030281:Insulin Cell [Cell]
   750   C1327616:Cell secretion [Cell Function]
   744   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C0036536:secretion [Biologic Function]
   744   C0036537:Secretion [Body Substance]
   744   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C1579433:Insulin [Pharmacologic Substance]
Processing 00000000.tx.599: J. 

Phrase: "J."
Processing 00000000.tx.600: Biol. 

Phrase: "Biol."
Processing 00000000.tx.601: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.602: 276, 36391-36396.[Abstract/Free FullText] Schreiber, E., Matthias, P., Muller, M. 

Phrase: "276,"

Phrase: "36391-36396."

Phrase: "[Abstract/Free FullText"

Phrase: "] Schreiber,"

Phrase: "E.,"

Phrase: "Matthias,"

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Muller,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.603: M. and Schaffner, W. 

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]

Phrase: "and"

Phrase: "Schaffner,"

Phrase: "W."
Processing 00000000.tx.604: (1988). 

Phrase: "(2001). GAD65-mediated glutamate decarboxylation reduces glucose-stimulated insulin secretion in pancreatic beta cells. J. Biol. Chem. 276, 36391-36396.[Abstract/Free FullText] Schreiber, E., Matthias, P., Muller, M. M. and Schaffner, W. (1988"

Phrase: "). GAD65-mediated glutamate decarboxylation reduces glucose-stimulated insulin secretion in pancreatic beta cells. J. Biol. Chem. 276, 36391-36396.[Abstract/Free FullText] Schreiber, E., Matthias, P., Muller, M. M. and Schaffner, W. (1988)."
Processing 00000000.tx.605: Identification of a novel lymphoid specific octamer binding protein (OTF-2B) by proteolytic clipping bandshift assay (PCBA). 

Phrase: "Identification of a novel lymphoid specific octamer binding protein"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C0020792:Identification [Mental Process]
   742   C0205396:Identification [Qualitative Concept]

Phrase: "(1988). Identification of a novel lymphoid specific octamer binding protein (OTF-2B"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0450354:2b [Intellectual Product]
   861   C1706096:2B [Research Activity]

Phrase: ")"

Phrase: "by proteolytic clipping bandshift assay (PCBA)."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0005507:Assay [Laboratory Procedure]
   812   C0243073:assay [Qualitative Concept]
   812   C1510438:Assay [Laboratory Procedure]
Processing 00000000.tx.606: EMBO J. 

Phrase: "EMBO J."
Processing 00000000.tx.607: 7, 4221-4229.[Abstract] Shimomura, I., Bashmakov, Y. and Horton, J. 

Phrase: "7,"

Phrase: "4221-4229."

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Shimomura,"

Phrase: "I.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Bashmakov,"

Phrase: "Y."

Phrase: "and"

Phrase: "Horton,"

Phrase: "J."
Processing 00000000.tx.608: D. 

Phrase: "D."
Processing 00000000.tx.609: (1999a). 

Phrase: "(OTF-2B) by proteolytic clipping bandshift assay (PCBA). EMBO J. 7, 4221-4229.[Abstract] Shimomura, I., Bashmakov, Y. and Horton, J. D. (1999a"

Phrase: ") by proteolytic clipping bandshift assay (PCBA). EMBO J. 7, 4221-4229.[Abstract] Shimomura, I., Bashmakov, Y. and Horton, J. D. (1999a)."
Processing 00000000.tx.610: Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. 

Phrase: "Increased levels of nuclear SREBP-1c"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   741   C0428479:Protein level [Laboratory or Test Result]
   739   C0441889:Levels [Qualitative Concept]
   706 E C0456079:Level [Classification]
   706 E C1547707:Level [Geographic Area]
   706 E C2946261:Level [Pharmacologic Substance]

Phrase: "associated with fatty livers"
Meta Candidates (Total=9; Excluded=5; Pruned=0; Remaining=4)
   833   C0015695:fatty livers [Disease or Syndrome]
   833   C0332281:Associated with [Qualitative Concept]
           Associated
   770   C0023884:Livers [Body Part, Organ, or Organ Component]
   737 E C0736268:LIVER [Body Part, Organ, or Organ Component]
   737 E C0750490:Associate [Idea or Concept]
   737 E C1278929:Liver [Body Part, Organ, or Organ Component]
   737 E C1706221:Associate [Professional or Occupational Group]
   737 E C2346688:LIVER [Food]

Phrase: "in two mouse"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0025914:Mouse [Mammal]
   861   C0025929:mouse [Mammal]
   861   C0026809:Mouse [Mammal]

Phrase: "models of diabetes mellitus."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   833   C0011849:Diabetes Mellitus [Disease or Syndrome]
           Diabetes
   770   C0011847:Diabetes [Disease or Syndrome]
   770   C3161035:Model [Intellectual Product]
Processing 00000000.tx.611: J. 

Phrase: "J."
Processing 00000000.tx.612: Biol. 

Phrase: "Biol."
Processing 00000000.tx.613: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.614: 274, 30028-30032.[Abstract/Free FullText] Shimomura, I., Bashmakov, Y., Ikemoto, S., Horton, J. 

Phrase: "274,"

Phrase: "30028-30032."

Phrase: "[Abstract/Free FullText"

Phrase: "] Shimomura,"

Phrase: "I.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Bashmakov,"

Phrase: "Y.,"

Phrase: "Ikemoto,"

Phrase: "S."

Phrase: ","

Phrase: "Horton,"

Phrase: "J."
Processing 00000000.tx.615: D., Brown, M. 

Phrase: "D."

Phrase: ","

Phrase: "Brown,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0678579:Brown [Natural Phenomenon or Process]

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.616: S. and Goldstein, J. 

Phrase: "S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]

Phrase: "and"

Phrase: "Goldstein,"

Phrase: "J."
Processing 00000000.tx.617: L. 

Phrase: "L."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]
Processing 00000000.tx.618: (1999b). 

Phrase: "(1999a). Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J. Biol. Chem. 274, 30028-30032.[Abstract/Free FullText] Shimomura, I., Bashmakov, Y., Ikemoto, S., Horton, J. D., Brown, M. S. and Goldstein, J. L. (1999b"

Phrase: "). Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J. Biol. Chem. 274, 30028-30032.[Abstract/Free FullText] Shimomura, I., Bashmakov, Y., Ikemoto, S., Horton, J. D., Brown, M. S. and Goldstein, J. L. (1999b)."
Processing 00000000.tx.619: Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. 

Phrase: "Insulin selectively"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "increases"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "SREBP-1c mRNA in the livers of rats"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   751   C1148853:mRNA binding [Genetic Function]
   736   C0035696:mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "with streptozotocin-induced diabetes."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   913   C0038433:Streptozotocin Diabetes [Experimental Model of Disease]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
Processing 00000000.tx.620: Proc. 

Phrase: "Proc."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1418943:PROC [Gene or Genome]
Processing 00000000.tx.621: Natl. 

Phrase: "Natl."
Processing 00000000.tx.622: Acad. 

Phrase: "Acad."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0268596:ACAD [Disease or Syndrome]
  1000   C2700624:ACAD [Cell Function]
Processing 00000000.tx.623: Sci. 

Phrase: "Sci."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3642273:SCI [Professional or Occupational Group]
Processing 00000000.tx.624: USA 96, 13656-13661.[Abstract/Free FullText] Shimomura, I., Hammer, R. 

Phrase: "USA 96,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0041703:USA [Geographic Area]

Phrase: "13656-13661."

Phrase: "[Abstract/Free FullText"

Phrase: "] Shimomura,"

Phrase: "I.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Hammer,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0181107:Hammer [Manufactured Object]

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.625: E., Ikemoto, S., Brown, M. 

Phrase: "E.,"

Phrase: "Ikemoto,"

Phrase: "S."

Phrase: ","

Phrase: "Brown,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0678579:Brown [Natural Phenomenon or Process]

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.626: S. and Goldstein, J. 

Phrase: "S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]

Phrase: "and"

Phrase: "Goldstein,"

Phrase: "J."
Processing 00000000.tx.627: L. 

Phrase: "L."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]
Processing 00000000.tx.628: (1999c). 

Phrase: "(1999b). Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc. Natl. Acad. Sci. USA 96, 13656-13661.[Abstract/Free FullText] Shimomura, I., Hammer, R. E., Ikemoto, S., Brown, M. S. and Goldstein, J. L. (1999c"

Phrase: "). Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc. Natl. Acad. Sci. USA 96, 13656-13661.[Abstract/Free FullText] Shimomura, I., Hammer, R. E., Ikemoto, S., Brown, M. S. and Goldstein, J. L. (1999c)."
Processing 00000000.tx.629: Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. 

Phrase: "Leptin"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0299583:Leptin [Amino Acid, Peptide, or Protein,Hormone]
  1000   C1416825:LEPTIN [Gene or Genome]

Phrase: "reverses"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1555029:Reverse [Idea or Concept]

Phrase: "insulin resistance"
Meta Candidates (Total=12; Excluded=5; Pruned=0; Remaining=7)
  1000   C0021655:Insulin Resistance [Pathologic Function]
  1000   C2700570:INSULIN RESISTANCE [Gene or Genome]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0237834:Resistance [Mental Process]
   861   C1514892:Resistance [Physiologic Function]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332325:Resistant [Functional Concept]
   789 E C1550464:resistent [Idea or Concept]
   789 E C2827757:RESISTANT [Laboratory or Test Result]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "diabetes mellitus in mice"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   833   C0011849:Diabetes Mellitus [Disease or Syndrome]
           Diabetes
   770   C0011847:Diabetes [Disease or Syndrome]

Phrase: "with congenital lipodystrophy."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0221032:Congenital lipodystrophy [Congenital Abnormality,Disease or Syndrome]
   861   C0023787:Lipodystrophy [Disease or Syndrome]
Processing 00000000.tx.630: Nature 401, 73-76.[CrossRef][Medline] Shimomura, I., Matsuda, M., Hammer, R. 

Phrase: "Nature 401,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0349590:Nature [Idea or Concept]
   861   C1262865:Nature [Functional Concept]
   789 E C0205296:Natural [Functional Concept]

Phrase: "73-76."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Shimomura,"

Phrase: "I.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Matsuda,"

Phrase: "M."

Phrase: ","

Phrase: "Hammer,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0181107:Hammer [Manufactured Object]

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.631: E., Bashmakov, Y., Brown, M. 

Phrase: "E.,"

Phrase: "Bashmakov,"

Phrase: "Y.,"

Phrase: "Brown,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0678579:Brown [Natural Phenomenon or Process]

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.632: S. and Goldstein, J. 

Phrase: "S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]

Phrase: "and"

Phrase: "Goldstein,"

Phrase: "J."
Processing 00000000.tx.633: L. 

Phrase: "L."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]
Processing 00000000.tx.634: (2000). 

Phrase: "(1999c). Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401, 73-76.[CrossRef][Medline] Shimomura, I., Matsuda, M., Hammer, R. E., Bashmakov, Y., Brown, M. S. and Goldstein, J. L. (2000"

Phrase: "). Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401, 73-76.[CrossRef][Medline] Shimomura, I., Matsuda, M., Hammer, R. E., Bashmakov, Y., Brown, M. S. and Goldstein, J. L. (2000)."
Processing 00000000.tx.635: Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. 

Phrase: "Decreased IRS-2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   901   C1334191:IRS-2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "and"

Phrase: "increased SREBP-1c"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
   954   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   845   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   845   C2246292:sterol binding [Molecular Function]
   818   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   818   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   795   C0013879:Element [Element, Ion, or Isotope]
   795   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   795   C0038323:Sterol [Steroid]
   795   C0220905:regulatory [Regulation or Law]
   795   C0243122:binding [Functional Concept]
   795   C1145667:Binding [Activity]
   795   C1167622:Binding [Molecular Function]
   795   C1704735:Regulatory [Conceptual Entity]
   795   C1705248:Element [Conceptual Entity]

Phrase: "lead to mixed insulin resistance"
Meta Candidates (Total=17; Excluded=1; Pruned=0; Remaining=16)
   806   C0021655:Insulin Resistance [Pathologic Function]
   806   C2700570:INSULIN RESISTANCE [Gene or Genome]
   765   C0356369:Mixed Insulins [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   762   C0332325:Resistant to [Functional Concept]
   760   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   760   C0205430:Mixed [Functional Concept]
   760   C0237834:Resistance [Mental Process]
   760   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   760   C1514892:Resistance [Physiologic Function]
   760   C1522538:Lead [Functional Concept]
   760   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C1579433:Insulin [Pharmacologic Substance]
   760   C2348269:Lead [Element, Ion, or Isotope]
   760   C3160715:Mixed [Finding]
   760   C3275067:LEAD [Therapeutic or Preventive Procedure]
   704 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]

Phrase: "and"

Phrase: "sensitivity in livers of lipodystrophic"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   760   C0036667:Sensitivity [Quantitative Concept]
   760   C0312418:Sensitivity [Mental Process]
   760   C0427965:Sensitivity [Finding]
   760   C1511883:Sensitivity [Quantitative Concept]
   760   C1522640:Sensitivity [Qualitative Concept]
   760   C2346484:SENSITIVITY [Phenomenon or Process]
   760   C2349185:Sensitivity [Qualitative Concept]

Phrase: "and"

Phrase: "ob/ob mice."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0025914:Mice [Mammal]
   827   C0025929:mice [Mammal]
   827   C0026809:Mice [Mammal]
Processing 00000000.tx.636: Mol. 

Phrase: "Mol."
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
  1000   C0027960:Mole [Neoplastic Process]
  1000   C0324740:Mole [Mammal]
  1000   C0439189:Mole [Quantitative Concept]
  1000   C1456781:mole [Neoplastic Process]
  1000   C1824986:mol [Gene or Genome]
   916 E C0026367:Molar [Body Part, Organ, or Organ Component]
   900 E C0027962:moles [Neoplastic Process]
Processing 00000000.tx.637: Cell 6, 77-86.[CrossRef][Medline] Sun, L., Halaihel, N., Zhang, W., Rogers, T. and Levi, M. 

Phrase: "Cell 6,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0007634:Cell [Cell]
   861   C1269647:Cell [Cell]
   861   C1704653:Cell [Medical Device]
   861   C1948049:Cell [Spatial Concept]

Phrase: "77-86."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Sun,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0038817:Sun [Natural Phenomenon or Process]
  1000   C0376223:Sun [Geographic Area]

Phrase: "L.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]

Phrase: "Halaihel,"

Phrase: "N.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]

Phrase: "Zhang,"

Phrase: "W.,"

Phrase: "Rogers,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C3463939:Roger [Eukaryote]

Phrase: "T."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "and"

Phrase: "Levi,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.638: (2002). 

Phrase: "(2000). Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol. Cell 6, 77-86.[CrossRef][Medline] Sun, L., Halaihel, N., Zhang, W., Rogers, T. and Levi, M. (2002"

Phrase: "). Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol. Cell 6, 77-86.[CrossRef][Medline] Sun, L., Halaihel, N., Zhang, W., Rogers, T. and Levi, M. (2002)."
Processing 00000000.tx.639: Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. 

Phrase: "Role of sterol regulatory element-binding protein 1"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   744   C0035820:Role [Social Behavior]
   744   C1705810:Role [Conceptual Entity]
   743   C0217529:Sterol Regulatory Element Binding Protein 1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   743   C1420398:STEROL REGULATORY ELEMENT-BINDING PROTEIN 1 [Gene or Genome]

Phrase: "in regulation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0851285:Regulation [Governmental or Regulatory Activity]
  1000   C1327622:Regulation [Biologic Function]

Phrase: "of renal lipid metabolism"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   913   C1373180:Renal Metabolism [Organ or Tissue Function]
   901   C0598783:Lipid Metabolism [Molecular Function]
   901   C1517898:Lipid Metabolism [Molecular Function]
   827   C0023779:Lipid [Lipid]
   827   C0025519:Metabolism [Organism Function]
   827   C0025520:metabolism [Functional Concept]

Phrase: "and"

Phrase: "glomerulosclerosis in diabetes mellitus."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0178664:Glomerulosclerosis [Disease or Syndrome]
   770   C1417247:glomerulosclerosis [Gene or Genome]
Processing 00000000.tx.640: J. 

Phrase: "J."
Processing 00000000.tx.641: Biol. 

Phrase: "Biol."
Processing 00000000.tx.642: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.643: 277, 18919-18927.[Abstract/Free FullText] Takahashi, A., Motomura, K., Kato, T., Yoshikawa, T., Nakagawa, Y., Yahagi, N., Sone, H., Suzuki, H., Toyoshima, H., Yamada, N. et al. 

Phrase: "277,"

Phrase: "18919-18927."

Phrase: "[Abstract/Free FullText"

Phrase: "] Takahashi,"

Phrase: "A.,"

Phrase: "Motomura,"

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Kato,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0721226:Kato [Inorganic Chemical,Pharmacologic Substance]
  1000   C1551914:Kato [Language]

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Yoshikawa,"

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Nakagawa,"

Phrase: "Y.,"

Phrase: "Yahagi,"

Phrase: "N.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]

Phrase: "Sone,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1564199:Sone [Pharmacologic Substance,Steroid]
  1000   C1825500:SONE [Gene or Genome]

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Suzuki,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0998924:suzuki [Fish]

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Toyoshima,"

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Yamada,"

Phrase: "N. et al."
Processing 00000000.tx.644: (2005). 

Phrase: "(2002). Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J. Biol. Chem. 277, 18919-18927.[Abstract/Free FullText] Takahashi, A., Motomura, K., Kato, T., Yoshikawa, T., Nakagawa, Y., Yahagi, N., Sone, H., Suzuki, H., Toyoshima, H., Yamada, N. et al. (2005"

Phrase: "). Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J. Biol. Chem. 277, 18919-18927.[Abstract/Free FullText] Takahashi, A., Motomura, K., Kato, T., Yoshikawa, T., Nakagawa, Y., Yahagi, N., Sone, H., Suzuki, H., Toyoshima, H., Yamada, N. et al. (2005)."
Processing 00000000.tx.645: Transgenic mice overexpressing nuclear SREBP-1c in pancreatic {beta}-cells. 

Phrase: "Transgenic mice"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0025936:Mice, Transgenic [Mammal]
   861   C0003069:Transgenic [Animal]
   861   C0025914:Mice [Mammal]
   861   C0025929:mice [Mammal]
   861   C0026809:Mice [Mammal]

Phrase: "overexpressing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1514559:overexpress [Genetic Function]

Phrase: "nuclear SREBP-1c"
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
   954   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   877   C0028589:Nuclear Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   877   C0949374:Nuclear Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   845   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   845   C2246292:sterol binding [Molecular Function]
   818   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   818   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   795   C0013879:Element [Element, Ion, or Isotope]
   795   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   795   C0038323:Sterol [Steroid]
   795   C0220905:regulatory [Regulation or Law]
   795   C0243122:binding [Functional Concept]
   795   C1145667:Binding [Activity]
   795   C1167622:Binding [Molecular Function]
   795   C1704735:Regulatory [Conceptual Entity]
   795   C1705248:Element [Conceptual Entity]

Phrase: "in pancreatic {beta}-cells."
Meta Candidates (Total=11; Excluded=3; Pruned=0; Remaining=8)
  1000   C0030281:Pancreatic beta Cells [Cell]
           Beta cell
   827   C0007634:Cells [Cell]
   827   C0030274:Pancreatic [Body Part, Organ, or Organ Component]
   827   C0330390:Beta [Plant]
   827   C0439096:Beta [Intellectual Product]
   827   C2004068:Beta [Qualitative Concept]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.646: Diabetes 54, 492-499.[Abstract/Free FullText] Takaishi, K., Duplomb, L., Wang, M. 

Phrase: "Diabetes 54,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: "492-499."

Phrase: "[Abstract/Free FullText"

Phrase: "] Takaishi,"

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Duplomb,"

Phrase: "L.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]

Phrase: "Wang,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.647: Y., Li, J. and Unger, R. 

Phrase: "Y.,"

Phrase: "Li,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3495095:Li+ [Element, Ion, or Isotope]

Phrase: "J."

Phrase: "and"

Phrase: "Unger,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.648: H. 

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.649: (2004). 

Phrase: "(2005). Transgenic mice overexpressing nuclear SREBP-1c in pancreatic {beta}-cells. Diabetes 54, 492-499.[Abstract/Free FullText] Takaishi, K., Duplomb, L., Wang, M. Y., Li, J. and Unger, R. H. (2004"

Phrase: "). Transgenic mice overexpressing nuclear SREBP-1c in pancreatic {beta}-cells. Diabetes 54, 492-499.[Abstract/Free FullText] Takaishi, K., Duplomb, L., Wang, M. Y., Li, J. and Unger, R. H. (2004)."
Processing 00000000.tx.650: Hepatic insig-1 or -2 overexpression reduces lipogenesis in obese Zucker diabetic fatty rats and in fasted/refed normal rats. 

Phrase: "Hepatic insig-1 or -2 overexpression"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   799   C1514559:Overexpression [Genetic Function]

Phrase: "reduces"

Phrase: "lipogenesis in obese Zucker diabetic fatty rats"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0596843:lipogenesis [Molecular Function]
   748   C1563744:Lipogenesis [Organism Function]

Phrase: "and in fasted/refed normal rats."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   753   C0034693:rats [Mammal]
   753   C0034721:Rats [Mammal]
   753   C0205307:Normal [Qualitative Concept]
   753   C0439166:% normal [Quantitative Concept]
   753   C1515981:And [Idea or Concept]
   753   C2347086:% Normal [Quantitative Concept]
   719   C0015663:Fast [Finding]
   719   C0456962:Fast [Qualitative Concept]
Processing 00000000.tx.651: Proc. 

Phrase: "Proc."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1418943:PROC [Gene or Genome]
Processing 00000000.tx.652: Natl. 

Phrase: "Natl."
Processing 00000000.tx.653: Acad. 

Phrase: "Acad."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0268596:ACAD [Disease or Syndrome]
  1000   C2700624:ACAD [Cell Function]
Processing 00000000.tx.654: Sci. 

Phrase: "Sci."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3642273:SCI [Professional or Occupational Group]
Processing 00000000.tx.655: USA 101, 7106-7111.[Abstract/Free FullText] Tobe, K., Suzuki, R., Aoyama, M., Yamauchi, T., Kamon, J., Kubota, N., Terauchi, Y., Matsui, J., Akanuma, Y., Kimura, S. et al. 

Phrase: "USA 101,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0041703:USA [Geographic Area]

Phrase: "7106-7111."

Phrase: "[Abstract/Free FullText"

Phrase: "] Tobe,"

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Suzuki,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0998924:suzuki [Fish]

Phrase: "R.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]

Phrase: "Aoyama,"

Phrase: "M."

Phrase: ","

Phrase: "Yamauchi,"

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Kamon,"

Phrase: "J.,"

Phrase: "Kubota,"

Phrase: "N.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]

Phrase: "Terauchi,"

Phrase: "Y.,"

Phrase: "Matsui,"

Phrase: "J.,"

Phrase: "Akanuma,"

Phrase: "Y.,"

Phrase: "Kimura,"

Phrase: "S. et al."
Processing 00000000.tx.656: (2001). 

Phrase: "(2004). Hepatic insig-1 or -2 overexpression reduces lipogenesis in obese Zucker diabetic fatty rats and in fasted/refed normal rats. Proc. Natl. Acad. Sci. USA 101, 7106-7111.[Abstract/Free FullText] Tobe, K., Suzuki, R., Aoyama, M., Yamauchi, T., Kamon, J., Kubota, N., Terauchi, Y., Matsui, J., Akanuma, Y., Kimura, S. et al. (2001"

Phrase: "). Hepatic insig-1 or -2 overexpression reduces lipogenesis in obese Zucker diabetic fatty rats and in fasted/refed normal rats. Proc. Natl. Acad. Sci. USA 101, 7106-7111.[Abstract/Free FullText] Tobe, K., Suzuki, R., Aoyama, M., Yamauchi, T., Kamon, J., Kubota, N., Terauchi, Y., Matsui, J., Akanuma, Y., Kimura, S. et al. (2001)."
Processing 00000000.tx.657: Increased expression of the sterol regulatory element-binding protein-1 gene in insulin receptor substrate-2(-/-) mouse liver. 

Phrase: "Increased expression of the sterol regulatory element-binding protein-1 gene"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   754   C0017262:Gene Expression [Genetic Function]
   754   C1171362:expression protein [Genetic Function]
   738   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "in insulin receptor substrate-2"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
  1000   C0381451:Insulin Receptor Substrate-2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
  1000   C1334141:INSULIN RECEPTOR SUBSTRATE 2 [Gene or Genome]
  1000   C1334191:Insulin Receptor Substrate 2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C0034818:Insulin Receptor [Amino Acid, Peptide, or Protein,Enzyme,Receptor]
   861   C1334133:INSULIN RECEPTOR [Gene or Genome]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   812   C1710236:Substrate [Manufactured Object]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "(2001). Increased expression of the sterol regulatory element-binding protein-1 gene in insulin receptor substrate-2(-/-"

Phrase: ")"

Phrase: "mouse liver."
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C1517914:Mouse Liver [Tissue]
   861   C0023884:Liver [Body Part, Organ, or Organ Component]
   861   C0736268:LIVER [Body Part, Organ, or Organ Component]
   861   C1278929:Liver [Body Part, Organ, or Organ Component]
   861   C2346688:LIVER [Food]
   805 E C0205054:Hepatic [Body Location or Region]
Processing 00000000.tx.658: J. 

Phrase: "J."
Processing 00000000.tx.659: Biol. 

Phrase: "Biol."
Processing 00000000.tx.660: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.661: 276, 38337-38340.[Abstract/Free FullText] Tontonoz, P., Kim, J. 

Phrase: "276,"

Phrase: "38337-38340."

Phrase: "[Abstract/Free FullText"

Phrase: "] Tontonoz,"

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Kim,"

Phrase: "J."
Processing 00000000.tx.662: B., Graves, R. 

Phrase: "B.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "Graves,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.663: A. and Spiegelman, B. 

Phrase: "A."

Phrase: "and"

Phrase: "Spiegelman,"

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.664: M. 

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.665: (1993). 

Phrase: "(-/-) mouse liver. J. Biol. Chem. 276, 38337-38340.[Abstract/Free FullText] Tontonoz, P., Kim, J. B., Graves, R. A. and Spiegelman, B. M. (1993"

Phrase: ") mouse liver. J. Biol. Chem. 276, 38337-38340.[Abstract/Free FullText] Tontonoz, P., Kim, J. B., Graves, R. A. and Spiegelman, B. M. (1993)."
Processing 00000000.tx.666: ADD1: a novel helix-loop-helix transcription factor associated with adipocyte determination and differentiation. 

Phrase: "ADD1"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1412230:ADD1 [Gene or Genome]

Phrase: ":"

Phrase: "a novel helix-loop-helix transcription factor"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0040648:TRANSCRIPTION FACTOR [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0040649:Transcription [Genetic Function]
   799   C1521761:Factor [Functional Concept]
   799   C2827422:Factor [Conceptual Entity]

Phrase: "associated with adipocyte determination"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   833   C0332281:Associated with [Qualitative Concept]
           Associated
   770   C0206131:Adipocyte [Cell]
   770   C1148554:determination [Laboratory Procedure]
   737 E C0750490:Associate [Idea or Concept]
   737 E C1706221:Associate [Professional or Occupational Group]

Phrase: "and"

Phrase: "differentiation."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0007589:Differentiation [Cell Function]
  1000   C1511938:Differentiation [Clinical Attribute]
  1000   C2945687:Differentiation [Functional Concept]
   928 E C0205615:Differentiated [Qualitative Concept]
Processing 00000000.tx.667: Mol. 

Phrase: "Mol."
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
  1000   C0027960:Mole [Neoplastic Process]
  1000   C0324740:Mole [Mammal]
  1000   C0439189:Mole [Quantitative Concept]
  1000   C1456781:mole [Neoplastic Process]
  1000   C1824986:mol [Gene or Genome]
   916 E C0026367:Molar [Body Part, Organ, or Organ Component]
   900 E C0027962:moles [Neoplastic Process]
Processing 00000000.tx.668: Cell. 

Phrase: "Cell."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0007634:Cell [Cell]
  1000   C1269647:Cell [Cell]
  1000   C1704653:Cell [Medical Device]
  1000   C1948049:Cell [Spatial Concept]
Processing 00000000.tx.669: Biol. 

Phrase: "Biol."
Processing 00000000.tx.670: 13, 4753-4759.[Abstract] Ueki, K., Kondo, T., Tseng, Y. 

Phrase: "13,"

Phrase: "4753-4759."

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Ueki,"

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Kondo,"

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Tseng,"

Phrase: "Y."
Processing 00000000.tx.671: H. and Kahn, C. 

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "and"

Phrase: "Kahn,"

Phrase: "C."
Processing 00000000.tx.672: R. 

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.673: (2004). 

Phrase: "(1993). ADD1: a novel helix-loop-helix transcription factor associated with adipocyte determination and differentiation. Mol. Cell. Biol. 13, 4753-4759.[Abstract] Ueki, K., Kondo, T., Tseng, Y. H. and Kahn, C. R. (2004"

Phrase: "). ADD1: a novel helix-loop-helix transcription factor associated with adipocyte determination and differentiation. Mol. Cell. Biol. 13, 4753-4759.[Abstract] Ueki, K., Kondo, T., Tseng, Y. H. and Kahn, C. R. (2004)."
Processing 00000000.tx.674: Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. 

Phrase: "Central role of suppressors of cytokine signaling proteins"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0035820:Role [Social Behavior]
   744   C1705810:Role [Conceptual Entity]

Phrase: "in hepatic steatosis,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0015695:hepatic steatosis [Disease or Syndrome]
  1000   C2711227:Hepatic steatosis [Disease or Syndrome]
   861   C0152254:Steatosis [Pathologic Function]
   861   C0205054:Hepatic [Body Location or Region]

Phrase: "insulin resistance,"
Meta Candidates (Total=12; Excluded=5; Pruned=0; Remaining=7)
  1000   C0021655:Insulin Resistance [Pathologic Function]
  1000   C2700570:INSULIN RESISTANCE [Gene or Genome]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0237834:Resistance [Mental Process]
   861   C1514892:Resistance [Physiologic Function]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332325:Resistant [Functional Concept]
   789 E C1550464:resistent [Idea or Concept]
   789 E C2827757:RESISTANT [Laboratory or Test Result]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "the metabolic syndrome in the mouse."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0524620:Metabolic syndrome [Disease or Syndrome]
   783   C1857276:THE SYNDROME [Disease or Syndrome]
   753   C0039082:Syndrome [Disease or Syndrome]
   753   C0311400:Metabolic [Functional Concept]
   753   C1524026:Metabolic [Cell Function]
   753   C2707259:Metabolic [Clinical Attribute]
Processing 00000000.tx.675: Proc. 

Phrase: "Proc."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1418943:PROC [Gene or Genome]
Processing 00000000.tx.676: Natl. 

Phrase: "Natl."
Processing 00000000.tx.677: Acad. 

Phrase: "Acad."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0268596:ACAD [Disease or Syndrome]
  1000   C2700624:ACAD [Cell Function]
Processing 00000000.tx.678: Sci. 

Phrase: "Sci."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3642273:SCI [Professional or Occupational Group]
Processing 00000000.tx.679: USA 101, 10422-10427.[Abstract/Free FullText] Unger, R. 

Phrase: "USA 101,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0041703:USA [Geographic Area]

Phrase: "10422-10427."

Phrase: "[Abstract/Free FullText"

Phrase: "] Unger,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.680: H. 

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.681: (2002). 

Phrase: "(2004). Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc. Natl. Acad. Sci. USA 101, 10422-10427.[Abstract/Free FullText] Unger, R. H. (2002"

Phrase: "). Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc. Natl. Acad. Sci. USA 101, 10422-10427.[Abstract/Free FullText] Unger, R. H. (2002)."
Processing 00000000.tx.682: Lipotoxic diseases. 

Phrase: "Lipotoxic diseases."
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   861   C0012634:Diseases [Disease or Syndrome]
   789 E C1836721:MALS [Finding]
   789 E C3538764:MALS [Gene or Genome]
   789 E C3540595:MAL [Gene or Genome]
Processing 00000000.tx.683: Annu. 

Phrase: "Annu."
Processing 00000000.tx.684: Rev. 

Phrase: "Rev."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347961:Rev. [Professional or Occupational Group]
Processing 00000000.tx.685: Med. 

Phrase: "Med."
Processing 00000000.tx.686: 53, 319-336.[CrossRef][Medline] Unger, R. 

Phrase: "53,"

Phrase: "319-336."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Unger,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.687: H. and Zhou, Y. 

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "and"

Phrase: "Zhou,"

Phrase: "Y."
Processing 00000000.tx.688: T. 

Phrase: "T."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]
Processing 00000000.tx.689: (2001). 

Phrase: "(2002). Lipotoxic diseases. Annu. Rev. Med. 53, 319-336.[CrossRef][Medline] Unger, R. H. and Zhou, Y. T. (2001"

Phrase: "). Lipotoxic diseases. Annu. Rev. Med. 53, 319-336.[CrossRef][Medline] Unger, R. H. and Zhou, Y. T. (2001)."
Processing 00000000.tx.690: Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. 

Phrase: "Lipotoxicity of beta-cells"

Phrase: "in obesity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0028754:Obesity [Disease or Syndrome]
  1000   C1963185:Obesity [Finding]

Phrase: "and in other causes of fatty acid spillover."
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   770   C0015684:Fatty acid [Lipid]
   744   C0001128:Acid [Chemical]
   744   C0015127:causes [Functional Concept]
   744   C0202406:Acid [Laboratory Procedure]
   744   C1314792:Causes [Functional Concept]
   744   C1515981:And [Idea or Concept]
   711 E C1524003:Cause [Conceptual Entity]
Processing 00000000.tx.691: Diabetes 50, S118-S121.[Free FullText] Unger, R. 

Phrase: "Diabetes 50,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: "S118-S121."

Phrase: "[Free FullText"

Phrase: "] Unger,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.692: H., Zhou, Y. 

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Zhou,"

Phrase: "Y."
Processing 00000000.tx.693: T. and Orci, L. 

Phrase: "T."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "and"

Phrase: "Orci,"

Phrase: "L."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]
Processing 00000000.tx.694: (1999). 

Phrase: "(2001). Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes 50, S118-S121.[Free FullText] Unger, R. H., Zhou, Y. T. and Orci, L. (1999"

Phrase: "). Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes 50, S118-S121.[Free FullText] Unger, R. H., Zhou, Y. T. and Orci, L. (1999)."
Processing 00000000.tx.695: Regulation of fatty acid homeostasis in cells: novel role of leptin. 

Phrase: "Regulation of fatty acid homeostasis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0851285:Regulation [Governmental or Regulatory Activity]
   760   C1327622:Regulation [Biologic Function]

Phrase: "in cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: ":"

Phrase: "novel role of leptin."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0035820:Role [Social Behavior]
   770   C1705810:Role [Conceptual Entity]
Processing 00000000.tx.696: Proc. 

Phrase: "Proc."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1418943:PROC [Gene or Genome]
Processing 00000000.tx.697: Natl. 

Phrase: "Natl."
Processing 00000000.tx.698: Acad. 

Phrase: "Acad."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0268596:ACAD [Disease or Syndrome]
  1000   C2700624:ACAD [Cell Function]
Processing 00000000.tx.699: Sci. 

Phrase: "Sci."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3642273:SCI [Professional or Occupational Group]
Processing 00000000.tx.700: USA 96, 2327-2332.[Abstract/Free FullText] Wang, H. and Iynedjian, P. 

Phrase: "USA 96,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0041703:USA [Geographic Area]

Phrase: "2327-2332."

Phrase: "[Abstract/Free FullText"

Phrase: "] Wang,"

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "and"

Phrase: "Iynedjian,"

Phrase: "P."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]
Processing 00000000.tx.701: B. 

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.702: (1997). 

Phrase: "(1999). Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc. Natl. Acad. Sci. USA 96, 2327-2332.[Abstract/Free FullText] Wang, H. and Iynedjian, P. B. (1997"

Phrase: "). Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc. Natl. Acad. Sci. USA 96, 2327-2332.[Abstract/Free FullText] Wang, H. and Iynedjian, P. B. (1997)."
Processing 00000000.tx.703: Modulation of glucose responsiveness of insulinoma beta-cells by graded overexpression of glucokinase. 

Phrase: "Modulation of glucose responsiveness of insulinoma beta-cells"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0443264:Modulation [Spatial Concept]

Phrase: "by graded overexpression"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1514559:Overexpression [Genetic Function]

Phrase: "of glucokinase."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0017713:Glucokinase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1415014:GLUCOKINASE [Gene or Genome]
Processing 00000000.tx.704: Proc. 

Phrase: "Proc."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1418943:PROC [Gene or Genome]
Processing 00000000.tx.705: Natl. 

Phrase: "Natl."
Processing 00000000.tx.706: Acad. 

Phrase: "Acad."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0268596:ACAD [Disease or Syndrome]
  1000   C2700624:ACAD [Cell Function]
Processing 00000000.tx.707: Sci. 

Phrase: "Sci."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3642273:SCI [Professional or Occupational Group]
Processing 00000000.tx.708: USA 94, 4372-4377.[Abstract/Free FullText] Wang, H. and Wollheim, C. 

Phrase: "USA 94,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0041703:USA [Geographic Area]

Phrase: "4372-4377."

Phrase: "[Abstract/Free FullText"

Phrase: "] Wang,"

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "and"

Phrase: "Wollheim,"

Phrase: "C."
Processing 00000000.tx.709: B. 

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.710: (2002). 

Phrase: "(1997). Modulation of glucose responsiveness of insulinoma beta-cells by graded overexpression of glucokinase. Proc. Natl. Acad. Sci. USA 94, 4372-4377.[Abstract/Free FullText] Wang, H. and Wollheim, C. B. (2002"

Phrase: "). Modulation of glucose responsiveness of insulinoma beta-cells by graded overexpression of glucokinase. Proc. Natl. Acad. Sci. USA 94, 4372-4377.[Abstract/Free FullText] Wang, H. and Wollheim, C. B. (2002)."
Processing 00000000.tx.711: ChREBP Rather than USF2 regulates glucose stimulation of endogenous L-pyruvate kinase expression in insulin-secreting cells. 

Phrase: "ChREBP"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C1826259:carbohydrate response element binding protein [Gene or Genome]
   937   C3158709:carbohydrate response element binding [Genetic Function]
   911   C0108401:carbohydrate-binding protein [Amino Acid, Peptide, or Protein,Receptor]
   875   C1148582:carbohydrate binding [Molecular Function]
   840   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0243122:binding [Functional Concept]
   804   C1145667:Binding [Activity]
   804   C1167622:Binding [Molecular Function]

Phrase: "Rather than"

Phrase: "USF2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1421377:USF2 [Gene or Genome]
  1000   C1447047:USF2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "regulates"

Phrase: "glucose stimulation of endogenous L-pyruvate kinase expression"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C1292856:Stimulation [Therapeutic or Preventive Procedure]
   744   C1948023:Stimulation [Natural Phenomenon or Process]

Phrase: "in insulin-secreting cells."
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
  1000   C0030281:Insulin-Secreting Cells [Cell]
           Insulin Cell
   827   C0007634:Cells [Cell]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.712: J. 

Phrase: "J."
Processing 00000000.tx.713: Biol. 

Phrase: "Biol."
Processing 00000000.tx.714: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.715: 277, 32746-32752.[Abstract/Free FullText] Wang, H., Maechler, P., Hagenfeldt, K. 

Phrase: "277,"

Phrase: "32746-32752."

Phrase: "[Abstract/Free FullText"

Phrase: "] Wang,"

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Maechler,"

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Hagenfeldt,"

Phrase: "K."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]
Processing 00000000.tx.716: A. and Wollheim, C. 

Phrase: "A."

Phrase: "and"

Phrase: "Wollheim,"

Phrase: "C."
Processing 00000000.tx.717: B. 

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.718: (1998). 

Phrase: "(2002). ChREBP Rather than USF2 regulates glucose stimulation of endogenous L-pyruvate kinase expression in insulin-secreting cells. J. Biol. Chem. 277, 32746-32752.[Abstract/Free FullText] Wang, H., Maechler, P., Hagenfeldt, K. A. and Wollheim, C. B. (1998"

Phrase: "). ChREBP Rather than USF2 regulates glucose stimulation of endogenous L-pyruvate kinase expression in insulin-secreting cells. J. Biol. Chem. 277, 32746-32752.[Abstract/Free FullText] Wang, H., Maechler, P., Hagenfeldt, K. A. and Wollheim, C. B. (1998)."
Processing 00000000.tx.719: Dominant-negative suppression of HNF-1alpha function results in defective insulin gene transcription and impaired metabolism-secretion coupling in a pancreatic beta-cell line. 

Phrase: "Dominant-negative suppression of HNF-1alpha function results"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   744   C0221103:Suppression [Pathologic Function]
   744   C0301625:Suppression [Organism Function]
   744   C0439181:% suppression [Quantitative Concept]
   744   C0728721:suppression [Mental Process]

Phrase: "in defective insulin gene transcription"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0040649:Gene Transcription [Genetic Function]
           Transcription

Phrase: "and"

Phrase: "impaired metabolism-secretion coupling in a pancreatic beta-cell line."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   739   C1948027:Coupling [Functional Concept]
Processing 00000000.tx.720: EMBO J. 

Phrase: "EMBO J."
Processing 00000000.tx.721: 17, 6701-6713.[Abstract/Free FullText] Wang, H., Maechler, P., Ritz-Laser, B., Hagenfeldt, K. 

Phrase: "17,"

Phrase: "6701-6713."

Phrase: "[Abstract/Free FullText"

Phrase: "] Wang,"

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Maechler,"

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Ritz-Laser,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0023089:Laser [Manufactured Object]
   861   C0458142:Laser [Phenomenon or Process]
   861   C1023865:Laser [Plant]
   861   C1706315:Laser [Medical Device]

Phrase: "B.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "Hagenfeldt,"

Phrase: "K."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]
Processing 00000000.tx.722: A., Ishihara, H., Philippe, J. and Wollheim, C. 

Phrase: "A.,"

Phrase: "Ishihara,"

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Philippe,"

Phrase: "J."

Phrase: "and"

Phrase: "Wollheim,"

Phrase: "C."
Processing 00000000.tx.723: B. 

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.724: (2001). 

Phrase: "(1998). Dominant-negative suppression of HNF-1alpha function results in defective insulin gene transcription and impaired metabolism-secretion coupling in a pancreatic beta-cell line. EMBO J. 17, 6701-6713.[Abstract/Free FullText] Wang, H., Maechler, P., Ritz-Laser, B., Hagenfeldt, K. A., Ishihara, H., Philippe, J. and Wollheim, C. B. (2001"

Phrase: "). Dominant-negative suppression of HNF-1alpha function results in defective insulin gene transcription and impaired metabolism-secretion coupling in a pancreatic beta-cell line. EMBO J. 17, 6701-6713.[Abstract/Free FullText] Wang, H., Maechler, P., Ritz-Laser, B., Hagenfeldt, K. A., Ishihara, H., Philippe, J. and Wollheim, C. B. (2001)."
Processing 00000000.tx.725: Pdx1 level defines pancreatic gene expression pattern and cell lineage differentiation. 

Phrase: "Pdx1 level"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0441889:Level [Qualitative Concept]
   861   C0456079:Level [Classification]
   861   C1547707:Level [Geographic Area]
   861   C2946261:Level [Pharmacologic Substance]

Phrase: "defines"

Phrase: "pancreatic gene expression pattern"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0449774:Pattern [Spatial Concept]

Phrase: "and"

Phrase: "cell lineage differentiation."
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   913   C0007589:Cell Differentiation [Cell Function]
           Differentiation
   827   C1511938:Differentiation [Clinical Attribute]
   827   C2945687:Differentiation [Functional Concept]
   755 E C0205615:Differentiated [Qualitative Concept]
   734   C0282637:Cell Lineage [Idea or Concept]
Processing 00000000.tx.726: J. 

Phrase: "J."
Processing 00000000.tx.727: Biol. 

Phrase: "Biol."
Processing 00000000.tx.728: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.729: 276, 25279-25286.[Abstract/Free FullText] Wang, H., Maechler, P., Antinozzi, P. 

Phrase: "276,"

Phrase: "25279-25286."

Phrase: "[Abstract/Free FullText"

Phrase: "] Wang,"

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Maechler,"

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Antinozzi,"

Phrase: "P."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]
Processing 00000000.tx.730: A., Herrero, L., Hagenfeldt-Johansson, K. 

Phrase: "A.,"

Phrase: "Herrero,"

Phrase: "L.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]

Phrase: "Hagenfeldt-Johansson,"

Phrase: "K."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]
Processing 00000000.tx.731: A., Bjorklund, A. and Wollheim, C. 

Phrase: "A.,"

Phrase: "Bjorklund,"

Phrase: "A."

Phrase: "and"

Phrase: "Wollheim,"

Phrase: "C."
Processing 00000000.tx.732: B. 

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.733: (2003). 

Phrase: "(2001). Pdx1 level defines pancreatic gene expression pattern and cell lineage differentiation. J. Biol. Chem. 276, 25279-25286.[Abstract/Free FullText] Wang, H., Maechler, P., Antinozzi, P. A., Herrero, L., Hagenfeldt-Johansson, K. A., Bjorklund, A. and Wollheim, C. B. (2003"

Phrase: "). Pdx1 level defines pancreatic gene expression pattern and cell lineage differentiation. J. Biol. Chem. 276, 25279-25286.[Abstract/Free FullText] Wang, H., Maechler, P., Antinozzi, P. A., Herrero, L., Hagenfeldt-Johansson, K. A., Bjorklund, A. and Wollheim, C. B. (2003)."
Processing 00000000.tx.734: The transcription factor SREBP-1c is instrumental in the development of beta-cell dysfunction. 

Phrase: "The transcription factor SREBP-1c"
Meta Candidates (Total=17; Excluded=0; Pruned=0; Remaining=17)
   923   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   880   C1336788:Transcription Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   869   C1149367:transcription factor binding [Genetic Function]
   836   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   836   C2246292:sterol binding [Molecular Function]
   820   C1564097:Regulatory Element, Transcriptional [Gene or Genome]
   812   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   812   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   793   C0013879:Element [Element, Ion, or Isotope]
   793   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   793   C0038323:Sterol [Steroid]
   793   C0220905:regulatory [Regulation or Law]
   793   C0243122:binding [Functional Concept]
   793   C1145667:Binding [Activity]
   793   C1167622:Binding [Molecular Function]
   793   C1704735:Regulatory [Conceptual Entity]
   793   C1705248:Element [Conceptual Entity]

Phrase: "is"

Phrase: "instrumental in the development of beta-cell dysfunction."
Processing 00000000.tx.735: J. 

Phrase: "J."
Processing 00000000.tx.736: Biol. 

Phrase: "Biol."
Processing 00000000.tx.737: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.738: 278, 16622-16629.[Abstract/Free FullText] Wang, M. 

Phrase: "278,"

Phrase: "16622-16629."

Phrase: "[Abstract/Free FullText"

Phrase: "] Wang,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.739: Y., Koyama, K., Shimabukuro, M., Mangelsdorf, D., Newgard, C. 

Phrase: "Y.,"

Phrase: "Koyama,"

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Shimabukuro,"

Phrase: "M."

Phrase: ","

Phrase: "Mangelsdorf,"

Phrase: "D."

Phrase: ","

Phrase: "Newgard,"

Phrase: "C."
Processing 00000000.tx.740: B. and Unger, R. 

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "and"

Phrase: "Unger,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.741: H. 

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.742: (1998). 

Phrase: "(2003). The transcription factor SREBP-1c is instrumental in the development of beta-cell dysfunction. J. Biol. Chem. 278, 16622-16629.[Abstract/Free FullText] Wang, M. Y., Koyama, K., Shimabukuro, M., Mangelsdorf, D., Newgard, C. B. and Unger, R. H. (1998"

Phrase: "). The transcription factor SREBP-1c is instrumental in the development of beta-cell dysfunction. J. Biol. Chem. 278, 16622-16629.[Abstract/Free FullText] Wang, M. Y., Koyama, K., Shimabukuro, M., Mangelsdorf, D., Newgard, C. B. and Unger, R. H. (1998)."
Processing 00000000.tx.743: Overexpression of leptin receptors in pancreatic islets of Zucker diabetic fatty rats restores GLUT-2, glucokinase, and glucose-stimulated insulin secretion. 

Phrase: "Overexpression of leptin receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1514559:Overexpression [Genetic Function]

Phrase: "in pancreatic islets"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0022131:Pancreatic Islets [Body Part, Organ, or Organ Component]
   861   C0030274:Pancreatic [Body Part, Organ, or Organ Component]

Phrase: "of Zucker diabetic fatty rats"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   902   C0034719:Rats, Zucker [Mammal]
   812   C0034693:rats [Mammal]
   812   C0034721:Rats [Mammal]

Phrase: "restores"

Phrase: "GLUT-2,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1420172:GLUT2 [Gene or Genome]
   861   C1335837:GLUT [Gene or Genome]
   861   C1705603:GLUT [Gene or Genome]

Phrase: "glucokinase,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0017713:Glucokinase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1415014:GLUCOKINASE [Gene or Genome]

Phrase: "and"

Phrase: "glucose-stimulated insulin secretion."
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   875   C1719133:Glucose/Insulin [Quantitative Concept]
   861   C1256369:insulin secretion [Cell Function]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0036536:secretion [Biologic Function]
   812   C0036537:Secretion [Body Substance]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]
Processing 00000000.tx.744: Proc. 

Phrase: "Proc."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1418943:PROC [Gene or Genome]
Processing 00000000.tx.745: Natl. 

Phrase: "Natl."
Processing 00000000.tx.746: Acad. 

Phrase: "Acad."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0268596:ACAD [Disease or Syndrome]
  1000   C2700624:ACAD [Cell Function]
Processing 00000000.tx.747: Sci. 

Phrase: "Sci."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3642273:SCI [Professional or Occupational Group]
Processing 00000000.tx.748: USA 95, 11921-11926.[Abstract/Free FullText] Weir, G. 

Phrase: "USA 95,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0041703:USA [Geographic Area]

Phrase: "11921-11926."

Phrase: "[Abstract/Free FullText"

Phrase: "] Weir,"

Phrase: "G."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]
Processing 00000000.tx.749: C. 

Phrase: "C."
Processing 00000000.tx.750: (1982). 

Phrase: "(1998). Overexpression of leptin receptors in pancreatic islets of Zucker diabetic fatty rats restores GLUT-2, glucokinase, and glucose-stimulated insulin secretion. Proc. Natl. Acad. Sci. USA 95, 11921-11926.[Abstract/Free FullText] Weir, G. C. (1982"

Phrase: "). Overexpression of leptin receptors in pancreatic islets of Zucker diabetic fatty rats restores GLUT-2, glucokinase, and glucose-stimulated insulin secretion. Proc. Natl. Acad. Sci. USA 95, 11921-11926.[Abstract/Free FullText] Weir, G. C. (1982)."
Processing 00000000.tx.751: Non-insulin-dependent diabetes mellitus: interplay between B-cell inadequacy and insulin resistance. 

Phrase: "Non-insulin-dependent diabetes mellitus"
Meta Candidates (Total=17; Excluded=2; Pruned=0; Remaining=15)
  1000   C0011860:Diabetes Mellitus, Non-Insulin-Dependent [Disease or Syndrome]
           Non-Insulin Dependent Diabetes
  1000   C2697407:DIABETES MELLITUS, NONINSULIN-DEPENDENT [Gene or Genome]
   937   C0011854:Diabetes Mellitus, Insulin-Dependent [Disease or Syndrome]
           Insulin Dependent Diabetes
   840   C0011849:Diabetes Mellitus [Disease or Syndrome]
           Diabetes
   804   C0011847:Diabetes [Disease or Syndrome]
   804   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   804   C0851827:Dependent [Qualitative Concept]
   804   C1518422:Non [Functional Concept]
   804   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   804   C1579433:Insulin [Pharmacologic Substance]
   804   C1701901:Dependent [Qualitative Concept]
   804   C3244310:dependent [Functional Concept]
   748 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   721 E C3537244:Insulins [Pharmacologic Substance]

Phrase: ":"

Phrase: "interplay between B-cell inadequacy"

Phrase: "and"

Phrase: "insulin resistance."
Meta Candidates (Total=12; Excluded=5; Pruned=0; Remaining=7)
  1000   C0021655:Insulin Resistance [Pathologic Function]
  1000   C2700570:INSULIN RESISTANCE [Gene or Genome]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0237834:Resistance [Mental Process]
   861   C1514892:Resistance [Physiologic Function]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332325:Resistant [Functional Concept]
   789 E C1550464:resistent [Idea or Concept]
   789 E C2827757:RESISTANT [Laboratory or Test Result]
   777 E C3537244:Insulins [Pharmacologic Substance]
Processing 00000000.tx.752: Am. 

Phrase: "Am."
Processing 00000000.tx.753: J. 

Phrase: "J."
Processing 00000000.tx.754: Med. 

Phrase: "Med."
Processing 00000000.tx.755: 73, 461-464.[CrossRef][Medline] Weir, G. 

Phrase: "73,"

Phrase: "461-464."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Weir,"

Phrase: "G."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]
Processing 00000000.tx.756: C., Laybutt, D. 

Phrase: "C., Laybutt,"

Phrase: "D."
Processing 00000000.tx.757: R., Kaneto, H., Bonner-Weir, S. and Sharma, A. 

Phrase: "R.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]

Phrase: "Kaneto,"

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Bonner-Weir,"

Phrase: "S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]

Phrase: "and"

Phrase: "Sharma,"

Phrase: "A."
Processing 00000000.tx.758: (2001). 

Phrase: "(1982). Non-insulin-dependent diabetes mellitus: interplay between B-cell inadequacy and insulin resistance. Am. J. Med. 73, 461-464.[CrossRef][Medline] Weir, G. C., Laybutt, D. R., Kaneto, H., Bonner-Weir, S. and Sharma, A. (2001"

Phrase: "). Non-insulin-dependent diabetes mellitus: interplay between B-cell inadequacy and insulin resistance. Am. J. Med. 73, 461-464.[CrossRef][Medline] Weir, G. C., Laybutt, D. R., Kaneto, H., Bonner-Weir, S. and Sharma, A. (2001)."
Processing 00000000.tx.759: Beta-cell adaptation and decompensation during the progression of diabetes. 

Phrase: "Beta-cell adaptation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0000934:adaptation [Organism Function]
   827   C0392673:Adaptation [Biologic Function]
   734   C0030281:Beta cell [Cell]

Phrase: "and"

Phrase: "decompensation during the progression of diabetes."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0231187:Decompensation [Finding]
Processing 00000000.tx.760: Diabetes 50, S154-S159.[Free FullText] Werstuck, G. 

Phrase: "Diabetes 50,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: "S154-S159."

Phrase: "[Free FullText"

Phrase: "] Werstuck,"

Phrase: "G."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]
Processing 00000000.tx.761: H., Lentz, S. 

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Lentz,"

Phrase: "S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]
Processing 00000000.tx.762: R., Dayal, S., Hossain, G. 

Phrase: "R.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]

Phrase: "Dayal,"

Phrase: "S."

Phrase: ","

Phrase: "Hossain,"

Phrase: "G."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]
Processing 00000000.tx.763: S., Sood, S. 

Phrase: "S."

Phrase: ","

Phrase: "Sood,"

Phrase: "S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]
Processing 00000000.tx.764: K., Shi, Y. 

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Shi,"

Phrase: "Y."
Processing 00000000.tx.765: Y., Zhou, J., Maeda, N., Krisans, S. 

Phrase: "Y.,"

Phrase: "Zhou,"

Phrase: "J.,"

Phrase: "Maeda,"

Phrase: "N.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]

Phrase: "Krisans,"

Phrase: "S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]
Processing 00000000.tx.766: K., Malinow, M. 

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Malinow,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.767: R. et al. 

Phrase: "R. et al."
Processing 00000000.tx.768: (2001). 

Phrase: "(2001). Beta-cell adaptation and decompensation during the progression of diabetes. Diabetes 50, S154-S159.[Free FullText] Werstuck, G. H., Lentz, S. R., Dayal, S., Hossain, G. S., Sood, S. K., Shi, Y. Y., Zhou, J., Maeda, N., Krisans, S. K., Malinow, M. R. et al. (2001"

Phrase: "). Beta-cell adaptation and decompensation during the progression of diabetes. Diabetes 50, S154-S159.[Free FullText] Werstuck, G. H., Lentz, S. R., Dayal, S., Hossain, G. S., Sood, S. K., Shi, Y. Y., Zhou, J., Maeda, N., Krisans, S. K., Malinow, M. R. et al. (2001)."
Processing 00000000.tx.769: Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. 

Phrase: "Homocysteine-induced endoplasmic reticulum stress"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   884   C3178870:Endoplasmic Reticulum Stress [Cell or Molecular Dysfunction]
   840   C0014239:Endoplasmic Reticulum [Cell Component]
   804   C0035295:Reticulum [Body Part, Organ, or Organ Component]
   804   C0038435:Stress [Finding]
   733 E C0231297:Stressful [Functional Concept]
   733   C0598268:Endoplasm [Cell Component]

Phrase: "causes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0015127:cause [Functional Concept]
  1000   C1314792:Causes [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]

Phrase: "dysregulation of the cholesterol"

Phrase: "and"

Phrase: "triglyceride biosynthetic pathways."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C1721101:Biosynthetic Pathways [Molecular Function]
   827   C1704259:Pathways [Molecular Function]
   827   C1705987:Pathways [Conceptual Entity]
Processing 00000000.tx.770: J. 

Phrase: "J."
Processing 00000000.tx.771: Clin. 

Phrase: "Clin."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1315013:CLIN [Intellectual Product]
Processing 00000000.tx.772: Invest. 

Phrase: "Invest."
Processing 00000000.tx.773: 107, 1263-1273.[Abstract/Free FullText] Withers, D. 

Phrase: "107,"

Phrase: "1263-1273."

Phrase: "[Abstract/Free FullText"

Phrase: "]"

Phrase: "Withers"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0230107:Withers [Body Part, Organ, or Organ Component]

Phrase: ","

Phrase: "D."
Processing 00000000.tx.774: J., Gutierrez, J. 

Phrase: "J.,"

Phrase: "Gutierrez,"

Phrase: "J."
Processing 00000000.tx.775: S., Towery, H., Burks, D. 

Phrase: "S."

Phrase: ","

Phrase: "Towery,"

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Burks,"

Phrase: "D."
Processing 00000000.tx.776: J., Ren, J. 

Phrase: "J.,"

Phrase: "Ren,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0022646:Ren [Body Part, Organ, or Organ Component]
  1000   C1419338:REN [Gene or Genome]
  1000   C1427479:REN [Gene or Genome]

Phrase: "J."
Processing 00000000.tx.777: M., Previs, S., Zhang, Y., Bernal, D., Pons, S., Shulman, G. 

Phrase: "M."

Phrase: ","

Phrase: "Previs,"

Phrase: "S."

Phrase: ","

Phrase: "Zhang,"

Phrase: "Y.,"

Phrase: "Bernal,"

Phrase: "D."

Phrase: ","

Phrase: "Pons,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0032639:Pons [Body Part, Organ, or Organ Component]
  1000   C1280999:Pons [Body Part, Organ, or Organ Component]
   966 E C1418754:PON [Gene or Genome]
   966 E C1709588:PON [Mammal]

Phrase: "S."

Phrase: ","

Phrase: "Shulman,"

Phrase: "G."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]
Processing 00000000.tx.778: I. et al. 

Phrase: "I. et al."
Processing 00000000.tx.779: (1998). 

Phrase: "(2001). Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J. Clin. Invest. 107, 1263-1273.[Abstract/Free FullText] Withers, D. J., Gutierrez, J. S., Towery, H., Burks, D. J., Ren, J. M., Previs, S., Zhang, Y., Bernal, D., Pons, S., Shulman, G. I. et al. (1998"

Phrase: "). Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J. Clin. Invest. 107, 1263-1273.[Abstract/Free FullText] Withers, D. J., Gutierrez, J. S., Towery, H., Burks, D. J., Ren, J. M., Previs, S., Zhang, Y., Bernal, D., Pons, S., Shulman, G. I. et al. (1998)."
Processing 00000000.tx.780: Disruption of IRS-2 causes type 2 diabetes in mice. 

Phrase: "Disruption of IRS-2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0332453:Disruption [Functional Concept]

Phrase: "causes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0015127:cause [Functional Concept]
  1000   C1314792:Causes [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]

Phrase: "type 2 diabetes in mice."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   862   C0011860:Type 2 Diabetes [Disease or Syndrome]
   806   C0441730:Type 2 [Classification]
   797   C1320657:Diabetes type [Finding]
   760   C0011847:Diabetes [Disease or Syndrome]
   760   C0011849:Diabetes [Disease or Syndrome]
   760   C0332307:Type [Qualitative Concept]
   760   C1547052:*Type [Quantitative Concept]
Processing 00000000.tx.781: Nature 391, 900-904.[CrossRef][Medline] Xu, A., Yin, S., Wong, L., Chan, K. 

Phrase: "Nature 391,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0349590:Nature [Idea or Concept]
   861   C1262865:Nature [Functional Concept]
   789 E C0205296:Natural [Functional Concept]

Phrase: "900-904."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Xu,"

Phrase: "A.,"

Phrase: "Yin,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2945618:yin [Idea or Concept]

Phrase: "S."

Phrase: ","

Phrase: "Wong,"

Phrase: "L.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]

Phrase: "Chan,"

Phrase: "K."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]
Processing 00000000.tx.782: W. and Lam, K. 

Phrase: "W."

Phrase: "and"

Phrase: "Lam,"

Phrase: "K."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]
Processing 00000000.tx.783: S. 

Phrase: "S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]
Processing 00000000.tx.784: (2004). 

Phrase: "(1998). Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391, 900-904.[CrossRef][Medline] Xu, A., Yin, S., Wong, L., Chan, K. W. and Lam, K. S. (2004"

Phrase: "). Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391, 900-904.[CrossRef][Medline] Xu, A., Yin, S., Wong, L., Chan, K. W. and Lam, K. S. (2004)."
Processing 00000000.tx.785: Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice. 

Phrase: "Adiponectin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0389071:Adiponectin [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "ameliorates"

Phrase: "dyslipidemia"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0242339:Dyslipidaemia [Disease or Syndrome]

Phrase: "induced by the human immunodeficiency virus protease inhibitor ritonavir"
Meta Candidates (Total=15; Excluded=0; Pruned=0; Remaining=15)
   849   C3536912:Human Immunodeficiency Virus Protease Inhibitor [Pharmacologic Substance]
   790   C0019682:Virus, Human Immunodeficiency [Virus]
   764   C0033607:Protease Inhibitor [Biologically Active Substance,Pharmacologic Substance]
   764   C0682458:immunodeficiency virus [Virus]
   764   C3536890:Protease Inhibitor [Pharmacologic Substance]
   762   C0318356:Human virus [Virus]
   742   C0021051:IMMUNO-DEFICIENCY [Disease or Syndrome]
   742   C0030946:Protease [Amino Acid, Peptide, or Protein,Enzyme,Pharmacologic Substance]
   742   C0042776:Virus [Virus]
   742   C0086418:Human [Human]
   742   C0205263:Induced [Functional Concept]
   742   C0292818:Ritonavir [Organic Chemical,Pharmacologic Substance]
   742   C0319157:virus [Virus]
   742   C1947941:Protease [Enzyme]
   742   C1999216:Inhibitor [Qualitative Concept]

Phrase: "in mice."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0025914:Mice [Mammal]
  1000   C0025929:mice [Mammal]
  1000   C0026809:Mice [Mammal]
Processing 00000000.tx.786: Endocrinology 145, 487-494.[Abstract/Free FullText] Yahagi, N., Shimano, H., Hasty, A. 

Phrase: "Endocrinology 145,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0014137:Endocrinology [Biomedical Occupation or Discipline]
   789 E C0694557:endocrinologic [Functional Concept]

Phrase: "487-494."

Phrase: "[Abstract/Free FullText"

Phrase: "] Yahagi,"

Phrase: "N.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]

Phrase: "Shimano,"

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Hasty,"

Phrase: "A."
Processing 00000000.tx.787: H., Amemiya-Kudo, M., Okazaki, H., Tamura, Y., Iizuka, Y., Shionoiri, F., Ohashi, K., Osuga, J. et al. 

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Amemiya-Kudo,"

Phrase: "M."

Phrase: ","

Phrase: "Okazaki,"

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Tamura,"

Phrase: "Y.,"

Phrase: "Iizuka,"

Phrase: "Y.,"

Phrase: "Shionoiri,"

Phrase: "F.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "Ohashi,"

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Osuga,"

Phrase: "J. et al."
Processing 00000000.tx.788: (1999). 

Phrase: "(2004). Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice. Endocrinology 145, 487-494.[Abstract/Free FullText] Yahagi, N., Shimano, H., Hasty, A. H., Amemiya-Kudo, M., Okazaki, H., Tamura, Y., Iizuka, Y., Shionoiri, F., Ohashi, K., Osuga, J. et al. (1999"

Phrase: "). Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice. Endocrinology 145, 487-494.[Abstract/Free FullText] Yahagi, N., Shimano, H., Hasty, A. H., Amemiya-Kudo, M., Okazaki, H., Tamura, Y., Iizuka, Y., Shionoiri, F., Ohashi, K., Osuga, J. et al. (1999)."
Processing 00000000.tx.789: A crucial role of sterol regulatory element-binding protein-1 in the regulation of lipogenic gene expression by polyunsaturated fatty acids. 

Phrase: "A crucial role of sterol regulatory element-binding protein-1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   739   C0035820:Role [Social Behavior]
   739   C1705810:Role [Conceptual Entity]

Phrase: "in the regulation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0851285:Regulation [Governmental or Regulatory Activity]
  1000   C1327622:Regulation [Biologic Function]

Phrase: "of lipogenic gene expression"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0017262:Gene Expression [Genetic Function]
   827   C0017337:Gene [Gene or Genome]
   827   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "by polyunsaturated fatty acids."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0032615:Polyunsaturated Fatty Acids [Biologically Active Substance,Lipid]
   901   C0015684:Fatty Acids [Lipid]
   827   C0001128:Acids [Chemical]
   793 E C0202406:Acid [Laboratory Procedure]
Processing 00000000.tx.790: J. 

Phrase: "J."
Processing 00000000.tx.791: Biol. 

Phrase: "Biol."
Processing 00000000.tx.792: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.793: 274, 35840-35844.[Abstract/Free FullText] Yahagi, N., Shimano, H., Hasty, A. 

Phrase: "274,"

Phrase: "35840-35844."

Phrase: "[Abstract/Free FullText"

Phrase: "] Yahagi,"

Phrase: "N.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]

Phrase: "Shimano,"

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Hasty,"

Phrase: "A."
Processing 00000000.tx.794: H., Matsuzaka, T., Ide, T., Yoshikawa, T., Amemiya-Kudo, M., Tomita, S., Okazaki, H., Tamura, Y. et al. 

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Matsuzaka,"

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Ide,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0328104:Ide [Fish]
  1000   C1415875:IDE [Gene or Genome]
  1000   C2826366:IDE [Idea or Concept]

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Yoshikawa,"

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Amemiya-Kudo,"

Phrase: "M."

Phrase: ","

Phrase: "Tomita,"

Phrase: "S."

Phrase: ","

Phrase: "Okazaki,"

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Tamura,"

Phrase: "Y. et al."
Processing 00000000.tx.795: (2002). 

Phrase: "(1999). A crucial role of sterol regulatory element-binding protein-1 in the regulation of lipogenic gene expression by polyunsaturated fatty acids. J. Biol. Chem. 274, 35840-35844.[Abstract/Free FullText] Yahagi, N., Shimano, H., Hasty, A. H., Matsuzaka, T., Ide, T., Yoshikawa, T., Amemiya-Kudo, M., Tomita, S., Okazaki, H., Tamura, Y. et al. (2002"

Phrase: "). A crucial role of sterol regulatory element-binding protein-1 in the regulation of lipogenic gene expression by polyunsaturated fatty acids. J. Biol. Chem. 274, 35840-35844.[Abstract/Free FullText] Yahagi, N., Shimano, H., Hasty, A. H., Matsuzaka, T., Ide, T., Yoshikawa, T., Amemiya-Kudo, M., Tomita, S., Okazaki, H., Tamura, Y. et al. (2002)."
Processing 00000000.tx.796: Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. 

Phrase: "Absence of sterol regulatory element-binding protein-1 (SREBP-1)"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   744   C0332197:absence [Quantitative Concept]
   744   C1689985:Absence [Anatomical Abnormality]
   743   C0217529:Sterol Regulatory Element Binding Protein 1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   743   C1420398:STEROL REGULATORY ELEMENT-BINDING PROTEIN 1 [Gene or Genome]

Phrase: "ameliorates"

Phrase: "fatty livers"
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
  1000   C0015695:fatty livers [Disease or Syndrome]
   861   C0023884:Livers [Body Part, Organ, or Organ Component]
   827 E C0736268:LIVER [Body Part, Organ, or Organ Component]
   827 E C1278929:Liver [Body Part, Organ, or Organ Component]
   827 E C2346688:LIVER [Food]
   789 E C0205054:Hepatic [Body Location or Region]

Phrase: "but"

Phrase: "not obesity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0028754:Obesity [Disease or Syndrome]
   861   C1963185:Obesity [Finding]

Phrase: "or"

Phrase: "insulin resistance in Lep(ob)/Lep(ob) mice."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   770   C0021655:Insulin Resistance [Pathologic Function]
   770   C2700570:INSULIN RESISTANCE [Gene or Genome]
   744   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C0237834:Resistance [Mental Process]
   744   C1514892:Resistance [Physiologic Function]
   744   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C1579433:Insulin [Pharmacologic Substance]
Processing 00000000.tx.797: J. 

Phrase: "J."
Processing 00000000.tx.798: Biol. 

Phrase: "Biol."
Processing 00000000.tx.799: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.800: 277, 19353-19357.[Abstract/Free FullText] Yamashita, T., Eto, K., Okazaki, Y., Yamashita, S., Yamauchi, T., Sekine, N., Nagai, R., Noda, M. and Kadowaki, T. 

Phrase: "277,"

Phrase: "19353-19357."

Phrase: "[Abstract/Free FullText"

Phrase: "] Yamashita,"

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Eto,"

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Okazaki,"

Phrase: "Y.,"

Phrase: "Yamashita,"

Phrase: "S."

Phrase: ","

Phrase: "Yamauchi,"

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Sekine,"

Phrase: "N.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]

Phrase: "Nagai,"

Phrase: "R.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]

Phrase: "Noda,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]

Phrase: "and"

Phrase: "Kadowaki,"

Phrase: "T."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]
Processing 00000000.tx.801: (2004). 

Phrase: "(2002). Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J. Biol. Chem. 277, 19353-19357.[Abstract/Free FullText] Yamashita, T., Eto, K., Okazaki, Y., Yamashita, S., Yamauchi, T., Sekine, N., Nagai, R., Noda, M. and Kadowaki, T. (2004"

Phrase: "). Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J. Biol. Chem. 277, 19353-19357.[Abstract/Free FullText] Yamashita, T., Eto, K., Okazaki, Y., Yamashita, S., Yamauchi, T., Sekine, N., Nagai, R., Noda, M. and Kadowaki, T. (2004)."
Processing 00000000.tx.802: Role of uncoupling protein-2 up-regulation and triglyceride accumulation in impaired glucose-stimulated insulin secretion in a beta-cell lipotoxicity model overexpressing sterol regulatory element-binding protein-1c. 

Phrase: "Role of uncoupling protein-2 up-regulation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0035820:Role [Social Behavior]
   748   C1705810:Role [Conceptual Entity]

Phrase: "and"

Phrase: "triglyceride accumulation in impaired glucose-stimulated insulin secretion"

Phrase: "in a beta-cell lipotoxicity model overexpressing sterol regulatory element-binding protein-1c."
Meta Candidates (Total=17; Excluded=0; Pruned=0; Remaining=17)
   881   C0038164:a protein [Amino Acid, Peptide, or Protein,Immunologic Factor,Indicator, Reagent, or Diagnostic Aid]
   871   C1750295:beta protein [Genetic Function]
   871   C2362547:Beta protein [Amino Acid, Peptide, or Protein]
   861   C0537474:Sterol Regulatory Element Binding Protein 1c [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   816   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   816   C2246292:sterol binding [Molecular Function]
   799   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   799   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   787   C0013879:Element [Element, Ion, or Isotope]
   787   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   787   C0038323:Sterol [Steroid]
   787   C0220905:regulatory [Regulation or Law]
   787   C0243122:binding [Functional Concept]
   787   C1145667:Binding [Activity]
   787   C1167622:Binding [Molecular Function]
   787   C1704735:Regulatory [Conceptual Entity]
   787   C1705248:Element [Conceptual Entity]
Processing 00000000.tx.803: Endocrinology 145, 3566-3577.[Abstract/Free FullText] Yan, L., Nairn, A. 

Phrase: "Endocrinology 145,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0014137:Endocrinology [Biomedical Occupation or Discipline]
   789 E C0694557:endocrinologic [Functional Concept]

Phrase: "3566-3577."

Phrase: "[Abstract/Free FullText"

Phrase: "] Yan,"

Phrase: "L.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]

Phrase: "Nairn,"

Phrase: "A."
Processing 00000000.tx.804: C., Palfrey, H. 

Phrase: "C., Palfrey,"

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.805: C. and Brady, M. 

Phrase: "C."

Phrase: "and"

Phrase: "Brady,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.806: J. 

Phrase: "J."
Processing 00000000.tx.807: (2003). 

Phrase: "(2004). Role of uncoupling protein-2 up-regulation and triglyceride accumulation in impaired glucose-stimulated insulin secretion in a beta-cell lipotoxicity model overexpressing sterol regulatory element-binding protein-1c. Endocrinology 145, 3566-3577.[Abstract/Free FullText] Yan, L., Nairn, A. C., Palfrey, H. C. and Brady, M. J. (2003"

Phrase: "). Role of uncoupling protein-2 up-regulation and triglyceride accumulation in impaired glucose-stimulated insulin secretion in a beta-cell lipotoxicity model overexpressing sterol regulatory element-binding protein-1c. Endocrinology 145, 3566-3577.[Abstract/Free FullText] Yan, L., Nairn, A. C., Palfrey, H. C. and Brady, M. J. (2003)."
Processing 00000000.tx.808: Glucose regulates EF-2 phosphorylation and protein translation by a protein phosphatase-2A-dependent mechanism in INS-1-derived 832/13 cells. 

Phrase: "Glucose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "regulates"

Phrase: "EF-2 phosphorylation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0031715:Phosphorylation [Molecular Function]
   827   C1158886:Phosphorylation [Molecular Function]
   734   C0059037:EF-2 [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "and"

Phrase: "protein synthesis in pancreatic  cells through dephosphorylation of the eukaryotic elongation factor (eEF2) (Yan et al., 2003) and initiation factor (eIF2) (Gomez et al., 2004) and activation of the guanine nucleotide exchange factor eIF2B (Gilligan et al., 1996). We, therefore, postulate that chronic high glucose could induce ER stress through overloading protein synthesis. Our data suggest that chronic high-glucose-induced ER stress could be the underlying mechanism in SREBP-1 processing/activation. Indeed, we found that treatment of isolated rat islets with chronic high glucose and two ER stress inducers, thapsigargin and tunicamycin, markedly increased the SREBP-1 binding activity to the IRS2 promoter. It has been well established that ER stress causes SREBP processing through S1P and S2P (Werstuck et al., 2001; Ye et al., 2000). SREBP-1c activation induced by ER stress has also been implicated in hyperhomocysteinemia-induced liver steatosis (Werstuck et al., 2001). Increased ER stress has been incriminated in ob/ob mice and in mice fed on a high-fat diet and proposed as the cause of insulin resistance (Ozcan et al., 2004). Likewise, response to ER stress has been reported in rat  cells treated with fatty acids (Kharroubi et al., 2004). Therefore, prolonged ER stress and SREBP-1c activation could be a common mechanism underlying both -cell dysfunction and insulin resistance in type 2 diabetes. It is noteworthy that the genetic studies have associated SREBP-1c polymorphisms with obesity, insulin resistance and type 2 diabetes (Eberle et al., 2004; Laudes et al., 2004). SREBP-1c is the upstream suppressor of IRS2 (Ide et al., 2004), and the transactivator of Ucp2, Ldlr, stearoyl-CoA desaturase 1 and many lipogenic genes (Bene et al., 2001; Horton et al., 2003; Medvedev et al., 2002; Wang et al., 2003; Yahagi et al., 1999). In addition to the aforementioned genes (IRS2, Ucp2 and Ldlr), stearoyl-CoA desaturase 1 (SCD1) deficiency has been shown to increase insulin sensitivity, fatty acid oxidation and energy expenditure, as well as promoting resistance to diet-induced obesity (Dobrzyn et al., 2004). We, therefore, propose that SREBP-1c is one of the causative genes for development of both -cell dysfunction and insulin resistance in type 2 diabetes. In fact, SREBP-1c over-activation has been associated with liver steatosis, lipodystrophy, diabetic renal disease and/or -cell lipotoxicity in many animal models of type 2 diabetes, such as ob/ob, db/db, IRS2-/- and ap2-nSREBP-1c mice, streptozotocin-induced diabetic rats, Zucker diabetic fatty rats, and mice with liver overexpression of Socs-1/-3 (Kakuma et al., 2000; Lin et al., 2000; Matsuzaka et al., 2004; Riddle et al., 2001; Shimomura et al., 1999a; Shimomura et al., 1999b; Shimomura et al., 1999c; Shimomura et al., 2000; Sun et al., 2002; Takaishi et al., 2004; Tobe et al., 2001; Ueki et al., 2004; Unger and Zhou, 2001; Unger et al., 1999; Werstuck et al., 2001; Xu et al., 2004; Yahagi et al., 2002; You et al., 2002), as well as in patients with severe lipodystrophy (Bastard et al., 2002; Petersen et al., 2002). Treatment with some antidiabetic drugs or hormones including metformin, troglitazone, leptin and adiponectin could prevent the diabetes-associated lipotoxicity in these animals and patients through inhibition of SREBP-1c activation (Lin et al., 2000; Petersen et al., 2002; Shimomura et al., 1999c; Xu et al., 2004). Genetic manipulations to suppress SREBP-1c function are shown to be equally effective (Engelking et al., 2004; Takaishi et al., 2004; Ueki et al., 2004). In summary, we found that chronic high glucose treatment alone could cause typical glucolipotoxicity and a gene expression profile resembling that caused by naSREBP-1c expression in INS-1 cells (Wang et al., 2003). This gene expression profile (Wang et al., 2003) has also been most recently confirmed in mice with -cell-specific overexpression of SREBP-1c (Takahashi et al., 2005), suggesting that the results in our INS-1 cell model correlate well with native  cells in vivo. However, it remains to be determined whether naSREBP-1c-induced apoptosis and impaired glucose-stimulated insulin secretion occurs via lipid accumulation or through an independent mechanism. Most importantly, we found that dominant-negative suppression of SREBP-1c function could prevent glucolipotoxicity in INS-1 cells. We have further implicated ERnstress in the activation of SREBP-1c, leading to -cell glucolipotoxicity. Therefore, the present study should help to clarify the molecular mechanisms underlying development of -cell glucolipotoxicity, a process thought to cause the loss of both -cell mass and insulin secretory response to glucose in type 2 diabetes. Prevention of excessive ER stress and SREBP-1c action should be considered for therapy aimed at protection of -cell function in type 2 diabetes.  Acknowledgments  We are grateful to D. Cornut-Harry, D. Nappey, Y. Dupr and V. Calvo for expert technical assistance. We are indebted to B. M. Spiegelman (for the naSREBP-1c and DN-SREBP-1c cDNAs), D. Ron (for the CHOP cDNA), R. Prywes (for the BIP cDNA), H. Bujard (for the PUHD 10-3 vector), and N. Quintrell (for the pTKhygro plasmid). This work was supported by the Swiss National Science Foundation (grant no. 32-66907.01 to C.B.W.) and Olga Mayenfisch Stiftung. The authors declare no conflict of interest.  References Top Summary Introduction Materials and Methods Results Discussion References  Ahlgren, U., Johnson, J., Johnson, L., Simu, K. and Edlund, H. (1998). Beta-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes. Genes Dev. 12, 1763-1768.[Abstract/Free FullText] Andreolas, C., da Silva Xavier, G., Diraison, F., Zhao, C., Varadi, A., Lopez-Casillas, F., Ferre, P., Foufelle, F. and Rutter, G. A. (2002). Stimulation of acetyl-CoA carboxylase gene expression by glucose requires insulin release and sterol regulatory element binding protein 1c in pancreatic MIN6 beta-cells. Diabetes 51, 2536-2545.[Abstract/Free FullText] Asfari, M., Janjic, D., Meda, P., Li, G., Halban, P. A. and Wollheim, C. B. (1992). Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines. Endocrinology 130, 167-178.[Abstract] Bastard, J. P., Caron, M., Vidal, H., Jan, V., Auclair, M., Vigouroux, C., Luboinski, J., Laville, M., Maachi, M., Girard, P. M. et al. (2002). Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 359, 1026-1031.[CrossRef][Medline] Bene, H., Lasky, D. and Ntambi, J. M. (2001). Cloning and characterization of the human stearoyl-CoA desaturase gene promoter: transcriptional activation by sterol regulatory element binding protein and repression by polyunsaturated fatty acids and cholesterol. Biochem. Biophys. Res. Commun. 284, 1194-1198.[CrossRef][Medline] Bonner-Weir, S., Trent, D. F. and Weir, G. C. (1983). Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release. J. Clin. Invest. 71, 1544-1553.[Medline] Brown, M. S. and Goldstein, J. L. (1997). The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89, 331-340.[CrossRef][Medline] Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A. and Butler, P. C. (2003). Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52, 102-110.[Abstract/Free FullText] Chan, C. B., Saleh, M. C., Koshkin, V. and Wheeler, M. B. (2004). Uncoupling protein 2 and islet function. Diabetes 53, S136-S142.[Abstract/Free FullText] Dentin, R., Pegorier, J. P., Benhamed, F., Foufelle, F., Ferre, P., Fauveau, V., Magnuson, M. A., Girard, J. and Postic, C. (2004). Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression. J. Biol. Chem. 279, 20314-20326.[Abstract/Free FullText] Diraison, F., Parton, L., Ferre, P., Foufelle, F., Briscoe, C. P., Leclerc, I. and Rutter, G. A. (2004). Over-expression of sterol-regulatory-element-binding protein-1c (SREBP1c) in rat pancreatic islets induces lipogenesis and decreases glucose-stimulated insulin release: modulation by 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR). Biochem. J. 378, 769-778.[CrossRef][Medline] Dobrzyn, P., Dobrzyn, A., Miyazaki, M., Cohen, P., Asilmaz, E., Hardie, D. G., Friedman, J. M. and Ntambi, J. M. (2004). Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver. Proc. Natl. Acad. Sci. USA 101, 6409-6414.[Abstract/Free FullText] Eberle, D., Clement, K., Meyre, D., Sahbatou, M., Vaxillaire, M., Le Gall, A., Ferre, P., Basdevant, A., Froguel, P. and Foufelle, F. (2004). SREBF-1 gene polymorphisms are associated with obesity and type 2 diabetes in French obese and diabetic cohorts. Diabetes 53, 2153-2157.[Abstract/Free FullText] Efanova, I. B., Zaitsev, S. V., Zhivotovsky, B., Kohler, M., Efendic, S., Orrenius, S. and Berggren, P. O. (1998). Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration. J. Biol. Chem. 273, 33501-33507.[Abstract/Free FullText] Engelking, L. J., Kuriyama, H., Hammer, R. E., Horton, J. D., Brown, M. S., Goldstein, J. L. and Liang, G. (2004). Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis. J. Clin. Invest. 113, 1168-1175.[Abstract/Free FullText] Flamez, D., Berger, V., Kruhoffer, M., Orntoft, T., Pipeleers, D. and Schuit, F. C. (2002). Critical role for cataplerosis via citrate in glucose-regulated insulin release. Diabetes 51, 2018-2024.[Abstract/Free FullText] Gilligan, M., Welsh, G. I., Flynn, A., Bujalska, I., Diggle, T. A., Denton, R. M., Proud, C. G. and Docherty, K. (1996). Glucose stimulates the activity of the guanine nucleotide-exchange factor eIF-2B in isolated rat islets of Langerhans. J. Biol. Chem. 271, 2121-2125.[Abstract/Free FullText] Gomez, E., Powell, M. L., Greenman, I. C. and Herbert, T. P. (2004). Glucose-stimulated protein synthesis in pancreatic beta-cells parallels an increase in the availability of the translational ternary complex (eIF2-GTP.Met-tRNAi) and the dephosphorylation of eIF2 alpha. J. Biol. Chem. 279, 53937-53946.[Abstract/Free FullText] Gossen, M., Freundlieb, S., Bender, G., Muller, G., Hillen, W. and Bujard, H. (1995). Transcriptional activation by tetracyclines in mammalian cells. Science 268, 1766-1769.[Medline] Harmon, J. S., Gleason, C. E., Tanaka, Y., Poitout, V. and Robertson, R. P. (2001). Antecedent hyperglycemia, not hyperlipidemia, is associated with increased islet triacylglycerol content and decreased insulin gene mRNA level in Zucker diabetic fatty rats. Diabetes 50, 2481-2486.[Abstract/Free FullText] Horton, J. D., Goldstein, J. L. and Brown, M. S. (2002). SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109, 1125-1131.[Free FullText] Horton, J. D., Shah, N. A., Warrington, J. A., Anderson, N. N., Park, S. W., Brown, M. S. and Goldstein, J. L. (2003). Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl. Acad. Sci. USA 100, 12027-12032.[Abstract/Free FullText] Ide, T., Shimano, H., Yahagi, N., Matsuzaka, T., Nakakuki, M., Yamamoto, T., Nakagawa, Y., Takahashi, A., Suzuki, H., Sone, H. et al. (2004). SREBPs suppress IRS-2-mediated insulin signalling in the liver. Nat. Cell Biol. 6, 351-357.[CrossRef][Medline] Iizuka, K., Bruick, R. K., Liang, G., Horton, J. D. and Uyeda, K. (2004). Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc. Natl. Acad. Sci. USA 101, 7281-7286.[Abstract/Free FullText] Ishii, S., Iizuka, K., Miller, B. C. and Uyeda, K. (2004). Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription. Proc. Natl. Acad. Sci. USA 101, 15597-15602.[Abstract/Free FullText] Joseph, J. W., Koshkin, V., Zhang, C. Y., Wang, J., Lowell, B. B., Chan, C. B. and Wheeler, M. B. (2002). Uncoupling protein 2 knockout mice have enhanced insulin secretory capacity after a high-fat diet. Diabetes 51, 3211-3219.[Abstract/Free FullText] Joseph, J. W., Koshkin, V., Saleh, M. C., Sivitz, W. I., Zhang, C. Y., Lowell, B. B., Chan, C. B. and Wheeler, M. B. (2004). Free fatty acid-induced beta-cell defects are dependent on uncoupling protein 2 expression. J. Biol. Chem. 279, 51049-51056.[Abstract/Free FullText] Kakuma, T., Lee, Y., Higa, M., Wang, Z., Pan, W., Shimomura, I. and Unger, R. H. (2000). Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. Proc. Natl. Acad. Sci. USA 97, 8536-8541.[Abstract/Free FullText] Kharroubi, I., Ladriere, L., Cardozo, A. K., Dogusan, Z., Cnop, M. and Eizirik, D. L. (2004). Free fatty acids and cytokines induce pancreatic beta-cell apoptosis by different mechanisms: role of nuclear factor-kappaB and endoplasmic reticulum stress. Endocrinology 145, 5087-5096.[Abstract/Free FullText] Kim, J. B. and Spiegelman, B. M. (1996). ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev. 10, 1096-1107.[Abstract] Kubota, N., Terauchi, Y., Tobe, K., Yano, W., Suzuki, R., Ueki, K., Takamoto, I., Satoh, H., Maki, T., Kubota, T. et al. (2004). Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus. J. Clin. Invest. 114, 917-927.[Abstract/Free FullText] Lameloise, N., Muzzin, P., Prentki, M. and Assimacopoulos-Jeannet, F. (2001). Uncoupling protein 2, a possible link between fatty acid excess and impaired glucose-induced insulin secretion? Diabetes 50, 803-809.[Abstract/Free FullText] Laudes, M., Barroso, I., Luan, J., Soos, M. A., Yeo, G., Meirhaeghe, A., Logie, L., Vidal-Puig, A., Schafer, A. J., Wareham, N. J. et al. (2004). Genetic variants in human sterol regulatory element binding protein-1c in syndromes of severe insulin resistance and type 2 diabetes. Diabetes 53, 842-846.[Abstract/Free FullText] Lin, H. Z., Yang, S. Q., Chuckaree, C., Kuhajda, F., Ronnet, G. and Diehl, A. M. (2000). Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat. Med. 6, 998-1003.[CrossRef][Medline] Lin, X., Taguchi, A., Park, S., Kushner, J. A., Li, F., Li, Y. and White, M. F. (2004). Dysregulation of insulin receptor substrate 2 in beta cells and brain causes obesity and diabetes. J. Clin. Invest. 114, 908-916.[Abstract/Free FullText] Loftus, T. M. and Lane, M. D. (1997). Modulating the transcriptional control of adipogenesis. Curr. Opin. Genet. Dev. 7, 603-608.[CrossRef][Medline] Matsuzaka, T., Shimano, H., Yahagi, N., Amemiya-Kudo, M., Okazaki, H., Tamura, Y., Iizuka, Y., Ohashi, K., Tomita, S., Sekiya, M. et al. (2004). Insulin-independent induction of sterol regulatory element-binding protein-1c expression in the livers of streptozotocin-treated mice. Diabetes 53, 560-569.[Abstract/Free FullText] Medvedev, A. V., Robidoux, J., Bai, X., Cao, W., Floering, L. M., Daniel, K. W. and Collins, S. (2002). Regulation of the uncoupling protein-2 gene in INS-1 beta-cells by oleic acid. J. Biol. Chem. 277, 42639-42644.[Abstract/Free FullText] Ozcan, U., Cao, Q., Yilmaz, E., Lee, A. H., Iwakoshi, N. N., Ozdelen, E., Tuncman, G., Gorgun, C., Glimcher, L. H. and Hotamisligil, G. S. (2004). Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306, 457-461.[Abstract/Free FullText] Petersen, K. F., Oral, E. A., Dufour, S., Befroy, D., Ariyan, C., Yu, C., Cline, G. W., DePaoli, A. M., Taylor, S. I., Gorden, P. et al. (2002). Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J. Clin. Invest. 109, 1345-1350.[Abstract/Free FullText] Poitout, V. and Robertson, R. P. (2002). Minireview: Secondary beta-cell failure in type 2 diabetes - a convergence of glucotoxicity and lipotoxicity. Endocrinology 143, 339-342.[Abstract/Free FullText] Riddle, T. M., Kuhel, D. G., Woollett, L. A., Fichtenbaum, C. J. and Hui, D. Y. (2001). HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J. Biol. Chem. 276, 37514-37519.[Abstract/Free FullText] Rishi, V., Gal, J., Krylov, D., Fridriksson, J., Boysen, M. S., Mandrup, S. and Vinson, C. (2004). SREBP-1 dimerization specificity maps to both the helix-loop-helix and leucine zipper domains: use of a dominant negative. J. Biol. Chem. 279, 11863-11874.[Abstract/Free FullText] Roche, E., Farfari, S., Witters, L. A., Assimacopoulos-Jeannet, F., Thumelin, S., Brun, T., Corkey, B. E., Saha, A. K. and Prentki, M. (1998). Long-term exposure of beta-INS cells to high glucose concentrations increases anaplerosis, lipogenesis, and lipogenic gene expression. Diabetes 47, 1086-1094.[Abstract] Roehrich, M. E., Mooser, V., Lenain, V., Herz, J., Nimpf, J., Azhar, S., Bideau, M., Capponi, A., Nicod, P., Haefliger, J. A. et al. (2003). Insulin-secreting beta-cell dysfunction induced by human lipoproteins. J. Biol. Chem. 278, 18368-18375.[Abstract/Free FullText] Rubi, B., Ishihara, H., Hegardt, F. G., Wollheim, C. B. and Maechler, P. (2001). GAD65-mediated glutamate decarboxylation reduces glucose-stimulated insulin secretion in pancreatic beta cells. J. Biol. Chem. 276, 36391-36396.[Abstract/Free FullText] Schreiber, E., Matthias, P., Muller, M. M. and Schaffner, W. (1988). Identification of a novel lymphoid specific octamer binding protein (OTF-2B) by proteolytic clipping bandshift assay (PCBA). EMBO J. 7, 4221-4229.[Abstract] Shimomura, I., Bashmakov, Y. and Horton, J. D. (1999a). Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J. Biol. Chem. 274, 30028-30032.[Abstract/Free FullText] Shimomura, I., Bashmakov, Y., Ikemoto, S., Horton, J. D., Brown, M. S. and Goldstein, J. L. (1999b). Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc. Natl. Acad. Sci. USA 96, 13656-13661.[Abstract/Free FullText] Shimomura, I., Hammer, R. E., Ikemoto, S., Brown, M. S. and Goldstein, J. L. (1999c). Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401, 73-76.[CrossRef][Medline] Shimomura, I., Matsuda, M., Hammer, R. E., Bashmakov, Y., Brown, M. S. and Goldstein, J. L. (2000). Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol. Cell 6, 77-86.[CrossRef][Medline] Sun, L., Halaihel, N., Zhang, W., Rogers, T. and Levi, M. (2002). Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J. Biol. Chem. 277, 18919-18927.[Abstract/Free FullText] Takahashi, A., Motomura, K., Kato, T., Yoshikawa, T., Nakagawa, Y., Yahagi, N., Sone, H., Suzuki, H., Toyoshima, H., Yamada, N. et al. (2005). Transgenic mice overexpressing nuclear SREBP-1c in pancreatic {beta}-cells. Diabetes 54, 492-499.[Abstract/Free FullText] Takaishi, K., Duplomb, L., Wang, M. Y., Li, J. and Unger, R. H. (2004). Hepatic insig-1 or -2 overexpression reduces lipogenesis in obese Zucker diabetic fatty rats and in fasted/refed normal rats. Proc. Natl. Acad. Sci. USA 101, 7106-7111.[Abstract/Free FullText] Tobe, K., Suzuki, R., Aoyama, M., Yamauchi, T., Kamon, J., Kubota, N., Terauchi, Y., Matsui, J., Akanuma, Y., Kimura, S. et al. (2001). Increased expression of the sterol regulatory element-binding protein-1 gene in insulin receptor substrate-2(-/-) mouse liver. J. Biol. Chem. 276, 38337-38340.[Abstract/Free FullText] Tontonoz, P., Kim, J. B., Graves, R. A. and Spiegelman, B. M. (1993). ADD1: a novel helix-loop-helix transcription factor associated with adipocyte determination and differentiation. Mol. Cell. Biol. 13, 4753-4759.[Abstract] Ueki, K., Kondo, T., Tseng, Y. H. and Kahn, C. R. (2004). Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc. Natl. Acad. Sci. USA 101, 10422-10427.[Abstract/Free FullText] Unger, R. H. (2002). Lipotoxic diseases. Annu. Rev. Med. 53, 319-336.[CrossRef][Medline] Unger, R. H. and Zhou, Y. T. (2001). Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes 50, S118-S121.[Free FullText] Unger, R. H., Zhou, Y. T. and Orci, L. (1999). Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc. Natl. Acad. Sci. USA 96, 2327-2332.[Abstract/Free FullText] Wang, H. and Iynedjian, P. B. (1997). Modulation of glucose responsiveness of insulinoma beta-cells by graded overexpression of glucokinase. Proc. Natl. Acad. Sci. USA 94, 4372-4377.[Abstract/Free FullText] Wang, H. and Wollheim, C. B. (2002). ChREBP Rather than USF2 regulates glucose stimulation of endogenous L-pyruvate kinase expression in insulin-secreting cells. J. Biol. Chem. 277, 32746-32752.[Abstract/Free FullText] Wang, H., Maechler, P., Hagenfeldt, K. A. and Wollheim, C. B. (1998). Dominant-negative suppression of HNF-1alpha function results in defective insulin gene transcription and impaired metabolism-secretion coupling in a pancreatic beta-cell line. EMBO J. 17, 6701-6713.[Abstract/Free FullText] Wang, H., Maechler, P., Ritz-Laser, B., Hagenfeldt, K. A., Ishihara, H., Philippe, J. and Wollheim, C. B. (2001). Pdx1 level defines pancreatic gene expression pattern and cell lineage differentiation. J. Biol. Chem. 276, 25279-25286.[Abstract/Free FullText] Wang, H., Maechler, P., Antinozzi, P. A., Herrero, L., Hagenfeldt-Johansson, K. A., Bjorklund, A. and Wollheim, C. B. (2003). The transcription factor SREBP-1c is instrumental in the development of beta-cell dysfunction. J. Biol. Chem. 278, 16622-16629.[Abstract/Free FullText] Wang, M. Y., Koyama, K., Shimabukuro, M., Mangelsdorf, D., Newgard, C. B. and Unger, R. H. (1998). Overexpression of leptin receptors in pancreatic islets of Zucker diabetic fatty rats restores GLUT-2, glucokinase, and glucose-stimulated insulin secretion. Proc. Natl. Acad. Sci. USA 95, 11921-11926.[Abstract/Free FullText] Weir, G. C. (1982). Non-insulin-dependent diabetes mellitus: interplay between B-cell inadequacy and insulin resistance. Am. J. Med. 73, 461-464.[CrossRef][Medline] Weir, G. C., Laybutt, D. R., Kaneto, H., Bonner-Weir, S. and Sharma, A. (2001). Beta-cell adaptation and decompensation during the progression of diabetes. Diabetes 50, S154-S159.[Free FullText] Werstuck, G. H., Lentz, S. R., Dayal, S., Hossain, G. S., Sood, S. K., Shi, Y. Y., Zhou, J., Maeda, N., Krisans, S. K., Malinow, M. R. et al. (2001). Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J. Clin. Invest. 107, 1263-1273.[Abstract/Free FullText] Withers, D. J., Gutierrez, J. S., Towery, H., Burks, D. J., Ren, J. M., Previs, S., Zhang, Y., Bernal, D., Pons, S., Shulman, G. I. et al. (1998). Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391, 900-904.[CrossRef][Medline] Xu, A., Yin, S., Wong, L., Chan, K. W. and Lam, K. S. (2004). Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice. Endocrinology 145, 487-494.[Abstract/Free FullText] Yahagi, N., Shimano, H., Hasty, A. H., Amemiya-Kudo, M., Okazaki, H., Tamura, Y., Iizuka, Y., Shionoiri, F., Ohashi, K., Osuga, J. et al. (1999). A crucial role of sterol regulatory element-binding protein-1 in the regulation of lipogenic gene expression by polyunsaturated fatty acids. J. Biol. Chem. 274, 35840-35844.[Abstract/Free FullText] Yahagi, N., Shimano, H., Hasty, A. H., Matsuzaka, T., Ide, T., Yoshikawa, T., Amemiya-Kudo, M., Tomita, S., Okazaki, H., Tamura, Y. et al. (2002). Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J. Biol. Chem. 277, 19353-19357.[Abstract/Free FullText] Yamashita, T., Eto, K., Okazaki, Y., Yamashita, S., Yamauchi, T., Sekine, N., Nagai, R., Noda, M. and Kadowaki, T. (2004). Role of uncoupling protein-2 up-regulation and triglyceride accumulation in impaired glucose-stimulated insulin secretion in a beta-cell lipotoxicity model overexpressing sterol regulatory element-binding protein-1c. Endocrinology 145, 3566-3577.[Abstract/Free FullText] Yan, L., Nairn, A. C., Palfrey, H. C. and Brady, M. J. (2003). Glucose regulates EF-2 phosphorylation and protein translation by a protein phosphatase-2A-dependent mechanism"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   764   C0597295:Protein Translation [Molecular Function]
           translation
   742   C0040712:Translation [Intellectual Product]
   742   C1519614:Translation [Genetic Function]

Phrase: "in"

Phrase: "INS-1-"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: "derived"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1441547:Derived [Qualitative Concept]
  1000   C3245521:derived [Idea or Concept]

Phrase: "832/13 cells."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   827   C0007634:Cells [Cell]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.809: J. 

Phrase: "J."
Processing 00000000.tx.810: Biol. 

Phrase: "Biol."
Processing 00000000.tx.811: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.812: 278, 18177-18183.[Abstract/Free FullText] Ye, J., Rawson, R. 

Phrase: "278,"

Phrase: "18177-18183."

Phrase: "[Abstract/Free FullText"

Phrase: "] Ye,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0043402:YE [Geographic Area]

Phrase: "J.,"

Phrase: "Rawson,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.813: B., Komuro, R., Chen, X., Dave, U. 

Phrase: "B.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "Komuro,"

Phrase: "R.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]

Phrase: "Chen,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0999213:Chen [Bird]

Phrase: "X.,"

Phrase: "Dave,"

Phrase: "U."
Processing 00000000.tx.814: P., Prywes, R., Brown, M. 

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Prywes,"

Phrase: "R.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]

Phrase: "Brown,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0678579:Brown [Natural Phenomenon or Process]

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.815: S. and Goldstein, J. 

Phrase: "S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]

Phrase: "and"

Phrase: "Goldstein,"

Phrase: "J."
Processing 00000000.tx.816: L. 

Phrase: "L."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]
Processing 00000000.tx.817: (2000). 

Phrase: "(2003). Glucose regulates EF-2 phosphorylation and protein translation by a protein phosphatase-2A-dependent mechanism in INS-1-derived 832/13 cells. J. Biol. Chem. 278, 18177-18183.[Abstract/Free FullText] Ye, J., Rawson, R. B., Komuro, R., Chen, X., Dave, U. P., Prywes, R., Brown, M. S. and Goldstein, J. L. (2000"

Phrase: "). Glucose regulates EF-2 phosphorylation and protein translation by a protein phosphatase-2A-dependent mechanism in INS-1-derived 832/13 cells. J. Biol. Chem. 278, 18177-18183.[Abstract/Free FullText] Ye, J., Rawson, R. B., Komuro, R., Chen, X., Dave, U. P., Prywes, R., Brown, M. S. and Goldstein, J. L. (2000)."
Processing 00000000.tx.818: ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs. 

Phrase: "ER stress"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C3178870:Endoplasmic Reticulum Stress [Cell or Molecular Dysfunction]
   901   C0014239:Endoplasmic Reticulum [Cell Component]
   827   C0035295:Reticulum [Body Part, Organ, or Organ Component]
   827   C0038435:Stress [Finding]
   755 E C0231297:Stressful [Functional Concept]
   755   C0598268:Endoplasm [Cell Component]

Phrase: "induces"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induce [Functional Concept]

Phrase: "SCAP) escorts SREBPs from the ER to the Golgi, where SREBPs are sequentially cleaved by site-1 protease (S1P) and site-2 protease (S2P). The processed mature SREBPs enter the nucleus and transactivate target genes (Brown and Goldstein, 1997). Three SREBP isoforms have been identified: SREBP-1a and -1c (alternatively known as adipocyte determination and differentiation factor-1; ADD-1) (Tontonoz et al., 1993) that are derived from the same gene through alternative splicing, and SREBP-2 that is encoded by a distinct gene (Brown and Goldstein, 1997). SREBPs are expressed ubiquitously, play an essential role in regulation of lipid homeostasis in animals and have been shown to directly activate the expression of more than 30 genes dedicated to the biosynthesis of cholesterol, fatty acids, triglycerides and phospholipids (Horton et al., 2002). Elevated expression of SREBP-1c has been demonstrated in islets and liver of many animal models of diabetes (Kakuma et al., 2000; Lin et al., 2000; Matsuzaka et al., 2004; Riddle et al., 2001; Shimomura et al., 1999a; Shimomura et al., 1999b; Shimomura et al., 1999c; Shimomura et al., 2000; Sun et al., 2002; Takaishi et al., 2004; Tobe et al., 2001; Ueki et al., 2004; Unger and Zhou, 2001; Unger et al., 1999; Werstuck et al., 2001; Xu et al., 2004; Yahagi et al., 2002; You et al., 2002) and patients with severe lipodystrophy (Bastard et al., 2002; Petersen et al., 2002). Lipid accumulation, impaired glucose-stimulated insulin secretion, defective -cell gene expression (insulin, Pdx1, glucokinase and Glut2), disorganized mitochondrial ultrastructure and `lipoapoptosis' have been reported in the  cells of diabetic animals (Unger and Zhou, 2001; Unger et al., 1999). Moreover, preventing SREBP-1c overexpression and activation is common to leptin, metformin, adiponectin and PPAR agonists. Thus there is a good correlation between suppression of SREBP-1c function and antidiabetic effects of these agents (Kakuma et al., 2000; Lin et al., 2000; Petersen et al., 2002; Shimomura et al., 1999a; Shimomura et al., 1999b; Shimomura et al., 1999c; Tobe et al., 2001; Unger and Zhou, 2001; Unger et al., 1999; Wang, M. Y. et al., 1998; Xu et al., 2004; Zhou et al., 2001). We and others have demonstrated that overexpression of a nuclear active form of SREBP-1c (naSREBP-1c) in insulinoma (INS-1 and MIN6) cells and isolated rat islets results in -cell lipotoxicity (Andreolas et al., 2002; Diraison et al., 2004; Wang et al., 2003; Yamashita et al., 2004). We have previously shown that long-term exposure of INS-1 cells to 30 mM glucose generated the mature nuclear form of SREBP-1c (Wang et al., 2003). Glucose also raises SREBP-1c mRNA levels in rat  cells (Flamez et al., 2002). It is well known that chronic high glucose treatment causes glucolipotoxicity in both insulinoma cells and rat islets (Efanova et al., 1998; Roche et al., 1998). We hypothesise that SREBP-1c activation could play an essential role in development of -cell glucolipotoxicity. To further substantiate this notion we established an INS-1 stable cell line that allowed suppression of SREBP-1c function through induction of a dominant-negative mutant of SREBP-1c (DN-SREBP-1c) (Kim and Spiegelman, 1996). Strong experimental evidence demonstrated that dominant-negative suppression of SREBP-1c activity markedly prevented -cell glucolipotoxicity. In addition, we found that ER-stress-generated SREBP-1c processing and activation could be the underlying mechanism in -cell glucolipotoxicity.  Materials and Methods Top Summary Introduction Materials and Methods Results Discussion References  Cell culture The standard rat insulinoma INS-1E cells and two previously established INS-1-derived stable cell lines, ChREBP*16 (Wang and Wollheim, 2002) and naSREBP-1c*233 (Wang et al., 2003), allowing inducible expression, respectively, of ChREBP and a nuclear active form of SREBP-1c, were cultured in RPMI1640 containing 11.2 mM glucose (Asfari et al., 1992), unless otherwise indicated. Establishment of INS-1 cells permitting inducible expression of DN-SREBP-1c The first step stable INS-r (also refer to as r9) cell line, which carries the reverse tetracycline/doxycycline-dependent transactivator (Gossen et al., 1995), was described previously (Wang and Iynedjian, 1997; Wang et al., 2001). The plasmid used in the secondary stable transfection was constructed by subcloning the cDNA encoding the dominant-negative form of SREBP-1c (DN-SREBP-1c/ADD1 1-403(Y320A) [(Kim and Spiegelman, 1996) kindly supplied by B.M. Spiegelman] into the expression vector PUHD10-3 [(Gossen et al., 1995) a generous gift from H. Bujard]. The procedures for stable transfection, clone selection and screening were described previously (Wang and Iynedjian, 1997). Immunofluorescence Cells grown on polyornithine-treated glass coverslips were treated for 24 hours with or without 500 ng/ml doxycycline. Cells were then washed, fixed in 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 in phosphate-buffered saline containing 1% BSA (PBS-BSA). The preparation was then blocked with PBS-BSA before incubating with the first antibody, anti-SREBP-1 (Santa Cruz, Basel, Switzerland; 1:100 dilution), followed by the second antibody labelling. Nuclear protein extraction and electrophoretic mobility-shift assay (EMSA) Nuclear extracts from INS-1 cells were prepared according to the method of Schreiber et al. (Schreiber et al., 1988). Rat islets were isolated by collagenase digestion as described previously (Rubi et al., 2001) and their nuclear proteins were extracted as previously reported (Schreiber et al., 1988). The double-stranded oligonucleotides corresponding to the sterol regulatory element (SRE) in the human insulin receptor substrate 2 (IRS2) promoter (Ide et al., 2004), 5'cctgcgtaacgccgagtcacatgttgtt3', was used as a probe. EMSA procedures, including conditions for probe labelling and binding reactions were performed as in Wang et al. (Wang, H. et al., 1998). Mouse monoclonal antibodies against SREBP-1 (NeoMarkers, Fremont CA, USA) and SREBP-2 (purified from the supernatant of the hybridoma cell line CRL2121, American Tissue Culture Collection, Rockville, MD, USA) were used for supershift experiments. Staining of lipid accumulation by Oil Red O Cells were cultured in standard (11.2 mM) or 30 mM glucose medium in the presence or absence of 500 ng/ml doxycycline for 48 hours. Cells were fixed and stained as previously reported (Kim and Spiegelman, 1996). Lipid droplets were visualized using phase-contrast microscopy (Nikon Diaphot). Measurements of insulin secretion and cellular insulin content Insulin secretion in INS-1E or DN-SREBP-1c#23 cells was measured in 24-well plates over a period of 30 minutes, in Krebs-Ringer-bicarbonate-Hepes buffer (KRBH, 140 mM NaCl, 3.6 mM KCl, 0.5 mM NaH2PO4, 0.5 mM MgSO4, 1.5 mM CaCl2, 2 mM NaHCO3, 10 mM Hepes, 0.1% BSA) containing the indicated concentrations of glucose. Cellular insulin content was determined after extraction with acid ethanol following the procedures of Wang et al. (Wang, H. et al., 1998). Insulin was detected by radio-immunoassay using rat insulin as a standard (Wang, H. et al., 1998). Total RNA isolation and northern blotting Total RNA was extracted and blotted to nylon membranes as described previously (Wang and Iynedjian, 1997). The membrane was prehybridized and then hybridized to 32P-labelled random primer cDNA probes according to the method of Wang and Iynedijian (Wang and Iynedjian, 1997). To ensure equal RNA loading and even transfer, all membranes were stripped and re-hybridized with a `house-keeping gene' probe, cyclophilin. cDNA fragments used as probes for SREBP-1c, ChREBP, glucokinase, GLUT2, L-pyruvate kinase, insulin, BIP, CHOP10 and PDX1 mRNA detection were digested from the corresponding plasmids. cDNA probes for rat mitochondrial uncoupling protein 2 (UCP2), aldolase B, fatty acid synthase, acetyl-CoA carboxylase, glycerol-phosphate acyltransferase, HMG-CoA reductase, P21WAF1/CIP1, BAD, APO1, BclXL, IRS2 and low density lipoprotein receptor (LDLR), were prepared by RT-PCR and confirmed by sequencing. Cell proliferation/viability and apoptosis Quantification of cell proliferation/viability was measured using a Quick Cell Proliferation Assay Kit (LabForce/MBL, Nunningen, Switzerland) according to manufacturer's protocol. This assay is based on the cleavage of a tetrazolium salt WST-1 to formazan by mitochondrial dehydrogenases. Expansion in the number of viable cells results in an increase in the overall activity of the mitochondrial dehydrogenases and subsequently an augmentation in the amount of formazan dye formed. The formazan dye produced by viable cells was quantified with a multiwell spectrophotometer by measuring the absorbance at 440 nm. Experiments for DNA fragmentation were performed using a Quick Apoptosis DNA Ladder Detection Kit (LabForce/MBL, Nunningen, Switzerland) following the manufacturer's protocol. Statistics Results are expressed as mean  s.e.m. and statistical analyses were performed using Student's t-test.  Results Top Summary Introduction Materials and Methods Results Discussion References  Effects of chronic high-glucose treatment on insulin secretion and -cell gene expression in INS-1E cells As shown in Fig. 1A, 30 mM glucose treatment of INS-1E cells for 48 hours resulted in reduced glucose- and leucine-stimulated insulin secretion. In contrast, KCl-depolarization-elicited insulin release was unaffected, suggesting that Ca2+-stimulated exocytosis was unaffected. We could also confirm, as previously reported (Roche et al., 1998), that chronic high glucose treatment led to lipid accumulation and INS-1 cell apoptosis (see below). To explore the underlying mechanism, quantitative northern blotting was performed to investigate the gene expression patterns in INS-1E cells treated for 48 hours with 30 mM glucose. The mRNA levels of essential -cell genes such as insulin, Pdx1, Glut2, glucokinase and IRS2 were drastically suppressed by high-glucose treatment (Fig. 1B). In addition, pro-apoptotic genes, P21, Bad and APO-1 were upregulated, whereas the anti-apoptotic gene Bclxl was downregulated (Fig. 1B). Furthermore, lipogenic genes, fatty acid synthase, acetyl-CoA carboxylase, glycerol-phosphate acyltransferase, HMG-CoA reductase and LDL receptor were all markedly induced by high glucose treatment (Fig. 1C). Similar alterations in all genes mentioned above have been reported in an INS-1 stable cell line expressing naSREBP-1c (Wang et al., 2003). This strikingly similar gene expression profile suggested that chronic high glucose could cause -cell glucolipotoxicity through activation of SREBP-1c. View larger version (60K): [in this window] [in a new window]  Fig. 1. Effects of chronic high glucose treatment on insulin secretion and gene expression in INS-1E cell. (A) INS-1E cells in 24-well dishes were cultured in either standard (11.2 mM) or 30 mM glucose medium for 48 hours. After 5 hours equilibration in 2.5 mM glucose medium, cells were washed twice with KRBH. Insulin release from INS-1E cells stimulated with 20 mM glucose, 20 mM leucine and 20 mM KCl in KRBH buffer containing 2.5 mM (referred to Basal) was determined by radio-immunoassay and expressed as a percentage of cellular insulin content. The equilibration period is necessary to see the glucose-responsiveness of insulin release in INS-1 cells. Cellular insulin content was decreased by 32.46.7% after 48 hours treatment with 30 mM glucose. Data represent mean  s.e.m. of six independent experiments. **P<0.001. (B,C) The gene expression patterns in INS-1E cells cultured in either standard (11.2 mM) or 30 mM glucose medium for 48 hours were quantified by northern blotting. Total RNA samples (20 g/lane) were analysed by hybridizing with the indicated cDNA probes. Four independent experiments are shown side by side to demonstrate the consistency of the results.  However, we have also reported that the transcription, nuclear translocation and DNA-binding activity of ChREBP are regulated by glucose in INS-1 cells (Wang and Wollheim, 2002). As demonstrated in Fig. 1C, mRNA levels of ChREBP, L-PK and aldolase B were markedly increased by high glucose. ChREBP is known to regulate lipogenic gene expression in the liver (Dentin et al., 2004; Iizuka et al., 2004; Ishii et al., 2004), we therefore examined whether it is also involved in -cell glucolipotoxicity. SREBP-1c rather than ChREBP is implicated in glucolipotoxicity in INS-1 cells Differential gene expression patterns in INS-1 cells induced by ChREBP and naSREBP-1c are illustrated in Fig. 2A,B. Quantitative northern blotting was performed in two stable INS-1 cell lines previously established to express, respectively, ChREBP (Wang and Wollheim, 2002) and naSREBP-1c (Wang et al., 2003) in a doxycycline-dependent manner. The results displayed in Fig. 2A indicate that ChREBP predominantly targeted L-PK and aldolase B, although induction of ChREBP also slightly enhanced the expression of fatty acid synthase and acetyl-CoA carboxylase. In contrast, induction of SREBP-1c drastically increased the lipogenic gene expression for proteins such as, fatty acid synthase, acetyl-CoA carboxylase, HMG-CoA reductase and LDL receptor, whereas it did not affect the mRNA levels of L-PK and aldolase B (Fig. 2B). It is noteworthy that the function of SREBP-1c may also overlap with the function of SREBP-2 on target gene expression in INS-1 cells since HMG-CoA reductase is regulated by naSREBP-1c. In addition, the expression of IRS2 was suppressed by naSREBP-1c but unaffected by ChREBP. It has been reported recently that SREBP-1c binds to the human IRS2 promoter and suppresses its activity in rat and mouse hepatocytes (Ide et al., 2004). View larger version (51K): [in this window] [in a new window]  Fig. 2. Comparison of gene expression patterns in INS-1 cells allowing inducible expression, respectively, of ChREBP and the nuclear active form (na) of SREBP-1c. (A) ChREBP*16 cells were cultured in standard medium (11.2 mM glucose) with 0, 75, 150 or 500 ng/ml doxycycline for 24 hours. The culture was continued in 2.5 mmol/l glucose medium with the indicated concentrations of doxycycline for 16 hours, followed by an additional 8 hours in culture medium with 2.5, 6, 12 and 24 mM glucose and with or without doxycycline. The equilibration period is necessary to see the glucose-responsiveness of gene expression. (B) SREBP-1c*233 cells were cultured in 2.5 mM glucose medium with the indicated concentrations of doxycycline for 16 hours, followed by an additional 8 hours in culture medium with 2.5, 6, 12 and 24 mM glucose and with or without doxycycline. SREBP-1c was induced for a total of 24 hours to avoid its apoptotic effects. Gene expression patterns in these cells were evaluated by quantitative northern blotting. 20 g total RNA samples were analysed by hybridising with indicated cDNA probes. WT, the endogenous wild-type SREBP-1c; NA, the induced nuclear active form of SRENP-1c. The experiments were repeated two times with similar results.  Induction of ChREBP in INS-1 cells did not affect glucose-stimulated insulin secretion or cell growth. In contrast to the effect of naSREBP-1c, induction of ChREBP with 500 ng/ml doxycycline for 48 hours did not alter glucose-stimulated insulin secretion or cellular insulin content. To assess the impact of ChREBP on INS-1 cell growth and viability, we performed the WST-1 assay (Fig. 3B). This assay is based on the cleavage of a tetrazolium salt WST-1 to formazan by mitochondrial dehydrogenases. Expansion in the number of viable cells results in an increase in the overall activity of the mitochondrial dehydrogenases and subsequently an augmentation in the amount of formazan dye formed. Unlike overexpression of naSREBP-1c (Wang et al., 2003), maximum induction of ChREBP for 48 hours did not cause INS-1 cell growth arrest (Fig. 3B) or apoptosis as assessed by DNA fragmentation experiments (data not shown). We have previously shown that similar induction of SREBP-1c caused apoptosis in INS-1 cells (Wang et al., 2003). View larger version (14K): [in this window] [in a new window]  Fig. 3. Overexpression of ChREBP did not affect glucose-stimulated insulin secretion or cell growth. (A) ChREBP*16 cells were cultured with (+Dox) or without (-Dox) 500 ng/ml doxycycline in standard medium (11.2 mM glucose) for 24 hours and then equilibrated in 2.5 mM glucose medium for a further 24 hours. Insulin release from ChREBP*16 cells in KRBH buffer containing the indicated concentrations of glucose was determined by radio-immunoassay and expressed as a percentage of cellular insulin content. Data represent six independent experiments. (B) A WST-1 assay, presented as optical density at 440 nm, showed that ChREBP*16 cell growth/survival was not affected by 48 hours treatment with 500 ng/ml doxycycline.  Establishment of INS-1 stable cell line permitting inducible expression of DN-SREBP-1c To further substantiate the implication of SREBP-1c in chronic high-glucose-induced glucolipotoxicity, we generated an INS-1 stable cell line expressing DN-SREBP-1c, called DN-SREBP-1c*23 cells. This mutant protein contains an intact dimerization domain but lacks DNA-binding activity (Kim and Spiegelman, 1996). DN-SREBP-1c therefore exerts its dominant-negative function by forming non-functional heterodimers with endogenous SREBPs (Kim and Spiegelman, 1996). Immunofluorescence staining with an antibody against the N terminus of SREBP-1c demonstrated that DN-SREBP-1c protein was induced by doxycycline in an all-or-none manner (Fig. 4A). View larger version (63K): [in this window] [in a new window]  Fig. 4. Characteristics of the INS-1 stable cell line expressing DN-SREBP-1c. (A) Phase-contrast images (top) and immunofluorescence staining (bottom) with a rabbit polyclonal antibody against SREBP-1 showed that DN-SREBP-1c protein was induced by doxycycline in an all-or-none manner. DN-SREBP-1c*23 cells were cultured with (+Dox) or without (-Dox) 500 ng/ml doxycycline for 48 hours. (B) Gel-shift assay of nuclear extracts from DN-SREBP-1c*23 cells using the SRE sequence of the IRS2 promoter. DN-SREBP-1c*23 cells were cultured in either standard (11.2 mM) or 30 mM glucose medium for 48 hours, in the presence (+Dox) or absence (-Dox) of 500 ng/ml doxycycline. Monoclonal SREBP-1-specific antibody was used for the supershift experiment. Experiments were repeated two to three times with similar results. (C) EMSA of nuclear extracts from non-induced DN-SREBP-1c*23 cells using the SRE sequence of the IRS2 promoter. DN-SREBP-1c*23 cells were cultured in either standard (11.2 mM) or 30 mM glucose medium for 48 hours. Monoclonal SREBP-2-specific antibody was used for the supershift experiment. Experiments were repeated twice with similar results.  Effects of DN-SREBP-1c on chronic high-glucose-induced glucolipotoxicity in INS-1 cells Induction of DN-SREBP-1c abolished chronic high-glucose-induced SREBP-1 binding to the IRS2 promoter. DN-SREBP-1c*23 cells were cultured in either standard (11.2 mM) or 30 mM glucose medium for 48 hours, in the presence (+Dox) or absence (-Dox) of 500 ng/ml doxycycline. EMSA with the SRE element of the human IRS2 promoter (Ide et al., 2004) showed that SREBP protein binding was increased 10-fold by 48 hours treatment with 30 mM glucose, which was diminished by 80% after induction of DN-SREBP-1c (Fig. 4B). The specificity of SREBP-1 binding complexes was confirmed by the observed supershift with a monoclonal anti-SREBP-1 antibody (Fig. 4B). However, we could not exclude binding activity of SREBP-2 to the IRS2-SRE-element, since it would also be inhibited by DN-SREBP-1c (Rishi et al., 2004). Indeed, monoclonal anti-SREBP-2 antibody also caused a supershift of the retarded complex but to a much lesser extent than the SREBP-1-specific antibody (Fig. 4C). These results suggest that SREBP-1 accounts for the majority of the glucose-induced binding activity to the IRS2 promoter. Induction of DN-SREBP-1c diminished chronic high-glucose-induced lipid accumulation, apoptosis and impaired insulin secretion in INS-1 cells. As shown by Oil-Red-O staining (Fig. 5A), 30 mM glucose treatment of DN-SREBP-1c*23 cells for 48 hours resulted in massive lipid accumulation, which was largely prevented by induction of DN-SREBP-1c. Similarly, treatment of DN-SREBP-1c*23 cells for 48 and 72 hours with 30 mM glucose caused typical DNA fragmentation (Fig. 5B), a characteristic hallmark of cells undergoing apoptosis. DN-SREBP-1c largely protected INS-1 cells from apoptosis (Fig. 5B). View larger version (48K): [in this window] [in a new window]  Fig. 5. Induction of DN-SREBP-1c largely prevented chronic high-glucose-induced glucolipotoxicity in INS-1 cells. (A) DN-SREBP-1c diminished lipid droplets accumulation, as seen by staining with Oil Red-O. DN-SREBP-1c*23 cells were cultured in either standard (11.2 mM; Control) or 30 mM glucose (High glucose) medium for 48 hours, in the presence (+Dox) or absence (-Dox) of 500 ng/ml doxycycline. (B) DN-SREBP-1c prevented apoptosis. DNA fragmentation was assessed in DN-SREBP-1c*23 cells cultured in 30 mM glucose medium for 0, 24, 48, and 72 hours, in the presence (+Dox) or absence (-Dox) of 500 ng/ml doxycycline. (C) DN-SREBP-1c partially restored glucose-stimulated insulin secretion. DN-SREBP-1c*23 cells in 24-well dishes were cultured in either standard (11.2 mM; Control) or 30 mM glucose (High Glucose) medium for 48 hours. After 5 hours equilibration in 2.5 mM glucose medium, cells were washed twice with KRBH. Insulin release from DN-SREBP-1c*23 cells stimulated with either 2.5 (Basal) or 20 mM glucose was determined by radio-immunoassay and expressed as a percentage of cellular insulin content. Data represent mean  s.e.m. of six independent experiments. *P<0.01; **P<0.001.  In agreement with the results obtained in INS-1E (Fig. 1A), treatment of DN-SREBP-1c*23 cells with 30 mM glucose for 48 hours also led to reduced glucose-stimulated insulin secretion (Fig. 5C). The glucose-stimulated insulin secretion was partially restored by expression of DN-SREBP-1c (Fig. 5C). Unexpectedly, induction of DN-SREBP-1c slightly increased basal (2.5 mM) insulin release in control cells (Fig. 5C). DN-SREBP-1c corrected defective gene expression in INS-1 cells treated with chronic high glucose As demonstrated in Fig. 6, treatment of DN-SREBP-1c*23 cells with 30 mM glucose for 48 hours increased the mRNA levels of L-PK, aldolase B and ChREBP, which were not affected by induction of DN-SREBP-1c. These results suggest that high glucose may promote the expression of L-PK and aldolase B through a SREBP-1c-independent but ChREBP-dependent pathway. In contrast, the protective effects of DNSREBP-1c in high-glucose-treated DN-SREBP-1c*23 cells revealed the SREBP-1c-dependent gene expression patterns, including upregulation of fatty acid synthase, HMG-CoA reductase, LDLR and P21, as well as downregulation of GLUT2, glucokinase, PDX1, IRS2 and BCLXL (Fig. 6). These data further substantiate the notion that SREBP-1c-target genes are implicated in chronic high-glucose-mediated -cell glucolipotoxicity. Ucp2 is also a downstream target gene of SREBP-1c in INS-1 cells (Wang et al., 2003; Yamashita et al., 2004). Interestingly, induction of DN-SREBP-1c suppressed UCP2, which may account for the increased basal insulin secretion observed (Fig. 5C). View larger version (66K): [in this window] [in a new window]  Fig. 6. Effects of DN-SREBP-1c on gene expression patterns induced by chronic high-glucose in INS-1 cells. DN-SREBP-1c*23 cells were cultured in either standard (11.2 mM; -) or 30 mM (+) glucose medium for 48 hours, in the presence (+Dox) or absence (-Dox) of 500 ng/ml doxycycline. The gene expression pattern in these cells was quantitatively evaluated by northern blotting. 20 g total RNA samples were analysed by hybridising with the indicated cDNA probes. The experiments were repeated twice with similar results.  ER-stress and SREBP-1 activation could be the molecular mechanisms underlying -cell glucolipotoxicity Increased expression of GADD153/CHOP10 and BIP are characteristics of ER stress response in many cell types. We found that treatment of INS-1E cells for 48 hours with 30 mM glucose markedly induced these ER stress marker genes (Fig. 7A). Therefore, chronic high-glucose-induced ER stress could be the underlying mechanism involved in SREBP-1 activation and subsequently INS-1 cell glucolipotoxicity, since it has been well documented that ER stress causes SREBP processing through S1P and S2P (Werstuck et al., 2001; Ye et al., 2000). View larger version (27K): [in this window] [in a new window]  Fig. 7. ER stress and SREBP-1 activation are implicated in -cell glucolipotoxicity. (A) The gene expression patterns in INS-1E cells cultured in either standard (11.2 mM; -) or 30 mM (+) glucose medium for 48 hours were quantified by northern blotting. Total RNA samples (20 g/lane) were analysed by hybridizing with the indicated cDNA probes. Four independent experiments are shown side by side to demonstrate the consistency of the results. (B) Gel-shift assay of nuclear extracts from isolated rat islets using the SRE sequence of the IRS2 promoter. SREBP-1 protein binding activity was assessed in rat islets treated with 30 mM glucose for 0 (freshly isolated), 1, 2, 3, 4, and 5 days or alternatively with two ER stress inducers, thapsigargin (1 M) and tunicamycin (10 g/ml) for 1 day. The mouse monoconal antibody against SREBP-1 was used for supershift experiments.  A similar mechanism may also apply to islet  cells. The EMSA shown in Fig. 7B indicates that treatment of isolated rat islets with either chronic high glucose or two ER stress inducers, thapsigargin and tunicamycin, drastically enhanced SREBP-1 binding to the SRE sequence of the IRS2 promoter. The specificity of retarded SREBP-1 complexes was confirmed by the supershift in the presence of the monoclonal antibody against SREBP-1 (Fig. 7B).  Discussion Top Summary Introduction Materials and Methods Results Discussion References  It is well known that chronic high-glucose treatment in vitro causes -cell glucolipotoxicity, including lipid accumulation, impaired glucose-stimulated insulin secretion and apoptosis (Efanova et al., 1998; Roche et al., 1998). These characteristics resemble the description of -cell lipotoxicity in ob/ob mice and Zucker Diabetic Fatty (ZDF) rats (Unger, 2002; Unger and Zhou, 2001). Overexpression or overactivation of SREBP-1c in the islets of these animals has been proposed as the causal factor (Unger, 2002; Unger and Zhou, 2001). Consistently, overexpression of a nuclear active form of SREBP-1c in insulinoma cells (INS-1 and MIN6) and isolated rat islets results in typical characteristics of -cell glucolipotoxicity (Andreolas et al., 2002; Diraison et al., 2004; Wang et al., 2003; Yamashita et al., 2004). Some investigators refer to lipotoxicity as the consequence of increased circulating free fatty acids and cellular lipid accumulation (Unger, 2002; Unger and Zhou, 2001; Unger et al., 1999), whereas others suggest that glucotoxicity is the prerequisite for lipotoxicity, at least in  cells (Bonner-Weir et al., 1983; Harmon et al., 2001; Poitout and Robertson, 2002; Roche et al., 1998; Weir, 1982; Weir et al., 2001). Therefore, glucolipotoxicity is a more proper term to describe  cell dysfunction in type 2 diabetes. To elucidate the molecular mechanisms underlying -cell glucolipotoxicity, we first investigated the quantitative gene expression patterns in INS-1 cells treated chronically with high-glucose. The drastically reduced expression of essential -cell genes such as IRS2, insulin, Pdx1, Glut2, glucokinase and Bclxl, and markedly increased mRNA levels of lipogenic and proapoptotic genes should contribute to the glucolipotoxicity. Interestingly, this gene expression profile is strikingly similar to what we have reported in the INS-1 cell line expressing naSREBP-1c (Wang et al., 2003). In contrast, the characteristics of these gene expression patterns as well as typical glucolipotoxicity were not observed in the INS-1 cell line overexpressing another lipogenic transcription factor ChREBP. Similar negative results were obtained in INS-1 cells expressing, PPAR or C/EBP (H.W. and C.B.W., unpublished data), suggesting that SREBP-1c is the predominant transcription factor responsible for -cell glucolipotoxicity. To further substantiate this hypothesis, we established an INS-1 stable cell line with inducible expression of DN-SREBP-1c. Induction of DN-SREBP-1c diminished the chronic high-glucose-induced SREBP-1 binding to the SRE fragment of the IRS2 promoter. Consequently, the inhibitory effects of chronic high glucose on IRS2 expression were largely attenuated by DN-SREBP-1c. It has been reported that SREBP-1c binds to the IRS2 promoter and suppresses IRS2 expression in rodent hepatocytes (Ide et al., 2004). Our results suggest a similar mechanism in pancreatic  cells. Deletion of IRS2 in mouse hypothalamus and  cells has recently been shown to cause a type 2 diabetes-like syndrome (Kubota et al., 2004; Lin et al., 2004). IRS2 is also known to promote  cell growth/survival (Withers et al., 1998). We therefore propose that suppression of IRS2 expression by SREBP-1c should contribute, at least in part, to -cell glucolipotoxicity. We also demonstrated that dominant-negative suppression of SREBP-1c activation largely prevented glucolipotoxicity in INS-1 cells, including lipid accumulation, impaired glucose-stimulated insulin secretion and apoptosis. The protective effects of DN-SREBP-1c could be explained by nomalized expression of fatty acid synthase, HMG-CoA reductase, LDLR, P21, GLUT2, glucokinase, PDX1, IRS2 and BCLXL. In addition, DN-SREBP-1c also suppressed the expression of UCP2. In contrast, DN-SREBP-1c did not affect the expression of L-PK and aldolase B, which were targeted by ChREBP. Glucokinase is the rate-limiting enzyme for glycolysis and serves as the -cell glucose sensor (Wang and Iynedjian, 1997). PDX1 is required for maintaining -cell-specific gene expression and the -cell phenotype (Ahlgren et al., 1998; Wang et al., 2001). Mouse islets deficient in LDLR have been shown to be resistant to LDL-induced apoptosis (Roehrich et al., 2003). Deletion of Ucp2 restores -cell function in ob/ob mice and in animals fed a high-fat diet (Chan et al., 2004; Joseph et al., 2002; Zhang et al., 2001). In addition, mouse islets deficient in UCP2 are protected from fatty acid-induced lipotoxicity (Joseph et al., 2004), whereas its overexpression leads to impaired glucose-stimulated insulin secretion (Lameloise et al., 2001; Yamashita et al., 2004). Therefore, chronic high glucose may act through SREBP-1 to target multiple genes, causing -cell glucolipotoxicity. Most intriguingly, we found that chronic high glucose treatment caused ER stress response in INS-1 cells, evidenced by elevated expression of two characteristic genes, CHOP and BIP. It has been reported that glucose stimulates protein synthesis in pancreatic  cells through dephosphorylation of the eukaryotic elongation factor (eEF2) (Yan et al., 2003) and initiation factor (eIF2) (Gomez et al., 2004) and activation of the guanine nucleotide exchange factor eIF2B (Gilligan et al., 1996). We, therefore, postulate that chronic high glucose could induce ER stress through overloading protein synthesis. Our data suggest that chronic high-glucose-induced ER stress could be the underlying mechanism in SREBP-1 processing/activation. Indeed, we found that treatment of isolated rat islets with chronic high glucose and two ER stress inducers, thapsigargin and tunicamycin, markedly increased the SREBP-1 binding activity to the IRS2 promoter. It has been well established that ER stress causes SREBP processing through S1P and S2P (Werstuck et al., 2001; Ye et al., 2000). SREBP-1c activation induced by ER stress has also been implicated in hyperhomocysteinemia-induced liver steatosis (Werstuck et al., 2001). Increased ER stress has been incriminated in ob/ob mice and in mice fed on a high-fat diet and proposed as the cause of insulin resistance (Ozcan et al., 2004). Likewise, response to ER stress has been reported in rat  cells treated with fatty acids (Kharroubi et al., 2004). Therefore, prolonged ER stress and SREBP-1c activation could be a common mechanism underlying both -cell dysfunction and insulin resistance in type 2 diabetes. It is noteworthy that the genetic studies have associated SREBP-1c polymorphisms with obesity, insulin resistance and type 2 diabetes (Eberle et al., 2004; Laudes et al., 2004). SREBP-1c is the upstream suppressor of IRS2 (Ide et al., 2004), and the transactivator of Ucp2, Ldlr, stearoyl-CoA desaturase 1 and many lipogenic genes (Bene et al., 2001; Horton et al., 2003; Medvedev et al., 2002; Wang et al., 2003; Yahagi et al., 1999). In addition to the aforementioned genes (IRS2, Ucp2 and Ldlr), stearoyl-CoA desaturase 1 (SCD1) deficiency has been shown to increase insulin sensitivity, fatty acid oxidation and energy expenditure, as well as promoting resistance to diet-induced obesity (Dobrzyn et al., 2004). We, therefore, propose that SREBP-1c is one of the causative genes for development of both -cell dysfunction and insulin resistance in type 2 diabetes. In fact, SREBP-1c over-activation has been associated with liver steatosis, lipodystrophy, diabetic renal disease and/or -cell lipotoxicity in many animal models of type 2 diabetes, such as ob/ob, db/db, IRS2-/- and ap2-nSREBP-1c mice, streptozotocin-induced diabetic rats, Zucker diabetic fatty rats, and mice with liver overexpression of Socs-1/-3 (Kakuma et al., 2000; Lin et al., 2000; Matsuzaka et al., 2004; Riddle et al., 2001; Shimomura et al., 1999a; Shimomura et al., 1999b; Shimomura et al., 1999c; Shimomura et al., 2000; Sun et al., 2002; Takaishi et al., 2004; Tobe et al., 2001; Ueki et al., 2004; Unger and Zhou, 2001; Unger et al., 1999; Werstuck et al., 2001; Xu et al., 2004; Yahagi et al., 2002; You et al., 2002), as well as in patients with severe lipodystrophy (Bastard et al., 2002; Petersen et al., 2002). Treatment with some antidiabetic drugs or hormones including metformin, troglitazone, leptin and adiponectin could prevent the diabetes-associated lipotoxicity in these animals and patients through inhibition of SREBP-1c activation (Lin et al., 2000; Petersen et al., 2002; Shimomura et al., 1999c; Xu et al., 2004). Genetic manipulations to suppress SREBP-1c function are shown to be equally effective (Engelking et al., 2004; Takaishi et al., 2004; Ueki et al., 2004). In summary, we found that chronic high glucose treatment alone could cause typical glucolipotoxicity and a gene expression profile resembling that caused by naSREBP-1c expression in INS-1 cells (Wang et al., 2003). This gene expression profile (Wang et al., 2003) has also been most recently confirmed in mice with -cell-specific overexpression of SREBP-1c (Takahashi et al., 2005), suggesting that the results in our INS-1 cell model correlate well with native  cells in vivo. However, it remains to be determined whether naSREBP-1c-induced apoptosis and impaired glucose-stimulated insulin secretion occurs via lipid accumulation or through an independent mechanism. Most importantly, we found that dominant-negative suppression of SREBP-1c function could prevent glucolipotoxicity in INS-1 cells. We have further implicated ERnstress in the activation of SREBP-1c, leading to -cell glucolipotoxicity. Therefore, the present study should help to clarify the molecular mechanisms underlying development of -cell glucolipotoxicity, a process thought to cause the loss of both -cell mass and insulin secretory response to glucose in type 2 diabetes. Prevention of excessive ER stress and SREBP-1c action should be considered for therapy aimed at protection of -cell function in type 2 diabetes.  Acknowledgments  We are grateful to D. Cornut-Harry, D. Nappey, Y. Dupr and V. Calvo for expert technical assistance. We are indebted to B. M. Spiegelman (for the naSREBP-1c and DN-SREBP-1c cDNAs), D. Ron (for the CHOP cDNA), R. Prywes (for the BIP cDNA), H. Bujard (for the PUHD 10-3 vector), and N. Quintrell (for the pTKhygro plasmid). This work was supported by the Swiss National Science Foundation (grant no. 32-66907.01 to C.B.W.) and Olga Mayenfisch Stiftung. The authors declare no conflict of interest.  References Top Summary Introduction Materials and Methods Results Discussion References  Ahlgren, U., Johnson, J., Johnson, L., Simu, K. and Edlund, H. (1998). Beta-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes. Genes Dev. 12, 1763-1768.[Abstract/Free FullText] Andreolas, C., da Silva Xavier, G., Diraison, F., Zhao, C., Varadi, A., Lopez-Casillas, F., Ferre, P., Foufelle, F. and Rutter, G. A. (2002). Stimulation of acetyl-CoA carboxylase gene expression by glucose requires insulin release and sterol regulatory element binding protein 1c in pancreatic MIN6 beta-cells. Diabetes 51, 2536-2545.[Abstract/Free FullText] Asfari, M., Janjic, D., Meda, P., Li, G., Halban, P. A. and Wollheim, C. B. (1992). Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines. Endocrinology 130, 167-178.[Abstract] Bastard, J. P., Caron, M., Vidal, H., Jan, V., Auclair, M., Vigouroux, C., Luboinski, J., Laville, M., Maachi, M., Girard, P. M. et al. (2002). Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 359, 1026-1031.[CrossRef][Medline] Bene, H., Lasky, D. and Ntambi, J. M. (2001). Cloning and characterization of the human stearoyl-CoA desaturase gene promoter: transcriptional activation by sterol regulatory element binding protein and repression by polyunsaturated fatty acids and cholesterol. Biochem. Biophys. Res. Commun. 284, 1194-1198.[CrossRef][Medline] Bonner-Weir, S., Trent, D. F. and Weir, G. C. (1983). Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release. J. Clin. Invest. 71, 1544-1553.[Medline] Brown, M. S. and Goldstein, J. L. (1997). The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89, 331-340.[CrossRef][Medline] Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A. and Butler, P. C. (2003). Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52, 102-110.[Abstract/Free FullText] Chan, C. B., Saleh, M. C., Koshkin, V. and Wheeler, M. B. (2004). Uncoupling protein 2 and islet function. Diabetes 53, S136-S142.[Abstract/Free FullText] Dentin, R., Pegorier, J. P., Benhamed, F., Foufelle, F., Ferre, P., Fauveau, V., Magnuson, M. A., Girard, J. and Postic, C. (2004). Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression. J. Biol. Chem. 279, 20314-20326.[Abstract/Free FullText] Diraison, F., Parton, L., Ferre, P., Foufelle, F., Briscoe, C. P., Leclerc, I. and Rutter, G. A. (2004). Over-expression of sterol-regulatory-element-binding protein-1c (SREBP1c) in rat pancreatic islets induces lipogenesis and decreases glucose-stimulated insulin release: modulation by 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR). Biochem. J. 378, 769-778.[CrossRef][Medline] Dobrzyn, P., Dobrzyn, A., Miyazaki, M., Cohen, P., Asilmaz, E., Hardie, D. G., Friedman, J. M. and Ntambi, J. M. (2004). Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver. Proc. Natl. Acad. Sci. USA 101, 6409-6414.[Abstract/Free FullText] Eberle, D., Clement, K., Meyre, D., Sahbatou, M., Vaxillaire, M., Le Gall, A., Ferre, P., Basdevant, A., Froguel, P. and Foufelle, F. (2004). SREBF-1 gene polymorphisms are associated with obesity and type 2 diabetes in French obese and diabetic cohorts. Diabetes 53, 2153-2157.[Abstract/Free FullText] Efanova, I. B., Zaitsev, S. V., Zhivotovsky, B., Kohler, M., Efendic, S., Orrenius, S. and Berggren, P. O. (1998). Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration. J. Biol. Chem. 273, 33501-33507.[Abstract/Free FullText] Engelking, L. J., Kuriyama, H., Hammer, R. E., Horton, J. D., Brown, M. S., Goldstein, J. L. and Liang, G. (2004). Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis. J. Clin. Invest. 113, 1168-1175.[Abstract/Free FullText] Flamez, D., Berger, V., Kruhoffer, M., Orntoft, T., Pipeleers, D. and Schuit, F. C. (2002). Critical role for cataplerosis via citrate in glucose-regulated insulin release. Diabetes 51, 2018-2024.[Abstract/Free FullText] Gilligan, M., Welsh, G. I., Flynn, A., Bujalska, I., Diggle, T. A., Denton, R. M., Proud, C. G. and Docherty, K. (1996). Glucose stimulates the activity of the guanine nucleotide-exchange factor eIF-2B in isolated rat islets of Langerhans. J. Biol. Chem. 271, 2121-2125.[Abstract/Free FullText] Gomez, E., Powell, M. L., Greenman, I. C. and Herbert, T. P. (2004). Glucose-stimulated protein synthesis in pancreatic beta-cells parallels an increase in the availability of the translational ternary complex (eIF2-GTP.Met-tRNAi) and the dephosphorylation of eIF2 alpha. J. Biol. Chem. 279, 53937-53946.[Abstract/Free FullText] Gossen, M., Freundlieb, S., Bender, G., Muller, G., Hillen, W. and Bujard, H. (1995). Transcriptional activation by tetracyclines in mammalian cells. Science 268, 1766-1769.[Medline] Harmon, J. S., Gleason, C. E., Tanaka, Y., Poitout, V. and Robertson, R. P. (2001). Antecedent hyperglycemia, not hyperlipidemia, is associated with increased islet triacylglycerol content and decreased insulin gene mRNA level in Zucker diabetic fatty rats. Diabetes 50, 2481-2486.[Abstract/Free FullText] Horton, J. D., Goldstein, J. L. and Brown, M. S. (2002). SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109, 1125-1131.[Free FullText] Horton, J. D., Shah, N. A., Warrington, J. A., Anderson, N. N., Park, S. W., Brown, M. S. and Goldstein, J. L. (2003). Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl. Acad. Sci. USA 100, 12027-12032.[Abstract/Free FullText] Ide, T., Shimano, H., Yahagi, N., Matsuzaka, T., Nakakuki, M., Yamamoto, T., Nakagawa, Y., Takahashi, A., Suzuki, H., Sone, H. et al. (2004). SREBPs suppress IRS-2-mediated insulin signalling in the liver. Nat. Cell Biol. 6, 351-357.[CrossRef][Medline] Iizuka, K., Bruick, R. K., Liang, G., Horton, J. D. and Uyeda, K. (2004). Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc. Natl. Acad. Sci. USA 101, 7281-7286.[Abstract/Free FullText] Ishii, S., Iizuka, K., Miller, B. C. and Uyeda, K. (2004). Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription. Proc. Natl. Acad. Sci. USA 101, 15597-15602.[Abstract/Free FullText] Joseph, J. W., Koshkin, V., Zhang, C. Y., Wang, J., Lowell, B. B., Chan, C. B. and Wheeler, M. B. (2002). Uncoupling protein 2 knockout mice have enhanced insulin secretory capacity after a high-fat diet. Diabetes 51, 3211-3219.[Abstract/Free FullText] Joseph, J. W., Koshkin, V., Saleh, M. C., Sivitz, W. I., Zhang, C. Y., Lowell, B. B., Chan, C. B. and Wheeler, M. B. (2004). Free fatty acid-induced beta-cell defects are dependent on uncoupling protein 2 expression. J. Biol. Chem. 279, 51049-51056.[Abstract/Free FullText] Kakuma, T., Lee, Y., Higa, M., Wang, Z., Pan, W., Shimomura, I. and Unger, R. H. (2000). Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. Proc. Natl. Acad. Sci. USA 97, 8536-8541.[Abstract/Free FullText] Kharroubi, I., Ladriere, L., Cardozo, A. K., Dogusan, Z., Cnop, M. and Eizirik, D. L. (2004). Free fatty acids and cytokines induce pancreatic beta-cell apoptosis by different mechanisms: role of nuclear factor-kappaB and endoplasmic reticulum stress. Endocrinology 145, 5087-5096.[Abstract/Free FullText] Kim, J. B. and Spiegelman, B. M. (1996). ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev. 10, 1096-1107.[Abstract] Kubota, N., Terauchi, Y., Tobe, K., Yano, W., Suzuki, R., Ueki, K., Takamoto, I., Satoh, H., Maki, T., Kubota, T. et al. (2004). Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus. J. Clin. Invest. 114, 917-927.[Abstract/Free FullText] Lameloise, N., Muzzin, P., Prentki, M. and Assimacopoulos-Jeannet, F. (2001). Uncoupling protein 2, a possible link between fatty acid excess and impaired glucose-induced insulin secretion? Diabetes 50, 803-809.[Abstract/Free FullText] Laudes, M., Barroso, I., Luan, J., Soos, M. A., Yeo, G., Meirhaeghe, A., Logie, L., Vidal-Puig, A., Schafer, A. J., Wareham, N. J. et al. (2004). Genetic variants in human sterol regulatory element binding protein-1c in syndromes of severe insulin resistance and type 2 diabetes. Diabetes 53, 842-846.[Abstract/Free FullText] Lin, H. Z., Yang, S. Q., Chuckaree, C., Kuhajda, F., Ronnet, G. and Diehl, A. M. (2000). Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat. Med. 6, 998-1003.[CrossRef][Medline] Lin, X., Taguchi, A., Park, S., Kushner, J. A., Li, F., Li, Y. and White, M. F. (2004). Dysregulation of insulin receptor substrate 2 in beta cells and brain causes obesity and diabetes. J. Clin. Invest. 114, 908-916.[Abstract/Free FullText] Loftus, T. M. and Lane, M. D. (1997). Modulating the transcriptional control of adipogenesis. Curr. Opin. Genet. Dev. 7, 603-608.[CrossRef][Medline] Matsuzaka, T., Shimano, H., Yahagi, N., Amemiya-Kudo, M., Okazaki, H., Tamura, Y., Iizuka, Y., Ohashi, K., Tomita, S., Sekiya, M. et al. (2004). Insulin-independent induction of sterol regulatory element-binding protein-1c expression in the livers of streptozotocin-treated mice. Diabetes 53, 560-569.[Abstract/Free FullText] Medvedev, A. V., Robidoux, J., Bai, X., Cao, W., Floering, L. M., Daniel, K. W. and Collins, S. (2002). Regulation of the uncoupling protein-2 gene in INS-1 beta-cells by oleic acid. J. Biol. Chem. 277, 42639-42644.[Abstract/Free FullText] Ozcan, U., Cao, Q., Yilmaz, E., Lee, A. H., Iwakoshi, N. N., Ozdelen, E., Tuncman, G., Gorgun, C., Glimcher, L. H. and Hotamisligil, G. S. (2004). Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306, 457-461.[Abstract/Free FullText] Petersen, K. F., Oral, E. A., Dufour, S., Befroy, D., Ariyan, C., Yu, C., Cline, G. W., DePaoli, A. M., Taylor, S. I., Gorden, P. et al. (2002). Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J. Clin. Invest. 109, 1345-1350.[Abstract/Free FullText] Poitout, V. and Robertson, R. P. (2002). Minireview: Secondary beta-cell failure in type 2 diabetes - a convergence of glucotoxicity and lipotoxicity. Endocrinology 143, 339-342.[Abstract/Free FullText] Riddle, T. M., Kuhel, D. G., Woollett, L. A., Fichtenbaum, C. J. and Hui, D. Y. (2001). HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J. Biol. Chem. 276, 37514-37519.[Abstract/Free FullText] Rishi, V., Gal, J., Krylov, D., Fridriksson, J., Boysen, M. S., Mandrup, S. and Vinson, C. (2004). SREBP-1 dimerization specificity maps to both the helix-loop-helix and leucine zipper domains: use of a dominant negative. J. Biol. Chem. 279, 11863-11874.[Abstract/Free FullText] Roche, E., Farfari, S., Witters, L. A., Assimacopoulos-Jeannet, F., Thumelin, S., Brun, T., Corkey, B. E., Saha, A. K. and Prentki, M. (1998). Long-term exposure of beta-INS cells to high glucose concentrations increases anaplerosis, lipogenesis, and lipogenic gene expression. Diabetes 47, 1086-1094.[Abstract] Roehrich, M. E., Mooser, V., Lenain, V., Herz, J., Nimpf, J., Azhar, S., Bideau, M., Capponi, A., Nicod, P., Haefliger, J. A. et al. (2003). Insulin-secreting beta-cell dysfunction induced by human lipoproteins. J. Biol. Chem. 278, 18368-18375.[Abstract/Free FullText] Rubi, B., Ishihara, H., Hegardt, F. G., Wollheim, C. B. and Maechler, P. (2001). GAD65-mediated glutamate decarboxylation reduces glucose-stimulated insulin secretion in pancreatic beta cells. J. Biol. Chem. 276, 36391-36396.[Abstract/Free FullText] Schreiber, E., Matthias, P., Muller, M. M. and Schaffner, W. (1988). Identification of a novel lymphoid specific octamer binding protein (OTF-2B) by proteolytic clipping bandshift assay (PCBA). EMBO J. 7, 4221-4229.[Abstract] Shimomura, I., Bashmakov, Y. and Horton, J. D. (1999a). Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J. Biol. Chem. 274, 30028-30032.[Abstract/Free FullText] Shimomura, I., Bashmakov, Y., Ikemoto, S., Horton, J. D., Brown, M. S. and Goldstein, J. L. (1999b). Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc. Natl. Acad. Sci. USA 96, 13656-13661.[Abstract/Free FullText] Shimomura, I., Hammer, R. E., Ikemoto, S., Brown, M. S. and Goldstein, J. L. (1999c). Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401, 73-76.[CrossRef][Medline] Shimomura, I., Matsuda, M., Hammer, R. E., Bashmakov, Y., Brown, M. S. and Goldstein, J. L. (2000). Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol. Cell 6, 77-86.[CrossRef][Medline] Sun, L., Halaihel, N., Zhang, W., Rogers, T. and Levi, M. (2002). Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J. Biol. Chem. 277, 18919-18927.[Abstract/Free FullText] Takahashi, A., Motomura, K., Kato, T., Yoshikawa, T., Nakagawa, Y., Yahagi, N., Sone, H., Suzuki, H., Toyoshima, H., Yamada, N. et al. (2005). Transgenic mice overexpressing nuclear SREBP-1c in pancreatic {beta}-cells. Diabetes 54, 492-499.[Abstract/Free FullText] Takaishi, K., Duplomb, L., Wang, M. Y., Li, J. and Unger, R. H. (2004). Hepatic insig-1 or -2 overexpression reduces lipogenesis in obese Zucker diabetic fatty rats and in fasted/refed normal rats. Proc. Natl. Acad. Sci. USA 101, 7106-7111.[Abstract/Free FullText] Tobe, K., Suzuki, R., Aoyama, M., Yamauchi, T., Kamon, J., Kubota, N., Terauchi, Y., Matsui, J., Akanuma, Y., Kimura, S. et al. (2001). Increased expression of the sterol regulatory element-binding protein-1 gene in insulin receptor substrate-2(-/-) mouse liver. J. Biol. Chem. 276, 38337-38340.[Abstract/Free FullText] Tontonoz, P., Kim, J. B., Graves, R. A. and Spiegelman, B. M. (1993). ADD1: a novel helix-loop-helix transcription factor associated with adipocyte determination and differentiation. Mol. Cell. Biol. 13, 4753-4759.[Abstract] Ueki, K., Kondo, T., Tseng, Y. H. and Kahn, C. R. (2004). Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc. Natl. Acad. Sci. USA 101, 10422-10427.[Abstract/Free FullText] Unger, R. H. (2002). Lipotoxic diseases. Annu. Rev. Med. 53, 319-336.[CrossRef][Medline] Unger, R. H. and Zhou, Y. T. (2001). Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes 50, S118-S121.[Free FullText] Unger, R. H., Zhou, Y. T. and Orci, L. (1999). Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc. Natl. Acad. Sci. USA 96, 2327-2332.[Abstract/Free FullText] Wang, H. and Iynedjian, P. B. (1997). Modulation of glucose responsiveness of insulinoma beta-cells by graded overexpression of glucokinase. Proc. Natl. Acad. Sci. USA 94, 4372-4377.[Abstract/Free FullText] Wang, H. and Wollheim, C. B. (2002). ChREBP Rather than USF2 regulates glucose stimulation of endogenous L-pyruvate kinase expression in insulin-secreting cells. J. Biol. Chem. 277, 32746-32752.[Abstract/Free FullText] Wang, H., Maechler, P., Hagenfeldt, K. A. and Wollheim, C. B. (1998). Dominant-negative suppression of HNF-1alpha function results in defective insulin gene transcription and impaired metabolism-secretion coupling in a pancreatic beta-cell line. EMBO J. 17, 6701-6713.[Abstract/Free FullText] Wang, H., Maechler, P., Ritz-Laser, B., Hagenfeldt, K. A., Ishihara, H., Philippe, J. and Wollheim, C. B. (2001). Pdx1 level defines pancreatic gene expression pattern and cell lineage differentiation. J. Biol. Chem. 276, 25279-25286.[Abstract/Free FullText] Wang, H., Maechler, P., Antinozzi, P. A., Herrero, L., Hagenfeldt-Johansson, K. A., Bjorklund, A. and Wollheim, C. B. (2003). The transcription factor SREBP-1c is instrumental in the development of beta-cell dysfunction. J. Biol. Chem. 278, 16622-16629.[Abstract/Free FullText] Wang, M. Y., Koyama, K., Shimabukuro, M., Mangelsdorf, D., Newgard, C. B. and Unger, R. H. (1998). Overexpression of leptin receptors in pancreatic islets of Zucker diabetic fatty rats restores GLUT-2, glucokinase, and glucose-stimulated insulin secretion. Proc. Natl. Acad. Sci. USA 95, 11921-11926.[Abstract/Free FullText] Weir, G. C. (1982). Non-insulin-dependent diabetes mellitus: interplay between B-cell inadequacy and insulin resistance. Am. J. Med. 73, 461-464.[CrossRef][Medline] Weir, G. C., Laybutt, D. R., Kaneto, H., Bonner-Weir, S. and Sharma, A. (2001). Beta-cell adaptation and decompensation during the progression of diabetes. Diabetes 50, S154-S159.[Free FullText] Werstuck, G. H., Lentz, S. R., Dayal, S., Hossain, G. S., Sood, S. K., Shi, Y. Y., Zhou, J., Maeda, N., Krisans, S. K., Malinow, M. R. et al. (2001). Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J. Clin. Invest. 107, 1263-1273.[Abstract/Free FullText] Withers, D. J., Gutierrez, J. S., Towery, H., Burks, D. J., Ren, J. M., Previs, S., Zhang, Y., Bernal, D., Pons, S., Shulman, G. I. et al. (1998). Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391, 900-904.[CrossRef][Medline] Xu, A., Yin, S., Wong, L., Chan, K. W. and Lam, K. S. (2004). Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice. Endocrinology 145, 487-494.[Abstract/Free FullText] Yahagi, N., Shimano, H., Hasty, A. H., Amemiya-Kudo, M., Okazaki, H., Tamura, Y., Iizuka, Y., Shionoiri, F., Ohashi, K., Osuga, J. et al. (1999). A crucial role of sterol regulatory element-binding protein-1 in the regulation of lipogenic gene expression by polyunsaturated fatty acids. J. Biol. Chem. 274, 35840-35844.[Abstract/Free FullText] Yahagi, N., Shimano, H., Hasty, A. H., Matsuzaka, T., Ide, T., Yoshikawa, T., Amemiya-Kudo, M., Tomita, S., Okazaki, H., Tamura, Y. et al. (2002). Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J. Biol. Chem. 277, 19353-19357.[Abstract/Free FullText] Yamashita, T., Eto, K., Okazaki, Y., Yamashita, S., Yamauchi, T., Sekine, N., Nagai, R., Noda, M. and Kadowaki, T. (2004). Role of uncoupling protein-2 up-regulation and triglyceride accumulation in impaired glucose-stimulated insulin secretion in a beta-cell lipotoxicity model overexpressing sterol regulatory element-binding protein-1c. Endocrinology 145, 3566-3577.[Abstract/Free FullText] Yan, L., Nairn, A. C., Palfrey, H. C. and Brady, M. J. (2003). Glucose regulates EF-2 phosphorylation and protein translation by a protein phosphatase-2A-dependent mechanism in INS-1-derived 832/13 cells. J. Biol. Chem. 278, 18177-18183.[Abstract/Free FullText] Ye, J., Rawson, R. B., Komuro, R., Chen, X., Dave, U. P., Prywes, R., Brown, M. S. and Goldstein, J. L. (2000). ER stress induces cleavage of membrane-bound ATF6"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0010813:cleavage [Cell Function]
   760   C0596311:Cleavage [Phenomenon or Process]
   760   C1330957:cleavage [Cell Function]

Phrase: "by the same proteases"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0030940:Proteases [Amino Acid, Peptide, or Protein,Enzyme]
   861   C0030946:proteases [Amino Acid, Peptide, or Protein,Enzyme,Pharmacologic Substance]
   861   C1947941:Proteases [Enzyme]

Phrase: "that process SREBPs."
Meta Candidates (Total=15; Excluded=0; Pruned=0; Remaining=15)
   947   C1566548:Sterol Regulatory Element Binding Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   878   C0033666:process protein [Molecular Function]
   858   C0815047:regulatory proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   858   C2246292:sterol binding [Molecular Function]
   827   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0242210:Binding Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0013879:Element [Element, Ion, or Isotope]
   799   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0038323:Sterol [Steroid]
   799   C0220905:regulatory [Regulation or Law]
   799   C0243122:binding [Functional Concept]
   799   C1145667:Binding [Activity]
   799   C1167622:Binding [Molecular Function]
   799   C1704735:Regulatory [Conceptual Entity]
   799   C1705248:Element [Conceptual Entity]
Processing 00000000.tx.819: Mol. 

Phrase: "Mol."
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
  1000   C0027960:Mole [Neoplastic Process]
  1000   C0324740:Mole [Mammal]
  1000   C0439189:Mole [Quantitative Concept]
  1000   C1456781:mole [Neoplastic Process]
  1000   C1824986:mol [Gene or Genome]
   916 E C0026367:Molar [Body Part, Organ, or Organ Component]
   900 E C0027962:moles [Neoplastic Process]
Processing 00000000.tx.820: Cell 6, 1355-1364.[CrossRef][Medline] You, M., Fischer, M., Deeg, M. 

Phrase: "Cell 6,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0007634:Cell [Cell]
   861   C1269647:Cell [Cell]
   861   C1704653:Cell [Medical Device]
   861   C1948049:Cell [Spatial Concept]

Phrase: "1355-1364."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "You,"

Phrase: "M."

Phrase: ","

Phrase: "Fischer,"

Phrase: "M."

Phrase: ","

Phrase: "Deeg,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.821: A. and Crabb, D. 

Phrase: "A."

Phrase: "and"

Phrase: "Crabb,"

Phrase: "D."
Processing 00000000.tx.822: W. 

Phrase: "W."
Processing 00000000.tx.823: (2002). 

Phrase: "(2000). ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs. Mol. Cell 6, 1355-1364.[CrossRef][Medline] You, M., Fischer, M., Deeg, M. A. and Crabb, D. W. (2002"

Phrase: "). ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs. Mol. Cell 6, 1355-1364.[CrossRef][Medline] You, M., Fischer, M., Deeg, M. A. and Crabb, D. W. (2002)."
Processing 00000000.tx.824: Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). 

Phrase: "Ethanol"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001962:Ethanol [Organic Chemical]

Phrase: "induces"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induce [Functional Concept]

Phrase: "fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP)."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   755   C1514528:Protein Activation Pathway [Functional Concept]
   755   C3156336:protein activation pathway [Molecular Function]
   736   C1704259:Pathways [Molecular Function]
   736   C1705987:Pathways [Conceptual Entity]
   734   C1514829:Regulatory Pathway [Functional Concept]
Processing 00000000.tx.825: J. 

Phrase: "J."
Processing 00000000.tx.826: Biol. 

Phrase: "Biol."
Processing 00000000.tx.827: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.828: 277, 29342-29347.[Abstract/Free FullText] Zhang, C. 

Phrase: "277,"

Phrase: "29342-29347."

Phrase: "[Abstract/Free FullText"

Phrase: "] Zhang,"

Phrase: "C."
Processing 00000000.tx.829: Y., Baffy, G., Perret, P., Krauss, S., Peroni, O., Grujic, D., Hagen, T., Vidal-Puig, A. 

Phrase: "Y.,"

Phrase: "Baffy,"

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "Perret,"

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Krauss,"

Phrase: "S."

Phrase: ","

Phrase: "Peroni,"

Phrase: "O.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439114:O NOS [Intellectual Product]

Phrase: "Grujic,"

Phrase: "D."

Phrase: ","

Phrase: "Hagen,"

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Vidal-Puig,"

Phrase: "A."
Processing 00000000.tx.830: J., Boss, O., Kim, Y. 

Phrase: "J.,"

Phrase: "Boss,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0265514:BOS [Disease or Syndrome]
  1000   C1265540:Bos [Mammal]

Phrase: "O.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439114:O NOS [Intellectual Product]

Phrase: "Kim,"

Phrase: "Y."
Processing 00000000.tx.831: B. et al. 

Phrase: "B. et al."
Processing 00000000.tx.832: (2001). 

Phrase: "(2002). Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). J. Biol. Chem. 277, 29342-29347.[Abstract/Free FullText] Zhang, C. Y., Baffy, G., Perret, P., Krauss, S., Peroni, O., Grujic, D., Hagen, T., Vidal-Puig, A. J., Boss, O., Kim, Y. B. et al. (2001"

Phrase: "). Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). J. Biol. Chem. 277, 29342-29347.[Abstract/Free FullText] Zhang, C. Y., Baffy, G., Perret, P., Krauss, S., Peroni, O., Grujic, D., Hagen, T., Vidal-Puig, A. J., Boss, O., Kim, Y. B. et al. (2001)."
Processing 00000000.tx.833: Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. 

Phrase: "Uncoupling protein-2 negatively"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   923   C0536847:uncoupling protein-2 [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   923   C1421314:UNCOUPLING PROTEIN 2 [Gene or Genome]
   812   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "regulates"

Phrase: "insulin secretion"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C1256369:insulin secretion [Cell Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036536:secretion [Biologic Function]
   861   C0036537:Secretion [Body Substance]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "is"

Phrase: "a major link between obesity,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1517892:Link [Intellectual Product]
   760   C1704666:Link [Intellectual Product]

Phrase: "beta cell dysfunction,"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
  1000   C1969875:Beta-cell dysfunction [Finding]
   827   C0031847:dysfunction [Functional Concept]
   827   C0277785:Dysfunction, NOS [Qualitative Concept]
   771 E C0231174:Malfunction [Functional Concept]
   771 E C1881681:MALFUNCTION [Phenomenon or Process]
   734   C0030281:Beta cell [Cell]

Phrase: "and"

Phrase: "type 2 diabetes."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]
Processing 00000000.tx.834: Cell 105, 745-755.[CrossRef][Medline] Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N. et al. 

Phrase: "Cell 105,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0007634:Cell [Cell]
   861   C1269647:Cell [Cell]
   861   C1704653:Cell [Medical Device]
   861   C1948049:Cell [Spatial Concept]

Phrase: "745-755."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Zhou,"

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "Myers,"

Phrase: "R.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]

Phrase: "Li,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3495095:Li+ [Element, Ion, or Isotope]

Phrase: "Y.,"

Phrase: "Chen,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0999213:Chen [Bird]

Phrase: "Y.,"

Phrase: "Shen,"

Phrase: "X.,"

Phrase: "Fenyk-Melody,"

Phrase: "J.,"

Phrase: "Wu,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1431628:wu [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "M."

Phrase: ","

Phrase: "Ventre,"

Phrase: "J.,"

Phrase: "Doebber,"

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Fujii,"

Phrase: "N. et al."
Processing 00000000.tx.835: (2001). 

Phrase: "(2001). Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell 105, 745-755.[CrossRef][Medline] Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N. et al. (2001"

Phrase: "). Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell 105, 745-755.[CrossRef][Medline] Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N. et al. (2001)."
Processing 00000000.tx.836: Role of AMP-activated protein kinase in mechanism of metformin action. 

Phrase: "Role of AMP-activated protein kinase"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0035820:Role [Social Behavior]
   753   C1705810:Role [Conceptual Entity]
   716   C2350345:AMP-Activated Protein Kinase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "in mechanism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0441712:Mechanism [Functional Concept]
  1000   C1706376:Mechanism [Manufactured Object]

Phrase: "of metformin action."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0441472:Action [Functional Concept]
   861   C3266814:Action [Activity]
Processing 00000000.tx.837: J. 

Phrase: "J."
Processing 00000000.tx.838: Clin. 

Phrase: "Clin."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1315013:CLIN [Intellectual Product]
Processing 00000000.tx.839: Invest. 

Phrase: "Invest."
Processing 00000000.tx.840: 108, 1167-1174.[Abstract/Free FullText] Related articles in JCS: SREBP stressed out by glucose JCS 2005 118: 1702. 

Phrase: "108,"

Phrase: "1167-1174."

Phrase: "[Abstract/Free FullText"

Phrase: "] Related articles in JCS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   737   C1706852:Article [Intellectual Product]

Phrase: ":"

Phrase: "SREBP"
Meta Candidates (Total=13; Excluded=0; Pruned=0; Remaining=13)
   875   C0815047:Regulatory Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   875   C2246292:sterol binding [Molecular Function]
   840   C0034987:Regulatory Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   840   C0242210:Binding Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0013879:Element [Element, Ion, or Isotope]
   804   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0038323:Sterol [Steroid]
   804   C0220905:regulatory [Regulation or Law]
   804   C0243122:binding [Functional Concept]
   804   C1145667:Binding [Activity]
   804   C1167622:Binding [Molecular Function]
   804   C1704735:Regulatory [Conceptual Entity]
   804   C1705248:Element [Conceptual Entity]

Phrase: "stressed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0038435:stressed [Finding]

Phrase: "out by glucose JCS 2005 118"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   753   C0439787:Out [Spatial Concept]
   753   C0849355:Out [Qualitative Concept]

Phrase: ":"

Phrase: "1702."
Processing 00000000.tx.841: [Full Text]  This Article Summary Figures Only Full Text (PDF) All Versions of this Article: jcs.02513v1 118/17/3905 most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JCS Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Wang, H. 

Phrase: "[Full Text"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C1527021:Text [Intellectual Product]
   861   C1554111:Text [Idea or Concept]
   861   C1705606:Text [Intellectual Product]
   861   C3541382:Text [Intellectual Product]

Phrase: "]"

Phrase: "This Article Summary"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1552616:summary [Intellectual Product]
   861   C1706244:Summary [Intellectual Product]

Phrase: "Figures"

Phrase: "Only Full Text"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C1527021:Text [Intellectual Product]
   827   C1554111:Text [Idea or Concept]
   827   C1705606:Text [Intellectual Product]
   827   C3541382:Text [Intellectual Product]

Phrase: "(2001). Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167-1174.[Abstract/Free FullText] Related articles in JCS: SREBP stressed out by glucose JCS 2005 118: 1702. [Full Text]  This Article Summary Figures Only Full Text (PDF)"

Phrase: "All Versions of this Article"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C0333052:versions [Functional Concept]
   726 E C2607870:Version [Spatial Concept]

Phrase: ":"

Phrase: "jcs.02513v1 118/17/3905 most recent Alert"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   793   C0239110:ALERT [Finding]

Phrase: "me"

Phrase: "when"

Phrase: "this article"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1706852:Article [Intellectual Product]

Phrase: "is"

Phrase: "cited"

Phrase: "Alert"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0239110:ALERT [Finding]

Phrase: "me"

Phrase: "if"

Phrase: "a correction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1705565:CORRECTION [Intellectual Product]
  1000   C1947976:Correction [Functional Concept]

Phrase: "is"

Phrase: "posted"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0687676:Post [Temporal Concept]
   966   C1704687:Post [Manufactured Object]

Phrase: "Services"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0557854:Services [Occupational Activity]
   966 E C2825316:Service [Manufactured Object]
   966 E C3245478:service [Idea or Concept]

Phrase: "Email"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0013849:E-Mail [Intellectual Product]
  1000   C1705961:E-mail [Intellectual Product]

Phrase: "this article to a friend Related articles"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1706852:Article [Intellectual Product]

Phrase: "in JCS Similar articles"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   793   C1706852:Article [Intellectual Product]

Phrase: "in this journal Similar articles"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   896   C0282420:Journal Article [Intellectual Product]
   793   C1706852:Article [Intellectual Product]

Phrase: "in PubMed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1138432:PubMed [Intellectual Product]

Phrase: "Alert"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0239110:ALERT [Finding]

Phrase: "me to new issues of the journal Download"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   744   C0162443:Journal [Intellectual Product,Manufactured Object]
   744   C0205314:New [Temporal Concept]
   711   C0033213:Issue [Finding]
   711   C1706387:Issue [Intellectual Product]

Phrase: "to citation manager Google Scholar Articles"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   771   C1706852:Article [Intellectual Product]

Phrase: "by Wang,"

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.842: Articles by Wollheim, C. 

Phrase: "Articles by Wollheim,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   756   C1706852:Article [Intellectual Product]

Phrase: "C."
Processing 00000000.tx.843: B. 

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.844: Articles citing this Article PubMed PubMed Citation Articles by Wang, H. 

Phrase: "Articles"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1706852:Article [Intellectual Product]

Phrase: "citing"

Phrase: "this Article PubMed PubMed Citation Articles by Wang,"

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.845: Articles by Wollheim, C. 

Phrase: "Articles by Wollheim,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   756   C1706852:Article [Intellectual Product]

Phrase: "C."
Processing 00000000.tx.846: B.

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

